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Abstract 
99mTc-PEI-MP and 188Re-PEI-MP for Imaging and Therapy of the Bladder 
Malignant Tumours – An Experimental Study 
Bladder cancer is the most common malignancy of the urinary tract, and is the 
fifth most common tumour world-wide, being responsible for about 2% of all 
cancer deaths. Current methods of diagnosis of the bladder cancer are mainly 
morphologic imaging techniques, while physiological imaging techniques, like 
nuclear medicine imaging that would enable to detect the disease in a very 
early stage, is not being fully availed for this type of cancer. The main methods 
to treat bladder cancer are aggressive and invasive to the patient, in a time 
where conservative management, with organ preservation, is now the standard 
of care in numerous malignancies. There is no reference to the use of 
radiopharmaceuticals for bladder cancer therapy, nevertheless, the existence of 
a specific radiopharmaceutical to bladder cancer could enable the delivery of 
high doses of radiation to the target tissue with minimal side effects, and some 
current therapy modalities could be substituted. Searching for a molecule for 
use in the palliative therapy of bone metastasis, the water soluble polymer 
polyethyleneiminomethyl phosphonic acid (PEI-MP), was synthesized. Pre-
clinical studies performed with PEI-MP labelled with several radionuclides, 
demonstrated the high value of accumulation and retention by the bladder wall, 
which could demonstrate some affinity of PEI-MP to bladder cells, and possibly 
by bladder cancer cells. Thus, the aim of this work was to explore in vitro and in 
vivo the potential of PEI-MP radiolabelled with 99mTc or 188Re, for imaging and 
radionuclide therapy of bladder cancer. In a first stage it was prepared the PEI-
MP kits for a quick and easy radiolabelling with 99mTc or 188Re, and to ensure 
high radiochemical purity. For in vitro studies, the cell lines of human bladder 
carcinoma (HT-1376) and human osteosarcoma (MNNG/HOS) were used. The 
osteosarcoma cells were used considering the original intent of using PEI-MP, 
and in order to make comparisons. Considering that PEI-MP should act only as 
a carrier for nuclear medicine imaging and therapy, cellular cytotoxicity of PEI-
MP was analysed by the evaluation of the cellular metabolic activity and viability 
through spectrophotometry and flow cytometry. Cellular uptake and retention 
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studies of 99mTc-PEI-MP and 188Re-PEI-MP were also performed. In vivo and ex 
vivo studies consisted on imaging and biodistribution studies performed in 
balb/c mice and balb/c n/nu mice with xenografts of bladder carcinoma and 
osteosarcoma, after the administration of 99mTc-PEI-MP and 188Re-PEI-MP. The 
PEI-MP kits demonstrated to be suitable for radiolabelling, allowing to achieve a 
high radiochemical purity over 5 hours, revealing the stability of the kit 
formulation. PEI-MP didn’t inhibit the metabolic activity or decreased the cell 
viability significantly and therefore would act as a carrier. Cellular uptake studies 
demonstrated that the uptake and retention of 99mTc-PEI-MP was, respectively, 
at least 5 and 4 times superior than the 99mTc-Pertechenetate for both cell lines. 
The same studies demonstrated that the uptake and retention of 188Re-PEI-MP 
was, respectively, at least 62 and 194 times superior than the 188Re-Perrhenate 
for both cell lines. These studies demonstrated the specificity of PEI-MP. In vivo 
and ex vivo studies demonstrated that 99mTc-PEI-MP and 188Re-PEI-MP were 
mainly excreted through the renal system and a small amount by enterohepatic 
circulation. Also it was confirmed the uptake of 99mTc-PEI-MP and 188Re-PEI-MP 
by lungs. The uptake of 99mTc-PEI-MP and 188Re-PEI-MP by the xenografts of 
bladder carcinoma or osteosarcoma, that demonstrated to be superior to 1 in 
relation to muscle, may be related not only with the blood perfusion to the 
tumour or the enhanced permeability and retention effect associated with PEI-
MP, but also with the presence of specific membrane receptors in the case of 
bladder carcinoma and high concentrations of Ca2+ in both tumour types. 
Tumour/bladder, tumour/liver, tumour/lung and tumour/bone were always 
inferior to one. These results demonstrated that for diagnostic nuclear medicine 
a bladder carcinoma and its metastases would present as cold lesions allowing 
identifying them in the images. One the other hand the therapy of bladder 
carcinoma and its metastasis seem not to be feasible if administered 
intravenously, considering the high dosimetry to other organs. 
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Resumo 
99mTc-PEI-MP e 188Re-PEI-MP para Imagiologia e Terapia de Tumores 
Malignos da Bexiga – Um Estudo Experimental  
O cancro da bexiga é a neoplasia maligna mais comum do trato urinário, e é o 
quinto tumor mais comum em todo o mundo, sendo responsável por cerca de 
2% de todas as mortes relacionadas com o cancro. Os métodos actuais de 
diagnóstico para o cancro da bexiga são principalmente técnicas de imagem 
morfológicas, sendo que as técnicas de imagem fisiológicas, como as da 
medicina nuclear que permitiriam detectar a doença numa fase inicial, não 
estão ser totalmente aproveitadas para este tipo de cancro. Os principais 
métodos de terapia para o cancro da bexiga são agressivos e invasivos para o 
doente, numa época em que o tratamento conservador, com preservação de 
órgãos, é agora o padrão para o tratamento de diversas neoplasias. Não há 
nenhuma referência à utilização de radiofármacos para a terapia do cancro da 
bexiga, no entanto, a existência de um radiofármaco específico pode permitir a 
entrega de elevadas doses de radiação ao tecido alvo e com mínimos efeitos 
secundários, e algumas modalidades de tratamento actuais poderão vir a ser 
substituídas. Na procura de uma molécula para o tratamento paliativo de 
metástases ósseas, o ácido fosfónico solúvel em água polietilenoiminometil 
(PEI-MP), foi sintetizado. Estudos pré-clínicos realizados com o PEI-MP 
marcado com vários radionuclídeos, demonstraram uma elevada captação e 
retenção pela parede da bexiga, evidenciando a possível afinidade do PEI-MP 
para as células da bexiga e possivelmente para células de cancro da bexiga. 
Assim, o objetivo deste trabalho foi explorar in vitro e in vivo o potencial do PEI-
MP radiomarcado com 99mTc ou 188Re, para a imagiologia e terapia com 
radionuclídeos do cancro da bexiga. Numa primeira fase, foram preparados os 
kits de PEI-MP para uma radiomarcação rápida e fácil com o 99mTc ou 188Re, e 
para assegurar a alta pureza radioquímica. Para os estudos in vitro, foram 
utilizadas as linhas celulares humanas de carcinoma da bexiga (HT-1376) e de 
osteossarcoma (MNNG/HOS). As células de osteossarcoma foram usadas 
tendo em conta a intenção inicial do PEI-MP, e de modo a fazer comparações. 
Considerando que o PEI-MP deve servir apenas como um veículo para a 
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imagiologia e terapia de medicina nuclear, a citotoxicidade celular do PEI-MP 
foi analisada avaliando a actividade metabólica e viabilidade celular através da 
espectrofotometria e citometria de fluxo. Também foram realizados estudos de 
captação e retenção celulares do 99mTc-PEI-MP e 188Re-PEI-MP. Os estudos in 
vivo consistiram na realização de imagens e na análise da biodistribuição em 
ratinhos balb/c e balb/c nu/nu com xenoenxertos de carcinoma da bexiga e 
osteossarcoma após a administração de 99mTc-PEI-MP e 188Re-PEI-MP. Os kits 
de PEI-MP mostraram-se adequados para a marcação radioactiva, permitindo 
obter um elevado grau de pureza radioquímica 5 horas após a marcação, 
revelando a estabilidade da formulação do kit. O PEI-MP não inibiu a actividade 
metabólica ou diminuiu de forma significativa a viabilidade celular, podendo 
assim ser usado como um veículo. Os estudos de captação celular 
demonstraram que a captação e retenção do 99mTc-PEI-MP foi, 
respecivamente, 5 e 4 vezes superior à do 99mTc-pertecnetato para ambas as 
linhas celulares. Os mesmos estudos demonstraram que a captação e retenção 
do 188Re-PEI-MP foi, respectivamente, 62 e 194 vezes superior à do 188Re-
perrenato para ambas a linhas celulares. Estes estudos demonstraram a 
especificidade de PEI-MP. Os estudos in vivo e ex vivo demonstraram que o 
99mTc-PEI-MP e 188Re-PEI-MP são excretados maioritariamente por via renal e 
uma pequena quantidade pela circulação entero-hepática. A captação do 
99mTc-PEI-MP e 188Re-PEI-MP pelos xenotransplantes de carcinoma da bexiga 
ou osteosarcoma, que demonstrou ser superior ao valor de um em relação ao 
músculo, pode estar relacionada não só com a perfusão sanguínea para o 
tumor ou o efeito do aumento da permeabilidade e retenção associado ao PEI-
MP, mas também com a presença de receptores de membrana específicos, no 
caso de carcinoma da bexiga e de concentrações elevadas de Ca2+ em ambos 
os tipos de tumores. As razões tumor/bexiga, tumor/fígado, tumor/pulmão e 
tumor/osso foram sempre inferiores ao valor de um. Estes resultados 
demonstraram que para o diagnóstico de carcinoma da bexiga e suas 
metástases em medicina nuclear, o tumor e as metástases surgiriam nas 
imagens como lesões frias, permitindo a sua identificação. Por outro lado, a 
terapia de carcinoma da bexiga e suas metástases parece não ser viável se 
administrado por via intravenosa, considerando a dosimetria elevada para 
outros órgãos. 
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A research article was submitted to an international journal and is waiting for 
revision, and is expected to compose and submit another research article until 
the beginning of next year.  
This work is organized in sections starting with the preamble, followed by the 
literature review, the experimental studies, the discussion and conclusions and 
finally the bibliography. The literature review, or section II, is organized in 
chapter 1 to 4, where general topics are reviewed such as what is cancer and 
what is implied and the current diagnostic and therapy techniques, following by 
more specific revisions in order to know the history of PEI-MP and be familiar 
with the particularities of bladder cancer and what are the current methods of 
diagnosis and therapy. The section III, dedicated to the experimental studies is 
organized in chapter 5 and 6, where are presented the material and methods, 
results, and discussion of the experimental studies carried out in vitro and in 
vivo/ex vivo. 
Considering that it was not possible to obtain a second generator of 188W/188Re, 
some studies were not concluded, especially with respect to the in vitro studies. 
Despite this situation the studies with 188Re allowed to draw final conclusions. 
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Section II. Literature Review 
Chapter 1.Cancer 
 
1.1. Introduction  
Development, differentiation, and the maintenance of vital functions involve 
exact regulation of the time and location of the cell divisions and self-elimination 
programmed cell death, or apoptosis. A tumour arises as a result of 
uncontrolled cell division and failure of programmed cell death [1, 2]. 
Most tumours can be classified clinically as benign or malignant [3, 4]. The cells 
of the malignant tumours are pleomorphic, varying in size and shape. 
Furthermore, these cells are less differentiated, or anaplastic, then their benign 
counterparts [4]. Malignant tumours occur as a result of mutations in three basic 
types of genes: DNA (Deoxyribonucleic acid) repair genes, tumour suppressor 
genes, and proto-oncogenes. Alterations in these genes are responsible for the 
deregulated control mechanisms, that are the hallmarks of cancer cells [1, 2, 5].  
 
1.2. Hallmarks of cancer   
Cells must acquire a series of traits in order to become malignant. These traits 
have been grouped in categories, as represented in fig. 1 [6, 7].  
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1.2.1. Sustaining proliferative signalling 
Normal tissues control the production and release of growth-promoting signals, 
giving instructions for the progression through the cell growth-and-division 
cycle, ensuring the maintenance of cell number and of normal tissue 
architecture and function [6]. These signals are transmitted into the cell by 
transmembrane receptors that bind to unique classes of signalling molecules, 
namely diffusible growth factors, extracellular matrix components and cell-to-cell 
adhesion/interaction molecules.  
Such behaviour contrasts strongly with that of tumour cells. Tumour cells 
generate many of their own growth signals, thus reducing their dependence on 
stimulation from their normal tissue microenvironment [7]. 
Cancer cells can acquire the capability to maintain proliferative signalling in a 
number of different ways, namely producing growth factor ligands (to which they 
can respond via the expression of cognate receptors, resulting in autocrine 
proliferative stimulation) and sending signals to stimulate normal cells within the 
supporting tumour-associated stroma, which respond by supplying the cancer 
cells with a variety of growth factors [6].  
Figure 1.The hallmarks of cancer, organized in six categories, namely the sustaining 
proliferative signals, evading growth suppressors, resisting cell death, replicative 
immortality, angiogenesis, invasion and metastasis (Hanahan D. et al., 2011). 
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Growth factor receptors, often carrying tyrosine kinase activity in their 
cytoplasmic domains, are over-expressed in many cancers. Receptor over-
expression may facilitate the cancer cell to become hyper-responsive to normal 
levels of growth factors that usually would not trigger proliferation [6, 7]. 
Cancer cells also control the expression of the types of extracellular matrix 
receptors (integrins), favouring ones that transmit pro-growth signals. The 
successful binding to specific moieties of the extracellular matrix, enable the 
transduction of signals into the cytoplasm by the integrin receptors, that 
influence cell behaviour, ranging from quiescence to motility in normal tissue, 
resistance to apoptosis, and entrance into the cell cycle. On the other hand, the 
failure of integrins to build these extracellular links can prejudice cell motility, 
induce apoptosis, or cause cell cycle arrest [6, 7].  
 
1.2.2. Evading growth suppressors 
Multiple anti-proliferative signals operate to maintain cellular quiescence and 
tissue homeostasis in normal tissue. Both soluble growth inhibitors and 
immobilized inhibitors embedded in the extracellular matrix and on the surfaces 
of nearby cells are anti-proliferative signals [7]. 
Antigrowth signals can block proliferation by two distinct mechanisms: 
– cells may be forced out of the proliferative cycle into the quiescence state 
(G0) from which they may remerge when extracellular signals allow; 
– cells may be induced to permanently give up their proliferative potential by 
being induced to enter into post-mitotic states, typically associated with 
acquisition of particular differentiated-associated traits [7]. 
To prosper, cancer cells must evade these anti-proliferative signals. Much of the 
circuitry that enables normal cells to respond to antigrowth signals is linked with 
the cell cycle clock, particularly the component governing the transit of the cell 
through the G1 phase. At the molecular level, many of the anti-proliferative 
signals are funnelled through the retinoblastoma protein and its two relatives, 
the retinoblastoma-like protein 1 and 2 [7]. When in a hypophosphorylated 
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state, retinoblastoma protein blocks proliferation by sequestering and changing 
the function of transcription factor family that control the expression of banks of 
genes, that are essential to the progression from G1 into S phase [8]. 
Disruption of the retinoblastoma protein pathway liberates transcription factors 
and consequently allows cell proliferation, turning cells insensible to antigrowth 
factors that operate along this pathway to block advance through the G1 phase 
of the cell cycle. The soluble signalling molecule TGFβ (Transforming growth 
factor beta) acts in a number of ways to stop the phosphorylation that 
inactivates retinoblastoma protein, blocking the advance through G1. In some 
cell types, TGFβ suppresses expression of the c-MYC  (Myelocytomatosis 
oncogene) gene, which regulates the G1 cell cycle apparatus [7]. Also, TGFβ 
causes synthesis of the CDKN2B (Cyclin-dependent kinase 4 inhibitor B 
Protein) and CIP1 (Cyclin-dependent kinase Inhibitor 1) proteins, which block 
the CDK (Cyclin-dependent kinase) complexes responsible for the 
retinoblastoma protein phosphorylation [9]. 
Some lose responsiveness to TFGβ, through down regulation of their receptors, 
while others display dysfunctional receptors. The cytoplasmic SMAD4 (Mothers 
against decapentaplegic homolog 4) protein, responsible for the transduction of 
signals from ligand-activated TFGβ receptors to downstream targets, may be 
eliminated through mutation of its encoding gene [10]. The locus encoding 
CDKN2B may be deleted. Alternatively, the immediate downstream targets of 
its actions may become unresponsive to the inhibitory actions of CDKN2B given 
to mutations that create amino acid substitutions. The resulting CDK complexes 
are then given a free hand to inactivate retinoblastoma protein by 
hyperphosphorilation. Finally, functional retinoblastoma protein, may be lost 
through mutations of this gene [7]. 
 
1.2.3. Resisting cell death 
The capability of tumour cell populations to increase in number is determined 
not only by the rate of cell proliferation but also by the rate of cell attrition. 
Apoptosis represents the major source of this attrition [7]. 
 
 
8 
 
The apoptotic machinery is composed of both upstream and downstream 
effectors components [11]. The regulators, in turn, are divided into two major 
circuits, one receiving and processing extracellular death-inducing signals (the 
extrinsic apoptotic program, involving the FAS (Type-II transmembrane protein) 
ligand/FAS receptor, and the other sensing and integrating a variety of signals 
of intracellular origin (the intrinsic program).  
Each of these programs culminates in the activation of caspases 8 and 9, which 
proceeds to initiate a cascade of proteolysis involving effectors caspases that 
are responsible for running apoptosis, in which the cell is progressively 
disassembled and then consumed, both by its neighbours and by phagocyte 
cells. Currently, the intrinsic apoptotic program is more widely implicated as a 
barrier to cancer pathogenesis [6, 7]. 
Many of the signals that elicit apoptosis converge on the mitochondria, which in 
turn respond to pro-apoptotic signals by releasing cytochrome C, that is a 
potent catalyst of apoptosis [7]. The “apoptotic trigger” that conveys signals 
between the regulators and effectors is controlled by counterbalancing pro- and 
anti-apoptotic members of the BCL-2 (B-cell lymphoma 2 protein) family of 
regulatory proteins [11]. Members of the BCL-2 family, whose members have 
either pro-apoptotic (BAX, BAK, BID, BIM) or anti-apoptotic (BCL-2, BCL-XL, 
BCL-W) function, act partly by governing mitochondrial death signalling through 
cytochrome C release. The release of cytochrome C, activates a cascade of 
caspases that act via their proteolytic activities, inducing the multiple cellular 
changes associated with the apoptotic program [6, 7]. Several abnormality 
sensors that play key roles in tumour development have been identified [11, 12]. 
Most prominent is a DNA-damage sensor that functions via the P53 tumour 
suppressor gene [13]. P53 induces apoptosis by up-regulating expression of the 
NOXA (Phorbol-12-myristate-13-acetate-induced protein 1) and PUMA (P53 
upregulated modulator of apoptosis) proteins, in response to substantial levels 
of DNA breaks and other chromosomal abnormalities [6]. 
The most frequently occurring loss of a pro-apoptotic regulator through mutation 
involves the P53 tumour suppressor gene. The resulting functional inactivation 
of its product, the P53 protein, is seen in more than 50% of human cancers and 
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results in the deletion of a key component of the DNA damage sensor that can 
induce the apoptotic effectors cascade [14]. Signal evoked by other 
abnormalities, including hypoxia and oncogene hyper-expression, result in part 
via TP53 to the apoptotic machinery. These two are impaired at eliciting 
apoptosis when P53 function is lost [15]. Additionally the PI3K-PKB 
(Phosphoinositide 3-kinase and protein kinase B) pathway, which transmits anti-
apoptotic survival signals, is probably involved with apoptosis in a substantial 
fraction of human tumours [7]. 
 
1.2.4. Enabling replicative immortality 
A decade ago, it was widely accepted that cancer cells require infinite 
replicative potential in order to produce tumours. This capability is a marked 
contrast comparatively with “normal cells”, which are able to pass through only 
a limited number of cell growth-and-division cycles. This limitation has been 
associated with two different barriers to proliferation: senescence and crises. 
Senescence is an irreversible entrance into a non proliferative but viable state, 
and crisis involves cell death. Accordingly, when cells are propagated in culture, 
repeated cycles of cell division lead to senescence and after, the cells that 
succeed in circumventing this barrier, progresses to crisis phase in which the 
great majority of cells die. On rare occasions, cells emerge from a population in 
crisis and exhibit unlimited replicative potential. This transition has been called 
immortalization, an attribute that most established cell lines possess since they 
can proliferate in culture without evidence of either senescence or crisis [6, 7]. 
Multiple evidences indicate that telomeres who protecting the ends of 
chromosomes, have a pivotal role on the capability for unlimited proliferation 
[16]. In fact, telomere length underlies the number of times a cell can have 
successive division. In each cell division, the telomeres decrease the length 
which means that they lose their function of protection causing cell death [6]. 
The telomerase is an enzyme that adds, to the end of the telomere, repetitive 
DNA sequences. Without telomerase, the cells can only divide 50 to 70 times, 
but after they become senescent and stop the cell division. This is what 
 
 
10 
 
happens in the normal cells, non-immortalized. If telomerase is present, any cell 
can divide without limit. This is what happens in immortalized cells that include 
cancer cells. In fact, cancer cells can spontaneously become immortalized. By 
extending telomeric DNA, telomerase is able to respond to the progressive 
telomere erosion that would otherwise occur in its absence. The presence of 
telomerase activity, both in spontaneously immortalized cells or in the context of 
cells engineered to express the enzyme, is correlated with a resistance to the 
induction of both senescence and crisis. Conversely, suppression of telomerase 
activity leads to telomere shortening and to the activation of one or more of 
these proliferative barriers [6, 7]. 
 
1.2.5. Inducing angiogenesis 
For the cell function and survival, the oxygen and nutrients supplied by the 
vasculature are crucial. Therefore, virtually all cells in a tissue should reside 
within 100 µm of a capillary blood vessel. This closeness is ensured during 
organogenesis, by coordinated growth of vessels and parenchyma. Once a 
tissue is formed, the angiogenesis (growth of new blood vessels) is transitory 
and carefully regulated [7]. However, if the cells are within aberrant proliferative 
lesions, initially they lack angiogenic ability, which reduces their capability for 
expansion [17]. 
The dominance of positive or negative signals determines the promotion or the 
blocking of angiogenesis. Some of these signals are transmitted by soluble 
factors who bind to receptors located on the surface of endothelial cells. In this 
context, also integrins and some adhesion molecules who mediate cell-matrix 
and cell-cell relations have a critical role. The initiation signals of angiogenesis 
are due to the vascular endothelial growth factor (VEGF) and acidic and basic 
fibroblast growth factors which bind to transmembrane tyrosine kinase receptors 
in the endothelial cells [18]. A typical example of an angiogenesis inhibitor is the 
thrombospondin-1, which binds to cluster of differentiation 36, a transmembrane 
receptor on endothelial cells coupled to intracellular sarcoma-like tyrosine 
kinases [7]. 
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Like any tissue, tumours need oxygen and nutrients as well as eliminate carbon 
dioxide and metabolic waste. These two functions are achieved by the 
neovasculature associated with the tumour. During embryogenesis, two 
processes are involved in the vasculature development, the vasculogenesis and 
the angiogenesis. The vasculogenesis is the appearing of new endothelial cells 
and their combinations to form the tubular system whereas the angiogenesis 
determines the appearance of new vessels from existing ones. After this stage, 
the normal vasculature becomes virtually quiescence, except in cases of a 
wound healing and female reproductive cycling, where angiogenesis is turned 
on transiently [6]. Oppositely during tumour progression, the process of 
angiogenesis remains switched on and new vessels are continually generated, 
helping to maintain the expanding growth [17]. 
Many tumours produce growth factors that stimulate angiogenesis whereas 
others are able to induce surrounding normal cells to synthesize and to secrete 
such factors [5]. The blood vessels produced inside the tumours as a result of 
the angiogenenic process are typically aberrant. In fact, the tumour 
neovasculature is marked by precocious capillary development, convoluted and 
excessive vessel branching, deformed and enlarged vessels, erratic blood flow, 
leakiness, and abnormal levels of endothelial cell proliferation and apoptosis 
[19]. The fundamental role of angiogenesis is also demonstrated by the effect of 
a large number of increasing catalogue of angiogenic substances to impair the 
growth of tumour cells inoculated subcutaneously in mice. Tumours arising in 
cancer-prone transgenic mice are similarly susceptible to angiogenic inhibitors 
[20]. 
 
1.2.6. Activating invasion and metastasis 
At least for a time some malignant tumours remain localized and encapsulated, 
but eventually they gain the ability to progress, and the cells may invade the 
surrounding tissues, or even get into the body’s circulatory system establishing 
secondary areas of proliferation (metastasis) [4, 5].   
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The metastases arise as amalgams of cancer cells and normal supporting cells 
from the host tissue. Successful invasion and metastasis depend upon all of the 
hallmarks capabilities [7].  
Invasion of new tissues is non-random, and depends on the nature of the 
metastasizing cell and the invaded tissue. If the cells produce growth factors 
and angiogenesis factors, metastasis is facilitated. Tissues under attack are 
most vulnerable if they also produce growth factors, and are more resistant if 
they produce anti-proliferative factors, inhibitors of proteolytic enzymes, and 
anti-angiogenesis factors [5]. 
To disseminate widely in the body, the cells of a typical solid tumour must lose 
the adhesion to their original neighbours, escape from the tissue of origin, 
burrow through other tissues until they reach a blood or a lymphatic vessel. 
Reaching the blood vessel the cells must cross the basal lamina and endothelial 
lining of the vessel to enter in the circulation, enabling the cells to reach 
anywhere in the body. Each of these steps requires different properties. For 
example, in a variety of carcinomas, loss of adhesion to neighbouring cells in an 
epithelium depends on loss of expression of the epithelial cell-cell adhesion 
molecule E-cadherin (Calcium-dependent adhesion). However the ability to 
burrow through tissues seems to depend on the production of proteolytic 
enzymes that are able to break down extracellular matrix. The frequently 
observed down-regulation and occasional mutational inactivation of E-cadherin 
in human carcinomas demonstrated its key role as a suppressor of this hallmark 
capability [21]. By E-cadherin bridges is possible the coupling between adjacent 
cells, that in turn results in the transmission of antigrowth and other signals via 
cytoplasmic contacts with β-catenin to intracellular signalling circuits, including 
the lymphoid enhancer-binding transcription factor [7]. 
Cancer cells have a complex relation to the extracellular and basal lamina. The 
cells must degrade the basal lamina to penetrate it and metastasize, however in 
some cases cells may migrate along the lamina. Many tumour cells secrete a 
protein plasminogen to the active protease plasmin. This increased plasmin 
activity promotes metastasis by digesting the basal lamina, consequently 
allowing its penetration by tumour cells [5, 22].  
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Matrix-degrading proteases are typically associated with the cell surface, by 
synthesis with a transmembrane domain, binding to specific protease receptors, 
or association with integrins [23, 24].  
Changes in integrin expression are also present in invasive and metastatic 
cells. Successful colonization of these new sites demand adaptation, which is 
achieved through shifts in the spectrum of integrin α or β subunits that are 
presented by the migrating cells [7]. 
The final steps in metastasis are probably the most difficult. Many tumours 
release large numbers of cells into the circulation, but fewer than 1 in 10000 
cells that escape the primary tumour survive to colonize another tissue and form 
metastatic tumour. More than escaping from the original tumour and enter the 
blood, tumour cells must adhere to an endothelial cell lining a capillary and then 
migrate across or through it into the underlying tissue [5, 22]. 
Additionally to important changes in cell-surface proteins, dramatic changes 
occur in the cytoskeleton during tumour cell formation and metastasis. These 
alterations can result from changes in the expression of genes encoding 
rhodopsin and other small hydrolyzed guanosine triphosphate enzymes that 
regulate the actin cytoskeleton. For instance, tumour cells have been found to 
over-express the rhodopsin gene, and this increased activity stimulates 
metastasis [5]. 
 
1.2.7. Emerging hallmarks of cancer 
New concepts for the formation and development of cancer have emerged. The 
chronic and often uncontrolled cell proliferation that represents the essence of 
neoplastic disease involves not only deregulated control of cell proliferation but 
also adjustments of energy metabolism in order to fuel cell growth and decision. 
Also, tumour formation involves the immune system that play a role in resisting 
or eradicating formation and progression of incipient neoplasias, late-stage 
tumours, and micrometastases [6]. 
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1.2.7.1. Reprogramming energy metabolism 
Normal cells, under aerobic conditions, process glucose, primary to pyruvate via 
glycolysis in the cytosol and subsequently to carbon dioxide in the mitochondria. 
Under anaerobic conditions, glycolysis is favoured and little pyruvate is 
dispatched to the oxygen-consuming mitochondria. Cancer cells, even in the 
presence of oxygen, can reprogram their glucose metabolism by limiting their 
energy metabolism to glycolysis, leading to a state that is called “aerobic 
glycolysis” [6]. 
This reprogramming of energy metabolism is apparently counterintuitive, given 
the fact that cancer cells must compensate the approximately 18-fold lower 
efficiency of adenosine triphosphate (ATP) production obtained by glycolysis in 
compared to mitochondrial oxidative phosphorylation. This is possible in part by 
up-regulating glucose transporters, particularly GLUT1 (Glucose transporter 1), 
which increases substantially glucose import into the cytoplasm [25, 26]. This 
markedly increased uptake and utilization of glucose, was documented in many 
human tumour types by noninvasively visualization glucose uptake using 
positron emission tomography (PET) with a radiolabelled analogue of glucose 
(18F-fluorodeoxyglucose, FDG) [6].  
The glycolytic fuelling has been shown to be connected with activated 
oncogenes such as RAS, or MYC, and mutant tumour suppressors such as 
TP53 [25, 26]. This dependence on glycolysis can be further accentuated under 
the hypoxic conditions that operate within many tumours. The hypoxia response 
system acts pleiotropically to up-regulate glucose transporters and multiple 
enzymes of the glycolytic pathway [25-27]. Therefore, both the RAS oncoprotein 
and hypoxia can independently increase the levels of the HIF1α/2α (Hypoxia-
Inducible factors 1-alpha/2-alpha) transcription factors, which in turn up-regulate 
glycolysis [28]. 
Curiously, some tumours have shown to contain two subpopulations of cancer 
cells that differ in their energy-generating pathways, but that function 
symbiotically. One subpopulation consists of glucose-dependent cells that 
secrete lactate, whereas cells of the second subpopulation preferentially import 
and utilize the lactate produced by their neighbours as their main energy 
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source, employing part of the citric acid cycle to do so [29]. Additionally, 
oxygenation ranging from normoxia to hypoxia, is not necessarily static in 
tumours but instead fluctuates temporally and regionally [30]. This situation may 
be a result of the instability and chaotic organization of the tumour 
neovasculature. 
 
1.2.7.2. Evading immune destruction 
The immune system plays a role in resisting or eradicating formation and 
progression of early neoplasias, late-stage tumours, and micrometastases. 
Therefore, according to this logic, solid tumours that appear have somehow 
managed to avoid detection by the immune system or have been able to limit 
the attack of the immunological defences, thereby evading eradication [6]. 
The role of defective immunological monitoring of tumours is validated by the 
striking increase of certain cancers in immunocompromised individuals [31]. 
However the great majority of these are virus-induced cancers, suggesting that 
much of the control of this class of cancers depends on the reduction of viral 
burden in infected individuals, partly through eliminating virus infected cells. 
These observations shed a little light on the possible role of the immune system 
in limiting formation of at least 80% of tumours of nonviral aetiology.  
In recent years, studies using genetically engineered mice and the clinical 
epidemiology, suggested that the immune system operates as a significant 
barrier to tumour formation and progression, at least in some forms of non-
virus-induced cancer. As an example, when mice genetically engineered to be 
immunocompromised were assessed for the development of carcinogen-
induced tumours, it was observed that tumours arose more frequently and/or 
grew more rapidly in the immunodeficient mice relative to immunocompetent 
controls. In particular, deficiencies in the development or function of the cluster 
of differentiation 8 positive cytotoxic T lymphocytes, cluster of differentiation 4 
positive T helper 1 cells, or natural killer cells each led to demonstrable 
increases in tumour incidence. Moreover, mice with combined 
immunodeficiencies in both T cells and natural killer cells were even more 
susceptible to cancer development. The result indicate that, at least in certain 
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experimental models, both the innate and adaptative cellular arms of the 
immune system are able to contribute significantly to immune surveillance and 
thus tumour eradication [32, 33]. 
 
1.3. Tumour grading and staging  
The most widely used staging system is called the TNM system. It is based on 
the size and/or extent of the primary tumour (T), the extent of spread to lymph 
nodes (N), and presence of metastases (M) [3, 4]. The TNM system is currently 
used worldwide, enabling clinical scientists from various institutions to 
standardize the staging of tumours and compare the therapeutic results. The 
TNM system is resumed in the table 1 [4, 34]. 
 
Table 1.The TNM system (McKinnell R.G. et al., 2006; AJCC, 2010). 
Primary tumour (T) 
TX Primary tumour cannot be evaluated. 
T0 No evidence of primary tumour. 
Tis Carcinoma in situ. 
T1-T4 Size and/or extent of the primary tumour. 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be evaluated. 
N0 No regional lymph node involvement. 
N1-N3 Degree of regional lymph node involvement. 
Distant metastasis (M) 
MX Distant metastasis cannot be evaluated. 
M0 No distant metastasis. 
M1 Distant metastasis present. 
Legend: The TNM system is organized in three categories, namely the size and/or extent of the 
primary tumour (T), the extent of spread to lymph nodes (N), and presence of metastases (M). 
For each of these categories, subdivisions can be made according with the extent, for example, 
the size of the tumour, the grade of invasion to lymph nodes and metastases. Therefore, for Tx, 
Nx or Mx, the primary tumour, regional lymph nodes or metastasis cannot be evaluated. For T0, 
N0 or M0, there is no evidence of tumour, regional lymph node involvement or metastasis. From 
the moment in which is assigned a number, in a growing sequence (1, 2, 3...), to T, N or M, the 
size of the tumour, the involvement of lymph nodes and the presence of metastasis increases 
to, and the prognosis deteriorates. 
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The patient’s prognosis deteriorates progressively if the tumour has invaded the 
stroma of an organ but has not penetrated it. It is worse if the wall is penetrated 
and even worse if its spreads to lymph nodes. It is dismal if there are distant 
metastases [4]. For many cancers, TNM combinations correspond to one of five 
stages resumed in table 2 [34].  
 
Table 2.Stages of cancer (AJCC, 2010). 
Stage Definition 
Stage 0 Carcinoma in situ (early cancer that is present only in the layer of 
cells in which it began). 
Stage I, II and III Higher numbers indicate more extensive disease: greater tumour 
size, and/or spread of the cancer to nearby lymph nodes and/or 
organs adjacent to the primary tumour. 
Stage IV The cancer has spread to distant tissues or organs. 
Legend: The combinations from the TNM system can result in five stages of cancer, starting 
from stage 0, representing the most benign stage, where the tumour is still in situ, and then 
progressing to stages I, II and III. In these last stages the tumour starts to invade the lymph 
nodes and adjacent organs. The last stage, and the worst, is the stage IV, where the cancer has 
spread to distant organs and tissues. 
 
Tumour grading is based on histological examination of tumours and is a semi-
quantitative assessment of the malignancy of each tumour. In this process, the 
pathologist will assess the individual cells and the architectural organization of 
the tumour tissue. In most instances, the tumours can be graded on scale from 
1 to 4, and are designated as well differentiated (grade 1), moderately well 
differentiated (grade 2), poorly differentiated (grade 3), or undifferentiated 
(grade 4) [3, 4]. 
In clinical practice, the tumour grading and tumour staging data are combined 
before additional therapy is recommended. The stage of the tumour at the time 
of diagnosis is also the most important prognostic parameter for most human 
tumours, and it can generally predict whether a tumour can be cured or not [3, 
4]. 
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1.4. Classification and nomenclature 
The cells of the benign tumours and many malignant ones retain some 
microscopic features of the tissue of their origin. Therefore, the tumours are 
classified according to the tissue and cell type from which they arise, and then a 
suffix is add to denote whether the tumour is benign or malignant. Some 
examples of benign and malignant tumours and its nomenclature is represented 
in table 3 [3, 22].  
 
Table 3.Classification and nomenclature of some benign and malignant tumours 
(Damjanov I., 2000; McKinnell R.G. et al., 2006; Alberts D. et al., 2008). 
Tumour Suffix Examples Tissue and/or Origin 
Benign Oma Fibroma  
Lipomas  
Chondromas  
Neuromas  
Osteoma   
Adenomas  
Fibrous connective 
Fat 
Cartilage 
Nervous 
Bone 
Epithelial 
Malignant Carcinoma 
 
Sarcoma 
 
Blastoma 
Carcinoma of the lung 
Adenocarcinoma of breast 
Osteosarcoma 
Chondrosarcoma 
Neuroblastoma 
Nephroblastomas  
Epithelial 
 
Mesenchymal tissues 
 
Embryonic cells 
Legend: The tumours can be classified as benign or malignant. In order to distinguish them is 
attributed a suffix, the “oma” for benign tumours, and the suffix “carcinoma”, “sarcoma” or 
“blastoma” for malignant tumours, depending on the tissue of origin. If the malignant tumour has 
its origin in epithelial cells is attributed the suffix “carcinoma”, if had its origin in mesenchymal 
cells is attributed the suffix “sarcoma”, and finally if has its origin from embryonic cells is 
attributed the suffix “blastoma”. 
 
Some malignant tumours cannot be classified as carcinomas, sarcomas, or 
blastomas. Most important among these are brain tumours which originate from 
glia cells and are thus called gliomas. Due to their location inside the brain 
these tumours cannot be completely removed and thus all gliomas are 
considered clinically malignant [4, 22]. 
Some tumours of the same name can be either benign or malignant. For 
example, islet cell tumours of the pancreas can be either benign or malignant. 
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Because the distinction cannot made clearly on histological examination, the 
noncommittal term islet cell tumour is used for most of these tumours. However, 
if such a tumour is accompanied by metastases, it is clearly malignant and so is 
designated a malignant islet cell tumour. Malignant tumours originating from 
lymphocytes are called lymphomas. Although their name sounds deceptively 
benign, it is worth notice that there are no benign lymphomas, and all tumours 
in this category should be considered malignant. Likewise, germ cell tumours 
composed of cell resembling the seminal cells of the testis have a benign-
sounding name-seminoma, but all of them are malignant. Malignant melanoma, 
a common malignant tumour of pigmented cells of the skin (melanocytes) is 
colloquially known as “melanoma” [3, 4, 22]. 
Sometimes, some tumours have eponym names, that is, are known under the 
name of the physician who has described first. Ewing’s sarcoma is a poorly 
differentiated sarcoma of bones and soft tissue. Since the cell of origin of 
Ewing’s sarcoma has not been identified, there are no alternative names for this 
neoplasm. On the other hand, Wilm’s tumour is a widely used name for 
nephroblastoma, a childhood renal tumour. In some cases, these medical 
eponyms are a godsend. As an example, Kaposi’s sarcoma is easier to 
remembered and pronounced than the original proposed name, attributed by 
the famous nineteenth-century Viennese dermatologist who described and 
named it in Latin as “idiopathic pigmented hemorrhagic sarcoma” [3, 4]. 
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Section II. Literature Review 
Chapter 2.Diagnosis and Therapy of Cancer 
 
2.1. Introduction  
The main goals of cancer diagnosis and treatment is to cure or prolong 
considerably the life of patients and to ensure the best possible quality of life to 
cancer survivors [35]. 
Cancer is easier to treat and cure, and as a result mortality can be reduced, if it 
is diagnosed early. Therefore, a huge amount of effort was done to the 
development of ways to detect early signs of the disease. The most effective 
treatment programmes are those that are provided in a sustained and equitable 
way, linked to early detection and that adhere to evidence-based standards of 
care and a multidisciplinary approach [35, 36]. 
Cancer diagnosis methods include imaging, endoscopy, biopsy, blood tests and 
other samples, etc.  
Driven by the diversity of genomic alterations involved in malignancy, a variety 
of assays had been developed with the purpose of complete tumour profiling. 
New molecular diagnostics, integrated into existing histomorphological 
classifications in surgical pathology, provides added stratification for a more 
accurate cancer prognosis [37]. Personalized treatment approaches are being 
developed based on the cancer diagnostic biomarkers [38]. These molecular 
markers can be products of altered genes/DNA or abnormal pathways. Some of 
the techniques involved in this group are: Fluorescence in situ hybridization 
technique, that uses probes to confirm the presence or absence of specific DNA 
sequences on chromosomes; Polymerase Chain Reaction, that permits 
amplification and analysis of target DNA regions in tumour samples; DNA 
microarray analysis is equipped to measure the expression levels of large 
number of genes concurrently; Immunocytochemistry used to detect antigens or 
protein expression on a fixed tissue section by means of an antibody that is 
specific for the antigen/protein; Flow cytometry to examine and differentiate 
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cells based on certain physical and chemical properties; Electron microscopy, 
used when specific cellular or intracellular structures need to be examined [37].  
Histological diagnosis is still essential to establish the diagnosis of cancer. 
However, a well designed imaging strategy is important in the management of a 
patient with cancer. Imaging in oncology is used for screening, detection, 
diagnosis, treatment and to follow the response to treatment. Imaging 
techniques enable doctors to create detailed pictures of what is going on in our 
bodies non-invasively. Some of the imaging techniques that can be used for the 
diagnosis of cancer are the morphological imaging techniques X-rays, CT 
(Computed tomography) scans, MRI (Magnetic resonance imaging) scans and 
ultrasound, and the physiological imaging techniques SPECT (Single photon 
emission tomography) and PET scans [37, 39]. 
Once the diagnosis and degree of spread of the tumour have been established, 
a decision have to be made regarding the most effective cancer treatment in the 
given socioeconomic setting [35]. 
This requires a careful selection of one or more of the major treatment 
modalities, such as surgery, radiotherapy and systemic therapy. This selection 
should be based on evidence of the best existing treatment given the resources 
available. Given that each patient and each cancer is different, treatment must 
be individualized. Therefore, the choice of the exact treatment or combination of 
treatments will depend on the patient, the disease and the stage of the disease 
as well as other considerations such as performance status, and comorbid 
conditions [37].  
When tumour is localized and small in size, sometimes, surgery or radiotherapy 
alone is only likely to be highly successful. Surgery plays a vital role in the 
prevention, diagnosis, staging, cure and palliation. Many premalignant lesions 
are frequently surgically removed, preventing the progression to cancer. 
Surgery forms the basis of therapy for early cancer, being applied for local 
treatment of small tumours, to reduce the bulk of the disease, and for removal 
of metastatic tumours. Although late stage cancers are generally treated by 
chemotherapy, surgery could offer palliation in advanced cancers [37]. 
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Chemotherapy alone can be effective for a small number of cancers, such as 
haematological neoplasm’s (leukaemia and lymphomas) [35-37]. As mentioned 
before, chemotherapeutic agents are used as primary treatment for advanced 
disease, but also as neoadjuvant to surgery/radiation for localized disease or as 
adjuvant therapy (with surgery and/or radiation) [37]. 
Recent advances in genetics and molecular cellular biology has led to an 
increase in the understanding of the molecular events that either initiate or 
sustain cancer growth. Traditional chemotherapeutic agents do not distinguish 
normal and cancer cells. However these new biological agents target specific 
molecular pathology (pathways and aberrant genes) in cancer cells. Target 
therapeutics can be monoclonal antibodies or small molecules, that can be 
used alone or in combination with other chemotherapeutics, surgery or radiation 
therapy [37]. 
Radiation therapy is the administration of ionizing radiation to a cancer patient 
with the purpose of cure, to provide palliation or as an adjunct to surgical 
treatment. Radiation therapy uses high-energy radiation to reduce the size of 
tumours and kill cancer cells. X-rays, gamma rays, and charged particles are 
types of radiation used for cancer treatment. In radiotherapy, radiation may be 
delivered by a machine outside the body (external-beam radiation therapy), it 
may come from radioactive material placed in the body near cancer cells 
(brachytherapy), or it may come by systemic administration of radioactive 
substances, that travel in the blood to kill cancer cells (therapy with 
radionuclides) [37, 40]. 
Radiation therapy is often used in conjunction with surgery for eradication of 
small and limited cancers. Preoperatively, radiation therapy may be given to 
reduce the size of inoperable tumours or to destroy unrecognized peripheral 
projections of the tumour. In addition, radiation therapy may be given to reduce 
the size of a tumour so it can be removed by surgery and be less likely to 
return. Radiation therapy given during surgery is called intraoperative radiation 
therapy. Alternatively, radiation therapy can be given post operatively to 
eradicate residual. Radiation therapy is also used for palliation (to relieve 
symptoms and reduce suffering) in cases where there is no cure possible, for 
example in cancers of the central nervous system and pathological metastasis 
to the bones [37, 40].  
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Despite conventional or external beam radiotherapy play a vital role in treatment 
of cancers, it is not effective for treatment of metastasis outside the treatment 
area. In contrast, systemic administration of radiopharmaceuticals that are 
designed for site specific localization, or radionuclides that have a natural 
affinity for some tissues, provides the opportunity for treatment of widely 
disseminated disease. Ideally, therapeutic radiopharmaceuticals should locate 
with high specificity at cancerous foci, even when the location of the tumour in 
the body is unknown, while producing minimal or tolerable radiation damage to 
normal and healthy tissues [41]. 
Even though radionuclide therapy has been available for many years, few are 
the methods routinely used on a large scale. The exceptions are for example 
131I iodide for the therapy of thyroid cancer [42, 43], 32P-orthophosphate for 
therapy of polycythemia and thrombocythemia [44, 45], Bexxar (Iodine-131) and 
Zevalin (Yttrium-90) for therapy of lymphomas with anti-B-lymphocyte antigen 
antibodies [46, 47], 131I labelled MIBG (meta-iodobenzylguanidine) for the 
treatment of pheochromocytoma and neuroblastoma [48-50] and Lutelium-177 
labelled somatostatin analogues for treatment of neuroendocrine tumours [51-
53].  
Gene therapy is one of the new methods for cancer therapy, and is anchored on 
the premise that many cancers are due to genetic alterations that eventually 
lead to malignant changes in tissues. Gene therapy involves the transfer of 
genetic material into a cell that in turn alters the cellular phenotype transiently or 
permanently. Different vectors exist for gene delivery into cancerous cells. 
Viruses (such as retroviruses) serve as a perfect tool for gene transfer [37]. 
 
2.2. Nuclear Medicine Imaging and Therapy  
A unique capability of the nuclear medicine is the imaging of organ function and 
disease states, using specific radiotracers called radiopharmaceuticals. Unlike 
other imaging modalities such as CT, MRI and Ultrasonography (US), nuclear 
medicine procedures are capable of mapping physiological function and 
metabolic activity, giving more precise information about the organ function and 
dysfunction. These images of functional morphology of organs, obtained after 
 
 
24 
 
the distribution in vivo of a radiopharmaceutical plays an important role in the 
diagnosis of many common diseases (malfunction organs or certain type of 
cancers) in a non-invasive manner [54]. 
Nuclear medical imaging is based on the detection of emissions from a 
radionuclide, associated or not with a molecule, which has been infiltrated in the 
metabolism of the body. Imaging in nuclear medicine is done by scintigraphy 
(two-dimensional images), SPECT or by PET (three-dimensional images). Both 
in scintigraphy and SPECT are detected gamma ray with energies ranging 100 
to 200 keV, which are emitted by radionuclides during its radioactive decay. The 
sensitivity and resolution of currently used gamma-cameras has been optimized 
for these gamma-ray energies, that is a consequence of the properties of 99mTc 
as the dominating radiolabel for non-PET diagnostics [55]. 
PET is a nuclear imaging technique that uses radionuclides that decay by 
positron emission. The principal behind PET imaging is the simultaneous 
detection of two gamma ray photons of 511 keV that are emitted in opposite 
directions, that results of the annihilation of the positron with an electron. To 
minimize the distance between the emission and the annihilation sites of the 
positron, the energy of the emitted positrons should be as small as possible 
[56].  
In diagnostic applications, tiny concentrations of molecules are added to the 
biological system as a tracer, which are detectable due to the emissions from 
their radioactive labels. The concentration of the radiolabelled tracer added to 
the biological system is so small that in principle it will not alter the properties of 
the process under investigation. This presumes that the radiolabelling of a 
molecule does not alter its physiological and biochemical properties, and the 
radiotracer have to behave in the system exactly as the native non-labelled 
molecule. The difference between the labelled and non-labelled molecule is that  
the first will allow a mapping of the physiological function and metabolism of a 
tissue, allowing to draw conclusions on tissue function or dysfunction [41, 54, 
55]. 
The development and availability of a rapidly increasing number of specific 
radiopharmaceuticals (currently more than 100) [54] and the availability of 
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suitable radionuclides produced in research reactors [57] or with accelerators 
[58], lead to the widespread utilization and growing demand for these 
techniques. 
In spite of all recent and future developments, the challenge in 
radiopharmaceutical development and production will remain finding the proper 
combination of a carrier molecule with a radionuclide that meets all 
requirements [41, 59]. 
Targeted radionuclide therapy involves the use of radiopharmaceuticals to 
selectively deliver therapeutic doses of ionizing radiation to specific diseases 
sites. In therapeutic applications is administered high radiation activity with the 
intention of destroying the target tissue. It is known that for a specific tissue of 
an individual, the biological radiotherapeutic effect is greater the higher the 
absorbed dose. Also is known that the same dose absorbed by different tissues 
from the same individual or different individuals of corresponding tissues, can 
cause uneven effects, reflecting a difference in radiosensitivity. For an effective 
therapy, there must be a high relationship between radiation dose to target 
organ and surrounding healthy tissues, thus allowing to reduce the side effects 
that can come from therapy [1, 41, 59].  
Ionizing radiation is energy transmitted via x-rays, gamma rays, beta particles, 
alpha particles, neutrons, protons, and other heavy ions. The physical factors 
affecting cell response to a specific radiation include the linear energy transfer 
(LET), the relative biologic effect (RBE) and the oxygen enhancement radio 
(OER). LET describes a measure of the rate at which energy is deposited as a 
charged particle travel through matter, and it is also a function of the physical 
characteristics of radiation, that is, mass and charge, therefore particles with 
charge and mass have a higher LET. Radiations that cause dense ionization 
along their track are called high-linear-energy-transfer (high-LET) radiation (ex. 
α particles, neutrons). Low-LET radiations produce ionizations only sparsely 
along their track (ex. gamma and x-rays, electrons). The higher LET of a 
radiation, the greater the chance for a biologic interaction. Thus, high-LET 
radiations are more destructive to biological material than low-LET radiations, 
because at the same dose, considering that high-LET radiations transfer most 
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  eOHOH 22 
of their energy to a small region of the cell. The localized DNA damage caused 
by high-LET radiations is more difficult to repair than the diffuse DNA damage 
caused by the sparse ionizations from low-LET radiations [1, 60].  
The relative effect of LET is quantitatively described by RBE. The OER is a 
numerically description of the biological response to radiation in the presence of 
oxygen. There is a strong evidence that DNA is the principal target for the 
biologic effects of radiation, including cell killing, carcinogenesis, and mutation. 
Radiation-induced ionizations may act directly on the cellular component 
molecules or indirectly on water molecules, causing water-derived radicals. The 
atoms of the target itself may be ionized or excited, thus initiating the chain of 
events that leads to a biologic change. This is called direct action of radiation, 
which is the dominant process if radiations with high LET are considered. On 
the other hand, the radiation may interact with other atoms or molecules in the 
cell, particularly water that may become ionized, to produce free radicals that 
are able to diffuse far enough to reach and damage the critical targets, namely 
DNA. This is called indirect action of radiation, which is the dominant process if 
radiations with low LET are considered [1, 60]. A free radical is an atom or 
molecule carrying an unpaired orbital electron in the outer shell, which is a state 
of high degree of chemical reactivity. This may be expressed as: 
 
H2O
+ is an ion radical with an extremely short life-time (10-10 second). They 
decay or react with other molecules of water to form free radicals, which are not 
charged but still have an unpaired electron, namely hydroxyl radical (OH·) [1, 
60].  
The hydroxyl radical is a highly reactive free radical which can spread quickly 
over a short distance allowing to reach a critical target in the cell. The hydroxyl 
radicals can recombine with each other, and form hydrogen peroxide (H2O2), 
which together with OH• radical are responsible for about two-thirds of all 
radiation injuries following the water radiolysis [1, 60]. 
Considering the indirect effects of radiation in the cell which are related with the 
free radicals produced, they are able to increase the cell damage if molecular 
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oxygen is present, allowing its reaction with the DNA. The DNA damaged by 
this route, can be chemically restored by reacting with an SH group. However if 
HO2 (hydroperoxyl) is formed instead of hydroxyl radical, that is an organic 
peroxide, the lesions occurred in the target material are non-restorable. Thus, a 
change in the chemical composition of the material occurs, resulting in cell 
death [1, 60].  
The major effect in cells is DNA breaks, and since DNA is formed by two 
complementary double strands, breaks of either a single strand or both strands 
can occur. Most single-strand breaks can be repaired by the normally 
mechanisms of cell repair, due to the complementary nature of the two strands, 
being the intact strand a template for repair the damaged opposite strand. If 
double-strand breaks occur, the repair is not only more difficult but also an 
erroneous re-arranje of the broken ends may occur. These misrepairs result in 
induction of mutations, chromosomal aberrations, or cell death [1, 60].  
The development of molecular carriers and the availability of radionuclides with 
high purity and adequate specific activity can contribute to the successful 
application of radionuclide therapy [54]. 
 
2.2.1. Radionuclides for Imaging and Therapy 
Radioisotopes (or radionuclides) are contributing significantly to improving 
health care in most countries. Globally there is a growth in the number of 
medical procedures involving the use of radionuclides, and with this the growth 
in the number of procedures requiring different radionuclides, for example in 
diagnostic nuclear medicine and radionuclide therapy [54]. 
A radionuclide is an element with an unstable combination of protons and 
neutrons (nucleons). When trying to reach stability is emitted radiation 
(radioactive decay or radioactivity). It entails a change from an unstable 
combination of neutrons and protons in the nucleus to a stable or more stable 
combination. The type of decay determines whether the ratio of neutrons to 
protons will increase or decrease to reach a more stable configuration, and also 
determines the type of radiation emitted [61]. 
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Radionuclides used in nuclear medicine are primarily produced in a cyclotron or 
a reactor. The type of radionuclide produced in a cyclotron or a reactor depends 
on the irradiating particle, its energy, and the target nuclei. The use of 
radionuclides with short half-life has grown considerably, and this has led to the 
development of radionuclide generators [61].  
In radionuclide generators a relatively long-lived parent radionuclide decays into 
a daughter radionuclide with a shorter half-life. Due to the different chemical 
properties of parent and daughter nuclide, the daughter can be chemically 
separated [55, 59].  
A radionuclide generator consists of a glass column filled with an absorbent 
material such as aluminium oxide or an ion-exchange resin to which the parent 
nuclide is bound. The column is filled with a filter at the outlet to retain 
particulate matter. On top is the elution platform, where an evacuated sterile vial 
is connected with the outlet of the column though which saline or another 
suitable eluent is drawn from the eluent reservoir [55].  
Radionuclide generators serve as a convenient source of radionuclides with 
short half-life for medical application. The lifetime of a generator system 
depends on the half-life of the parent nuclide, therefore, the longer the half-life 
of the parent, the longer can the daughter radionuclide be eluted in adequate 
amounts. This condition is favourable for both transport and the use of 
radionuclides with short half-life in diagnostic nuclear medicine [62]. 
There are various radionuclides that emit gamma-rays and are used for 
scintigraphy and SPECT. Some of these radionuclides, and its characteristics 
are organized in table 4.  
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Table 4.Most frequently used radionuclides for scintigraphy and SPECT imaging and 
their most relevant physical properties (Cantone M. et al., 2011). 
Nuclide Half-life Preferentially imaged 
y-energy (keV) 
Yield 
(%) 
Decay 
mode 
Source 
67Ca 78.28 hours 93.3 
184.6 
300.2 
38.81 
21.41 
16.64 
EC Cyclotron 
81mKr 13.10 hours 190.5 64.9 IT Generator 
99mTc 6.015 hours 140.5 89.06 IT Generator 
111In 67.31 hours 171.3 
245.4 
90.7 
94.1 
EC Cyclotron 
123I 13.22 hours 159.0 83.3 EC Cyclotron 
131I 8.025 days 364.5 81.5 β- Reactor 
133Xe 5.243 days 81.0 38.0 β- Reactor 
201Tl 73.01 hours 167.4 10.0 EC Cyclotron 
Legend: Most frequent radionuclides for scintigraphy and SPECT imaging, and its physical 
characteristics, namely the physical half-life, the mode of radioactive decay (EC - Electron 
Capture; IT – Isomeric Transition; β
- 
- Beta negative), how it is produced, and the energy of the 
gamma rays used for imaging. 
 
Technetium-99m (99mTc) is the most widely used radioisotope in diagnostic 
nuclear medicine. It has been estimated that over 80% of the nearly 25 million 
diagnostic nuclear medicine studies carried out annually are done with this 
single isotope [54]. It can be easily eluted at the hospital from a 99Mo/99mTc 
generator, making it widely available [55].  
The convenience of having a radionuclide generator that can be used for one 
week promoted the development of 99mTc radiochemistry and cold kits (so 
called because they do not contain radioactivity). Cold kits are an efficient way 
to formulate 99mTc-labelled radiopharmaceuticals from sodium pertechnetate 
(Na99mTcO4) solution eluted from a 
99mTc-generator [54]. 
The evolution of Positron Emission Tomography (PET) as a clinically useful 
imaging modality has its origin in the synthesis of the positron emitting 
radioisotope fluorine-18 radiolabelling fluorodeoxyglucose (18F-FDG) in 1976 at 
the Brookhaven National Laboratory, with the intention of applying 18F-FDG for 
mapping glucose metabolism in the brain, to understand and monitor 
neurological diseases. While it is also useful for studying myocardial viability, 
due to the greater utilization of glucose by the proliferating cells, the major use 
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of 18F-FDG subsequently emerged in the detection, staging and treatment follow 
up of various types of cancers [54, 55].  
Currently PET studies using 18F-FDG account for 10% of all nuclear medicine 
imaging. A number of other fluorine-18 labelled radiopharmaceuticals are being 
developed and a few of them are under clinical investigation [54].  
Also fluorine-18 is the radionuclide most used in PET, other radionuclides are 
being used. Some of these radionuclides and its characteristics are organized in 
table 5.   
 
Table 5.Most important PET radionuclides (Cantone M. et al., 2011). 
Nuclide Half-life Average β+-
energy (MeV) 
Mean range in tissue 
(mm) 
β+-yield (%) 
11C 20.385 min 0.386 0.3 99.75 
13N 9.965 min 0.492 1.4 99.80 
15O 2.037 min 0.735 1.5 99.90 
18F 109.77 min 0.250 0.2 96.73 
62Cu 9.673 min 1.314 2.3 97.43 
64Cu 12.701 h 0.278 0.2 17.60 
68Ga 67.71 min 0.830 1.9 89.14 
82Rb 76.38 s 1.479 2.6 95.43 
86Y 14.74 h 0.660 0.7 31.90 
89Zr 78.41 h 0.396 0.3 22.74 
124I 4.176 days 0.820 0.8 22.70 
Legend: Most important PET radionuclides, and its physical characteristics, namely the 
physical half-life, and the energy and range (mm) in tissues of β
+
 particles. 
 
The primary role of radiopharmaceuticals in cancer treatment will be towards 
the follow-up of patients with a known disease. Radiopharmaceuticals can 
provide useful information about the function and molecular biology of the 
tumour by measuring several of the causal factors of the tumour [54]. 
When planning radionuclide therapy, key factors should be considered for the 
selection of an effective radionuclide are: (i) the half-life; (ii) the radiation 
characteristics; (iii) the ability to produce the radionuclide with high specific 
activity (e.g. high amount of radioactivity per unit mass) and (iv) the radionuclide 
purity [63, 64]. 
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The physical half-life of the chosen radionuclide for therapeutic applications, 
should be ideally about two or three times longer than the time required for 
achieving maximum uptake of the radiopharmaceutical in the target tissue [55].  
An excessively long physical half-life increases the amount of radiation that is 
delivered to tumour cells to achieve therapeutic level before excretion, but also 
can create problems related with environmental safety in case of spill or early 
death of the patient [59, 65].  
On the other hand, an extremely short physical half-life may not allow enough 
time for the tumour-targeting process to take place, resulting that the majority of 
the radioactive decays occurs in the vicinity of or even in the health tissues [59, 
65]. 
Incorporated radionuclides are also characterized by their biological half-life, 
which is given by the time required to excrete half of the substance from the 
organism. The biological half-life depends also from the chemical form in which 
the radionuclide is present and that affects the metabolic pathways of excretion. 
The combined effect is described by the effective half-life, defined as in the 
equation 1 [55]: 
      
            
           
 
Equation 1.Equation for calculating the effective half-life, being T½e the effective half-
life, T½b the biological half-life and T½f the physical half-life (Cantone M. et al., 2011). 
 
If the travelling time of the carrier molecules in the body is too long, and the 
physical half-life of the radionuclide is short, the molecules will reach their 
targets after the radionuclide has already decayed. As a consequence, this will 
cause an unspecific, unacceptable radiation dose to healthy tissues. If the same 
carrier molecule is labelled with a radionuclide with a longer half-life, practically 
all carriers would deliver their radioactive charge to the target cells, but the dose 
rate might be too low for achieving a therapeutic effect [55, 61]. Therefore, the 
physical half-life of the radionuclides should preferably be of the same order of 
 
 
32 
 
magnitude as the biological half-life of the radionuclide or the radionuclide 
conjugate [59]. 
The characteristics of the radiation emitted during radionuclide decay are also 
an important point to be considered. If the radionuclide during its decay emits 
gamma photons with an appropriate energy to perform images, it could be 
useful to monitor the distribution of the radiopharmaceutical in the patient for 
assessing dosimetry [41].  
Radionuclides must be available with high purity, high activity concentration, 
and high specific activity (i.e. Ci/µg or GBq/µg). Radiolabelled compounds 
should be prepared as high specific activity drugs since they target low-capacity 
systems [41, 66]. For example, the therapeutic efficacy of a radiolabelled ligand 
may be compromised by molecules with improper labels that will competitively 
bind to the receptor site and may obscure the binding of the radiolabelled 
ligand, since the capacity to targeted receptors on malignant cells may be as 
low as a few nanomoles. Thus, specific activities ≥ 70-200 GBq/µg are required 
[41]. 
To meet the requirements, a radionuclide to use for therapy, should have some 
physical properties: 
– The radionuclide should emit alpha (α) or beta negative (β-) particles, Auger 
and/or conversion electrons in sufficient abundance to induce tumour cell 
death; 
– High abundance of high-energy gamma rays is undesirable since it gives 
whole-body irradiation; however, low abundance photons of 100 to 200 keV 
might be of advantage for imaging and therapy monitoring using a gamma-
camera; 
– A physical half-life of 1 to 14 days, depending on in vivo pharmacokinetics of 
the targeting agent, seems to be optimal to ensure the therapeutic effect; 
– To produce the radionuclide with a high specific radioactivity; 
– To produce the radionuclide in a cost-effective way, allowing it to be more 
available; 
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– High-yield labelling of proteins and peptides and provide a conjugate which 
is stable in the blood circulation, enabled by the chemical properties of the 
radionuclide; 
– To avoid the accumulation of radiocatabolites in normal organs or tissues 
they should be quickly excreted from the body [59, 67]. 
 
Radionuclides that decay by β--particle emission, α-particle emission, and 
Auger-electron are effective for delivering localized cytotoxic doses of ionizing 
radiation [41, 66]. Each type of these particles has different effective range, LET 
and RBE. The type of particle emission that is applicable will depend on the size 
of the tumour, intra-tumour distribution (i.e., degree of heterogeneity of 
radiotracer deposition), pharmacokinetics of the tracer, etc. Gamma-ray 
emission may be or may be not accompany the particle emission process and 
little will contribute to the therapeutic effectiveness, however will augment 
irradiation to non-target tissues. On the other hand, in cases where the gamma-
ray energy is in diagnostically useful range, is feasible to perform radionuclide 
imaging of tracer biodistribution.  
As referred before, the biological effect of radiation is directly related to the LET, 
which is the average energy deposited by a particle per unit track length 
(keV/µm). High-LET radiation like α-particle radiation (25-230 keV/µm) [59] can 
destroy cells even by single hits, whereas low β-radiation (LET ~1 keV/µm) is 
much less efficient. Auger emitters may reach the LET values of α-particles but 
confined in a range of about 10 nm, which explains why they should be targeted 
directly to DNA [59, 68]. 
The beta negative particles are high energy electrons emitted from the nucleus 
as a spectrum or continuum of energies (and ranges) up to a maximum value. 
The range of these high-energy electrons is much greater than α particles, and 
the low ionization density along their tracks accounts for their low LET [41, 66]. 
Radionuclides that decay by β--particle emission are used most extensively for 
radiotherapeutic applications in current clinical practice. Utilization of β--particle 
emitters provides a mechanism to produce a highly homogeneous radiation 
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dose even though their deposition is heterogeneously distributed in target 
tissues, considering their range. Therefore, these radionuclides are useful for 
treatment of bulky tumours and therefore, the long range can compensate the 
poor penetration of the targeting molecule into a tumour mass and overcome a 
possible heterogeneity of target expression. On the other hand, high energy 
beta negative particles are inefficient for destroying single cancer cells or small 
micrometastases, because most of the energy associated with the radionuclide 
decay is deposited outside the malignant cell [41, 59]. This means that 
considerable cross-fire will occur with possible sterilization of untargeted 
neoplastic cells from radioisotopes deposited on neighbouring tumour cells. 
Table 6 provides a list of β--particle emitting radionuclides with therapeutic 
potential [67, 69].  
 
                                            
1
 The Table 6 is a modified version of the Table 3 of the following publication: Ferreira S, Dormehl I, Botelho MF: 
Radiopharmaceuticals for bone metastasis therapy and beyond: a voyage from the past to the present and a look to the 
future. Cancer biotherapy & radiopharmaceuticals 2012, 27(9):535-551. 
Table 6.Physical properties of some β--emitting radionuclides considered for 
radionuclide therapy (Ferreira S. et al., 2012; Palmedo H., 2007). 
Nuclide Half-life 
(days) 
Average β 
energy (MeV) 
Average 
range (mm) 
Photon radiation (keV) 
High-energy beta-particles 
188Re 0.7 0.744 3.5 155 (15%) 
166Ho 1.1 0.666 3.2 80.5 (6.7%) 
90Y 2.7 0.935 3.9 _ 
76As 1.1 1.0 5.0 559 (45%); 657 (6.2%) 
89Sr 52 1.4 6.6 _ 
32P 1.4 1.7 8.1 _ 
Medium-energy beta-particles 
77As 1.6 0.228 1.2 _ 
153Sm 1.9 0.229 1.2 103 (30%) 
186Re 3.7 0.362 1.8 137 (9.4%) 
Low-energy beta-particles 
67Cu 2.6 0.141 0.71 91 (7%); 93 (16%); 185 (49%) 
131I 8.0 0.181 0.91 364 (82%) 
161Tb 6.9 0.154 0.77 75 (10%) 
177Lu 6.7 0.133 0.67 113 (6%); 208 (11%) 
Legend: Some radionuclides considered for β
-
 therapy, arranged according to the energy of β
- 
particles as high-energy (0.666 to 1.7 MeV), medium-energy (0.228 to 0.362 MeV) and low-
energy (0.133 to 0.181 MeV).
1
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Alpha particles are high-energy helium nuclei that produce high densities of 
ionization along their linear tracks and therefore are classified as high LET 
radiation. The alpha particles deposit their energy over short ranges (i.e. usually 
between 40 µm to 100 µm) [41, 66].  
Because of their relatively short range and high LET, alpha particles have the 
capability for producing a high degree of tumoricidal activity while normal 
surrounding tissues are spared [41, 66].  
The high LET of alpha particles limits the ability of cells to repair damage to 
DNA and is effective in killing cells in hypoxic conditions. The high RBE of this 
type of radiation results in inactivation of cells with few alpha particles in 
contrast to gamma radiation or beta particles. On the other hand, a 
disadvantage of alpha emitters is that they require binding of the carrier to most 
cancer cells in a tumour or to their near neighbours for irradiation of all cells [41, 
66]. In contrast to β--particle emitters, α-particle emitters are more compatible 
for use in treatment of tumours with small diameters (like metastasis) and where 
their localization within the tumour is more spatially homogeneous. Although 
more than 100 radionuclides exist which decay by the emission of alpha 
particles, the vast majority have half-lives that are too long to be compatible with 
in vivo applications, and are difficult to produce in large quantities with 
acceptable radionuclidic purity [41]. Table 7 provides a list of α-particle emitting 
radionuclides with therapeutic potential.  
 
Table 7.Some α-particle emitting radionuclides for radionuclide therapy (Cantone M. et 
al., 2011; Stigbrand T., 2008). 
 Nuclide Half-life Average α 
energy (MeV) 
Average range 
(µm) 
Photon radiation (keV) 
213Bi 45.6 min 8.320 85 440.5 (25.9%) 
212Bi 60.6 min 7.738 82 None 
211At 7.2 hours 6.746 65 None 
149Tb 4.1 hours 3.967 28 165 (26.4%) 
226Th 30.6 min 6.917 70 None 
225Ac 10.0 days 6.867 69 218.1 (11.4%); 440 (25.9%) 
224Ra 87.8 hours 6.566 64 241 (4.1%); 238.6 (43.6%) 
223Ra 11.4 days 5.668 53 269.5 (13.9%); 351 (12.9%) 
Legend: Some radionuclides considered for α therapy, and its physical characteristics, namely the 
physical half-life, the energy and range of α particles. Also is indicated if the radionuclides 
represented in the table are as well emitters of gamma radiation or not.  
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Low-energy Auger electrons, which are emitted during electron capture or 
isomeric transition decay, are also considered suitable particles for inactivation 
of single spread malignant cells. These particles, due to their high yield per 
decay, are extremely radiotoxic if they hit DNA, considering the high probability 
to induce a severe double-strand break, and, hence, inactivate the cell [70]. 
This is the result of the deposition of a concentrated amount of energy, emitted 
in the form of a shower of Auger electrons with energies ranging from a few to 
several hundred electron volts, into an extremely small volume within the 
nuclear DNA [41, 66].  
This type of radiation exposure produces decreasing survival curves with no 
shoulder at low doses and is relatively independent of oxygen effects. Since 
these auger electron emitter’s radionuclides are less cytotoxic if they are 
present in the cytoplasm or on the surface of target cells, they must be 
incorporated into the nucleus of cells [41, 66].  
In vivo and in vitro studies demonstrated that the toxicity of Auger electron 
emitters approximates that for low LET radiation when the emitter is localized in 
the cytoplasm and, on the other hand when Auger-electron emitter is covalently 
bound to DNA in the cellular nucleus, they approximates that for high LET 
radiation. Therefore, in order to complete eradication of cancer cells in a 
tumour, the Auger-emitting radiopharmaceuticals must be capable of localizing 
in all of the targeted cells [41]. 
While efforts are being made in designing therapeutic radiopharmaceuticals 
with several promising Auger-electron emitters, the design of effective Auger-
emitting targeting agents for in vivo targeting and treatment of cancers remains 
a challenge [41]. 
Table 8 provides a list of Auger and conversion electron emitters with 
therapeutic potential. 
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2.2.2. Physical and chemical characteristics of Technetium-99m 
Technetium-99m (99mTc) is the most commonly used isotope for nuclear 
imaging due to favourable physical properties for scintigraphy and its versatile 
chemistry that allows the incorporation of the label into a manifold of ligands. 
Technetium-99m decays with a half-life of 6.02 hours by isomeric transition and 
emission of gamma-rays of 140 keV, which is ideal for gamma-camera 
detection. The short half-life and the energy of the gamma-rays allow the use of 
significantly higher doses compared to other radioisotopes, resulting in higher 
count rates, contributing for the increase in the temporal resolution for dynamic 
studies. On the other hand, the lifetime is long enough to allow for target-
specific applications. Large amounts of radioactivity may be used with the 
SPECT technology, producing high-contrast images with the gamma-camera 
[71]. Technetium-99m is generator-produced from molybdenum-99 (99Mo), 
Table 8.Compilation of Auger and conversion electron emitters in use or in 
discussion for radionuclide therapy (Cantone M. et al., 2011; Stigbrand T., 2008). 
Nuclide Half-life Average e- properties Decay Mode 
Energy (keV) e-/decay 
51Cr 20.70 days 3.97 4.68 EC 
67Ga 78.28 hours 7.07 7.03 EC 
77Br 57.04 hours 4.13 4.96 EC, β+ 
94Tc 4.88 hours 5.17 6.42 EC 
99mTc 6.01 hours 0.96 4.67 IT 
111In 2.82 days 6.51 6.05 EC 
114In 49.51 days 4.15 7.74 EC 
115mIn 4.49 hours 2.85 5.04 IT, β- 
123I 13.20 hours 7.33 12.60 EC 
124I 4.18 days 4.87 8.60 EC, β+ 
125I 59.40 days 11.90 21.00 EC 
167Tm 9.25 days 13.60 11.40 EC 
193mPt 4.33 days 10.90 20.30 IT 
195mPt 4.01 days 21.80 31.5 IT 
201Tl 73.01 hours 15.27 36.9 EC 
203Pb 51.92 hours 11.63 23.3 EC 
Legend: Some radionuclides considered for auger and conversion electron therapy, and its 
physical characteristics, namely the physical half-life, the energy of auger and conversion 
electrons, and the type of radioactive decay (EC - Electron Capture; IT - Isomeric 
Transition). 
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which allows the general availability of the tracer. Molybdenum-99, with a half-
life of 66.02 hours, decays by several β-particle transitions producing 
metastable 99mTc with 87.5% intensity, while 12.5% decay directly to long-lived 
technetium-99 (99Tc). Subsequently, metastable 99mTc decays by isomeric 
transition to 99Tc. 99Tc decays with a half-life of 212000 years to stable 
ruthenium-99 (99Ru). The process of radioactive decay of 99Mo is represented in 
fig. 2 [72].  
 
 
 
The parent radionuclide 99Mo can be prepared in abundant quantities by the 
fission of uranium-235 in a nuclear reactor with a fission yield of about 6%. 
There are only a limited number of industrial companies producing 99Mo from 
fission products, but collectively they have adequate capacity to meet the 
world’s demand for 99Mo [54]. 
99Mo/99mTc generators produced for worldwide application have a sophisticated 
system for safe elution of the daughter radionuclide. The generator column is 
well shielded with lead, and the whole system must be adequately shielded to 
reduce radiation exposure of the operator to a permissible level [55]. 
Parent 99Mo and the daughter with shorter half-life, 99mTc, reach the transient 
equilibrium, characterized by the decay of both parent and daughter 
radionuclides with one apparent half-life, namely that of the 99Mo. Transient 
equilibrium is established when the half-life of parent is long with respect to 
daughter radionuclide, but parent activity changes perceptibly during the period 
Figure 2.Decay scheme of parent 99Mo to stable 99Ru (Cantone M. et al., 2011). 
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under consideration. Build-up of daughter 99mTc activity occurs until a maximum 
is reached, and then the “effective” half-life of the daughter activity will be 
essentially equal to the parent half-life, as long as parent activity continues to 
produce the daughter radionuclide. The ratio of daughter activity to parent 
activity is unchanging with respect to time, but the activity of each is declining 
with respect to time [55, 72]. 
Several methods have been used to separate the daughter nuclide 99mTc from 
parent 99Mo, the three most common methods are column chromatography, 
solvent extraction, and sublimation [72, 73]. The 99Mo/99mTc generator used in 
nuclear medicine is based on the chromatographic separation of 99mTc-
pertechnetate, where 99Mo is bound strongly to a bed of chromatographic-grade 
alumina. The daughter radionuclide 99mTc is eluted with sodium chloride from 
aluminium oxide (Al2O3) column, being obtained sodium pertechnetate 
(Na99mTcO4). A general representation of the components that constitutes a 
99Mo/99mTc generator is represented in fig. 3 [55]. 
 
 
 
Technetium-99m chemistry is primarily the chemistry of anionic pertechnetate 
(99mTcO4
-), obtained from the 99Mo/99mTc generator with high specific activity. 
Anionic pertechnetate is no-carrier-added because 99mTc activity is present in 
the radiopharmaceutical kit at 10-8 to 10-9 M [74].  
Figure 3.Components of the 99Mo/99mTc generator system (Cantone M. et al., 2011). 
 
 
40 
 
The element technetium belongs to the second-row elements of the group VIIB 
of the periodic table, between manganese and rhenium. The atomic radius of 
technetium is similar to rhenium, and thus, many similarities are found in the 
chemistry between these two elements. Technetium can exist in eight oxidation 
states, varying from (VII) to (-I). The most stable states are (VII), (V), (IV), (III), 
(I) and 0. The most difficult states to stabilize are (VI), (II) and (-I) [75]. 
The highest oxidation state (VII) is occupied by the pertechnetate anion (TcO4
-). 
The representation of the chemical structure of the pertechnetate anion is 
represented in fig. 4 [74].  
 
 
 
The chemical reactivity of the pertechnetate anion is negligible, therefore it does 
not bind directly to any ligand. Consequently, for the production of 99mTc 
pharmaceuticals, reduction to a lower oxidation state in the presence of a 
suitable ligand is a prerequisite for the synthesis of 99mTc-labelled molecules. 
During reduction, the ligand stabilizes the lower oxidation state, otherwise, 
colloidal TcO2 is formed in aqueous media [74]. 
The so-called coordination complexes of technetium (central metal) are formed 
by means of bonds between technetium acting as Lewis acid, and atoms or 
functional groups, acting as Lewis bases (donate electron pairs). Typical ligands 
for technetium complex formation may have one donor group (monodendate) 
such as amine, amide, thiol, phosphine, oxime, or isonitrile. With two donor 
groups, the complex is bidentate, where more than two groups form a single 
molecule bind to one Tc core, being designated chelate [74]. 
 
2.2.3. Physical and chemical characteristics of Rehnium-188 
Rhenium-188 (188Re) is a β- particle emitter, and is an excellent candidate for 
radionuclide therapy [76, 77]. This radionuclide is easily obtained carrier free as 
Figure 4.Pertechnetate anion (Mazzi U., 2007). 
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perrhenate ion (ReO4
-) in normal saline solution [78] or perrhenic acid (HReO4) 
in aqueous HCl or HNO3 [79] from a rugged and economical alumina based 
tungsten-188/rhenium-188 (188W/188Re) generator system. The alumina-based 
188W/188Re generator is completely analogous to the 99Mo/99mTc generator, 
nevertheless, the 188W/188Re generator system has a greater shelf life, since 
188W has a much longer physical half-life (69 days) than 99Mo (66 hours) [61, 
79, 80]. 188Re decays by emitting high energy β- particles (2.1 MeV) with a 
maximum penetration in tissue of 10–11mm making this radionuclide a suitable 
option for therapy of large tumour masses, as discussed before [66, 81]. Its 
gamma ray emission (0.155 MeV) can be exploited for dosimetry purposes and 
to monitor biological distribution during therapy [61, 66, 76, 82, 83]. It also has a 
relatively short physical half-life of 16.9 hours, which allows the use of high 
doses and reduces the problem of radioactive waste handling and storage [82, 
84].  
The element rhenium belongs to the third-row elements of the group VIIB of the 
periodic table. Rhenium can exist also in eight oxidation states, varying from 
(VII) to (-I). The highest oxidation state (VII) is occupied by a perrhenate anion 
(ReO4
-) [75]. 
An important factor that adds value to 188Re-labelled drugs is the fact that 99mTc 
is a chemical congener of Re, making the chemistry of both 99mTc and 188Re the 
same or nearly identical in many cases. Therefore, when the chemistries of 
these radionuclides are similar, the 99mTc agents can be used as the “matched 
pair” for the corresponding 188Re agent, making it feasible to obtain excellent 
diagnostic imaging in patients allowing for pre- and post-assessment of patients 
treated with therapeutic 188Re analogues. Strategies for synthesizing 188Re-
labelled site-specific radiopharmaceuticals are based on, and parallel to, efforts 
being made to develop new 99mTc drugs [41].  
 
2.2.4. Cold kits formulation for radionuclide labelling  
Radiopharmaceuticals are medical formulations containing radioisotopes which 
are safe for administration in humans for diagnosis or for therapy. Currently are 
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over 100 radiopharmaceuticals developed using either reactor or cyclotron 
produced radioisotopes [54]. 
The particularity of radiopharmaceuticals consist of their capability to retrieve 
information on a molecular level and to address systems with very low densities 
of receptor molecules in vivo and in a non-invasive way [41, 55]. 
The preparation of 99mTc pharmaceuticals is greatly facilitated by the availability 
of commercial cold kits containing the chemical ingredients as a lyophilized 
formulation ready for labelling with 99mTc-pertechnetate. The preparation of any 
99mTc pharmaceutical is performed by using a commercial cold kit and adding 
the required 99mTc activity in a certain volume of sodium pertechnetate. The 
labelled product is a sterile, pyrogen-free solution suitable for intravenous 
injection. Any abnormality observed by visual inspection of the injected solution 
is a cause to reject the preparation [71].  
Cold kits are prepared in such way as to have a long shelf life, ranging from 
several months to a few years, and may be transported at room temperature 
and then stored under refrigeration to ensure stability [54]. 
A kit contains the active ingredient (compound to be labelled with the 
radionuclide), a reducing agent, and may contain authorized excipients and 
additives, such as antimicrobial agents, antioxidants, buffer, a nitrogen 
atmosphere, etc. The reducing agent is responsible for the reduction of the 
radionuclide to a lower valency state. It’s considered an essential material, 
because without reduction, there is no labelling reaction, considering that, for 
example pertechnetate anion that is in the oxidation state (VII) is not chemically 
reactive and therefore it must be reduced. The shelf-life of lyophilised kits is 
usually in excess of 1 year. Freeze-drying, or lyophilisation, is the drying of 
frozen materials by sublimation, this is the direct transition from the frozen state 
into vapour, without any intermediate liquid phase [71, 85]. 
The lyophilisation method is similar to ordinary vacuum distillation with one 
essential difference, that is the material to be dried is first frozen and then 
subjected to a very low absolute pressure (high vacuum) and controlled heat 
input. The heat drives the water from the solid to the vapour state. Under these 
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conditions, the water content, in the form of an ice matrix, is selectively removed 
via sublimation [85].  
The same amount of heat that is required in the drying chamber for the 
sublimation of the water is subsequently liberated as the water vapour 
condenses at the ice condenser, and must be removed by means of 
refrigeration units. Therefore, three basic conditions have to be fulfilled in order 
to carry out the freeze-drying process: (i) the temperature of the material must 
be regulated so that thawing is avoided and vapour pressure above the material 
does not sink due to overcooling; (ii) the water vapour molecules escaping from 
the frozen material should be removed in such manner that saturation of vapour 
pressure above the substance to be dried is avoided; (iii) the process should 
take place in a vacuum so that removal of water molecules may not be impeded 
by the presence of residual gases [85]. 
In practice, the freeze-drying process should take place taking into account the 
following steps: 
1. The solution is dispensed into the vial from 0.5 to 2.5 cm height for an 
efficient drying. The vials are loosely capped with rubber stoppers, and then 
are put into the vacuum chamber. 
2. The vials with the product are gradually frozen below the eutectic point of 
the solution (typically to -40 °C). 
3. The condenser is turned on and observed until it reaches its maximum value 
(typically -50 °C). 
4. The vacuum pump is turned on until the lowest value of vacuum is obtained 
(typically 10 to 20 mHg). 
5. Heat is then applied to the product through a controlled heating-cooling 
system, to facilitate the sublimation process.  
6. A secondary drying cycle is usually applied so ensure the complete absence 
of humidity from the product. 
7. After completion of the drying cycles, the product is closed with a rubber 
stopper in the vacuum chamber under a nitrogen atmosphere [85]. 
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The 99mTc or 188Re eluate used for radiolabelling must comply with the 
specifications stated in the pharmacopeia. Additionally, the specific activity and 
the activity concentration (activity/ml) should be known. Labelling with 99mTc or 
188Re can be performed directly or by exchange. Direct labelling is performed by 
adding 99mTc or 188Re eluate in a suitable volume to a sterile kit. The labelling 
reaction requires reduction of pertechnetate/perrhenate, which is reacting with 
the ligand forming the labelled product in high yield (>90%). In a few 
exceptions, an intermediate ligand complex is formed that is stabilized by ligand 
exchange during heating [74].  
After dissolving the lyophilisate in the added volume, incubation is an essential 
step to obtain the radiolabelled medicinal product, considering that is in this 
phase that the chemical reactions take place, resulting in 99mTc or 188Re 
labelling. If incubation is inadequate, the labelling reaction may not be 
completed, and the radiopharmaceutical may not be suitable for administration. 
Each kit requires specific incubation conditions, but in general, this process is 
carried out at room temperature in a clean area. In certain cases, the incubation 
must be performed in a boiling water bath. Incubation is normally performed 
with occasional agitation of the shielded reaction vial [71]. 
Because there is no effective chemistry available to attach a pertechnetate or 
perrhenate ion to an organic moiety, reduction of 99mTc(VII) or 188Re(VII) in 
TcO4
- or 188ReO4
-, to a lower oxidation state is a prerequisite for 99mTc and 188Re 
complex formation in high yield and purity. Pertechnetate and Perrhenate are 
week oxidants, weaker than permanganate, being reduced by weak reductants 
in acid medium. Kits contain very low amounts of stannous ion for reduction of 
99mTc-pertechnetate or 188Re-perrhenate [74]. Nevertheless, SnCl2 (stannous 
chloride)is usually in high excess, most of the time because stannous slats are 
spontaneously oxidized in air, and also to assure validity of kits beyond the 
expiration date [61, 74]. The amount of stannous chloride is empirically 
optimized for each individual kit formulation, being necessary to maintain the 
balance between two parameters, the first is that a large excess of stannous 
chloride should be used with respect to the added pertechnetate or perrhenate 
activity and the second is that the amount of stannous chloride should be kept 
as low as possible in order to avoid further reduction of pertechnetate or 
 
 
45 
 
perrhenate to a lower oxidation state. The amount of stannous chloride in the 
commercially available kits, ranges normally from 0.0076-0.5 mg, corresponding 
to a ratio of Sn to 99mTc in the range of 103 to 105 [61, 86]. 
Formation of colloidal TcO2 or ReO2 is avoided in the presence of ligand, which 
competes for the reduced technetium or rhenium species, producing the 
labelled 99mTc or 188Re pharmaceutical. In the absence of ligand, a mixture of 
hydrolyzed, insoluble 99mTc or 188Re species, TcO2.nH2O and ReO2.nH2O, are 
formed. The kinetic mechanism of reduction-substitution is rather complicated, 
and sometimes it depends on the concentration of carrier 99mTcO4
- or 188ReO4
- 
[61, 86]. 
in conclusion, kit composition is optimized to ensure that the unique 99mTc- or 
188Re-labelled complex is obtained in high yield. Several factors influence the 
reduction/coordination process that is primarily the nature and the amounts of 
reductant and ligand, pH, and temperature. In order to provide suitable pH 
environment for the formation of a specific 99mTc or 188Re complex, buffers are 
important components in kit formulations [61, 74]. 
 
2.2.5. Quality control of radiopharmaceuticals 
Since radiopharmaceuticals are intended for human administration, it is 
imperative that they undergo strict quality control measures. Quality control 
involves several specific tests and measurements that ensure the purity, 
potency, product identity, biological safety, and efficacy of 
radiopharmaceuticals. The quality control tests are divided in physicochemical 
tests and biological tests. The physicochemical tests indicate the level of 
radionuclidic and radiochemical impurities, determine the pH, ionic strength, 
osmolality, and physical state of the sample. The biological tests establish the 
sterility, apyrogenicity, and toxicity of the material [55, 61]. 
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2.2.5.1. Radiochemical purity 
The radiochemical purity of a radiopharmaceutical is the fraction of the total 
radioactivity in the desired chemical form in the radiopharmaceutical. Values 
above 90% are desirable, because a different label will yield a different 
biodistribution, and thus will result in a distortion of the image and/or lead to 
problems in therapy. Radiochemical impurities arise from decomposition due to 
the action of several factors like the solvent, change in temperature or pH, light, 
presence of oxidizing or reducing agents in inadequate concentrations, and 
radiolysis. Examples of radiochemical impurities are free pertechnetate or 
perrhenate (99mTcO4
- or 188ReO4
-) and reduced/hydrolysed 99mTc or 188Re 
(TcO2.nH2O or ReO2.nH2O) [55, 61].  
A number of analytical methods are used to detect and determine the 
radiochemical impurities in a given radiopharmaceutical. One of the most 
important is the paper and thin-layer chromatography [55, 61].  
Paper and thin-layer chromatography (TLC) is commonly used for the 
determination of radiochemical purity in nuclear medicine. The principle of this 
analytical method is that a mobile phase (solvent) moves along a layer of 
adsorbent (stationary phase) due to capillary forces. Depending on the 
distribution of components between the stationary and mobile phase, a 
radioactive sample spotted onto the stationary phase will migrate with different 
velocities, and consequently, impurities are separated. The distance each 
component of a sample migrates is expressed as the Rf value. The Rf is the 
relative distance of migration of a component in relation to the solvent front 
(SF), and can be calculated following the equation 2 [55]: 
    
 istance from origin of the component
 istance of the SF
  
Equation 2.Equation for calculation of Rf. Rf is the distance of the migration of a 
certain component. SF is the solvent front (Cantone M. et al., 2011). 
 
The Rf values range from 0 to 1. If a component migrates with the solvent front, 
the Rf is 1, and if a component remains at the point of application (origin), the Rf 
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is 0. The main principles of separation are adsorption (electrostatic forces), 
partition (solubility), and ion exchange (charge). Depending on the movement of 
the mobile phase, TLC may be ascending or descending. In the nuclear 
medicine laboratory, ascending TLC is the method of choice [55, 87].  
TLC offers reliable separation properties with easy and rapid performance. The 
applied sample remains quantitatively on the plate, and thus, no losses of 
radioactivity during analysis occur. A broad range of stationary phases is 
commercially available including silica gel, reversed-phase silica, aluminium 
oxide, synthetic resins (ion-exchange chromatography), and cellulose (partition 
chromatography). The length of plates (foils) may vary between 10 and 20 cm. 
The main limitation for standard TLC techniques is the time required for 
analysis. Due to the particle size (20 µm) of adsorbent materials, the developing 
time is usually > 30 minutes, this is to long considering additional time for 
measurements and quantification [88]. Instant TLC (ITLC) materials are the 
most frequently used stationary phases in nuclear medicine, because they fulfil 
the need for rapid and accurate analysis of the radiochemical purity of 
radiopharmaceuticals. ITLC plates are made of fibreglass sheets, impregnated 
with an adsorbent, usually silica gel. Due to the fine mesh material, the 
migration properties are increased many-fold comparing to TLC materials. The 
time for development in an ITLC plate may be reduced to < 5 minutes, without 
affecting the separation of radiochemical impurities. Although ITLC materials 
are more expensive than TLC materials, fibreglass sheets offer high economy, 
since the flexible material may be cut to any size [55, 87, 88].  
The chemical properties of silica gel are based on siloxane (Si-O-Si) and silanol 
(Si-OH). Polar groups are responsible for the interaction of the adsorbent with 
water and with the sample to be analysed. Silica stationary phases (3-8 µm) 
have been produced for ITLC as silica gel (ITLC-SG) and silicic acid (ITLC-SA), 
being the ITLC-SG the most frequently used adsorbent for routine 
radiochemical purity determinations. Some separations of radiopharmaceuticals 
are based on adsorption chromatography with aluminium-coated plates. Also 
aluminium oxide (Al2O3) has polar properties it is also a weak anion exchange 
material.  
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Cellulose is an organic material that consists of polymerized glucose fibbers 
(400-500 molecules) in nature and also as a synthetic product (40-200 glucose 
molecules). Cellulose interacts with water and serves as stationary phase for 
the separation of polar substances by paper chromatography. As a powder, it is 
used as an adsorbent for TLC. Paper materials show low-resolution properties, 
however, since paper is robust and easy to cut, paper chromatography is still 
used for many applications. Like ITLC, paper chromatography is used 
“ascending” or “descending”. Likewise, a developing distance of 8-10 cm is 
usually sufficient for the separation of free pertechnetate or perrhenate and 
colloidal impurities. The developing time might be slightly higher, but usually it 
takes only 10 minutes if small sized paper strips are used. Whatman 3MM is the 
material of choice for determination of the radiochemical purity by partition 
chromatography [55]. The migration properties of free pertechnetate or 
perrhenate may be influenced by the choice of different mobile phases. When 
silica gel or paper is used as stationary phase, the migration of free 
pertechnetate or perrhenate depends on the solubility of this anion in the 
solvent. In a polar solvent like saline, 80% of methanol, acetone or 2-butanone 
(methyl ethyl ketone, or MEK) pertechnetate or perrhenate migrates with the SF 
(Rf = 0.6 – 1.0). If a non-polar, lipophilic solvent (e.g., ethylacetate, chloroform) 
is used and the sample is dried, free pertechnetate or perrhenate remains at the 
origin. Colloids do not migrate in most paper chromatography or ITLC systems 
since insoluble material will stay at the origin, and hanging the mobile or the 
stationary phase will not affect the migration properties of colloidal 99mTc or 
188Re [87, 88]. In saline, free pertechnetate or perrhenate and 99mTc or 188Re 
complex migrate with the SF, while reduced/hydrolysed 99mTc or 188Re remains 
at the start [55].  
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Section II. Literature Review 
Chapter 3.Primary Tumour and Metastases of Bone and the emerge of 
PEI-MP2 
 
3.1. Introduction 
Primary bone cancer means that the cancer originated from cells in the hard 
bone tissue [67]. Primary bone tumours are fairly rare (two in every 1000 
cancers). Some conditions that may simulate primary bone tumours, such as 
metastasis and non-neoplastic conditions for instance inflammatory processes, 
bone cysts, fibrous dysplasia, non-ossifying fibroma, Paget’s disease of bone, 
etc., by far outnumber the cases of true bone tumours. There are different types 
of primary bone cancer classified by the type of cell which occurs in the cancer. 
Types of benign bone tumours include osteoid osteoma, osteoblastoma, 
enchondroma, chondromyxoid fibroma. Types of malignant bone tumours 
include osteosarcoma, chondrosarcoma, Ewing’s sarcoma, malignant fibrous 
histiocytoma, fibrosarcoma, giant cell tumour bone and chordoma [67, 89, 90]. 
A short characterization of each of these malignant bone tumours is presented 
in table 9 [90, 91]. 
 
Table 9.Characterization of malignant bone tumours (NCI, 2008; ACS, 2012).  
Bone cancer Tissue of origin Affected bones 
Osteosarcoma Osteoide  Arms, legs and pelvis 
Chondrosarcoma Cartilage Trachea, larynx and chest wall 
Ewing’s sarcoma Bone, Soft tissue  Backbone, pelvis, legs and arms 
Malignant fibrous histiocytoma Soft tissue  Legs  and arms 
Fibrosarcoma Soft tissue Legs, arms and jaw  
Giant cell tumour bone Bone, Soft tissue Legs and arms 
Chordoma Soft tissue Skull and spine 
Legend: Characterization of some malignant bone tumours, considering the tissue of origin and 
the most affected bones in the body by type of tumour. 
 
                                            
2
 This Chapter is a modified version of the following publication: Ferreira S, Dormehl I, Botelho MF: 
Radiopharmaceuticals for bone metastasis therapy and beyond: a voyage from the past  to the present and a look to the 
future. Cancer biotherapy & radiopharmaceuticals 2012, 27(9):535-551. 
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The three most common genuine primary bone malignancies are 
osteosarcoma, chondrosarcoma, and Ewing’s sarcoma, accounting for only 
0.2% of all malignancies in the United Kingdom and United States of America. 
However in children (< 15 years), malignant bone tumours account for 
approximately 5% of all malignancies [67, 89, 90]. The treatment and prognosis 
for bone cancers depend, to a large extent, on the patient’s stage at diagnosis. 
One system that is used to stage all bone cancers is the American Joint 
Commission on Cancer (AJCC) system. It combines 4 factors to determine 
stage that go by the initials T, N, M, and G. The letter T stands for features of 
tumour (its size and if it is in more than one spot on the bone), N stands for 
spread of lymph nodes, M is for metastasis to distant organs, and G is for the 
tumour’s grade. The grade of a tumour is based on how abnormal the cells look 
when seen under a microscope. The higher the number, the more abnormal the 
cells appeared. Higher grade cancers tend to grow and spread more quickly 
than lower grade tumours [90]. The TMNG stages for bone cancer are 
summarized in table 10 [90, 92]. 
 
Table 10.TMNG stages of bone cancer (ACS, 2012; CRUK, 2013). 
Tumour (T) Description 
TX Primary tumour can’t be measured. 
T0 No evidence of the tumour. 
T1 Tumours that are 8 cm or less at their widest point. 
T2 Tumours larger than 8 cm. 
T3 High grade tumours where the tumour is in more than one place on 
the same bone. 
Node (N) Description 
N0 There are no cancer cells in lymph nodes close to the tumour. 
N1 There are cancer cells in nearby lymph nodes. 
Metastasis (M) Description 
M0 The cancer has not spread to any other part of the body. 
M1a The cancer has spread to the lung. 
M1b The cancer has spread to other areas of the body apart from the lungs 
Grade (G) Description 
G1-G2 Low grade. 
G3-G4 High grade. 
Legend: The TNMG stages of bone cancer is organized in four categories, namely the size of 
the primary tumour (T), the spread to lymph nodes (N), the presence of metastases (M) and the 
grade (G) of the tumour considering the number of abnormal cells, considering the origin. For 
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each of these categories, subdivisions may be made assigning a number to T, N, M or G, in a 
growing sequence, where the higher the number the lower is prognosis. For the category grade 
(G), two subdivisions are made, considering a low grade (G1-G2) and a high grade (G3-G4) 
tumour. 
 
This information about the tumour, lymph nodes, metastasis, and grade is 
combined in a process called the stage grouping. The stage is then described in 
Roman numerals from I to IV. This information is summarized in table 11 [90]. 
 
 
Table 11.Bone cancer staging (ACS, 2012; CRUK, 2013). 
Stage Description 
Stage I  
Stage IA 
 
 
 
 
Stage IB 
 
Low grade bone cancer that is still completely inside the bone in which 
is started. The tumour may press on the bone wall and cause swelling, 
but the cancer has not grown through the bone wall or spread to any 
other part of the body. This is called an intracompartmental bone 
cancer. T1, N0, M0, G1-G2. The tumour is 8 cm or less. 
Low grade bone cancer but has grown through the bone wall. It is called 
an extracompartmental bone cancer (this means the cancer has grown 
out of the area of the bone in which it started). T2 or T3, N0, M0, G1-G2. 
The tumour is either larger than 8 cm or it is in more than one place on 
the same bone. 
Stage II 
Stage IIA 
 
 
 
Stage IIB 
 
 
High grade bone cancer but still completely within the bone in which it 
started. It has not spread to other areas of bone or any other part of the 
body. It is an intracompartmental cancer. T1, N0, M0, G3-G4. The 
tumour is 8 cm or less. 
High grade bone cancer that have grown through the wall of the bone 
into nearby tissues. They are extracompartmental cancers. T2, N0, M0, 
G3-G4. The tumour is larger than 8 cm. 
Stage III Tumours have not spread outside the bone but are in more than one 
place on the same bone. They are high grade. T3, N0, M0, G3-G4. 
Stage IV 
Stage IVA 
 
Stage IVB 
 
Any size or grade of tumour that has spread to the lung. Any T, N0, 
M1a, G1-G4. 
Any size or grade of tumour that has spread to the lymph nodes and/or 
a part of the body other than the lung. Any T, N1, any M, G1-G4 or any 
T, any N, M1b, G1-G4. 
Legend: The combinations from the TNMG system can result in four stages of bone cancer, 
starting from stage I, representing a low grade bone cancer, where the tumour is still in situ, and 
then progressing to stages II, III and IV. The greater is the stage the higher the possibility of 
invasion to other bones, to lymph nodes and to other distant organs. These stages can also be 
subdivided in subcategories, representing an increase of severity within the group/stage. 
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The development of bone metastases is a common and often catastrophic 
event for the cancer patient. Overall, the skeleton is the third most common site 
of cancer metastases, surpassed only by lung and liver. Prostate, breast, and 
lung cancers are the most common malignancies in adults and are the most 
common tumours that metastasize to bone and about 70% of patients that had 
died from these cancers had evidence of metastatic bone disease [3, 67, 93]. 
Carcinomas of the thyroid, kidney, melanomas and bronchus also commonly 
give rise to bone metastasis, with an incidence at post mortem examination of 
30% to 40%. Tumours of the gastrointestinal tract rarely (5%) produce bone 
metastasis [93, 94].  
Bone metastasis is associated with increased morbidity and portends a poor 
outcome, with decreased survival, in cancer patients. Bone metastasis are 
classified as osteolytic, osteoblastic, or mixed, based on their radiographic 
appearance. Bone metastases from prostate cancer are predominantly 
osteoblastic, whereas metastatic lesions in bone from breast cancer can be 
osteoblastic, osteolytic, or mixed. Irrespective of the mechanisms involved in 
the generation of these radiographic phenotypes, the end result is a change in 
bone architecture, which predisposes the patient to a variety of skeletal 
complications [93, 95-97].  
Bone metastases are usually multifocal and have a predilection for the 
hematopoietic marrow sites in the proximal long bones and axial skeleton 
(vertebrae, pelvis ribs, and cranium) [93, 98]. Continuous and dynamic turnover 
of the bone matrix and bone marrow provides a fertile ground for tumour cells to 
utilize the vast available resources (cells, growth factors, cytokines, and 
receptors) for their homing and subsequent proliferation. Evidence exists that 
blood from some anatomic sites may drain directly into the axial skeleton. The 
drainage of blood to the skeleton via the vertebral-venous plexus may, at least 
in part, explain the tendency of breast and prostate cancers, as well as those 
arising in kidney, thyroid, and lung, to produce metastasis in the axial skeleton 
and limb girdles [67, 93, 94]. Of course, the vertebral-venous plexus does not 
provide the entire explanation of why these cancers metastasize to the 
skeleton. Molecular and cellular biological characteristics of the tumour cells 
and the tissues to which they metastasize are of paramount importance and 
influence the pattern of metastatic spread [99]. Abundant sinusoids and 
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sluggish blood flow in the metaphysic facilitate an intimate interaction between 
endothelium and tumour cells, which is necessary for their initial colonization in 
the bone marrow. Moreover, it appears that a subset of bone marrow cells 
(vascular endothelial growth factor receptor-1 expressing hematopoietic 
progenitor cells and fibroblasts) may form a “pre-metastatic niche” in response 
to the humeral factors secreted by the primary neoplasm. The cells comprising 
the pre-metastatic niche express cell surface ligands and receptors (integrin 
and fibronectin), which provide a permissive environment for the migrating 
tumour cells. In addition, various growth factors and cytokines in the bone 
marrow such as endothelin-1, basic fibroblast growth factor, transforming 
growth factor TGFβ, IL-6, and IL-8 serve as paracrine regulators of the initial 
growth of metastatic tumour cells. The interaction of receptor molecules in the 
bone marrow stroma (urokinase receptor, vascular cell adhesion molecule-1, 
and fibronectin) with the ligands that are over expressed on the tumour cells (β1, 
α4β1 and α5β1 integrins, cadherin-11, connective tissue growth factor, CXCR4 
and CXCL12) promotes colonization of circulating malignant cells in the bone 
marrow. The extracellular matrix proteins (especially type I collagen, type IV 
collagen, vitronectin, fibronectin, osteopontin, osteocalcin, bone sialoprotein, 
osteonectin, and stromal cell derived factor-1) are chemotactic for tumour cells 
and promote colonization of circulating tumour cells in the bone marrow [93, 
100].  
Although bone metastasis are rarely the cause of cancer-related death, they 
lead to serious complications that limit the patient`s mobility: (1) 30-60% of 
patients develop pain symptoms of varying intensity, related with different 
causes, like an inflammatory event or a spinal cord and/or nerve root 
compression; (2) predominantly the osteolytic type has the tendency to develop 
fractures resulting in considerable morbidity; (3) a hypercalcemic syndrome due 
to increased bone resorption of osteolytic metastasis can occur, and this can 
also appear as a paraneoplastic syndrome; and (4) if there is extensive 
metastatic disease the bone marrow can be destroyed and clinically relevant 
alterations of the blood counts can be observed [97, 101, 102]. 
Different sites of bone metastasis are associated with distinct clinical pain 
syndromes. Common sites of metastatic involvement associated with pain are 
the base of skull (in association with cranial nerve palsies, neuralgias, and 
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headache), vertebral metastasis (producing neck and back pain with or without 
neurologic complications secondary to epidural extension), and pelvic and 
femoral lesions (producing pain in the back and lower limbs, often associated 
with mechanical instability and incident pain). The pathophysiologic 
mechanisms of pain in patients with bone metastasis are poorly understood but 
probably include tumour-induced osteolysis, tumour production of growth 
factors and cytokines, direct infiltration of nerves, stimulation of ion channels, 
and local tissue production of endothelins and nerve growth factors [69, 96, 97, 
99]. 
It can be distinguish two types of pain, the nociceptive pain and the neurophatic 
or nerval pain. Pathophysiologicaly, it is difficult to differentiate these two types 
of pain. Nociceptive pain is mediated by free sensory nerve endings of the 
nociceptors that can be found throughout the body [69]. A large amount of 
nociceptors are located in the skin, the skeletal musculature, the tendons, the 
joints and the intestine [103]. Depending on their location, it’s possible to 
differentiate between somatic and visceral or superficially and deeply located 
nociceptive pain. Visceral excitations are frequently projected to special skin 
regions, the so called dermatome. While the nociceptive pain is generally 
described by the patient as being of a stinging, gnawing or dull character, 
neuropathic pain is described as burning and appearing suddenly [95]. 
Therefore, anamnesis will lead to a differentiation between the two pain entities 
at an early stage. This is extremely important because radionuclide therapy is 
useful in nociceptive pain patients but not for neuropathy pain [95].  
Physiologically, the nociceptor is not activated unless strong mechanical or 
thermal influences are present. However, the nociceptor can be sensitized by 
the production of endogenous pain mediators like those that occur in an arthritis 
patient that suffers from pain even if a small movement and/or a slight pressure 
is applied to an affected joint. In these cases, substances like prostaglandin E, 
bradykinin, histamine and interleukin act as pain mediators changing the 
microcirculation and permeability of vessels and leading to a decrease of 
excitation level [104]. Lymphocytes and macrophages assist in this process. 
The simultaneous excretion of different pain mediators can lead to an 
exponential increase in their effect. This principle is known in the field of 
pharmacology pain treatment, and therefore agents inhibiting the production of 
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prostaglandin E are successfully administered in pain patients. The nociceptor 
cell can also regulate its excitation level itself. By secretion of the so-called 
substance P, a vasodilatation and consequently an invasion of inflammatory 
cells and an enhanced secretion of pain mediators will occur. This process is 
often called a neurogenic inflammation. Bone metastasis can generate pain 
either by a strong mechanical impact to the nociceptor or by an osteoblastic 
excretion of pain mediators that result in the described sensitization of the 
nociceptors [69].  
 
3.2. Demographics and epidemiology  
Primary bone tumours are relatively uncommon and this has definitely limited 
the collection of data about their relative frequency, and as a consequence 
leads to the insufficient understanding of the risk factors. Although the incidence 
of benign bone tumours is higher than the incidence of primary malignant 
tumours, it is probable that benign lesions are underestimated considering that 
they often are asymptomatic and not clinically recognized. Therefore they 
remain undetected or are detected only incidentally at radiographic 
examinations for other reasons. In addition, primary bone tumours are 
outnumbered by metastases from carcinomas, melanoma, or hematologic 
malignancies [89, 105].  
More than 75% of malignant bone tumours are osteosarcoma, 
chondrosarcoma, and Ewing’s sarcoma [89]. The American Cancer Society’s 
estimates for cancer of the bones and joints in 2013 the diagnosis of about 
3,010 new cases and 1,440 deaths from these cancers. Primary cancers of 
bones account for less than 0.2% of all cancers. In adults, over 40% of primary 
bone cancers are chondrosarcomas. This followed by osteosarcomas (28%), 
chordomas (10%), Ewing’s sarcoma (8%), and malignant fibrous 
histiocytomas/fibrosarcomas (4%). In children and teenagers (younger than 20 
years), osteosarcoma (56%) and Ewing’s sarcoma (34%) are much more 
common than chondrosarcoma (6%). Chondrosarcomas develop most often in 
adults, with average age at diagnosis of 51, and less than 5% of cases occur in 
patients younger than 20. Chordomas are also more common in adults, and 
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less than 5% of cases occur in patients younger than 20. Both osteosarcoma 
and Ewin’s sarcoma occur most often in children and teens [90]. 
The incidence of malignant bone tumours shows a striking age-specific 
distribution, for example in the age group 0 to 40 years, there is an incidence 
peak between 10 and 20 years (primarily osteosarcoma and Ewing’s sarcoma) 
and for the age group above 40 years there is steady increase in incidence up 
to 80 years (primarily chondrosarcoma and to a lesser degree Paget’s related 
osteosarcoma) [89, 105]. 
In general, there is no significant gender predilection, although some tumours 
(e.g. Paget’s sarcoma, chordoma) show a higher prevalence in males. 
According to SEER data, in the period of 2004 to 2008, the median age at 
diagnosis for cancer of the bones and joints was 40 years of age. Approximately 
29.0% were diagnosed under age 20, 15.4% between 20 and 34, 10.5% 
between 35 and 44, 13.0% between 45 and 51, 11.4% between 55 and 64, 
8.3% between 65 and 74, 9.1% between 75 and 84, and 3.5% over 85 years of 
age [105, 106]. 
Benign bone tumours and many bone stimulating, non-neoplastic conditions 
also show a striking age distribution, occurring in the vast majority in the first 
two decades of life [89, 105].  
Several bone tumours may occur in the setting of inherited syndromes, 
nevertheless their histopathological features do not differ from those of sporadic 
cases. Additionally, although the majority of primary bone malignancies are de 
novo, there is increasing evidence that some develop in association with non-
neoplastic precursors or in the setting of previous benign tumours. Paget’s 
disease of bone, previous radiation therapy, and cartilaginous dysplasias are 
some of the most well known precancerous conditions for the development of 
bone sarcomas. High risk precursors are represented by Ollier’s disease and 
Maffucci syndrome, familial retinoblastoma syndrome and Rothmund Thompson 
syndrome, while conditions representing a moderate risk include multiple 
osteochondromas, Paget’s disease and radiation osteitis. A low risk for 
malignant transformation has been associated with fibrous dysplasia, bone 
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infarct, chronic osteomyelitis, prosthetic implants, osteogenesis imperfect, giant 
cell tumour, osteoblastoma and chondroblastoma [105]. 
The treatment of bone cancer is often very successful, particularly if the cancer 
has not spread to other parts of the body. Overall, more than 40 out of every 
100 men (over 40%) and more than half of woman (over 50%) will live more 
than 5 years after their primary bone cancer is diagnosed and treated. 
Considering that, if bone cancer is low grade it is more likely to be cured, on the 
other hand if cancer has spread beyond the bone it is more difficult to cure. 
Therefore, almost everyone with stage 1A, more than 95% of people with stage 
1B, more than 60% of people with stage 2A, over 40% of people with stage 2B 
bone cancer, lives more than 5 years [107]. 
Chemotherapy can work well at reducing the risk of the cancer coming back 
after surgery, particularly for Ewing’s sarcoma. For Ewing’s sarcoma that is 
localized and hasn’t spread elsewhere in the body, about 70 out every 100 
people (70%) live for at least 5 years after their diagnosis. If Ewing’s sarcoma 
has spread to the lungs, around 30 out of every 100 people (30%) will live for at 
least 5 years after their diagnosis. If Ewing’s sarcoma has spread to the brain 
then the 5 year survival is less than 10% [107]. 
Low grade osteosarcomas are not very common. However, over 90 out every 
100 people (90%) with this type of tumour live for at least 5 years after their 
diagnosis. Regardless of grade, localised osteosarcomas have a 5 year survival 
rate of about 60%, meaning that 60 out every 100 people (60%) with this type of 
cancer live for at least 5 years. In people whose chemotherapy works very well, 
survival may be more than 70%. In people whose osteosarcoma has spread to 
the lungs at the time of diagnosis the survival is lower, 10 out of every 100 
people (10%) live more than 5 years [107].  
Chondrosarcoma is more likely to be curable if it is low grade, considering that 
at least 80 out every 100 people (80%) will live for more than 10 years after 
treatment. But if the cancer is high grade the outlook is poorer and about 30 out 
of every 100 people (30%) will live for at least 5 years [107]. 
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3.2.1. Risk factors for primary bone cancer 
Most people with bone cancers do not have any apparent risk. The major risk 
factors for the development of bone cancers are the existence of genetic 
disorders, Paget disease, radiation, bone marrow transplantation and injuries 
[90].  
A very small number of bone cancers, especially osteosarcomas, appear to be 
hereditary and are caused by mutations in certain genes, for example, children 
with certain rare inherited syndromes have an increased risk of developing 
osteosarcoma. The Li-Fraumeni syndrome makes people much more likely to 
develop several types of cancer, including breast cancer, brain cancer, 
osteosarcoma, and other types of sarcoma. Most of those cases are caused by 
a mutation of the P53 tumour suppressor gene, but some are caused by 
mutations in the gene CHEK2 (Checkpoint kinase 2 gene). Another syndrome 
that includes bone cancer is the Rothmund-Thomson syndrome. Children with 
this syndrome are short, have skeletal problems, and rashes, and are more 
likely to develop osteosarcoma. This syndrome is caused by abnormal changes 
in the gene REQL4 (ATP-dependent DNA helicase Q4 gene) [90]. 
Retinoblastoma is a rare eye cancer of children that can be hereditary. The 
inherited form of retinoblastoma is caused by a mutation of the RB1 gene. 
Those with this mutation also have an inherited risk of developing bone or soft 
tissue sarcomas. Also, if radiation therapy is used to treat retinoblastoma, the 
risk of osteosarcoma in the bones around the eye is even higher. Finally there 
are several families with several members who have developed osteosarcoma 
without inherited changes in any of the known genes. Additionally, people with 
metal implants into bones, are more likely to develop osteosarcoma  [90, 91]. 
Paget disease is a benign but pre-cancerous condition that affects one or more 
bones. It results in formation of abnormal bone tissue and is mostly a disease of 
people older than 50. Affected bones are heavy, thick, and brittle. They are 
weaker than normal bones and are more likely to fracture. Bone cancer (usually 
osteosarcoma) develops in about 1% of those with Paget disease, usually when 
many bones are affected [90]. 
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Bone exposure to ionizing radiation may also increase the risk of developing 
bone cancer. A typical x-ray of a bone is not dangerous, but exposures to large 
doses of radiation pose a risk. Being treated at a younger age and/or being 
treated with higher doses of radiation (usually over 60 Gy) increases the risk of 
developing bone cancer. Exposure to radioactive materials such as radium and 
strontium can also cause bone cancer because these minerals build up in 
bones [90]. Osteosarcoma has been reported in a few patients who have 
undergone bone marrow transplantation. People have wondered whether injury 
to a bone can cause cancer, but this has never been proven [90]. 
Ewing sarcoma is not strongly associated with any hereditary cancer 
syndromes, congenital childhood diseases, or previous radiation exposure [90, 
91]. Multiple exostoses (sometimes called multiple osteochondromas) 
syndrome is inherited conditions that cause many bumps on a person’s bones. 
These bumps are made mostly of cartilage. They can be painful and cause 
bones to deform and/or fracture. This disorder is caused by a mutation in any of 
the 3 genes EXT1, EXT2, or EXT3. Patients with this condition have an 
inherited risk of chondrosarcoma. People who has multiple enchondromatosis 
(multiple enchondroma), have an increased risk of developing 
chondrosarcomas [90, 91].  
Chordomas seem to run in some families. The genes responsible have not yet 
been found, but familial chordoma has been linked to changes on chromosome 
7. Patients with inherited syndrome tuberous sclerosis, which can be caused by 
mutations in either of the genes TSC1 and TSC2, seem to have a high risk of 
chordomas during childhood [90, 91]. 
Simply having cancer is a risk factor for bone metastases. Among people with 
the same kind of cancer, tumours that are larger and have already spread to 
lymph nodes are generally more likely to spread to bone. For some kinds of 
cancer, a high grade and certain genetic changes make the cancer more likely 
to spread to bones [98]. For patients with prostate, breast, or lung cancers, the 
risk of metastasis to bones is very high [67]. 
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3.3. Diagnosis 
A patient´s symptoms, physical exam, and results of imaging tests, and blood 
tests may suggest that bone cancer is present. The main signs and symptom of 
a bone cancer are pain, swelling, fractures, and other symptoms like height 
loss, fatigue, and symptoms associated with the organs affected by the spread 
of the cancer. Pain in the affected bone is the most common complain of 
patients with bone cancer. At first, the pain is not constant, and it may be worse 
at night or when the bone is used. As the cancer grows, the pain will be there 
constantly. The pain increases with activity and the person might limp if the leg 
is involved [90]. 
If cancer is diagnosed, bone metastases may sometimes be found before they 
have a chance to cause any symptoms. Since single bone metastasis can have 
the same sign and symptoms as a primary bone tumour, many doctors require 
a biopsy to diagnose a patient’s first bone metastasis [90]. The biopsy is the 
only way to know that the tumour is cancer and not some other bone disease, 
or if it is a primary bone cancer or metastases. Several types of tissue and cell 
samples are used to diagnose bone cancer. The surgeon will choose a biopsy 
method based on whether the tumour looks benign or malignant and exactly 
what type of tumour is most likely. Some kinds of bone tumours can be 
recognized from needle biopsy samples, but larger samples are often needed to 
diagnose other types. [89, 90]. 
Several imaging techniques may be used for the diagnosis of primary bone 
cancer namely x-ray scans, bone scan, computed tomography (CT) scan, 
magnetic resonance imaging (MRI) procedure, positron emission tomography 
(PET) scan, and angiogram. Some of these imaging tests may be required to 
see how far the cancer has spread. This may be done before, during and after 
treatment [90, 91]. 
X-ray scans are often among the first tests ordered if a person with cancer is 
having bone pain or other symptoms. X-rays scans allow obtaining the 
information about location, size and shape of bone tumour. The bone at the site 
of the cancer may appear “ragged” instead of solid, and also appear as a hole 
in the bone. In osteolytic metastases, cancer cells will dissolve some of the 
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minerals in the bone, making an area of the bone less dense, therefore these 
changes will appear on x-ray as a darker hole in the gray-white bone image. In 
the case of osteblastic metastases, the area will appear denser and sclerotic. 
Also x-rays can show fractures in bones that have been weakened by 
metastases. CT and MRI allows obtaining more detailed morphologic images of 
the bones and tumours. The CT scans are also helpful in staging cancer helping 
to determine if the cancer has spread to other organs. CT scans can be useful 
especially if the bone metastases are likely to be osteolytic (hard to visualize in 
bone scans). A CT scan is sometimes used to guide a biopsy when a bone 
metastasis is deep in the body. CT scans are also good for judging the size and 
shape of a tumour in the bone and for assessing how stable a bone containing 
a tumour is. MRI scans are often best test to outlining a bone tumour, and are 
particularly helpful for looking at the brain and spinal cord. Bone scan and PET 
allows obtaining information, respectively, about the osteoblastic/osteoclastic 
activity and glucose metabolism (when administered 18F-FDG). Bone scan 
allows determining if the cancer has spread to other bones. It can find 
metastasis earlier than regular x-rays, and also show how much damage the 
primary cancer has caused in the bone. Areas of active bone changes appear 
as hot spots on the skeleton. These areas may suggest the presence of cancer, 
but other bone diseases can also cause the same pattern. PET scan give useful 
information about the spread of the cancer to other organs, but this images lack 
on resolution, therefore newer machines combine PET and CT or PET and MRI 
[90, 91]. 
Some types of cancer release certain substances called tumour markers into 
the bloodstream. Patients with these types of cancer may have to do blood tests 
at regular intervals to see if levels of these markers are rising. An increase in 
tumour markers levels mean that the cancer has spread, but it doesn’t show 
where the cancer has spread. Other tests will be needed to show if the 
metastases are in the bone or if they are somewhere else in the body. Prostate-
specific antigen is an example of a tumour marker, more specifically from 
prostate cancer. Other examples of tumour markers are high blood calcium and 
alkaline phosphatase levels. These markers result from the presence of bone 
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metastases that can dissolve the bone. Also, several substances can be 
released into urine when bone is damaged, namely N-telopeptide [98]. 
 
3.4. Therapy 
Treatment options depend on the type, size, location, and stage of the cancer, 
as well as the person´s age and general health [91]. Treatment options for 
primary bone cancer include surgery, chemotherapy, and radiation therapy [90, 
91].  
Surgery is the major treatment for most bone cancers, and it may be used to 
obtain a biopsy of the cancer. The type of surgery used will depend on the size 
of the cancer, the location in the body and whether it has grown into the tissues 
surrounding the bone. The main goal of the surgery is to remove all of the 
cancer, considering that if even a few cancer cells are left behind, they can 
grow and multiple to make a new tumour. Trying to be sure that this doesn’t 
happen, surgeons remove the tumours plus some of the normal surrounding 
tissue.  Various techniques can be used, namely the removal of the entire bone 
affected by the cancer, the limb sparing surgery, the amputation (when is a leg 
or arm) and the surgery to remove metastasis. Bone amputation may be 
performed if the tumour has spread into the tissues surrounding the bone, 
affecting the major nerves and blood vessels or muscles, or if the position of the 
tumour makes impossible the resource to limb sparing surgery. Sometimes, 
when a bone cancer has spread, the number and size of metastasis is small 
and the location is favourable, and can be removed surgically [90, 91].  
Patients who have bone cancer usually receive a combination of anticancer 
drugs (chemotherapy). Chemotherapy works very well for some types of bone 
cancers, particularly Ewing’s sarcomas and osteosarcomas, but not for all 
patients. Chemotherapy is often given before surgery to help shrink the tumour 
and make it easier to remove or after surgery to reduce the risk of the cancer 
coming back. Also, chemotherapy can be used to relieve the symptoms, by 
shrinkage of cancer. Chemotherapy is sometimes used for bone cancer that 
has spread through the bloodstream to the lungs and/or other organs. The 
drugs mainly used to treat bone cancer include the doxorubicin, cisplatin, 
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carboplatin, etoposide, ifosfamide, cyclophosphamide, methotrexate, and 
vincristine. Usually several drugs (two or three) are given together, for example, 
a very common combination is cisplastin and doxorubicin, ifosfamide and 
etoposide or ifosfamide and doxorubicin [90, 91]. 
Radiotherapy may also be used before surgery to shrink the tumour and make it 
easier to remove, or after surgery to help lower the risk of the cancer coming 
back. It is often used on tumours that do not respond well to chemotherapy, in 
patients who refuse surgery, or in unresectable bone tumours [90, 91]. 
For systemic treatment, and for most of the cases for palliative treatment, of 
bone metastasis, besides chemotherapy, also its possible to resort to hormone 
therapy (reducing osteoclast formation), immunotherapy, stimulation of bone 
formation (implanting biomaterials targeted with molecular signals designed to 
trigger the body’s repair mechanism), growth factors, gene therapy, 
diphosphonates (inhibitors of bone resorption), and radiation therapy using 
radiopharmaceuticals [98, 108, 109].  
Chronic pain syndrome is the most important complication of bone metastasis 
and has a negative impact on quality of life and at the social environment of the 
patient [101, 102]. Up to one-half of patients do not receive adequate pain 
treatment. About two-thirds of pain patients complain about break-through pain, 
meaning a simultaneous appearance of strong pain in spite of the intake of 
analgesics. It is therapeutically relevant that, in most of these patients with 
break-through pain, optimization of pain therapy is possible [69]. Nonsteroidal 
anti-inflammatory drugs are the first weapon to use in the treatment of such 
pain, followed up by opiates in a stepwise approach recommended by World 
Health Organization guidelines [110]. Some of the drugs have gastrointestinal 
side effects and lead to hepatic damage [111, 112]. Although narcotics are 
generally effective in relieving pain, the somnolence, nausea, and constipation 
that result from their use almost inevitably decrease the quality of life of the 
patient with advanced cancer [110].  
Chemotherapy is used as the main treatment for many types of metastatic 
cancer that has spread, and is often able to shrink tumours reducing pain. 
Besides chemotherapy drugs kill cancer cells it also damage some normal cells, 
causing side effects (e.g. nausea, loss of appetite, loss of hair, mouth sores, 
diarrhoea, etc.) [98].   
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Hormones in the body drive the growth of some common cancers, for example 
estrogen (produced in the ovaries) promotes growth of some breast cancers, 
and androgens (testosterone produced in testicles) promote growth of most 
prostate cancers. One of the main ways to treat breast and prostate cancers is 
to surgically remove the organs that make the hormones. More often, drugs are 
given to keep the hormones from being made. Both for men and women, 
respectively with prostate or breast cancer, can be given drugs such as 
luteinizing hormone-releasing hormone agonists or antagonists, which block 
testosterone and estrogen production. Also, for women in menopause, the 
ovaries no longer make hormones, a small amount of estrogen is still made in 
fat tissue. Drugs called aromatase inhibitors stop this estrogen from being 
produced. Another approach is preventing the hormones from affecting the 
cancer cells, and in this case it can be given anti-androgens or anti-estrogens 
(e.g. tamoxifen). Side effects of hormone treatments depend on the type of 
treatment used, being the most common side effect hot flashes. Hormone 
therapy for prostate cancer can lead to anaemia, weight gain, loss of sex drive, 
etc. Tamoxifen use increases the risk of blood clots and uterine cancer [98]. 
Immunotherapy, sometimes called biologic therapy or biotherapy, is a systemic 
therapy that uses certain parts of the immune system to fight diseases such as 
cancer. This can be done by stimulating the immune system to work harder or 
smarter to attack cancer cells, or by giving man made versions of immune 
system proteins to kill cancer cells. It is used by itself to treat some cancers, but 
for many cancers it seems to work best when used along with other types of 
treatment. Several types of immunotherapy are used to treat patients with 
metastatic cancer, including monoclonal antibodies, tumours vaccines, and 
cytokines. Monoclonal antibodies (mAbs) are men-made versions of immune 
system proteins, and are very useful in treating cancer because they can be 
designed to attack a very specific part of a cancer cell, targeting specific 
antigens. A major advantage of these drugs is that they may have only mild side 
effects if the right antigen is identified. For cancer, this is not always easy, and 
so far mAbs have proven to be more useful against some cancers than others. 
Cancer vaccines are substances putt into the body to start an immune response 
against certain diseases, helping to prevent or treat cancer. Because some 
cancers are caused by viruses, like uterine cervix carcinoma caused by human 
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papilomas virus and liver cancer caused by hepatitis B virus, some vaccines 
may help to protect against infections and prevent some cancers resulting from 
these viruses. Cancer treatment vaccines are different from the vaccines that 
work against viruses, considering that these vaccines try to get the immune 
system to mount an attack against cancer cells in the body. Instead of 
preventing disease, they are meant to get the immune system to attack a 
disease that already exists. Sipuleucel-T is the only vaccine approved by the 
United States Food and Drug Administration (FDA) to help treat cancer, and is 
used to treat advanced prostate cancer that is no longer being helped by 
hormone therapy. Non-specific immunotherapies do not target a certain cell or 
antigen, they boost the immune system in a very general way, but may still 
result in more activity against cancer cells. Some examples of non-specific 
immunotherapy’s are the ones that uses cytokines, interleukins, interferon’s, 
and granulocyte-macrophage colony-stimulating factor [98, 113].  
Diphosphonates or biphosphonates are analogues of pyrophosphate, a natural 
inhibitor of bone demineralization. They bind to hydroxyapatite crystals of the 
bone by adsorption, resulting in stabilization of bone mineral and inhibition of its 
dissolution. Moreover, it inhibits osteoclast function by various not fully 
understood mechanisms [98, 99, 114]. Recently, Yoneda et al. [115], in an 
experimental study with animal models of bone metastasis have shown that 
diphosphonates impaired the progression of bone metastasis primarily through 
enhancing apoptosis of osteoclasts and breast cancer cells colonised in bone 
[115]. However, the rate of bone resorption varies both between patients and 
within patients during periods of disease remission and progression, so it is 
somewhat simplistic to assume that all patients require the same dose of 
diphosphonates for treatment. Patients with normal or only minimally 
accelerated bone resorption probably do not need the intensity of treatment 
provided by current schedules of highly potent aminodiphosphonates. 
Additionally, clinical benefit from diphosphonates derivatives seems to be 
related to the effective suppression of accelerated bone resorption. There is 
growing evidence that treatment with diphosphonate in advanced cancer 
normalizes bone resorption, as in benign bone diseases [99]. Well known 
examples of diphosphonates include pamidronate (1-hydroxy-3-
aminopropylidene-diphosphonic acid - APD) and etidronate (1-hydroxy-
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ethylene-diphosphonic acid - HEDP), used to treat Paget´s disease, 
osteoporosis, and osteogenesis imperfecta, a hereditary bone disorder. 
 
3.4.1. Targeted radionuclide therapy of bone metastases and PEI-MP 
The delivery of ionizing radiation to a bone containing a metastatic tumour can 
be achieved using either radiation from an external X-ray or gamma ray beam 
or injecting radioisotopes that localize in the bone [108]. Radiotherapy with 
external beams is a treatment of primary importance in bone metastasis pain 
palliation despite these patients being by definition incurable [111, 112, 116]. 
However, palliative radiotherapy can reduce or eliminate pain from bone 
metastasis in 80% of patients [117]. Although higher doses of radiation can 
better control the tumour, the dose that can be delivered is limited by the 
possibility of damaging normal tissue surrounding the tumour. Ulceration, 
fistulas, severe fibrosis, and strictures may develop months or years after 
treatment, severely affecting the quality of life. On the other hand, if a small 
portion of the cancer is excluded from the irradiated volume the treatment can 
fail. Recent advances in conformal radiotherapy allow better dose distribution to 
the target volume with better adjustment to the shape of the tumour. The value 
of conformal techniques has been demonstrated in the treatment of localized 
prostate cancer. Prospective dose escalation studies have shown that higher 
doses can be delivered with a marked improvement at 5-years, without any 
increase of latent toxicity [118, 119].  
Treatment using tracer molecules to target radiation to tumour is well 
established [120, 121] and while local external beam irradiation is the first 
choice for palliative treatment for patients with a limited number of lesions [122], 
systemic radiotherapy with radiopharmaceuticals is preferable when widespread 
bone metastasis are present with multifocal sites of pain [84].  
Interest in designing an effective radiopharmaceutical for palliative therapy and 
treatment of bone metastasis has increased in recent years [102]. This is 
primarily due to the emergence of new sophisticated molecular carriers that 
may provide vehicles for selective deposition of radioactivity in the vicinity of 
cancer cells. In order to develop effective radiopharmaceuticals for therapy, it is 
essential to carefully consider the choices of appropriate radionuclides in 
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conjunction with the in vivo localization and pharmacokinetic properties of the 
radiotracer [123]. The treatment with radionuclides is a safe and effective tool in 
medicine because it acts mostly in the peripheral nerve endings, where tumour, 
inflammatory and immune cells cumulate and release substances [116]. An 
ideal radiopharmaceutical for the treatment of neoplastic bone disease would be 
a radiolabelled compound that predominantly accumulates in bone lesions, with 
low toxicity to the bone marrow and limited uptake by normal bone and other 
organs [111, 112]. In order to get radiopharmaceuticals that predominantly 
accumulate in bone lesions they must have affinity for hydroxyapatite and its 
components, allowing a selective accumulation in bone, with special emphasis 
on the affected areas with high bone-turnover [108]. The therapeutic 
radiopharmaceuticals are commonly composed by two key components: a 
radionuclide and a targeting ligand with which it is complexed. The radionuclide 
produces a relief after selective uptake at the target, ideally with negligible 
damage to healthy tissue. The function of the ligand is prevent dissociation of 
the complex and facilitate the transfer of the radionuclide to the target, as in the 
case of secondary bone metastasis requiring that it should be bone-seeking. 
The ligand of choice should selectively accumulate in regions of high Ca2+ 
concentration which is characteristic of areas affected by secondary bone 
metastasis [59, 102, 124]. Although, the mechanisms by which pain is relieved 
remain poorly understood it is speculated that the radiopharmaceuticals used in 
pain palliation treatment work by adsorption or fixation on bone in the areas of 
increased osteoblastic activity. Radiation of the attached radionuclide will then 
cause death in a fraction of cells within the range of the particles emitted and 
depending on their energy. The resulting decrease in intra-osseous mass and 
pressure brings relief to the patient. However, it is found that the reduction of 
the pain intensity takes a few days as tumour mass shrinks. So, the mechanism 
by which radiotherapy achieves analgesia probably is a mixed response due 
both to tumour shrinkage and to inhibition of pain mediators, such as 
prostaglandins and neurogenic peptides [101].  
In recent years there has been interest in the application of diphosphonates as 
potential radiopharmaceuticals for effective pain-palliation of metastatic bone 
cancer [112, 125, 126]. These versatile molecules are characterized by a P-C-P 
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structural element, and have a variety of important uses such as metal chelation 
ligands [127], therapeutic use in patients with two main types of disorders, 
ectopic calcification and ossification, and increased bone resorption [79] and in 
nuclear medicine as ligands for radiometals in bone-seeking diagnostic and 
therapeutic agents [128]. 
Phosphonates are known to have a particular affinity for calcium (Ca2+), so they 
accumulate selectively in bone [102]. Some (di)phosphonic acid derivates 
include EDTMP (ethylene-diamine-tetramethylene-phosphonate), MDP 
(methylene-diphosphonic acid), HEDP (1-hydroxy-ethylene-diphosphonic acid), 
APD (1-hydroxy-3-aminopropylidene-diphosphonic acid), APDDMP (N,N,-
dimethylene-phosphonate-1-hydroxy-4- aminopropylidene-diphosphonate) and 
recently, PEI-MP (polyethyleneiminomethyl phosphonic acid) [129]. The two last 
improve the properties of 153Sm-EDTMP, widely used in the pain palliation 
therapy of patients suffering from bone cancer, not only providing pain relief but 
also suppressing and decreasing bone metastasis and even osteosarcomas 
[59, 102, 124]. APD had been applied in the inhibition of osteoclast activity by 
adsorption on the bone surface (hydroxyapatite). In addition to minimizing 
resorption, APD also regenerates bone tissue by mobilizing Ca2+ and Mg2+ from 
blood plasma and subsequent deposition onto bone [125]. Being such a 
versatile ligand, attempts were made to capitalize its capabilities by complexing 
it to a radioactive metal-ion, and use it as a bone-cancer diagnostic agent (e.g. 
99mTc-APD for bone scintigraphy) [130]. However, in studies with trivalent 
lanthanides such as [131] 166Ho3+ and 153Sm3+ a neutral complex (MLH)0 is 
obtained and, hence, a colloid is formed at pH 7.4, which results in excessive 
liver uptake. Furthermore, APD exhibited a high affinity for Ca2+ which inhibits 
the delivery of the radionuclide 166Ho3+ to the bone. In an endeavour to avoid the 
formation of neutral species, APD was modified by adding two charged 
methylenephosphonate groups at the primary amine centre, resulting in the 
synthesis of APDDMP – with a net charge of 7. The radiolabelling of APDDMP 
with the same trivalent lanthanides resulted in complexes with a negative 
charge. Subsequent studies in animal models, using the complexes 166Ho-
APDDMP and 153Sm-APDDMP demonstrated that the uptake by the liver was 
avoided to a large extent. However, only the complex 153Sm-APDDMP showed 
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a good bone uptake, although was less than 153Sm-EDTMP [132]. MDP is use 
as a radioactive bone imaging agent after labelling with 99mTc (99mTc-MDP). 
HMDP (hydroxymethylene diphosphonate) is sometimes used to replace MDP 
to target bone. Comparing both agents, studies showed that the 
cancerous/compact bone uptake is greater for HMDP than for MDP. Another 
ligand used is HEDP. Although the bone uptake of 99mTc-HEDP is lower and its 
blood clearance slower than of 99mTc-MDP, it gives a greater contrast between 
regions of higher and lower calcification rates. As the areas with higher rates of 
calcification should be the target of a possible palliative radiopharmaceutical, 
HEDP seems to be a promising candidate [133]. 
There are several beta-emitting radioisotopes currently being used for pain 
relief including phosphorus-32 (32P), strontium-89 (89Sr), yttrium-90 (90Y), 
samarium-153 (153Sm), holmium-166 (166Ho), rhenium-186 (186Re), rhenium-188 
(188Re) and Lutetium-177 (177Lu). The individual nuclides differ in terms of 
efficacy, duration of pain relief, tumoricidal effects, repeatable treatments, 
toxicity and expense. Despite these differences all of the radionuclides or their 
attached ligands preferentially target osteoblastic surfaces, suggesting a greater 
benefit in metastasis associated with increased osteoblastic activity [59, 66]. 
The application of radionuclides for treatment of painful metastasis has been 
investigated for several decades. In 1960s, the first nuclide administered for 
pain therapy of multiple osseous metastases was 32P [134]. Initially it was 
believed that its effect was mainly from incorporation into the tumour itself. 
However, the tumour to non-tumour ratio was not very favourable and the relief 
of pain is primarily because of its uptake by the bone mineral, and not by the 
tumour. In addition, uptake was high in a rapidly dividing tissue such as the 
bowel, but particularly in the red marrow itself [65]. Today, it’s known that 32P is 
incorporated into the DNA of rapidly proliferating cells of the bone marrow as 
well as in the trabecular and cortical structures of the bone. The ratio of normal 
bone to metastatic tissue was calculated as 1:2, and therefore is relatively low 
[120]. This unfavourable ratio and the frequently observed strong 
myelosuppression were the reasons for abandoning of the 32P [69]. Also, the 
absence of any gamma radiation emitted during its decay complicated the study 
of its biodistribution and biokinetics in humans [65].  
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Many different beta-emitting radiopharmaceuticals like 89Sr-chloride, 90Y-citrate, 
90Y-DOTA-HBP, 153Sm-EDTMP, 166Ho-EDTMP, 186/188Re-HEDP, 186/188Re-MDP, 
have been investigated for use in therapy [134, 135].  
Strontium-89 chloride was the nuclide most widely used in nuclear medicine for 
therapy. It has a long physical half-life, requiring a low administered activity, 
resulting in a rather low initial dose rate. In addition, it does not need repeated 
administrations for effect [134]. Laing et al. treated 119 prostate cancer patients 
with painful metastatic bone disease, who did not respond to conventional 
therapy, by application of 89Sr. A total of 75% of the patients demonstrated a 
marked improvement of the pain status and 20% of these patients were almost 
completely pain free. The effect of 89Sr treatment began 10-20 days post 
injection and reached a maximum after 6 weeks [135, 136]. The pain 
improvement lasted for 6 months on average with a variation between 4 and 15 
months. The authors could not find a significant advantage of an activity of 3.0 
MBq/kg body weight above that of 1.5 or 2.2 MBq/kg, resulting in a 
recommended activity of 150 MBq of 89Sr. This activity has been considered the 
standard ever since [136]. Lewington et al. performed a randomized, placebo-
controlled, double-blinded study in prostate cancer patients who were refractory 
to hormonal treatment and external radiation therapy. The patients treated with 
89Sr showed a significant pain reduction compared to the patients in the placebo 
group. Considering that these patients were end-stage patients who had failed 
all conventional therapy, the effect of 89Sr treatment is impressive. Further 
studies confirmed the beneficial effect of 89Sr for pain treatment in prostate 
cancer patients [137]. Quilty et al. demonstrated in 284 prostate cancer patients 
that one injection of 89Sr was as efficient as a hemibody irradiation which often 
showed intolerable side effects [134, 138]. Depending on the extension of the 
metastatic disease, the tracer uptake in the skeletal system ranges between 
12% and 90% of the administered activity. With extensive presence of bone 
metastasis the higher the uptake in to the skeleton is. The accumulation of 89Sr-
chloride in the metastatic lesions is 5-20 times as high as the accumulation in 
normal bone tissue. Ninety days after the administration, 10-88% of the injected 
89Sr activity was found in metastatic bone lesions [139]. The effective half-life 
was calculated to be over than 50 days, thus 89Sr-chloride delivers a low dose 
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rate radiation [69]. Robinson RG reported a response rate of 81% in breast 
cancer patients with multiple bone metastases on investigating 500 patients 
with different tumours after injection of 89Sr at a standard activity [140]. Baziotis 
et al. treated 64 breast cancer patients by a single injection with 2MBq/kg body 
weight of 89Sr. They found an improvement of the pain situation in 80% of the 
cases including 35% of the patient demonstrating almost complete pain relief. 
The average time response was 3 months [141]. 
Like strontrium-89, the calcium analogue (it follows the biochemical pathways of 
calcium in the body) yttrium-90 (90Y) is taken up by the bone depending on the 
intensity of the osseous metabolism [69, 138]. Yttrium-90 (90Y) is a pure high 
energy beta emitter. Used as the citrate salt, it shows 80% uptake in the bones 
[142, 143]. In this form it has been used for pain palliation of metastatic disease. 
It has also the chemical properties suitable for chelation to several commonly 
used compounds or macrocyclic ligands such as DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) [143]. Although 90Y-citrate 
indicates high accumulation in the bone, a part of the Y3+ released by the 
dissociation of the citrate complex binds to serum, which results in delayed 
blood clearance and accumulation in the liver. Ogawa K et al. hypothesized that 
a bone-specific 90Y-labelled radiopharmaceutical could be developed. So, they 
chose DOTA as the chelating site, and DOTA was conjugated with 4-amino-1-
hydroxybutylidene-1,1-bisphosphonate (HBP). They studied the biodistribution 
of 90Y-DOTA-HBP and compared it with 90Y-citrate. Their results showed that 
90Y-DOTA-HBP had superior biodistribution characteristics as a bone-seeking 
agent and led to a decrease in the level of unnecessary radiation exposure 
compared to 90Y-citrate. Even so, the plasma stability of 90Y-DOTA-HBP was 
not as high as expected. In addition, in the case of the absorbed dose to red 
marrow, which is the dose-limiting factor of radiopharmaceuticals for palliation 
of metastatic bone pain, the ratios of the absorbed dose in red marrow to that in 
osteogenic cells were almost the same for 90Y-DOTA-HBP and 90Y-citrate. Both 
compounds might show similar degrees of myelosuppression, which is the most 
important side effect. Because the radiation dose to bone marrow is highly 
influenced by the accumulation of radioactivity in the bone, improvement in the 
clearances from the blood and other tissues do not contribute much to the 
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radiation dose to red marrow. Meanwhile, although the ratios of the absorbed 
dose in soft tissues to that in osteogenic cells of 90Y-DOTA-HBP were also 
lower than those of 153Sm-EDTMP, 153Sm-EDTMP has the advantage over 90Y-
DOTA-HBP in terms of the effective dose equivalent (0.387 mGy/MBq of 153Sm-
EDTMP compared with 0.840 mGy/MBq of 90Y-DOTA-HBP) and effective dose 
(0.232 mGy/MBq of 153Sm-EDTMP compared with 0.652 mGy/MBq of 90Y-
DOTA-HBP). It is attributed to the difference in the radiation of red marrow. 
Therefore 153Sm could be preferred to 90Y as a radionuclide used in palliation 
therapy because the energy of the 90Y β particles could be too high [142]. 
Samarium-153 is one of the vital radionuclides amongst the lanthanide 
elements from the point of view of nuclear medicine. Due to its short half-life, 
153Sm replaced the comparatively long-lived 89Sr isotope. The therapeutic 
activity is 30 times more economic than the 89Sr-chloride. Clinical studies show 
that the toxicity is lower but the palliative effect is of shorter duration than 
desired [144, 145]. Samarium-153 chelated with EDTMP, is widely used in the 
clinic for the effective palliative treatment of widespread skeletal metastasis as it 
can be concentrated in bone metastasis having an osteoblastic component. 
Samarium-153 has a short physical half-life that can be advantageous because 
it can be administered repeatedly. However, because of its short physical half-
life and its production by reactor, delivery is difficult. The range of its beta 
particles is short (average 0.55 mm), resulting in good bone to bone marrow 
ratios [65]. One hundred and eighteen patients with painful bone metastasis 
were randomly assigned to receive a single dose of 18.5MBq/kg of 153Sm-
EDTMP. The results of a patient-rated scale revealed a progressive decrease in 
pain during the first four weeks of the study in the treatment groups. 153Sm-
EDTMP is rapidly cleared from the blood into the urine and only 1% of injected 
activity remains in the blood four hours post-administration whereas it is 
retained in the bone for a long time [144-146]. Alberts et al. concluded from a 
trial with 35 patients that 0.04 MBq/kg activity is adequate for 153Sm-EDTMP, 
often requiring multiple applications for safe palliation of pain associated with 
metastatic bone cancer [128, 147, 148]. Palliative and even curative effects 
have been demonstrated in dogs using 153Sm-EDTMP to treat a variety of 
skeletal neoplasias, both primary and metastatic. In a double-blind placebo-
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controlled study, Serafini et al. investigated the effect of 153Sm-EDTMP in 80 
prostate cancer patients. Four weeks after the injection of a single dose of 0.03 
MBq/kg body weight, an improvement of the pain situation was observed in 
72% of the patients. In 31% of the patients, an almost complete pain reduction 
could be found. Four months after the treatment, 43% of the patients showed a 
continuing improvement of pain symptoms. In this study, a visual analogue 
scale for different regions of the body, the consumption of analgesics and pain 
scoring performed by the physician served as criteria for treatment response. 
The response rate of 153Sm-EDTMP group was significantly better than that of 
the placebo group, showing response rates of 40% and 2% after 4 weeks and 4 
months, respectively [149]. However, Tian et al. were not able to confirm in their 
multicenter trial that the two different activity groups of 153Sm experienced 
different quality on pain palliation [150]. Collins et al reported that the onset of 
pain relief can be expected after 7-14 days [151].  
In an attempt to improve on the success of 153Sm-EDTMP, two possible 
strategies may be deployed. The first alternative is to use higher-energy β-
emitting radionuclides, as was attempted with 166Ho-EDTMP. Holmium-166 is a 
radionuclide that emits higher-energy β--particles, which is thought to improve 
the therapeutic efficacy of bone-seeking radiopharmaceuticals due to the 
deeper soft tissue penetration. However, in the past few years others have 
argued that minimizing the dose to bone marrow by using low-energy particle 
emitters such as 117mSn, will spare the bone marrow and is, therefore, more 
likely to deliver a therapeutic dose to the cortical bone. However, the chemistry 
of a substitute radionuclide (which generally belongs to a different chemical 
element) will differ from that of 153Sm. Even when the radionuclides are 
chemically similar and occur in the same oxidation state (3+ for Sm), there may 
still be a significant difference in their in vivo behaviour, as was proven for 
Ho(III). A different radionuclide normally requires a different ligand, so that the 
complex radiopharmaceutical shows a bone uptake which would resemble that 
of 153Sm-EDTMP. The high natural abundance of 165Ho, from which 166Ho is 
easily produced by neutron activation, lowers the cost of production compared 
with that of 153Sm. The attempts with the above-mentioned ligand together with 
166Ho proved to be unsuccessful, not because of the radiation characteristics of 
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166Ho, but rather due to the chemical properties of Ho(III) in combination of the 
ligands investigated. With 166Ho-EDTMP the in vivo stability of the complex 
proved to be inadequate (owing to changes in the Ho(III)-EDTMP formation 
constants, compared with Sm(III)-EDTMP), resulting in incomplete bone uptake 
[102]. 
186Re and 188Re are excellent examples of β--emitting radionuclides that could 
be used for pain palliation of bone metastasis [76, 77]. 186Re-HEDP is the 
diphosphonate complex most frequently studied [152-154]. This 
radiopharmaceutical can also be prepared using 188Re to form 188Re-HEDP, 
requiring both the carrier Re to ensure a good yield of the bone seeking agent 
[148, 155]. The physical half-life of 186Re allows frequent repeat administrations 
in a short period of time. However, the average beta energy is considerably 
higher than of the 153Sm and, consequently, the range is higher what is 
undesirable for the bone marrow [65]. Reaction conditions for the synthesis of 
186Re-MDP must be acidic (pH 1.4 –1.6) in order to facilitate reduction of the 
perrhenate with stannous ion and to keep the reduced species from being 
oxidized [156]. The synthesis and stabilization of 186Re-HEDP is different and 
can be accomplished at pH 5–8 [65]. It has also been reported that the 
comparative instability of the 186Re-HEDP radiopharmaceutical to in vivo 
oxidation in to perrhenate is a possible advantage [123]. The 
radiopharmaceutical 186Re-HEDP washes off from normal bone faster than it 
does from cancerous bone and, consequently, the abnormal/normal bone 
uptake ratio increases with time [128, 148]. 188Re-HEDP has shown therapeutic 
efficacy in the treatment of metastatic bone pain associated with cancer of the 
breast, prostate, lung and others [77, 84, 157]. Both 186Re-HEDP and 188Re-
HEDP have been used quite successfully in alleviating pain and for treatment of 
multiple metastatic foci of bone in bone cancer patients [65]. Hsieh B-T et al. 
compared various rhenium-188-labelled diphosphonates for the treatment of 
bone metastasis. In this study, they labelled MDP, HEDP, and HDP with 188Re 
and they analysed the biodistribution and bone uptakes following an 
intravenous injection in rabbits. Their results showed that 188Re-MDP and 188Re-
HDP tended to accumulate in the soft tissue and the liver. They believe that 
reactions between rhenium and diphosphonates are not the same as those 
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between technetium and diphosphonates, irrespective of being in the same 
group on the periodic table. In fact, technetium is inherently a better oxidant 
than rhenium. More SnCl2 needs to be added in the labelling of the rhenium-
diphosphonate complex. In this study, they concluded that the presence of 
carrier significantly affects the biodistribution of 188Re-HEDP in rabbits. The 
bone to soft tissue ratio of 188Re-HEDP significantly increased after adding the 
carrier to the preparation. However, carrier did not affect the biodistribution of 
188Re-MDP or 188Re-HDP. The mechanism of the carrier effect is still not clear, 
requiring further study. Thus the authors concluded that the HEDP was better 
than MDP and HDP as a bone-seeking tracer together with 188Re [148]. 
177Lu can be produced at adequate specific activities by irradiation of the natural 
lutetium target in moderate-flux reactors, and its long half-life allows for 
shipment over long distances. Additionally, its 208-keV gamma-emission (11% 
abundance) allows imaging of its distribution to facilitate dose calculations. 
Recently, the usefulness of 177Lu-1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetramethylene phosphonate (177Lu-DOTMP) was demonstrated in a study 
performed in a mouse model [158]. The polyazamacrocyclic ligand framework 
may offer a complex which is kinetically more inert than 153Sm-EDTMP [159]. 
Dogs with osteosarcomas were previously demonstrated to be important 
models of naturally occurring disease in humans [160]. The results showed that 
the dogs receiving 177Lu-DOTMP tolerated the administration and the effects of 
the compound without apparent clinical toxicity, supporting the further 
evaluation in tumour-bearing dogs of 177Lu-DOTMP as a potential therapy for 
metastatic bone cancer and primary bone tumours in humans and dogs [143]. 
In contrast to the beta-emitters, the alpha-particle emitters deliver a much more 
energetic and localized radiation, defined as high-linear energy-transfer (LET) 
radiation [1, 160]. Despite the fact that alpha-emitters are more toxic and 
mutagenic than beta emitters, these adverse properties can be compensated in 
the targeted therapy due to irradiation of smaller volumes of normal cells when 
alpha emitters are targeting tumour cell clusters. Also the spatial distribution of 
the hydroxyapatite target within an osteoblastic tumour would facilitate a volume 
distribution of the radionuclide where the tumour cells would be easier reached 
by alpha-particles despite the limited track lengths [120].  
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The progress in the biomedical application of alpha emitters have been delayed 
by the low availability of radionuclides with proper physical and chemical 
characteristics, supply limitations, as well as the costs for the most popular 
alpha emitters, 211At (astatine-211; t½ = 7.2 h), 213Bi (bismuth 213; t½ = 45.6 
min) and 225Ac (actinium-225; t½ = 10 days) [59, 120]. Recent research on 
alpha emitters led to the development of long term operating generators that 
can provide them in large quantities. Examples of such alpha-emitters are 223Ra 
(radium-223; t½ = 11.4 days), 224Ra (radium-224; t½ = 3.7 days), 227Th 
(thorium-227; t½ = 18.7 days) and the alpha-emitter 212Pb (lead-212; t½ = 10.6 
h). In the absence of suitable complexing agents for radium isotopes 
investigation of 223Ra in radioimmunotherapy could not occur, but methods have 
recently been developed to encapsulate 223Ra and 225Ac into liposomes, 
ensuring adequate stability [120]. 
Like strontium, radium is a natural bone seeker that has previously been used 
for targeting non-malignant skeletal diseases, such as in the use of 224Ra 
(Radium-224) for treating ankylosing spondylitis, characterized by elevated 
bone synthesis [137]. Radium-223 (123Ra) is the most promising radium isotope, 
with favourable properties for use in targeted radiotherapy. 223Ra decays via a 
chain of daughter radionuclides with shorter half-life into stable lead, producing 
four alpha-particles. Radium-223 can be effectively produced in large amounts 
from sources of the precursor 227Ac (t½ = 21.7 years) in a long-term operating 
generator. Moreover, 223Ra half-life provides enough time for its preparation, 
distribution (including long distance shipment), and administration to patients. 
Its low gamma-irradiation facilitates handling, radiation protection, and 
treatment on an outpatient basis [120]. Based on the excellent physical 
characteristics of 223Ra, were performed a series of studies, aiming to analyse 
the potential of this radioisotope in the treatment of bone metastases. In a study 
with 223Ra in mice, biodistribution was measured at 1h, 6h, 24h, 3 days, and 14 
days after injection. A rapid uptake and prolonged retention was demonstrated 
in the skeleton, whereas soft tissue radioactivity cleared relatively rapidly [161, 
162]. Animal data and dosimetric studies have indicated that bone-targeting 
alpha-emitters can deliver therapeutically useful radiation doses to bone 
surfaces and skeletal metastases, at activity levels that are acceptable for 
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sparing bone marrow [163]. In a comparative study of 223Ra and the beta-
emitter 89Sr it was found out that 223Ra and 89Sr had similar bone uptake, and 
estimates of dose deposition in bone marrow demonstrated a clear advantage 
of alpha-particle emitters being bone marrow sparing [164].  
The therapeutic efficacy of 223Ra was studied in a nude mice model. In this 
study the animals were injected with 10 million MT-1 human breast cancer cells 
into the left ventricle. Seven days later they were treated with 223Ra dosage, 
ranging 6 to 30 kBq per animal. All untreated control animals had to be sacrified 
due to tumour induced paralysis 20 to 30 days following injection of tumour 
cells, whereas the mice treated with an activity superior to 10 kBq of 223Ra 
showed a significantly increased symptom-free survival. Based on the 
encouraging preclinical results, a phase I study has been conducted. This study 
involved 25 patients with bone metastases (10 females and 15 males). Each of 
the patients received a single injection of 223Ra and were monitored closely at 
the injection day, days 1, 2 and 7, and thereafter weekly to 8 week after the 
injection of 223Ra. Five patients were enrolled at each dosage level; starting at 
46 kBq/kg and then increasing to 93, 163, 213 and 250 kBq/kg of body weight. 
223Ra was well tolerated at therapeutically relevant dosages. The mild 
myelotoxicity, the generally weak side effects, and the encouraging pain scores 
found in this study encouraged the authors to conduct a phase II study [161]. 
In a randomised, double-blind, placebo-controlled, multicentre phase II study, 
the aim was to investigate the effect of repeated 223Ra doses in men with 
symptomatic, hormone-refractory prostate cancer. Sixty four patients due to 
receive local-field, external-beam radiotherapy to relieve pain from bone 
metastases were assigned to receive either four repeated monthly injections of 
50 kBq/kg 223Ra (33 patients) or repeated injections of saline (31 patients). 
Treatment lasted for 12 weeks, during which four injections were given at 4-
week intervals, with the first injection given at the time of external-beam 
radiotherapy and no later than 7 days afterwards. The results showed that 223Ra 
was well tolerated with little or no myelotoxic effect, and showed promising 
evidence of efficacy [165]. 
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A phase III, randomized, placebo-controlled, double-blind international human 
study had been conducted, comparing Alpharadin against placebo in men with 
symptomatic castration-resistant prostate cancer that has metastasized to the 
bone (ALSYMPCA – Alpharadin in Symptomatic Prostate Cancer). It involved 
921 patients, in over 100 centres in 19 different nations. They were all either 
ineligible for docetaxel, could not tolerate it, or had not responded to the therapy 
with docexatel. Patients were given either Alpharadin or a placebo intravenously 
up to six times, four weeks apart. In this study 809 patients of the 921 patients 
were included in a planned interim analysis. In June 3, 2011 the Independent 
Data Monitoring Committee recommended stopping the trial early due to 
evidence of a significant treatment benefit. The more recent data of the 921 
patients showed that Alpharadin improved overall survival by 44%, resulting in a 
30.5% reduction in the risk of death compared to placebo. The median overall 
survival benefit with Alpharadin was 3.6 months (14.9 months in patients given 
Alpharadin vs. 11.3 months with placebo). In addition to improving overall 
survival, 223Ra dichloride led to a statistically significant delay in the time to 
skeletal-related events.  Alpharadin has been granted Fast Track designation by 
the FDA. Bayer plans to file Alpharadin seeking marketing approval for 
castration-resistant prostate cancer with regulatory authorities in the United 
States and Europe based on the ALSYMPCA data in the second half of 2012 
[166, 167]. 
A radionuclide that could prove promising is radioactive 177mSn. It emits mono-
energetic conversion electrons (energies of 126-158 keV) with a discrete range 
(0.2-0.3 mm) in bone tissue, which allows for larger bone radiation doses 
without excessive radiation to the bone marrow. Being an Auger emitting 
radionuclide, 117mSn will introduce a highly localized distribution of the electrons 
once inside or close to the cell. Furthermore, 117mSn possesses a favourable 
half-life of 13.6 days that, depending on in vivo pharmacokinetics, is long 
enough to deliver more auger electrons for the treatment. In addition to these 
favourable radiation characteristics, tin-ions exhibit an inherent affinity for bone 
as is observed in biodistribution experiments with rats and adsorption studies of 
hydroxyapatite [112]. Although difficult to produce with the required specific 
activity, the interest in 117mSn arises from its favourable half-life and discrete 
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range in bone tissue, as compared with 153Sm, 32P and 166Ho [148]. In a study of 
Atkins HL, a bone to marrow ratio of 11 has been recorded for 117mSn-DTPA, 
which is far better than its closest rival, 153Sm-EDTMP. Considering 166Ho, its 
short half-life (26.7 h), might prove to be inadequate, while 117mSn (13.6 days 
half-life) would be ideal with a long half-life which is not too long to require 
radiation safety precautions. The oxidation state of the Sn is also important 
[102]. Zeevaart JR et al. sought an improved bone-seeking 
radiopharmaceutical, so they used 117mSn (II)–APDDMP. The results, using 
ECCLES (blood plasma model based on thermodynamic equilibrium), clearly 
showed that the target organs were the kidneys and bladder. ECCLES could in 
this case accurately predict that 117mSn (II)–APDDMP would have some bone as 
well as liver uptake. It furthermore, could explain the reasons for the high kidney 
uptake, namely 117mSn (II) radiopharmaceuticals are also dependant on the 
weakness of the complex between Sn (II) and the ligand carrier. This was 
verified by animal experiments with 117mSn (II)–APDDMP [94, 168]. 
A recent approach to develop an effective radiopharmaceutical for therapy of 
bone cancer, ensuring the selective uptake of the radiopharmaceutical, was to 
design a water-soluble polymer which is bone-seeking, and which would exploit 
the disrupted vasculature in tumours according to “Enhanced Permeability and 
Retention” (EPR) effect, as discussed by Maeda et al. [169] and Seymour [170] 
– the process in which macromolecules accumulate within tumour tissue due to 
leaky blood vessels and poor lymphatic clearance. The principal behind this 
scenario is that water-soluble macromolecules accumulate passively in solid 
tumours [171, 172]. 
The EPR effect is commonly observed in most solid tumours, either primary or 
metastatic in nature. In tumour biology, little is known about selective or tumour-
specific characteristics compared with those of normal tissues or organs. The 
concept of the EPR effect in solid tumours is one of the few tumour-specific 
characteristics that are becoming a gold standard in antitumor drug delivery 
[169]. 
Lyer A et al. explained this phenomenon by analysing the anatomy of the 
tumour vasculature [173]. The blood vessels in the tumour are irregular in 
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shape, dilated, leaky or defective, and the endothelial cells are poorly aligned or 
disorganized with large fenestration. Also the perivascular cells and the 
basement membrane, or the smooth-muscle layer, are frequently absent or 
abnormal in the vascular wall. The tumour vessel has a wide lumen, whereas 
tumour tissues have poor lymphatic drainage. This anatomical defect, along 
with functional abnormalities, results in extensive leakage of blood plasma 
components, such as macromolecules, nanoparticles and lipid particles, into the 
tumour tissue. Moreover, the slow venous return to tumour tissue and the poor 
lymphatic clearance mean that macromolecules are retained in the tumour, 
whereas extravasation into the tumour interstitium continues. The EPR effect is 
also modulated or mediated by various factors produced by tumour cells, 
infiltrating leukocytes or even tumour-surrounding normal cells. Blood vessels 
near tumour tissue are affected by vascular mediators, such as vascular 
permeability factor, bradykinin and prostaglandins, nitric oxide, peroxynitrite and 
matrix metalloproteinases, which increase the vascular permeability of the 
tumour tissue [171, 173, 174]. 
Through this phenomenon very high local concentrations of polymeric drugs at 
the tumour site can be achieved, for instance 10-50-fold higher than in normal 
tissue within 1-2 days. Interestingly, the EPR effect does not apply to low-
molecular-weight drugs because of their rapid diffusion into the circulating blood 
followed by renal clearance [173]. The polymer must, therefore, be large 
enough not to be taken up by healthy tissue, but not so large as to trapped in 
organs such as the liver or kidneys [111]. 
Because accumulation of macromolecules by the EPR effect is a progressive 
phenomenon, it is essential that the drugs are stable in the plasma for long 
periods. In addition to prolonging the half-life in plasma of low-molecular-weight 
drugs or proteins, polymer conjugation also guides the drugs or radionuclides to 
their target by the EPR effect. The alteration in conformation of some proteins 
or molecules constituting a drug gave a stealth character and the ability to 
suppress the antigenicity, as well as diminishes uptake by the 
reticuloendothelial system or macrophages. For example, succinylation of  
proteins or conjugation of poly(D-Glu-D-Ala-D-Lys) or poly(D-Glu-D-Lys) were 
all found to decrease substantially the immunogenicity of albumin, lactoglobulin, 
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myoglobin, γ-globulin and lysozyme. Therefore, the half-life of polymeric drugs 
in the blood circulation can be extended greatly [173]. 
Owing to the prolonged retention of the polymeric complexes by the EPR effect 
and the enhanced plasma half-life, polymer-conjugated drugs or radionuclides 
require less frequent administration compared with free drugs, which is a great 
benefit to patients [173, 175]. So, tumour-selective properties combined with a 
radionuclide with a short tissue penetration (with the resulting higher possible 
administered dose) could enable a very effective way of producing a 
radiopharmaceutical that would have not only palliative, but also therapeutic 
properties [102]. 
Dormehl IC et al., aiming for a molecule for use in palliative therapy for bone 
metastases after suitable radiolabelling and considering the EPR effect, 
developed PEI-MP (polyethyleneiminomethyl phosphonic acid), a water-soluble 
polymer polyethyleneimine, functionalised with methyl phosphonate groups, 
synthesized by condensation of polyethyleneimine, phosphonic acid and 
formaldehyde [111]. In addition to being bone-seeking, PEI-MP would 
accumulate in solid tumours due to the EPR effect. Studies followed to establish 
the biodistribution and pharmacokinetic properties of different complexes PEI-
MP/metal (99mTc, 117mSn and 186Re) [129, 168]. 
They used various molecular sized PEI-MP radiolabelled with 99mTc, taking into 
account the EPR effect, choosing three different sizes of the PEI-MP, namely 
30-300 kDa, 100-300 kDa and 10-30 kDa, to compare differences in their 
biodistribution and pharmacokinetics, using a normal primate model and 
scintigraphy. From the results, macromolecules with sizes ranging between 30-
300 kDa were characterized by excessive liver (21-57%) and kidney (40%) 
uptake and accompanying long residence times (t1/2 up to 24 hours). The 
percentage bone uptake averaged at 8% for these particles excluding sizes 
100-300 kDa, where very little bone uptake was seen (<1%). In this case the 
blood clearance was also slow (t1/2 approximately 2 hours). The fraction size 10-
30 kDa had comparatively low accumulation and short residence times in the 
liver (20%; 22 minutes) and kidneys (17.5%; 20 minutes) and although the bone 
uptake of 18% in this case was high, it is still low for a bone-seeking agent. 
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These particles cleared from the blood with t1/2 of 25 minutes, and seemed 
suitable for labelling with a therapeutic radioisotopic agent. Anionic species in 
the fraction of 10 to 30 kDa achieve good tumour uptake with minimum uptake 
in healthy bone, kidneys or liver. The polymer clearly demonstrates the potential 
to deliver a therapeutic radionuclide selectively to tumours [111]. 
Zeevaart et al. proposed that PEI-MP could be combined with radioactive 
117mSn. For the EPR effect to apply, the macromolecules of 117mSn-PEI-MP 
should be larger than 40 kDa, i.e. large enough to avoid renal clearance [102]. 
Choosing two different sizes of the PEI-MP, namely 30-50 kDa and 10-30 kDa, 
Jansen D et al. compared differences in their absorption characteristics when 
radiolabelled with 117mSn in two different oxidation states (Sn2+ and Sn4+). In 
addition to the size of the polymer, the oxidation state of the tin had a significant 
effect on the adsorption behaviour. The affinity of the tin in both valence forms 
was governed by the size of the PEI-MP ligand, with a four-fold increase in the 
affinity constants, accompanied by a slight improvement in the maximum 
absorption capacities when in presence of the smaller fraction, namely PEI-MP 
(10-30 kDa). In general, the optimum results were with Sn2+ in the presence of 
PEI-MP (10-30 kDa), where the metal-ion exhibited a higher affinity than the 
ligand whilst the adsorption capacity of the two were essentially equivalent. 
However this may not necessarily be an optimal combination when considering 
the EPR effect, in which the larger PEI-MP fraction could predominate, whilst 
the adsorption characteristics serve merely to complement the EPR 
accumulation. Furthermore, the Tin-PEI-MP complexes were not effectively 
desorbed and became immobilized on the hydroxyapatite surface, which may 
be advantageous for therapy, thereby facilitating passive accumulation of the 
radiopharmaceutical  [176]. 
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Section II. Literature Review 
Chapter 4.Bladder Cancer 
 
4.1. Introduction  
Bladder cancer is the most common malignancy of the urinary tract. The three 
main types of cancers that affect the bladder are urothelial carcinoma 
(transitional cell carcinoma), squamous cell carcinoma, and adenocarcinoma. 
Transitional cell carcinoma originate from the epithelial cells of the inner lining of 
the bladder wall, squamous cell carcinoma originate in thin, and flat squamous 
cells and adenocarcinoma originate in glandular cells that make and release 
mucus and other fluids. The cells that form squamous cell carcinoma and 
adenocarcinoma develop in the inner lining of the bladder as a result of 
metaplasia and chronic irritation and inflammation [177, 178].  
Transitional cell carcinoma is by far the most common form of bladder cancer 
accounting for more than 90% of these cancers, and is the second most 
common malignancy of genitourinary tract and the third most common cause of 
death among genitourinary tumours. Squamous cell carcinoma account for only 
6% to 8%, and adenocarcinoma account for 3% of all bladder cancers [177, 
178]. Transitional cell carcinoma is the 7th most common cancer in men and the 
17th most common in women worldwide [179].  
Transitional cell carcinoma can be subdivided by grade, stage and subtype 
[180]. Pathologic staging of bladder cancer is clinically the most powerful 
determinant in regard to patient prognosis and treatment decision in addition to 
grading [181-183]. Pathologic staging is based on the presence or absence of 
invasion and, in the case of invasive tumours, on the extent of invasion into the 
bladder wall, with the layers of the bladder wall and adjacent organs serving as 
staging landmarks [181].  
Transitional cell carcinoma has been traditionally characterized as either 
superficial or invasive. The clinical staging of bladder carcinoma is determined 
by the depth of invasion of the bladder wall by the tumour. This determination 
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requires a cytoscopy examination that includes biopsy, and examination under 
anaesthesia to assess the size and mobility of palpable masses, the degree of 
invasion of the bladder wall, and the presence of extravesical extension or 
invasion of adjacent organs. Bladder cancer tends to spread progressively from 
its origin in the mucosa to the lamina propria, muscularis, perivesical fat, and 
subsequently to contiguous pelvic structures, with an increasing incidence of 
pelvic lymph node metastases at each stage. Obviously, distant metastasis 
occurs via haematogenous dissemination, with increasing incidence of distant 
metastasis with higher stage of disease. The most affected organs by distant 
metastases of a bladder cancer are liver, lungs and bones [184]. It is important 
to note that even at the earliest stages of invasive bladder cancer, distant 
metastases can develop [177]. Most cases of transitional cell carcinoma (70%) 
present as superficial, limited to the mucosa, submucosa, or lamina propria 
[185, 186]. In general, progressive invasion into the bladder wall by microscopic 
level increases stage, including papillary urothelial carcinoma confined to the 
mucosa (pTa), papillary or nodular tumours with involvement of the lamina  
propria (pT1), nonexophytic or “flat” carcinoma in situ (CIS) confined to the 
urethelium (pTis), superficial or deep muscularis propria (pT2a and pT2b, 
respectively), perivesical fat either microscopically (pT3a) or macroscopically 
(pT3b), and adjacent organs (pT4a) or the pelvic/abdominal wall (pT4b). A 
schematic representation of transitional cell carcinoma staging is represented in 
fig. 5 [181, 185, 187].  
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The National Cancer Institute organizes and describes the stages for bladder 
carcinoma, as shown in the table 12, from stage 0 to IV [188]. 
Table 12.The National Cancer Institute staging for Bladder Carcinoma (NCI, 2014). 
Stage  Description 
Stage 0a Called papillary carcinoma, may look like tiny mushrooms 
growing from the lining of the bladder. 
Stage 0is Called carcinoma in situ, is a flat tumour on the tissue lining 
the inside of the bladder. 
Stage I Cancer has spread to the layer below the inner lining of the 
bladder. 
Stage II Cancer has spread to either the inner half or outer half of the 
muscle wall of the bladder. 
Stage III Cancer has spread from the bladder to the fatty layer of 
tissue surrounding it, and may have spread to the 
reproductive organs (prostate, uterus, and vagina). 
Stage IV Cancer has spread from the bladder to the wall of the 
abdomen or pelvis. Cancer may have spread to one or more 
lymph nodes or to other parts of the body. 
Legend: According to the National Cancer Institute, bladder carcinoma can be grouped in six 
stages. It starts by stages 0a and 0is that correspond to initial stages of the cancer where the 
cancer is still very superficial and contained. As it progresses to stages I, II, III and IV, the 
invasion to adjacent tissues or distant organs is increasingly likely. 
Figure 5.Transitional cell carcinoma staging. Carcinoma in situ, Tis or cis, are flat 
lesions showing dysplasia and are believed to be precursors to invasive urothelial cell 
carcinomas. Ta tumours represent the mildest form and show exophytic growth but do 
not engage the lamina propria. T1 tumours have transverse the basal membrane and 
engage the lamina propria. These tumours may also show a more solid growth pattern. 
Invasive tumours engage the underlying muscles and the surrounding organs in the 
most severe forms. Ta and T1 tumours are occasionally grouped together and 
characterized as superficial (Hoglund M., 2007). 
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The 2002 revision of the American Joint Committee on Cancer/International 
Union Against Cancer/Union International Contre le Cancer (AJCC/UICC) TNM 
system is the most widely used staging system at this time, and is summarized 
in table 13. This version was updated in 2009, but it has no changes for bladder 
tumours [189, 190]. 
 
Table 13.The 2009 TMN Staging System for Bladder Cancer (Edge S.B. et al., 2010). 
Primary tumour (T) 
TX 
T0 
Ta 
Tis 
T1 
T2 
   T2a 
   T2b 
T3 
   T3a 
   T3b 
T4 
 
   T4a 
   T4b 
Primary tumour cannot be assessed. 
No evidence of primary tumour. 
Non-invasive papillary carcinoma. 
Carcinoma in situ: “flat tumour”. 
Tumour invades subepithelial connective tissue (lamina propria). 
Tumour invades muscle (muscularis propria) of bladder wall. 
Tumour invades superficial muscle (inner half). 
Tumour invades deep muscle (outer half). 
Tumour invades perivesical tissue. 
Microscopically. 
Macroscopically (extravesical mass). 
Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, 
and abdominal wall. 
Tumour invades prostate, uterus or vagina. 
Tumour invades pelvic or abdominal wall. 
Regional lymph nodes (N) 
NX 
N0 
N1 
 
N2 
 
 
N3 
Regional lymph nodes cannot be assessed. 
No regional lymph node metastasis. 
Metastases in a single lymph node in the true pelvis (hypogastric, 
obturator, external iliac, or presacral), 2 cm or less in greatest dimension. 
Metastases in a single lymph node in the true pelvis (hypogastric, 
obturator, external iliac, or presacral), more than 2 cm but not more than 
5 cm in greatest dimension. 
Metastasis in iliac lymph node(s), more than 5 cm in greatest dimension. 
Distant Metastasis (M) 
MX 
M0 
M1 
Distant metastasis cannot be assessed. 
No distant metastasis. 
Distant metastasis. 
Legend: The TNM staging system for bladder cancer stages is organized in three categories, 
namely the size of the primary tumour (T), the spread to lymph nodes (N), and the presence of 
metastases (M). For each of these categories, subdivisions may be made assigning a number 
to T, N or M, in a growing sequence, where the higher the number the lower is prognosis. TX, 
NX or MX means that the tumour, invasion to regional lymph nodes and the presence of 
metastases cannot be assessed. 
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In addition to the TNM system, the cancer may also be evaluated and assigned 
a grade (G). Physicians use the term “grade” to describe how much the tumour 
tissue looks like normal bladder tissue under a microscope. Pathologic grade, 
which is based on cellular atypia, nuclear abnormalities, and the number of 
mitotic figures, is of great prognostic importance. Many urologic surgeons 
classify grading based on the chance that the cancer will recur or progress, and 
plan their treatment based on the grade. In 2004 the World Health Organization 
(WHO) developed a new grading system for early bladder cancer, which is 
increasingly being used. This system divides bladder cancers into the following 
groups, summarized in table 14 [188, 191]: 
 
Table 14.The 2004 WHO Grading System for Bladder Cancer (Miyamoto H. et al., 
2010). 
Grading Description 
Urothelial papilloma Non cancerous (benign) tumour. 
Papillary urothelial neoplasm of low 
malignant potential (PUNLMP) 
Very slow growing and unlikely to spread. 
These types of cancer may recur but 
have a low risk of progressing. 
Low grade papillary urothelial carcinoma Slow growing and unlikely to spread. 
These types of cancer are more likely to 
recur and progress compared with 
PUNLMP. 
High grade papillary urothelial carcinoma More quickly growing and more likely to 
spread. These types of cancer are the 
most likely to recur and progress. 
Legend: The 2004 WHO grading system for bladder cancer, is divided in four groups, starting 
with the urothelial papilloma that is a benign tumour, followed by groups with a increasingly 
higher malignancy, the papillary urothelial neoplasm, the low grade papillary urothelial 
carcinoma, ending with the high grade papillary urothelial carcinoma. The higher the grade, the 
greater is the ability of invasion and growth. 
 
Ta lesions account for approximately 70% of superficial transitional cell 
carcinoma. Histologically, these papillary tumours are composed of a branching 
fibrovascular core and mucosa greater than 8 cells layers with features of 
anaplasia [192, 193]. Most Ta tumours are low grade, rarely progress, and are 
associated with a favourable prognosis, whereas high-grade Ta and T1 tumours 
represent a significant risk of tumour progression and recurrence. Carcinoma in 
situ, Tis, is a flat lesion commonly found in association with malignant tumours 
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and is generally believed to be precursor of invasive cancer, being considered 
of high grade [187, 194].  
Transitional cell carcinoma is characterized by a number of chromosomal and 
genetic alterations. Cytogenetic loss and loss of heterozygosity of chromosome 
9 is particularly frequent occurring in 40-50% of the cases [187]. The most 
commonly lost region in 9p includes CDKN2A (Cyclin-dependent kinase 
inhibitor 2A gene) that frequently also shows homozygous losses. Several 
regions of chromosome arm 9q have been suggested to harbour tumour 
suppressor genes but no definite gene has so far been identified [195]. The 
receptor gene FGFR3 (Fibroblast growth factor receptor 3 gene) is activated by 
mutations in up to 70% of the Ta tumours but less frequently in invasive 
tumours [196]. The reverse pattern is seen for P53. This has led to the 
suggestion that transitional cell carcinoma may constitute two entities of 
tumours developing through two different genetic pathways [197]. 
 
4.2. Demographics and epidemiology  
Bladder cancer is the fifth most common tumour world-wide and is responsible 
for about 2% of all cancer deaths [183, 198]. More than 110.000 new cases 
were diagnosed in Europe in 2008 [199], and the estimated incidence of bladder 
cancer in the United States is approximately 70.000 new cases a year [183]. It 
is less common in women than men, ranking as the eight most common cancer 
and tenth leading cause of cancer-related death in women. A genetic 
susceptibility to bladder cancer is suggested by the marked differences in the 
gender and ethnic-related incidences of this cancer [194]. Although most 
patients are older than 60 years of age, bladder cancer may affect younger 
patients [180]. 
In most countries of the Western world, bladder cancer is predominantly of 
transitional cell type; and the great majority of cases are thought to be induced 
by inhaled carcinogens in cigarette smoke, whereas in countries in which 
bilharziasis is endemic, most bladder cancers are squamous cell carcinomas. 
There are significant variations in incidence, morbidity, and mortality rates of 
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bladder cancer in different countries and ethnic groups [200]. African American 
men have a much lower incidence of bladder cancer, but their mortality rates 
are similar to whites [201]. 
The incidence of transitional cell carcinoma ranks it as the sixth most common 
cancer and as the fourth most common if transitional cell carcinoma stage Ta is 
included. The variations noted can partly be attributed to different methodology, 
mainly the inclusion  of transitional cell carcinoma stage Ta or carcinoma in situ 
in different national registries, thus even among countries with comparable 
intensity of care and similar transitional cell carcinoma risks, epidemiologic data 
vary [179]. 
Non-muscle-invasive tumours have a high prevalence because their low 
progression rates allow many patients to survive a long time, while patients with 
muscle-invasive disease are at significantly higher risk of dying from their 
disease. The prevalence of transitional cell carcinoma is among the highest for 
all urologic malignancies [179]. 
 
4.2.1. Risk factors for urothelial bladder cancer 
Risk factors are best differentiated into inherited genetic predispositions and 
external exposures [179]. 
The risk of bladder cancer is two-fold higher in first-degree relatives of bladder 
cancer patients. Inherited genetic factors, such as the genetic slow acetylator N-
acetyltransferase 2 variants and glutathione S-transferase mu 1 null genotypes, 
have been established as risk factors for bladder cancer. Factors such as slow 
acetylation may not intrinsically lead to bladder cancer but may confer additional 
risk to exposure of carcinogens such as tobacco products [179]. 
Smoking is recognized as the most important risk factor for urothelial bladder 
cancer and is estimated to account for 50% of tumours [202]. In 1956 Lillienfield 
et al [203] first documented an association between cigarette smoking and 
bladder cancer, and this relationship has since been confirmed in multiple 
epidemiologic studies. Smokers have a 4-times higher increased incidence of 
 
 
90 
 
cancer versus non-smokers, and this risk correlates with number of cigarettes, 
duration of smoking, and degree of inhalation [182, 204]. Tobacco smoke 
contains aromatic amines, such as β-naphthylamine, and polycyclic aromatic 
hydrocarbons known to cause urothelial bladder cancer. These are renally 
excreted and exert a carcinogenic effect on the entire urinary system. Tobacco 
consumption is common, and thus its epidemiologic impact is massive [202]. 
Following smoking, occupational exposures to carcinogens – namely, aromatic 
amines (benzidine, 4-aminobiphenyl, 2-naphthylamine, 4-chloro-o-toluidine), 
polycyclic aromatic hydrocarbons, and chlorinated hydrocarbons – is viewed as 
the second most important risk factor for urothelial bladder cancer. Roughly 
20% of all urothelial bladder cancers have been suggested to be related to such 
exposure, mainly in industrial areas processing paint, dye, metal, and petroleum 
products [179, 180, 194, 205]. Detoxification of these carcinogens by the rapid 
acetylation of aromatic amines may prevent their carcinogenic action [206]. 
Higher bladder cancers rates are also seen in those with defects in the P450 
cytochrome oxidase system, suggesting a role for this system in carcinogen 
detoxification [207]. The number of bladder cancers resulting from exposure to 
aromatic amines is at this time very small, given to the banning of many of 
these carcinogens and their derivates from the workplace.   [194].  
As for other cancers, nutritional aspects have been attributed to urothelial 
bladder cancer risk. Fluid intake is commonly evaluated because of its impact 
on voiding, but the association with bladder cancer is controversial. On one 
hand, the amount of fluid ingested may reduce exposure of urothelial tissue to 
carcinogens by diluting urine and increasing the frequency of micturition, but on 
the other hand, the type of fluid is related to urothelial bladder cancer risk if it 
contains relevant carcinogens such as arsenic and disinfection by-products 
[179, 208]. 
Michaud et al performed a case-control study finding water intake to be 
inversely associated with urothelial bladder cancer risk, as they observed 
urothelial bladder cancer risk halved in subjects consuming greater compared 
with smaller amounts of fluids per day. Chlorination of drinking water and 
subsequent levels of trihalomethanes have been viewed as one source of 
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relevant carcinogens [209]. While coffee, a complex mixture of chemicals, has 
been suggested as a possible urothelial bladder cancer relevant carcinogen, 
such an effect remains controversial. Villanueva et al recently evaluated the 
relation of coffee consumption to urothelial bladder cancer incidence in a case-
control study and found only a modest increase in risk among coffee drinkers, 
which was confounded by smoking [210]. In a recent meta-analysis of 16 case-
control and 3 cohort studies, Pelucchi et al found no association between 
amount of alcohol consumption and urothelial bladder cancer risk [211]. 
Besides fluid intake, dietary habits have been considered relevant in urothelial 
bladder cancer tumorigenesis, as many carcinogens ingested via food are 
excreted into the urine, resulting in direct exposure of the urothelium. In other 
cancers, consumption of meat has been suggested to increase risk while 
consumption of vegetables and fruits has been suggested to be beneficial. In 
urothelial bladder cancer, however, neither effect is evident [179]. 
With regard to gender, women have a lower urothelial bladder cancer incidence 
and a higher mortality rate than men. Palou et al found female gender to be an 
adverse prognosticator of time of recurrence, progression, and cancer-specific 
survival in patients with pT1 urothelial bladder cancer undergoing bacillus 
Calmette-Guérin therapy [212]. While there is no uniform theory to explain these 
phenomena, unequal access to health care, delays in diagnosis and treatment, 
environmental exposure to carcinogens, anatomic and hormonal factors have 
been suggested [179].  
Few data on the impact of race in urothelial bladder cancer incidence exist. 
However, African Americans show a lower age-standardized incidence rate per 
100 000 of 13, compared with 22 in white individuals in the United States, and 
black race has been reported to be associated with adverse stage at initial 
presentation and reduced survival in a recent Surveillance Epidemiology and 
End Results (SEER) analysis [213]. 
In a further SEER analysis, marital status has been reported to affect urothelial 
bladder cancer survival, as married men had better survival than unmarried 
men independent of other factors such as race, socioeconomic status, 
comorbidities, or aggressive treatment [214]. Low socioeconomic status has 
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been related to unfavourable urothelial bladder cancer-specific survival in an 
analysis of patients receiving social welfare medical aid in a recent analysis, 
while previous reports did not find such an effect [215]. While no stringent 
explanations have been established for these phenomena, reduced access to 
health care and increased exposure to the main urothelial bladder cancer-
related carcinogen – that is, smoking – have been postulated [179]. 
Medical conditions may predispose individuals to bladder tumorigenesis through 
direct causation or as a side effect of treatment. Examples of direct causative 
roles include chronic urinary retention and upper tract dilation increasing 
urothelial exposure to carcinogens and carcinogenesis associated with chronic 
inflammation or schistosomiasis [179].   
Chemotherapeutic agents and pelvic radiotherapy have also been implicated in 
the development of bladder cancer. Cyclophosphamide induces bladder cancer 
in human beings in a dose-response relationship that may be related to the 
development of drug-induced hemorrhagic cystitis. Overall, patients treated with 
cyclophosphmide have up to a 9-fold increased risk of bladder cancer [216]. 
Pelvic radiotherapy results in a 4-fold increase in the risk of bladder cancer in 
women receiving between 30 and 60 Gy for the treatment of cervical cancer 
[217] 
The risk factors for the development of superficial transitional cell carcinoma are 
summarized in table 15. 
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Table 15.Major risk factors for development of superficial transitional cell carcinoma 
(Amling C.L., 2001; Burger M. et al., 2013). 
Cigarette smoking 
       4-Aminobiphenyl 
       O-toluidine 
Occupational arylamine exposure 
       2-Naphthylamine 
       Benzidine 
       4-Aminobiphenyl 
Chemotherapy 
      Cyclophosphamide 
Pelvic radiotherapy 
Legend: The major risk factors for the development of superficial transitional cell carcinoma are 
mainly the exposition to aromatic amines, polycyclic aromatic hydrocarbons, and chlorinated 
hydrocarbons resulted from cigarette smoking and occupational exposure. Also the exposure to 
chemotherapeutic agents and pelvic radiation resulted from pelvic radiotherapy, are risk factors 
for the development of superficial transitional cell carcinoma. 
 
4.3. Diagnosis 
Physical examination should include rectal and vaginal bimanual palpation. A 
palpable pelvic mass can be found in patients with locally advanced tumours. In 
addition, bimanual examination under anaesthesia should be carried out before 
and after transurethral resection to assess whether there is a palpable mass or 
if the tumour is fixed to the pelvic wall. However, considering the discrepancy 
between bimanual examination and pT stage after cystectomy (11% clinical 
overstaging and 31% clinical understaging) some caution is suggested with the 
interpretation of bimanual examination [188]. 
The most common sign of bladder cancer is haematuria. Approximately 80% of 
all patients with transitional cell carcinoma will be diagnosed with either gross or 
microscopic haematuria [218]. The distinction between gross and microscopic 
haematuria is not a useful guideline to distinguish between patients who need 
evaluation and those who do not [183]. Cystoscopy must usually be included for 
an adequate evaluation of haematuria and remains the cornerstone for the 
diagnosis of bladder cancer. Urine cytologic study is an important non-invasive 
tool used in the diagnosis and follow-up of patients with transitional cell 
carcinoma. It can be obtained from both voided and bladder barbotage urine 
specimens [219]. The disadvantage of urine cytologic study is its poor sensitivity 
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for detection of low-grade cancers. Because the cells of such tumours closely 
resemble normal urothelium, it is much more difficult to identify them as 
abnormal [220].  
However, although bladder cancer is usually asymptomatic, some patients 
(particularly those with carcinoma in situ) will initially be seen with significant 
symptoms of bladder irritability, including urinary frequency, urgency, and 
dysuria [194]. 
Various imaging modalities are used not only for detection but also for staging 
of infiltrating urothelial carcinoma. They include ultrasound, intravenous 
urography (IVU), CT and MRI [180]. 
Transabdominal ultrasonography of the bladder is quick, non-invasive, 
inexpensive and available in most institutions. However, staging accuracy is 
less than 70% for infiltrating bladder tumours. Sensitivity reaches only 63%, yet 
with a specificity of 99% [180]. Ultrasonography may be useful in detecting the 
presence of a renal mass and in determining whether it is solid or cystic in 
nature. However, is inadequate to evaluate the urothelium for filling defects that 
would be most consistent with transitional cell carcinoma [183]. 
While IVU is reliable in diagnosing intraluminal processes in ureter, pelvis and – 
with lesser accuracy – in bladder, it fails to detect the extent of extramural 
tumour [180]. Although it has obvious limitations, IVU is still the preferred initial 
imaging modality. The upper urinary tract collecting system is usually well 
visualized by IVU with or without concomitant retrograde pyelography. However, 
IVU is significantly more sensitive in detecting filling defects in the upper urinary 
tract than in the bladder [183].  
Recent studies have begun to explore the utility of CT scanning in the initial 
evaluation of microscopic haematuria. The advantage of this modality is a more 
sensitive evaluation of the renal parenchyma for small renal masses, improved 
detection of non-urologic disease processes that otherwise would have been 
missed on IVU [194].  In most institutions CT is used as a primary staging tool 
as it is more accessible and more cost effective than MRI. However, both CT 
and MRI scanning often fail to differentiate between edema post-transurethral 
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resection and tumour [180]. The urothelium is not well evaluated by CT, 
particularly for identification of smaller urothelial lesions. In the bladder, CT 
scanning is unable to detect tumours smaller than 1 cm and cannot differentiate 
between superficial and intramural tumour invasion [194]. Staging accuracy of 
CT has been described in the range of 55% for urothelial carcinoma in the 
urinary bladder. Understaging of lymph node metastases in up to 40% and 
overstaging 6% of the cases are the major causes of error [180]. However, CT 
scanning can detect extravesical tumour extension (stages T3 and T4) with 
80% accuracy and is useful in ruling out lymph node involvement and distant 
metastases [221]. MRI appears to be somewhat better to assess the depth of 
intramural invasion and extravesical tumour growth but does not exceed 83% 
[180]. 
Unlike in other tumours diagnostic accuracy of positron emission tomography 
(PET) in patients with invasive carcinoma of the bladder is poor [180]. 
If a bladder tumour has been visualised unequivocally in earlier imaging studies, 
such as CT, MRI, or US, a diagnostic cytoscopy may be omitted and the patient 
can proceed directly to TUR for a histological diagnosis. The goal of TUR is to 
enable histopathological diagnosis and staging, which requires the inclusion of 
bladder muscle in the resection biopsies. The strategy of resection depends on 
the size of the lesion. Small tumours (less than 1 cm) can be resected en bloc, 
where the specimen contains the complete tumour plus a part of the underlying 
bladder wall including bladder muscle. Larger tumours have to be resected 
separately in fractions, which include the exophytic part of the tumour, the 
underlying bladder wall with the detrusor muscle and the edges of the resection 
area [188, 222].  
 
4.4. Therapy 
Systemic treatment options for bladder cancer include surgery, chemotherapy, 
radiation, and immunotherapy. Treatment modalities are often combined. In 
early bladder cancer, transurethral resection is a common mode while partial or 
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radical cystectomy is performed for muscle-invasive and locally advanced 
bladder cancer [177]. 
The standard initial treatment of superficial bladder cancer is transurethral 
resection of all visible bladder lesions. This establishes the diagnosis and allows 
pathologic analysis of the resected tumour specimen for tumour grade and 
depth of bladder invasion [177, 194]. A significant number of patients with 
superficial bladder cancer who are treated with transurethral resection alone will 
have development of tumour recurrence or progression at some point in their 
follow-up. Sixty to seventy percent of superficial bladder cancers recur, and 
20% to 30% of these recurrent tumours will eventually progress to higher stage 
or grade disease. The high recurrence rate and the probability of disease 
progression have led to widespread use of intravesical therapy after initial 
tumour resection. The main goal of intravesical therapy in the treatment of 
superficial bladder cancer is to prevent tumour recurrence and progression 
[223].  
In patients with low-risk tumours, that is, tumours that are small, solitary, well-
differentiated, and pathologic stage Ta, adjuvant treatment after surgical 
resection may be unnecessary. These patients have a relatively benign type of 
superficial cancer that is unlikely to recur after transurethral resection. A much 
larger group of patient consists of those who will have development of a 
superficial recurrence of their cancer without progression. In these patients, 
intravesical chemotherapies may be given to decrease the recurrence rate 
[224].  
Some chemotherapeutic agents used for intravesical therapy are thiopeta, 
doxorubicin, mitomycin-C, epirubicin and ethoglucid.  
Thiopeta is an alkylating agent that inhibits the synthesis of nucleic acid, 
therefore interfering with protein synthesis. Because its molecular weight is 
relatively low at 189, systemic absorption and toxicity can occur [194].  
Doxorubicin is an anthracycline antibiotic that exerts its antineoplastic effect by 
binding to pairs of DNA, interrupting DNA replication and transcription and 
inhibits protein synthesis. Although it is classified as a non-cell cycle-specific 
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agent, its most toxic effect is seen in the S-phase of the cell cycle. Doxorubicin 
has a relatively high molecular weight of 580, and thus absorption and systemic 
toxicity is extremely rare [225].  
Mitomycin-C is an alkylating agent with a mechanism of action that is poorly 
understood. Some evidence suggests that it acts by binding to DNA resulting in 
synthesis intubation and strand breakage. Although it is classified as a non-cell 
cycle-specific agent, mitomycin-C is most sensitive in late G1 and the early S-
phase. With a molecular weight of 334 kDa, mitomycin-C is minimally absorbed 
[194].  
Epirubicin is an anthracycline derivative of doxorubicin. The mechanism of 
action of this agent is similar to that of doxorubicin. The toxicity profile, however, 
appears to be more favourable [226].  
Ethoglucid is a podophyllin derivative with molecular weight of 262 kD. Its 
mechanism of action is similar to that of an alkylating agent [227].  
In a review of the long-term results of intravesical therapy in superficial bladder 
cancer, Lamm [228] found that in a group of 3899 patients the percentage of 
patients with short-term recurrences decreased 14% with the use of intravesical 
chemotherapeutic agents. The results among various chemotherapeutic agents 
were comparable. However, the modest 14% short-term advantage to 
intravesical chemotherapy disappears within a period of 5 years with no 
apparent advantage to the use of maintenance therapy [229]. The use of 
chemotherapy should be restricted to patients with tumours of intermediate or 
low-risk.  
Photodynamic therapy is another option that allows effective ablation of most 
superficial tumours. The advantages of laser treatment are minimal bleeding, 
ability to use with flexible cytoscopes, and the potential for less postoperative 
irritative symptoms [230]. Photodynamic therapy relies on the photosensitization 
of cancerous cells with subsequent administration of light therapy.  
Treatment of superficial bladder cancer with photodynamic therapy was first 
described in 1975 [231]. A hemoporphyrin photosensitizer was given 
intravenously with subsequent activation by mercury light illumination of the 
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bladder [232]. Effective photosensization and cell death requires oxygen in 
addition to the sensitizer and the light source. After excitation by light exposure, 
the photosensitizer reacts with oxygen to form cytotoxic free radicals [233]. 
Photodynamic therapy is less effective in larger bladder cancers, likely because 
of the relative lack of oxygen in portions of these tumours.  
Photofrin (porfimer sodium), a porphyrin mixture of dihematoporphrin ethers and 
esters, is the most commonly used sensitizer in bladder cancer [232]. Although 
photodynamic therapy appears to be effective, its widespread use has been 
limited by its toxicity. Most patients have significant irritative bladder symptoms 
associated with microscopic haematuria that usually peaks on the second post-
treatment day. Dermal sensitivity resulting in sunburn has been reported in 19% 
of patients. Decreased bladder volume (at least 50%) occurs in 16% of patients 
and debilitating bladder fibrosis can also occur, leading to cystectomy [232]. 
Intravesical immunotherapy is used successfully in patients in whom other 
forms of intravesical therapy failed [194]. Immunotherapy can be used to 
enhance the host immune functions against tumour cells. Intravesical 
immunotherapy in bladder cancer has been attempted with agents such as 
bacilli Calmette-Guerin (BCG), interferon, bropirimine, keyhole limpet 
hemocyanin, etc.  
BCG is commonly used and is the most effective immunotherapeutic agent 
against superficial transitional cell carcinoma [234, 235] and is known to 
decrease the rate of progression [236, 237]. However, only two thirds of patient 
respond to BCG and one third of the responses will have recurrent disease 
[238-241]. The exact mechanism of action of BCG remains uncertain, however 
it is known that BCG organisms bind to the urothelium, facilitated by fibronectin, 
and initiate an immune response [242, 243]. It is uncertain whether the 
antitumor effect of BCG is due to a tumour antigen-specific humoral or cell 
mediated response or whether it is due to local release of cytokines. However, 
although an intact T-cell immune system appears to be necessary for antitumor 
effect of BCG, tumour-specific T cells have not been shown to be induced by 
BCG treatment [244]. Also care should be taken to avoid the toxicity associated 
with this agent [245].  
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Keyhole-limpet hemocyanin (KLH) is a high-molecular weight protein antigen 
derived from the hemolymph of the giant keyhole limpet (sea mollusk). It is a 
nonspecific immunostimulant inducing both a cell-mediated (delayed type) and 
humoral (antibody) response in human beings. Olsson et al [246] reported the 
first use of KLH for superficial bladder cancer in 1974. A randomized control 
study demonstrated that KLH was as effective as mitomycin-C in the 
prophylaxis of recurrent tumours [247]. KHL appears to be less effective than 
BCG with regard to tumour prophylaxis [247].  
Interferon-α has been the most extensively studied interferon for the treatment 
of bladder cancer. Interferon’s are produced by several cell types in response to 
antigenic stimuli and have multiple antitumor activities. It is effective with either 
papillary disease or carcinoma in situ and can be useful in patients whose 
conditions have failed to respond to BCG previously [248]. 
For muscle invasive bladder cancer the standard treatment is radical 
cystectomy. Although 70% muscle invasive bladder cancer recur or progress to 
metastatic disease despite radical treatment, radical cystectomy with bilateral 
pelvic lymph node dissection remains the gold standard for patient management 
and is associated with 5 and 10 year relapse-free survival rates of respectively 
68% and 66% [249].  
Conservative management with organ preservation is now the standard of care 
in numerous malignancies, including carcinomas of the breast, the anus, and 
the head and neck region, where radical surgery can be avoided in most 
patients without compromising survival [250].  
Radical cystectomy may cause important changes in the lives of patients, not 
only in urinary and sexual function, but also in social function, daily living 
activities and satisfaction with body image [186, 251]. Bladder preservation to 
the patient means less surgery, no need for a urinary diversion, and the 
possibility of a normal sexual life. Modern sophisticated techniques for urinary 
diversion have not altered the fact that cystectomy is still associated with 
physical and psychological limitations [252].  
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The non-surgical treatment of invasive bladder cancer has been traditionally 
reserved for patients who are unfit for, or refuse radical cystectomy, but there is 
growing evidence that the evolution of radiotherapy techniques and the 
availability of new chemotherapeutic protocols have made bladder-saving 
treatment a competitive alternative to radical cystectomy in selected patients 
[198]. However, although bladder preservation may be attained by means of 
transurethral resection, chemotherapy or radiotherapy as single treatments, 
historical series show that local disease in controlled in only about 20% of 
patient treated with transurethral resection alone [253, 254] and  40% treated 
with radiotherapy alone [255, 256].  
Some studies have shown that combined transurethral resection and 
chemotherapy [230, 257] or radiotherapy and chemotherapy [258, 259] can 
improve the disease, but the best results are obtained using a trimodality 
strategy in which radiochemotherapy follows transurethral resection.  
Current therapy options may be summarized and organized according to the 
stage of the tumour, as can be seen in table 16.  
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Table 16.Current treatment options for bladder carcinoma, according with the stage of 
tumour (Witjes J.A. et al., 2013). 
Stage Treatment options 
Stage 0 TUR with fulguration alone, followed by intravesical BCG or intravesical 
chemotherapy. 
Segmental cystectomy (rarely indicated) or radical cystectomy in selected 
patients with extensive or refractory superficial tumour. 
Stage I TUR with fulguration alone, followed by intravesical BCG or intravesical 
chemotherapy. 
Segmental cystectomy (rarely indicated) or radical cystectomy in selected 
patients with extensive or refractory superficial tumour. 
Interstitial implantation of radioisotopes with or without external-beam 
radiation therapy. 
Stage II Radical cystectomy with or without pelvic lymph node dissection. 
Neoadjuvant platinum-based combination chemotherapy followed by 
radical cystectomy. 
External-beam radiation therapy (EBRT) with or without concurrent 
chemotherapy. Interstitial implantation of radioisotopes before or after 
EBRT. 
TUR with fulguration (in selected patients). 
Segmental cystectomy (in selected patients). 
Stage III Radical cystectomy with or without pelvic lymph node dissection. 
Neoadjuvant platinum-based combination chemotherapy followed by 
radical cystectomy. 
EBRT with or without concurrent chemotherapy or with interstitial 
implantation of radioisotopes 
Segmental cystectomy (in highly selected cases). 
Stage IV Radical cystectomy with pelvic lymph node dissection. 
External-beam radiation therapy. 
Urinary diversion or cystectomy for palliation. 
Chemotherapy as an adjunct to local treatment. 
Legend: The current treatment options for bladder cancer according with the stage of the 
tumour are TUR and segmental cystectomy for initial stages, resorting to more aggressive 
therapies in the more advanced stages of the tumour, like radical cystectomy, chemotherapy 
and radiotherapy. As can be seen, the therapy is not achieved by applying only one technique, 
but rather by combining several therapeutic techniques. 
 
Over the last decade, the growing use of targeted therapies in everyday clinical 
practice has led to dramatic changes in the medical treatment of all but a few 
tumours. Unfortunately, bladder cancer is not one of these: a number of trials of 
epidermal growth factor receptor and/or vascular endothelial growth factor-
targeting tyrosine-kinase inhibitors have led to discouraging results when 
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administered alone to patients with advanced disease [260-264], and the role of 
monoclonal antibodies combined with chemotherapy in unclear [265, 266]. 
Also there is no reference to the use of radionuclides/radiopharmaceuticals for 
systemic radiotherapy, it is important to notice that some molecules with specific 
properties, properly radiolabelled could have an important potential to be used 
as agents for directed therapy, or even diagnosis, of bladder cancer and its 
metastasis. As described in Chapter 3, from the various studies performed with 
PEI-MP labelled with several radionuclides, the dosimetric calculations 
demonstrated that the critical organ was consistently the bladder [111, 129, 
174, 267]. The high value of accumulation and retention by the bladder wall by 
different radiolabelled PEI-MP complexes seems something that deserves to be 
further and better studied. If these complexes are highly uptake by normal 
bladder cells, could it be that the uptake by bladder tumour cells is also high? 
And also taking in consideration the EPR effect associated with PEI-MP [169, 
170], thus this polymer has a potential for therapy or diagnosis after convenient 
radiolabelling? These are some questions that led to the development of this 
work. 
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Section III. Experimental Studies 
Chapter 5.In vitro 
 
5.1. Introduction 
As described in Chapter III, polyethyleneiminomethyl phosphonic acid (PEI-MP) 
was developed by Dormehl IC et al [111], is a water-soluble polymer for use in 
palliative therapy of bone metastases after suitable radiolabelling [67, 111]. 
After preliminary experiments to achieve biodistribution of and pharmacokinetic 
properties of different complexes PEI-MP/metal radionuclides [129, 174, 267],  it 
was clear that the bladder wall was the critical organ [111, 267]. The high 
uptake and retention by the bladder wall cells of different PEI-MP/metal 
radionuclides seems something that deserves to be further and better studied. 
As referred in Chapter 4, the possibility of a high uptake of PEI-MP complexes 
by bladder tumour cells, associated with the EPR effect [169, 170], assigns a 
high potential to the PEI-MP, if appropriately radiolabelled, for diagnosis and 
therapy of bladder cancer. More specifically, through the use of 99mTc-PEI-MP 
for nuclear medicine imaging or of 188Re-PEI-MP for radionuclide therapy. This 
second complex could be used as a theranostic agent. 
Thus, the aim in this chapter is to explore in vitro, the potential of PEI-MP 
radiolabelled with 99mTc or 188Re, for the early diagnosis and therapy of bladder 
cancer, through the evaluation of the chemical properties of PEI-MP, the 
radiotoxicity of 99mTc and the kinetics of 99mTc-PEI-MP and 188Re-PEI-MP  in a 
human bladder transitional cell carcinoma cell line. It is also an objective to 
compare the potential of those complexes in a human osteosarcoma cell line, 
taking into account the original intent of the synthesis of PEI-MP.  
To perform this work, it is reported the synthesis, the radiolabelling procedures, 
the quality control protocol, the partition coefficient determination of 99mTc-PEI-
MP, the evaluation of cytotoxicity of PEI-MP by MTT assay and flow cytometry, 
the evaluation of radiotoxicity of 99mTc by clonogenic assay and flow cytometry 
and the cellular uptake and retention studies of the 99mTc-PEI-MP and of the 
188Re-PEI-MP. 
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5.2. Material and methods 
5.2.1. Synthesis of PEI-MP 
Synthesis of the polymer PEI-MP was achieved by condensation of 
polyethyleneimine (PEI), phosphorous acid and formaldehyde by a modified 
Mannich-type reaction in the presence of hydrochloric acid, as described by 
Moedritzer and Irani [111, 132, 268], and prepared in the Radiochemistry 
Department of the Nuclear Energy Corporation of South Africa (NECSA) 
laboratories by doctors Werner Louw and Jan Zeevaart. The reaction was 
performed under an inert atmosphere by continuous purging with argon. 
Phosphorous acid (18.4 g) (Riedel-de Haën AG) was dissolved in 51.3 ml of 
concentrated hydrochloric acid (32%, pro analysis, E Merck, Darmstadt) and 
then was added to a reaction vessel equipped with a thermometer, a magnetic 
stirrer bar, a dropping funnel and a condenser. Dissolution of the phosphorous 
acid was achieved by stirring and heating to 80ºC. The dropping funnel was 
charged with 32% formaldehyde solution (23.3 ml) (pro analysis, E Merk, 
Darmstsdt) which was added drop wise to the reaction mixture. On completion 
the temperature was raised to 90ºC (refluxing temperature) and a solution of 
polyethyleneimine (8.33 g in 40 ml of water, PolyminTM Water-Free, a BASF 
product in which the ratio of primary, secondary and tertiary amine groups is 
1:1:1) was slowly added to the reaction mixture at a rate of 0.3 ml/min with the 
aid of a peristaltic pump. On completion of the addition of polyethyleneimine, 
the mixture was stirred under reflux for an additional hour, then allowed to cool 
slowly during which the product separated as viscous oil. After decanting the 
mother liquor, 50 ml of water was added to oil which formed a doughy mass 
upon stirring. The liquid phase was decanted and the process repeated twice. 
The doughy material was dissolved in 37 ml molar sodium carbonate solution to 
form the water-soluble sodium salt of the PEI-MP. After lyophilisation, 12 g of 
product were obtained.  
To obtain 10 to 30 kDa fraction, the macromolecule PEI-MP was further purified 
into different macromolecular sized MW-fractions using membrane ultrafiltration 
(polyether sulfone membranes). An aqueous solution of sodium PEI-MP was 
subjected to a sequential filtration process through a sequence of 300, 100, 50, 
30, 10 and 3 kDa ultrafiltration membranes (Filtron Technology Corporation. 
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Mass., USA). The membrane was washed with distilled water to a theoretically 
calculated purity of 99%, to yield 3-10, 10-30, 30-50, 50-100 and 100-300 kDa 
macromolecular sized MW-fractions. Typical elemental analysis gave a C:N 
molar ratio of 2.97:1, which on the basis of an empirical formula of a PEI-MP 
monomer of C9H18N3O9P3, indicates a high level of methylphosphonation, in 
contrast to PEI with a monomer empirical formula of C6H5N3 and a ratio C:N of 
2:1 [111, 269]. The chemical structure of PEI-MP is represented in fig. 6 [270]. 
 
 
 
5.2.2. Preparation of PEI-MP labelling kits 
The reconstitution of the PEI-MP labelling kits were performed by adding 500 
mg of PEI-MP (10 to 30 kDa) in 25 ml of water (pH = 6.0). The solution was 
purged with argon during 15 minutes and subsequently was filtrated through a 
0.22 µm filter (Frilabo 1520012). To this solution was added 0.05 ml of a 
solution previously prepared, comprising 0.5 mg of SnCl2.2H2O (Merck 
1116845) dissolved in 1.0 ml 10M hydrochloric acid (Sigma H1758), pH = 5.0 to 
6.0. The volume of this solution was adjusted with water and 1ml was 
dispensed into sterile vials. This solution was lyophilized and the vials flushed 
and filled with sterile argon.  
 
Figure 6.Chemical structure of PEI-MP (Milner R.J., 2013). 
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5.2.3. Preparation of 99mTc- PEI-MP and 188Re-PEI-MP  
For the preparation of 99mTc-PEI-MP, it was added directly to the PEI-MP kit, 
1739 to 1850 MBq (47 to 50 mCi) of sodium pertechnetate (Na99mTcO4) in a 
volume of 2 ml, without introducing air. The kit was inverted a few times to 
dissolve the freeze-dried contents. It was left to stabilize at room temperature 
for 15 minutes before use. The labelling was possible given to the reduction of 
99mTc from the oxidation state +7 to +5, making 99mTc reactive and able to form 
chemical bonds with  the nitrogen of the amine groups in PEI, and/or make 
chemical bonds with phosphorus in the methyl-phosphonate groups [74, 269]. 
All 99mTc-pertechnetate was given by the Departments of Nuclear Medicine of 
the Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitário de 
Coimbra, and Instituto Português de Oncologia de Coimbra Francisco Gentil, 
E.P.E.  
For the preparation of 188Re-PEI-MP, it was necessary to acquire an 188W/188Re 
generator (itm AG Rhenium-188 Generator), to obtain sodium perrhenate 
(Na188ReO4). For the preparation of 
188Re-PEI-MP, a more complex labelling 
process was needed. The range of 188Re activities obtained by the elution of 
188W/188Re to perform the labelling of PEI-MP at this time were about 370-740 
MBq (10-20 mCi), and the specific activity of 188Re was 982 Ci/mg, meaning 
that for 10 mCi there was 10 ng of 188Re. For the amount of PEI-MP present in 
the labelling kits, the introduction of 10 mCi of 188Re would result in poor 
radiochemical purity. To this reason it was needed to add cold rhenium in the 
form of sodium perrhenate (NaReO4).  
For the preparation of cold NaReO4 it was dissolved 5 mg of Re-metal were 
dissolved in 2 ml of 10% hydrogen peroxide (H2O2). The solution was left to 
react during 2 hours at room temperature to form perrhenic acid (HReO4). The 
HReO4 was neutralized with a stoichiometric amount of 0.1M of sodium 
hydroxide (NaOH) to form NaReO4. The solution was then evaporated to 
dryness (80-90 ºC) overnight.  
To the labelling it was used only deoxygenated solvents and solutions, and 
performed all operations under an inert atmosphere of argon. The labelling kit 
was dissolved in 1.0 ml of ultrapure and deoxygenated water, and was added 
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an appropriate volume of NaReO4 (3.83 mg/ml) and 370-740 MBq (10-20 mCi) 
of Na188ReO4. The pH of the solution was adjusted to 1 with 1M hydrochloric 
acid (HCl). The kit was heated in boiling water bath during 30 minutes and after 
left to cool to room temperature. After, citrate buffer 1.0M was added and the 
pH was adjusted to 5.0-7.0 with NaOH 1M. The solution was then, 3 times 
submitted to ultrasound during 7 minutes and left to stabilize overnight, and 
filtered before use.  
The labelling was possible given to the reduction of 188Re from the oxidation 
state +7 to +5, making 188Re reactive and able to form chemical bonds with  the 
nitrogen of the amine groups in PEI, and/or make chemical bonds with 
phosphorus in the methyl-phosphonate groups  [74, 269], in the same way as it 
happens with the labelling of PEI-MP with 99mTc. 
 
5.2.4. Radiochemical quality control 
The radiochemical purity of 99mTc-PEI-MP and 188Re-PEI-MP was evaluated 
using ascendant thin-layer chromatography, at 1, at 2, at 3, at 4 and at 5 hours 
after the radiolabelling. To accomplish this goal two chromatographic systems 
were used: the first one to isolate free pertechenetate/perrhenate and the 
second one to isolate colloidal forms. The first consisted of instant thin layer of 
silica gel impregnated glass-fibre sheets (ITLC-SG, Varian, US) as stationary 
phase and acetone (CH3(CO)CH3; Sigma-Aldrich 34850) as mobile phase. The 
second system was Whatman 3MM cellulose paper (3MM, Maidstone, UK) as 
stationary phase and a solution of citrate buffer (pH = 7.0, 1.0 M) as mobile 
phase. These two systems were chosen to determine the percentage of free 
99mTc or 188Re and the percentage of hydrolysed/reduced 99mTc or 188Re 
species, respectively for the first and second system [87, 271]. The strips of the 
stationary phases were prepared by marking the final length that corresponds to 
the solvent front with a colour pen and the start (origin) with a pencil. When the 
solvent gets in contact with the marker, the colour also migrates with the 
solvent, indicating that the solvent reach the end of the development. The strip 
should be marked in such a way that the colour does not interfere with the 
sample track to avoid artificial results [87]. A sample of 5 µl of 99mTc-PEI-
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MP/188Re-PEI-MP was spotted in the middle of origin of the stationary phase, 
which was placed vertically in a chromatographic chamber previously prepared 
with a saturated atmosphere. After applying the sample, the strip must be 
placed into the chromatographic chamber and developed immediately, without 
drying the spot. Dried samples may lead to artificial results due to oxidation of 
99mTc/188Re complexes and formation of free pertechnetate/perrhenate. The 
strip was placed into the chamber vertically and carefully avoiding any damage 
of the surface. These solid phases, have limited mechanical resistance, 
whereby should be supported (e.g., clipped to the lid of the chamber), otherwise 
they will slip into the solution or touch the chamber wall during the development. 
The solvent should cover the bottom no more than 5 mm high, to be below the 
level of the origin line of the stationary phase [87].  The strips were prepared as 
demonstrated in fig. 7. 
 
 
 
 
When the solvent reached the final mark, the strips were removed from their 
respective chromatographic chambers and allowed to dry at room temperature. 
Subsequently each strip was cut in half, and each half after being cut in small 
pieces, was placed into radioimmunoassay (RIA) tubes, and the radioactivity 
present in each portion was measured separately in a well-type gamma counter 
(Gamma-C 12 DPC, Berthold, Germany), to quantify radioactivity on each half 
Figure 7.Schematic representation of a stationary phase for radiochemical quality 
control. 
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strip. The results of measurements are used to calculate the radiochemical 
purity as the ratio between the radioactivity corresponding to the half-strip of 
interest, divided by the total recovered radioactivity of the chromatogram. The 
final results are shown as a percentage. The background radioactivity is 
subtracted from each count leading to a more accurate analysis. Each 
experiment was performed in 3 different sets of tests.  
There are several methods for the quantification of radiochromatograms. 
Depending on the available instrumentation, the resolution will vary, and the 
amount of the radioactivity used for analysis will differ considerably. The 
quantification with a well-type gamma counter has as an advantage the 
sensitivity. The resolution is dependent on the sample geometry which should 
be maintained at the counting tube bottom. For this reason each half-strip is cut 
in small pieces kept together at the bottom of the RIA tube. The main limitations 
of this method are that the saturation of the counter due to the activities of the 
half-strip of interest, and the time consumption once the procedure has many 
sequential steps such as cut the samples and fill the RIA tubes, time of 
measurements, and posterior percentage calculations. Also a gamma-camera 
could be used to perform this quantification. The dried strip can be placed over 
the head of the gamma camera, and images are acquired. Using the region of 
interest (ROI) technique, for each ROI drawn the total counts are obtained and 
the radiochemical purity is expressed as a fraction of the total strip activity. As 
advantage of this methodology is the use of undiluted sample for 
chromatography allowing measurement with high count rates. The main 
disadvantage is related with the time-consuming procedure (measurement and 
analysis), and consequently, the time of machine [87].  
In order to investigate the effect of temperature and cell culture medium 
(Dulbecco´s Modified Eagle´s Medium, Sigma D-5648)  in radiochemical purity 
of 99mTc-PEI-MP, and using the same chromatographic systems and methods of 
quantification, the radiochemical purity was assessed over time (30 minutes, 1h, 
3h and 5h). The solution of 99mTc-PEI-MP and in saline with and without cell 
culture medium was exposed to temperatures of 22°C, 37°C and 45°C. The 
temperatures were regulated by a digital thermoblock (FALC Instruments, 
Treviglio, Italy). Each experiment was performed in 4 independent sets of tests.  
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5.2.5. Determination of partition coefficient of 99mTc-PEI-MP 
Partition coefficient (log Po/w) of 
99mTc-PEI-MP was calculated after the 
determination of Po/w, that is the ratio of specific activities of the organic and 
aqueous phases [272, 273], 1h, 2h, 3h and 4 h after radiolabelling. A mixture of 
1 ml of 1-octanol (Sigma O4500) and 1 ml of 0.9% sodium chloride (0.9% NaCl, 
Braun) containing 3.7 MBq (0.1 mCi) of 99mTc-PEI-MP at 37 °C was vortexed for 
2 minutes and left 5 minutes to rest. Following centrifugation at 1872 g (3000 
rpm) (Multifuge 1L-R, Germany) for 5 minutes, equal aliquots (100 µl) of sample 
were taken from each phase and counted for radioactivity in a well-type counter 
(Gamma-C 12 DPC, Berthold, Germany). Each experiment was performed in 
duplicate and repeated in 4 independent sets of tests. 
 
5.2.6. Cell culture 
Human bladder transitional carcinoma cell line (HT-1376 - ATCC® CRL1472™) 
and human osteosarcoma cell line (MNNG/HOS – ATCC®CRL-1547™) (fig. 8), 
acquired from American Type Culture Collection (ATCC), were cultured in 
Dulbecco´s Modified Eagle´s Medium (Sigma D-5648) supplemented with 100 
mM sodium pyruvate (Gibco 11360), 5% heat-inactivated foetal bovine serum 
(Sigma F7524), and 1% antibiotic/antimycotic (100 U/ml penicillin, 10 µg/ml 
streptomycin and 25 µg/ml amphotericin B, Sigma A5955) (fig. 9).  
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Cells were maintained at 37 °C with 95% air and 5% CO2 (fig. 10) in a cell 
incubator (BINDER, CO² incubator C 150, 150 litres, 230 V, 1 N, 50/60 Hz). 
Figure 9.Culture medium Dulbecco´s Modified Eagle´s Medium supplemented with 100 
mM sodium pyruvate, 5% heat-inactivated foetal bovine serum, and 1% 
antibiotic/antimycotic. 
Figure 8.HT-1376 (A) and MNNG/HOS (B) cell lines in culture, visualized in a optical 
microscope (Nikon Eclipse TS100, Japan) with a magnification of 10x. 
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In order to obtain cell suspensions for use in the in vitro studies, cells were 
washed with PBS, than harvested with a solution of 0.25% trypsin/EDTA (Sigma 
T4049), centrifuged at 209 G (1000 rpm) (Multifuge 1L-R, Germany) during 5 
minutes and finally resuspended in medium. To count the number of viable cells 
in each cell suspension, it was used the trypan blue exclusion method. The 
trypan blue exclusion method is based on the principle that viable cells had 
intact membranes that prevent entry of the dye, while the disrupted membranes 
of the non-viable cells can’t prevent that penetration of the dye into the cell. 
Upon entry into the cell, the dye crosses the nuclear membrane, and the nuclei 
are stained in blue. Thus, the blue cells correspond to dead cells while the 
viable cells have a shiny appearance (not stained of blue) [274]. To perform this 
procedure, an aliquot of 20μl of cell suspension is added to 20μl of trypan blue 
(Sigma T0776) in an eppendorf tube, and after homogenization, cell suspension 
was placed in a haemocytometer using a micropipette, to be viewed under an 
optical microscope (Nikon Eclipse TS100, Japan). The cell count was 
performed in the four quadrants of the haemocytometer. 
 
 
 
Figure 10.Cells in adherent culture flasks maintained at 37 ºC with 95% air and 5% 
CO2 in the incubator. 
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5.2.7. Evaluation of the cytotoxicity of PEI-MP 
5.2.7.1. Metabolic activity 
To evaluate the effect of PEI-MP in the metabolism of cells, it was used the 
colorimetric test MTT (3-(4,5-dimethylthiazolyl-2)2,5-diphenyltetrazolium 
bromide; Sigma M2128). The dehydrogenase enzymes, present in metabolically 
active cells, have the ability to cleave the tetrazolium ring of MTT and form dark 
blue formazan crystals (fig. 11) that can subsequently be solubilised and the 
colour of the resulting solution quantified by spectrophotometry [275-277].  
 
 
 
For each experiment, cells were plated in 48 multiwells plates (Corning Costar, 
USA) in a concentration of 25 000 cells/ml and kept in the incubator overnight to 
allow the cells attachment. Cells were incubated with different concentrations of 
PEI-MP (1, 5, 15, 25, 50, 100, 250, 500 and 1000 µM), obtained by dissolving 
the PEI-MP with 0.9% sodium chloride (0.9% NaCl, Braun), during 24, 48, 72 
and 96 hours. After these periods of time, cell metabolism was evaluated. For 
this purpose, culture medium was removed, 500 µl of phosphate buffered saline 
(PBS) was added and then discarded, and finally a 100 µl of MTT solution (5 
mg/ml, Sigma M2128) was added. After 3 hours, 100 µl of a solution of 
isopropanol (Sigma 279544) in 0.04M hydrochloric acid (Sigma H1758) was 
added and cells were re-suspended. The content of each well was transferred 
Figure 11.Representation of coloured solutions obtained after MTT test showing the 
blue coulour as a result of formazan crystals formation. 
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to a plate with 96 wells (Sarstedt, USA) and the absorbance was quantified at 
570 nm with a reference filter of 620 nm in an ELISA spectrophotometer (SLT-
Spectra). Each experiment was performed in duplicate and repeated in 5 
independent sets of tests. These tests were performed in the two cell lines 
referred above. 
 
5.2.7.2. Flow cytometry 
To characterize the redox intracellular environment after incubation of PEI-MP, 
it was chosen the maximum concentration of 1000 µM to determine by flow 
cytometry the cell viability, the reactive oxygen species (ROS) production, the 
expression of reduced glutathione (GSH) and the changes of mitochondrial 
membrane potential. The analysis was performed using a six-parameter four-
color FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) equipped 
with a 15 nW argon laser. For each assay, at least 104 events were collected 
using Cell Quest software (Becton Dickinson, San Jose, CA, USA), and 
analysed using Paint-a-Gate software (Becton Dickinson, San Jose, CA). For 
flow cytometry analysis, 400 000 cells were seeded in 75 cm2 adherent culture 
flasks (Corning, USA) and after 5 days were incubated with 1000 µM of PEI-
MP. After 24 hours, cells were washed with PBS, harvested with a solution of 
0.25% trypsin/EDTA (Sigma T4049), centrifuged at 1300 G (2500 rpm) 
(Multifuge 1L-R, Germany) during 5 minutes and finally in phosphate buffered 
saline (PBS) for examination by flow cytometry. Each experiment was 
performed in duplicate and repeated in 4 independent sets of tests. These tests 
were performed in the two cell lines referred above. 
 
a) Cell viability and death 
The first cell death to be defined was necrosis, and then the apoptosis [278]. 
Apoptosis is a regulated process, carried out in a controlled manner to ensure 
the safety of surrounding cells and tissues. Apoptosis is strictly defined by 
morphological criteria including changes of the nucleus (chromatin 
condensation and margination, condensation and reduction in the size of the 
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cell nucleus associated with its fragmentation) cellular shrinkage and ruffling of 
the plasma membrane, called budding [279]. The DNA is furthermore 
fragmented in several steps to form mono- and/or oligomers of 200 base pairs 
[280]. Eventually the cell becomes divided in apoptotic bodies, which consist of 
cell organelles and/or nuclear material surrounded by an intact plasma 
membrane. Apoptotic bodies expose phosphatidylserine residues, that normally 
exist in the inner leaflet of plasma membranes [281]. This allows for the 
recognition of apoptotic bodies, which are generally phagocyted and destroyed 
by neighbouring cells without damage to adjacent tissue. The execution of 
apoptosis is closely linked to serial activation of a family of proteases called 
caspases [282, 283], even though caspase-independent apoptosis pathways 
also exist through apoptosis inducing factor, Endonuclease G, and/or serine 
protease HTRA2 (HtrA serine peptidase 2) [284, 285]. Necrosis is generally 
considered to be an accidental and unregulated cell death [279] even though 
programmed necrosis also has been described [286]. When necrosis is 
induced, a rapid plasma membrane permeabilization occurs, which leads to 
leakage of cell content and induction of inflammation. Necrosis is usually 
defined in a negative fashion, as a type of cell demise that involves rupture of 
the plasma membrane without the hallmarks of and without massive autophagic 
vacuolization [287]. The main features of necrosis include an improvement of 
cell volume that finally culminates in rupture of the plasma membrane, and the 
unorganized dismantling of swollen organelles.  
To evaluate cell viability, a double labelling with annexin-V and propidium iodide 
(AV/PI) was used. One of the main features of cell death by apoptosis is the 
redistribution of plasma membrane phosphatidylserine, a phospholipid that, in 
apoptotic cells, is translocated from the inner to the outer leaflet of the plasmatic 
membrane and binds to annexin-V. Complementarily, PI, which does not 
permeate viable cells, in cells with membrane lesions like cells on late apoptotic 
and/or necrosis, can reach the nucleus and binds to deoxyribonucleic acid 
(DNA) intercalating between the bases [288]. In this assay, 106 cells were 
incubated during 15 minutes, at room temperature in the dark, with a binding 
buffer with 2.5 µl of Annexin V (Immunostep, Salamanca, Spain) and 1 µl of PI 
(Immunostep, Salamanca, Spain), subsequently cell suspension was vortexed 
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to homogenize. In the cytometer cells were excited with a light of a wavelength 
of 525 nm for AV and with 640 nm for PI, collecting 104 events to assess the 
percentage of viable, early apoptotic, late apoptotic/necrotic, and necrotic cells 
[289]. 
 
b) Detection of intracellular peroxides and superoxide 
There are many types of radicals, but those of most important in biological 
systems are derived from oxygen, and known collectively as reactive oxygen 
species. Oxygen has two unpaired electrons in separate orbitals in its outer 
shell. This electronic structure makes oxygen especially susceptible to radical 
formation. Sequential reduction of molecular oxygen leads to formation of a 
group of reactive oxygen species like superoxide anion (O2
−), peroxide (O2
2−) 
and hydroxyl radical (OH•). Oxygen-derived radicals are generated constantly 
as part of normal aerobic life, being formed in mitochondria as oxygen is 
reduced along the electron transport chain. Mitochondria are unique organelles, 
as they are the main site of oxygen metabolism, accounting for approximately 
85–90% of the oxygen consumed by the cell. Incomplete processing of oxygen 
and/or release of free electrons results in the production of oxygen radicals. 
Mitochondria constantly metabolize oxygen thereby producing reactive oxygen 
species (ROS) as a by-product. This organelle has its own ROS scavenging 
mechanisms that are required for cell survival. Under normal conditions, the 
effects of ROS are counteracted by a variety of antioxidants, by both enzymatic 
and non-enzymatic mechanisms. Oxidative stress is considered to be the result 
of an imbalance of two opposing and antagonistic forces, ROS and 
antioxidants, in which the effects of ROS are more potent than the 
compensatory capacity of antioxidants [290]. Reactive oxygen species are also 
formed as necessary intermediates in a variety of enzyme reactions. Other 
situations may lead to the formation of reactive oxygen species, like drugs with 
oxidizing effects or ionizing radiation. The production of ROS is associated with 
many forms of apoptosis. Excessive ROS can induce apoptosis through both 
the extrinsic and intrinsic pathways. In the extrinsic pathway of apoptosis, ROS 
are generated by FAS ligand as an upstream event for FAS activation via 
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phosphorylation, which is necessary for subsequent recruitment of Fas-
associated protein with death domain and caspase 8 as well as apoptosis 
induction. In the intrinsic pathway, ROS function to facilitate cytochrome c 
release by activating pore-stabilizing proteins (BCL-2 and BCL-XL) as well as 
inhibiting pore-destabilizing proteins (BCL-2-associated X protein, BCL-2 
homologous antagonist/killer). Even higher ROS levels can result in both 
apoptosis and necrosis in cancer cells. ROS can also induce cell death through 
autophagy, which is a self-catabolic process involving sequestration of 
cytoplasmic contents (exhausted organelles and protein aggregates) for 
degradation in liposomes [291-293]. 
2,7-dichlorodihydrofluorescein diacetate (DCFH2-DA) a lipid permeable and 
non-fluorescent compound, is cleaved by intracellular esterase by entering cells 
and leads to 2,7-dichlorodihydrofluorescein (DCFH2). In the presence of 
peroxides, DCFH2 is oxidised with formation of dichlorofluorescein (DCF), a 
highly green fluorescent compound, upon excitation at 488 nm, proportional to 
the concentration of intracellular peroxides [294]. Peroxides, along with 
superoxide are responsible to activate the intrinsic apoptotic pathway, and 
therefore an increase in the amount of free radicals will signify an increase in 
apoptosis [295]. A cell suspension of 106 cells was incubated with 5 µM of 
DCFH2-DA (Sigma D6883) (1 µl) for 45 minutes at 37 °C in the dark. 
Subsequently, the cells were centrifuged at 1300 G (2500 rpm) (Multifuge 1L-R, 
Germany) during 5 minutes, then the supernatant was discarded and the cells 
were washed with PBS and analysed by flow cytometry. The analysis was 
performed with an excitation light with a wavelength of 504 nm, being the 
emission wavelength 529 nm. The results were obtained as mean fluorescence 
intensity (MFI) values, and then were normalized in relation to the control to 
which was assigned the value of 1. 
Dihydroethidium (DHE) easily crosses cell membranes and is converted by 
superoxide radical to ethidium, a red fluorescent compound that merges the 
DNA remaining inside the cell [296]. A cell suspension of 106 cells was 
resuspended in PBS and incubated with 5 µM of DHE (Sigma 37291) dissolved 
in DMSO (Sigma D8418) (2.5 µl) for 15 minutes at 37 °C in the dark. 
Subsequently, the cells were centrifuged at 1300 G (2500 rpm) (Multifuge 1L-R, 
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Germany) during 5 minutes, then the supernatant was discarded and the cells 
were washed with PBS and analysed by flow cytometry. The analysis was 
performed with an excitation light with a wavelength of 620 nm. The results 
were obtained as mean fluorescence intensity (MFI) values, and then were 
normalized in relation to the control to which was assigned the value of 1. 
 
c) GSH expression  
L-glutamyl-L-cysteinyl-glycine (GSH) in its reduced form is a tripeptide 
enzymatically formed by glycine, cysteine and glutamate, and is the most 
abundant non-protein thiol in mammalian cells. GSH acts as a reducing agent 
and as a major antioxidant within cells by maintaining a tight control of the redox 
status. GSH is also involved in many distinct physiological reactions including 
cellular signalling, metabolism of xenobiotics, thiol disulfide exchange reactions, 
and as an important reservoir of cysteine. Intracellular GSH depletion is an early 
hallmark of progression of cell death in response to different apoptotic stimuli. 
Has been reported that GSH depletion during apoptosis induced by cytotoxic 
agents, such as xenobiotics, chemotherapeutics, and metals, may induce 
oxidative stress mediated by GSH oxidation to glutathione disulphide (GSSG) 
by reactive species of oxygen (ROS) and nitrogen (RNS), or by its conjugation 
to highly reactive compounds. GSH depletion has been shown to regulate both 
extrinsic and intrinsic apoptotic signalling cascades at distinct checkpoints. GSH 
depletion may predispose cells to apoptosis or, alternatively, directly trigger cell 
death which can result from, by modulation of the permeability transition pore 
formation or by activation of execution caspases [295, 297].  
The expression of GSH, was performed by flow cytometry using the fluorescent 
compound mercury orange [295]. This compound binds stoichiometrically to 
mercurial sulphydryl groups with the formation of fluorescent ducts. However, 
this compound faster reacts with GSH than with the sulphydryl groups of 
proteins and the reaction product emits an intense red fluorescence when 
excited with an argon laser at a wavelength of 488 nm [298]. A cell suspension 
of 106 cells was incubated with 1 µl of mercury orange (Sigma 83377) in 
acetone (Sigma 650501) for 15 minutes at room temperature in the dark. 
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Subsequently, the cells were centrifuged at 1300 G (2500 rpm) (Multifuge 1L-R, 
Germany) during 5 minutes, the supernatant discarded and the cells washed 
with PBS and analysed by flow cytometry. The analysis was performed with an 
excitation light with a wavelength of 620 nm. The results were obtained as 
mean fluorescence intensity (MFI) values, and then were normalized in relation 
to the control to which was assigned the value of 1. 
 
d) Mitochondrial membrane potential measurement 
The intrinsic pathways of apoptosis involve the mitochondria, the endoplasmatic 
reticulum, and the DNA damaging pathways. These pathways are activated by 
a wide variety of stimuli including chemotherapeutic and cytotoxic agents 
(environmental pollutants, xenobiotics, drugs), stress (radiation, 
hyperglycaemia, hypoxia, oxidative and osmotic stress), and cytokine 
withdrawal. Activation of the mitochondria pathway mediates the release of 
cytochrome c that is associated with the opening of the mitochondrial 
permeability transition pore and loss of the mitochondrial membrane potential. 
Also mitochondria use substrates able to be oxidized to produce a membrane 
potential in the form of a proton gradient across the mitochondrial inner 
membrane. It was shown recently that the supply of these substrates to 
mitochondria depends on the concentration of external growth factors. 
Withdrawal of growth factors or loss of the extracellular glucose supply will lead 
to a decline of mitochondrial membrane potential. If growth factor or glucose 
deprivation persists, cells ultimately undergo apoptosis that is initiated by 
cytochrome c release from mitochondria [295, 299]. The lipophilic cationic 
5,5´,6,6´-tetrachloro-1,1´,3,3´-tetraethylbenzimidazol-carbocyanine iodide (JC-1) 
is a molecule able to selectively enter the cell and which exists in two forms, 
monomers (M) and aggregates (A), depending on the state of 
polarization/depolarization of the mitochondrial membrane, that will be reduced 
when the cell is apoptotic [295]. When the membrane potential is high, the JC-1 
forms aggregates that emit red fluorescence (590 nm). On the other hand, as 
the mitochondrial membrane potential decreases or in cases where the 
membrane is depolarized, JC-1 is excluded from mitochondria and remains in 
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the cytoplasm in the form of monomers that emits green fluorescence (529 nm). 
Thereby the ratio between the intensities of green and red fluorescence’s (M/A), 
determined by flow cytometry, provides an estimate of mitochondrial membrane 
potential [300]. To perform JC-1 (Invitrogen, T-3168) assay the cells were 
incubated at a final concentration of 5 mg/ml, in DMSO (1 µl) during 15 minutes 
at 37 °C in the dark. Subsequently, the cells were centrifuged at 1300 G (2500 
rpm) (Multifuge 1L-R, Germany) during 5 minutes, the supernatant discarded 
and the cells washed with PBS and analysed by flow cytometry. The results 
were obtained as aggregate/monomer ratio, and then were normalized in 
relation to the control to which was assigned the value of 1. 
 
5.2.8. Evaluation of the radiocytotoxicity of 99mTc 
5.2.8.1. Clonogenic activity 
The clonogenic cell survival assay determines the ability of a cell to proliferate, 
thereby retaining its reproductive ability to form a large colony or a clone. 
Although clonogenic cell survival assays were initially described for studying the 
effects of radiation on cells and have played an essential role in radiobiology, 
they are now widely used to examine the effects of agents with potential 
applications in the clinic. Several mechanisms have been described for cell 
death; however, loss of reproductive integrity and the inability to proliferate are 
the most common features. Therefore, a cell that keeps its ability to synthesize 
proteins and DNA and go through one or two mitoses, but is unable to divide 
and produce a large number of progeny is considered dead. This is very 
commonly referred to as loss of reproductive integrity or reproductive death and 
is the end point measured with cells in culture. On the other hand, a cell that is 
not reproductively dead and has retained the capacity to divide and proliferate 
can produce a large clone or a large colony of cells and is referred as 
“clonogenic.” The ability of a single cell to grow into a large colony that can be 
visualized with the naked eye is proof that it has retained its capacity to 
reproduce. The loss of this ability as a function of dose of radiation or 
chemotherapy agent is described by the dose-survival curve. A cell survival 
curve is therefore defined as the relationship between the dose of the agent 
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used to produce an insult and the fraction of cells that retain their ability to 
reproduce [301]. Technetium-99m, besides emitting gamma rays also emits 
less than 1% of auger electrons per decay. These electrons have been 
recognized as potentially useful for targeted tumour radiotherapy, specially do 
to the auger electron range (which is of manometer range) and the high 
ionization density of electrons [302]. However, to this study, the aim of using 
this radioisotope is for diagnostic imaging, and therefore in the range of 
diagnostic radiation doses, the 99mTc shouldn’t be radiotoxic to cells. The 
effective doses for most nuclear medicine diagnostic procedures varies 
between 0.3 and 20 mSv (equivalent to 0.3 and 20 mGy) [303]. With the 
clonogenic assay the aim was to determine cell survival based on the ability of a 
single cell to grow and form a colony after the cells being subjected to doses of 
radiation, either being irradiated externally (determining gamma radiation 
effects) or internally (determining gamma radiation and auger electrons effects). 
For this study, 2 million cells were seeded in 75 cm2 adherent culture flasks 
(Corning, USA). After 24 hours the cells where irradiated externally or internally 
with 2, 5, 10 and 20 mGy of 99mTc. For external irradiation the flaks containing 
cells were placed on top of a 75 cm2 adherent culture flasks filled with water, 
were it was added the correct amount of Na99mTcO4. For internal irradiation it 
was added the correct activity of Na99mTcO4 to the flaks containing the cells. 
The time of exposure was calculated for the doses taking in consideration the 
distance, added activity and decay. After irradiation the cells where washed with 
PBS, harvested with a solution of 0.25% trypsin/EDTA (Sigma T4049) and 
finally medium was added. After, for HT-1376 cells, 300 and 600 cells were 
seeded in triplicate in a six well plate (Corning Costar 3516, USA), and for 
MNNG/HOS 100 and 200 cells were seeded also in triplicate in a six well plate 
(Corning Costar 3516, USA). After 5 days, the medium was changed and at 
twelfth day the colonies were prepared for visualization. For that, culture 
medium was aspirated, cells were washed with PBS, and methanol (Sigma 
34860) was added to fix the colonies, a procedure that was repeated twice. 
After, the plates have been dried, and the crystal violet dye (Sigma M2128; 
0.5% diluted in methanol) was added. Subsequently, the plates were washed 
with warm water and allowed to dry, after which the number of colonies were 
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counted and the plate efficiency (equation 3) and survival factor (equation 4) 
determined following the formulas below [276]. 
                    
                          
                         
     
Equation 3.Percentage of plate efficiency, that is determined by the ratio of the 
number of counted colonies and the number of seeded colonies. 
 
 
                   
                                  
                                   
     
Equation 4.Percentage of survival factor, which is determined by the ratio of the plate 
efficiency of treated samples and the plate efficiency of control samples. 
 
Each experiment was performed in triplicate and repeated in 4 independent sets 
of tests for internal irradiation and 5 independent sets of tests for external 
irradiation. These tests were performed in the two cell lines referred above. 
 
5.2.8.2. Flow cytometry 
To characterize the redox intracellular environment after internal or external 
irradiation with 99mTc, it was chosen the dose of 20 mGy, to determine by flow 
cytometry the cell viability, the reactive oxygen species (ROS) production, the 
expression of reduced glutathione (GSH), changes of mitochondrial membrane 
potential and distribution of cells in cell cycle. The analysis and process was 
performed using the equipment and procedures described before.  
For flow cytometry analysis, 2 million cells were seeded in 75 cm2 adherent 
culture flasks (Corning, USA). After 24 hours the cells where irradiated 
externally or internally with 20 mGy with 99mTc following the procedures 
described in clonogenic assays. After 24 hours, cells were washed with PBS, 
than harvested with a solution of 0.25% trypsin/EDTA (Sigma T4049) and finally 
resuspended in phosphate buffered saline (PBS) for examination by flow 
cytometry. Each experiment was performed in duplicate and repeated in 4 
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independent sets of tests. These tests were performed in the two cell lines 
referred above. 
Procedures of flow cytometry to evaluate cell viability, detection of intracellular 
peroxides and superoxide radical, GSH expression and mitochondrial 
membrane potential was the same as described before. Although the procedure 
is similar, is necessary to understand some concepts, namely the induction of 
apoptosis and necrosis by ionizing radiation. Radiation induced apoptosis can 
be subdivided into early apoptosis, or interphase apoptosis which occurs within 
hours following the apoptotic stimuli, and delayed apoptosis, or post-mitotic 
apoptosis which occurs days after exposure to the stimuli, during or following 
mitosis [304-306]. Radiation induced early apoptosis occurs only a few hours 
after exposure in interphase and as premitotic event without requirement for cell 
division. This mode of radiation induced apoptosis has been characterized and 
demonstrated to include pyknosis, cell shrinkage and internucleosomal 
breakdown of chromatin, all of which are hallmarks of apoptotic death [306]. 
This apoptotic process is highly radiosensitive and most often activated in a 
P53-dependent way. However, the relatively low levels of radiation induced 
apoptosis that take place in solid tumours are generally observed much later 
following mitotic catastrophe. This delayed type of apoptosis, has been reported 
that occurs in association to the G2/M arrest or as post-mitotic event [306-309]. 
The morphology of this delayed type of radiation induced apoptosis can differ 
from that of classical apoptosis as it often occurs in cells that are “giant” instead 
of cells with shrunken volume [310, 311]. Radiation induced necrosis can be 
subdivided into early necrosis and delayed necrosis. Early necrosis is an ultra-
fast cell death that is induced following particularly strong stimuli, such as high 
doses of irradiation (i.e. bigger than 100 Gy) [312]. Delayed necrosis is a slow 
cell death and one of the mechanisms by which mitotic catastrophe is executed 
[313]. 
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a) Cell cycle  
The cell cycle is divided into the tour fundamental parts: 1) mitosis, during which 
one cell divides into two identical progeny cells; 2) G1 phase; 3) S phase, in 
which occurs DNA synthesis; and 4) G2 phase [1, 59, 314]. The length of cell 
cycle varies from hundreds of hours for some stem cells to 24 hours for quick 
dividing mammalian cells. DNA damage delays normal cell cycle progression. A 
complex network of responses is activated as soon as the damage is registered 
in the genome, and these are rapidly manifested at cell cycle checkpoints. 
Massive insults to DNA, such as double-strand DNA breaks after cellular 
exposure to ionizing radiation, may induce changes in any cell cycle checkpoint, 
ultimately leading to the outcome of cell survival if DNA is properly repaired or, if 
not, to cell death. The checkpoint protein P53 has been established as one of 
the most important and it plays a major role in the complex cellular responses to 
radiation. The most important function for P53 after irradiation exposure is its 
acting as transcription factor with action in target genes that influences cell 
cycle arrest, DNA repair, apoptosis, senescence and autophagy. In general, 
cells are most radiosensitive in M and G2 phases and most radioresistant in 
latter part of S phase, while for cells with long cycle time, it’s possible to see 
another peak of resistance in early G1 [1, 59, 314]. After irradiation, DNA 
damage can cause a progression delay in G1, S and G2 phases, to give cells 
time to repair the damages. In each checkpoint there are a series of cyclin-
dependent kinases (CDK), which regulate cell progression from one phase to 
another. If DNA damage happened in G1 phase, the G1/S arrest will give to cell 
time to repair the damage before entry into S phase avoiding replication of the 
damaged DNA damaged. There is a very close relationship between the 
functional status of P53 and G1 arrest. The DNA damage can cause the 
accumulation of P53, which in turn up-regulate the CIP1 protein. CIP1 binds to 
cyclin/CDK complex and inhibit its activity resulting in the delay of cell cycle. 
Similarly, the G2/M arrest can enable the cell to repair DNA damage before cell 
division. G2 phase arrest is a prominent checkpoint of DNA damage and the 
mechanisms of DNA damage-induced G2 arrest have been intensively studied. 
Currently, two main mechanisms are proposed for G2 phase arrest, one related 
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to the cyclin B1/p34cdc2 complex and another involves the oncogene RAS. The 
S phase arrest occurs only after relatively high dose radiation [1, 59, 314]. 
Propidium Iodide (PI) is the most commonly used dye for DNA and cell cycle 
analysis for flow cytometry. The PI binds to DNA by intercalating into the double 
stranded macromolecule. PI also binds to RNA, and is necessary to remove the 
RNA with a nucleases treatment (RNase) for optimal DNA resolution. The 
quantification of the DNA, allows the knowledge about distribution of a cell 
population along the different phases of the cell cycle. The principle with these 
dyes is that they are stoichiometric, this is they bind in proportion to the amount 
of DNA present in the cell. In this way cells that are in S phase will have more 
DNA than cells in G1. They will take up proportionally more dye and will 
fluoresce more brightly until they have doubled their DNA content. The cells in 
G2 will be approximately twice more bright then G1 cells [315]. In this assay, 
106 cells were vortex with 200 µl of 70% ethanol and incubated during 30 
minutes in the dark at a refrigerator. Since PI is membrane impermeable, 
ethanol is used to both fix and permeabilize cells. After the cells were washed 
with PBS and centrifuged at 1300 G (2500 rpm) (Multifuge 1L-R, Germany) 
during 5 minutes. Supernatant was discarded and 500 µl of PI/RNase solution 
was added, with a gently stir in the vortex. The cells were incubated during 15 
minutes, at room temperature in the dark, in binding buffer with 500 µl of 
PI/RNase (Immunostep, Salamanca, Spain). Subsequently, cells were excited 
with a light of a wavelength of 640 nm and 104 events to assess the percentage 
of cells in Pre-G1, G0/G1, S, and G2/M were collecting. 
 
5.2.9. Cellular uptake and retention studies 
To evaluate the in vitro cellular kinetics of 99mTc-PEI-MP and 188Re-PEI-MP it 
was proceeded to the evaluation of the cellular uptake (what enters to the cell) 
and retention (what stays in the cell) over time. These studies were performed 
in both cell lines HT-1376 and MNNG/HOS. 
Cells were washed with PBS, than harvested with a solution of 0.25% 
trypsin/EDTA (Sigma T4049) and finally resuspended in medium to obtain a 
concentration of 2×106 cells/ml in 25 cm2 flasks. After 1 hour of incubation at 
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37°C 99mTc-PEI-MP or 188Re-PEI-MP was added to the cell suspension with an 
activity of 0.925MBq/ml (25µCi/ml), following methodologies described 
elsewhere [316]. Duplicate samples of 200 µl were collected to eppendorf tubes 
containing ice-cold PBS for determination of tracer uptake at 1 (only for 99mTc-
PEI-MP), 5, 15, 30, 45, 60, 90, 120, 150, 210 and 240 minutes. These samples 
are then centrifuged at 5585 G (10000 rpm) (Costar Mini Centrifuge, USA), 
during 60 seconds to separate pellet from the supernatant, twice. Radioactivity 
of cell pellets and supernatants was measured separately in a well-type gamma 
counter (Gamma-C 12  PC, Berthold, Germany) to determine tracer’s uptake 
percentage, and then draw the influx curves. The obtained experimental values 
of cellular uptake were fitted to an exponential model (equation 5) using the 
software OriginPro (OriginLab Corporation, Northampton, EUA), version 8.0: 
                                 
Equation 5.Percentage of cellular uptake, where A is the maximum uptake obtained 
(steady state) and T50% is the time needed to reach half of the maximum uptake.  
 
To determine the percentage of retention over time, the procedure was very 
similar to the protocol of the uptake studies. The preparation of the cell 
suspension to the studies was the same, obtaining a cell suspension of 
2×106/ml in a 50 ml falcon. 99mTc-PEI-MP or 188Re-PEI-MP was added to the 
cell suspension with an activity of 0.925MBq/ml (25µCi/ml), and incubated at 
37°C during 150 minutes. After this time the cell suspension was centrifuged at 
3512 G (4000 rpm) (Multifuge 1L-R, Germany) during 1 minute at 4°C and then 
it was substituted the culture medium. The cell suspension was transferred to 
25 cm2 flasks and duplicate samples of 200 µl were collected to eppendorf 
tubes containing ice-cold PBS to determination of tracer retention at 1, 3 (times 
1 and 3 only for 99mTc-PEI-MP), 5, 7, 15, 30, 45, 60, 90, 120, 150, 210 and 240 
minutes. During tracer retention studies, for every sample taken, the cells were 
resuspended in order to ensure uniformity. These samples are then centrifuged 
at 5585 G (10000 rpm) (Costar Mini Centrifuge, USA) during 60 seconds to 
separate pellet from the supernatant. This procedure was repeated twice. 
Radioactivity of cell pellets and supernatants was measured separately in a 
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well-type gamma counter (Gamma-C 12 DPC, Berthold, Germany) to determine 
tracer’s retention percentage in the cells. The obtained experimental values for 
the cellular retention were fitted to an exponential model (equation 6) using the 
software OriginPro (OriginLab Corporation, Northampton, EUA), version 8.0: 
                                      
Equation 6.Percentage of cellular retention, where A is the minimum retention 
obtained (steady state) and Tm is the time delay to reach 50% of the retention plus A/2, 
this is, the midpoint between 100% and the minimal retention.  
 
As a control, the uptake and retention percentages were determined after the 
addition of 99mTc-Pertechnetate or 188Re-Perrhenate, following the same 
protocols for each complex. For the retention studies, cell suspensions were 
incubated with 99mTc-Pertechnetate or 188Re-Perrhenate during 60 minutes 
before starting the studies. Each experiment was performed in duplicate and 
repeated in 4 independent sets of tests. These tests were performed in the two 
cell lines referred above. 
 
5.2.10. Statistical analysis 
The obtained results were analysed using the software IBM SPSS (IBM 
Corporation, Armonk, New York, EUA), version 20, at a significance level of 5% 
(p < 0.05). The descriptive analysis of quantitative variables under study, was 
performed by calculating estimators of central tendency, dispersion and 
location. In inferential analysis, the normal distribution of quantitative variables 
was assessed using the Shapiro-Wilk test.  
The comparison of values from the radiochemical purity of 99mTc/188Re-PEI-MP, 
and the partition coefficient of 99mTc-PEI-MP over time, were made according to 
the Friedman test with multiple comparisons according to Bonferroni correction. 
The comparison of values from the radiochemical purity of 99mTc-PEI-MP over 
time, at several temperatures and incubation with culture medium, were made 
according to the Friedman test with multiple comparisons according to 
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Bonferroni correction, and between conditions according to Kruskal-Wallis. The 
results of the MTT assay obtained after the incubation with various 
concentrations of PEI-MP by MTT assay were compared for each cell line and 
time of incubation. The comparison of values between concentrations was 
made according to the ANOVA test in case they check a normal distribution and 
homogeneity of variance or according to the Kruskal-Wallis otherwise. The 
multiple comparisons were performed according to the Bonferroni correction. 
The comparison of the results of cell death, peroxides and superoxide radical 
production, GSH expression, mitochondrial membrane potential and cell cycle, 
between groups and cell lines, in both studies cytotoxicity of PEI-MP and 
radiotoxicity of 99mTc by flow cytometry, were made according to the t Student 
test for independent samples in case they check a normal distribution or 
according to the Mann-Whitney otherwise. The comparison of peroxides and 
superoxide radical production, GSH expression and mitochondrial membrane 
potential values after exposure to PEI-MP, with the control, was performed 
according to the t Student test for a mean, comparing the sample values to 1. 
The comparison of peroxides and superoxide radical production and 
mitochondrial membrane potential values after exposure to doses of 99mTc, with 
the control, was performed according to the t Student test for a mean, 
comparing the sample values to 1. For the cell viability and cell cycle the 
comparison was performed according to the t Student test for independent 
samples or Mann-Whitney, according to the previously explained. 
The comparison of values from the clonogenic activity after external and internal 
irradiation for each cell line and with the control were made according to the t 
Student test for a mean in comparison with the control (reference value 1), and 
using the test ANOVA of a factor (in the case of normal distribution and 
homogeneity of variances) or according to the Kruskal-Wallis test (otherwise) 
with multiple comparisons, with Bonferroni correction for the comparison 
between the remaining doses. 
The parameters obtained in uptake and retention studies were compared using 
the ANOVA test of a factor, with multiple comparisons according to the 
Bonferroni correction. It was considered a type I error of 0.05 for all the 
comparisons. 
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5.3. Results 
5.3.1. Radiochemical quality control 
The radiochemical purity was evaluated over time, using two chromatographic 
systems described before. When the acetone migrates through the ITLC-SG 
strip, 99mTc-Pertechnetate or 188Re-Perrhenate migrates with the solvent front 
(Rf = 1.0), allowing the determination of the percentage of these impurities. On 
the other hand, when citrate migrates through the W3MM strip, 99mTc/188Re-
Hydrolyzed/Reduced remains at the origin (Rf = 0.0), and the rest of the 
99mTc/188Re species migrates with the solvent front, allowing the determination 
of the percentage of these radiochemical impurities [87, 271]. By analysing the 
radiochemical purity of 99mTc-PEI-MP kit over time (during 5 hours after 
radiolabelling), it’s possible to verify that the labelling efficiency remained high, 
varying from 89.46% in the first hour to 92.72% five hours after the 
radiolabelling (table 17), revealing the high stability of the labelling kit 
formulation and the high labelling efficiency just one hour after the 
radiolabelling. The variation of the labelling efficiency over time was not 
statistically significant. 
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By analysing the radiochemical purity of 188Re-PEI-MP kit over time (during 5 
hours after radiolabelling), it’s possible to verify that the labelling efficiency 
remained relatively high, varying from 85.00% in the first hour to 81.73% five 
hours after the radiolabelling (table 18), revealing the high stability of the 
labelling kit formulation and the high labelling efficiency just one hour after the 
radiolabelling, even though less than that obtained with 99mTc-PEI-MP. The 
variation of the labelling efficiency over time was only statistically significant 
between 4 and 5 hours after radiolabelling (p = 0.019), decreasing from 90.50% 
at 4h to 81.73% at 5h. The decrease of the radiochemical purity seems to be 
associated with the increase of the percentage of the reduced/hydrolyzed 188Re 
species between 4h (4.80%) and 5h (17.00%), with statistical significant 
differences (p = 0.019). 
 
 
 
 
 
 
 
 
 
 
 
Legend: Percentage of 
99m
Tc species over time (1, 2, 3, 4 and 5 hours after radiolabelling), 
for radiochemical purity control. The percentage of the desired 
99m
Tc-PEI-MP was always 
superior to 89% over time. 
Table 17.99mTc-PEI-MP radiochemical purity control over time. The results express 
the average of 3 independent experiments  standard deviation. 
Time 
(hours) 
%99mTc-PEI-MP 
% 99mTc-Reduced/ 
Hydrolyzed 
%99mTc-Pertechnetate 
1 89.460.47 10.480.44 0.080.02 
2 90.021.55 9.891.46 0.030.02 
3 91.140.96 8.740.86 0.090.07 
4 90.231.32 9.661.25 0.110.07 
5 92.721.11 7.271.12 0.020.01 
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Also it was investigated the effect of temperature (22, 37 and 45°C) and of cell 
culture medium (DMEM) in radiochemical purity of 99mTc-PEI-MP over time (30 
minutes, 1h, 3h and 5h). The changes in temperatures are important because 
the human body temperature is 37°C as well as the cell culture propagation. As 
room temperature is normally around 22°C, we also choose this value. The 
higher temperature (45°C) was chosen in order to have a high value. By 
analysing the table 19, we can observe that the variation of the labelling 
efficiency over time, among temperatures and among temperatures plus DMEM 
was not statistically significant, and the values remained relatively constant, 
showing that both the variation of temperature and exposure to DMEM has no 
influence on the radiochemical purity. 
 
 
 
 
 
 
 
 
Legend: Percentage of 
188
Re species over time (1, 2, 3, 4 and 5 hours after radiolabelling), for 
radiochemical purity control. The percentage of the desired 
188
Re-PEI-MP was always superior 
to 81% over time. 
 
Table 18.188Re-PEI-MP radiochemical purity control over time. The results express 
the average of 3 independent experiments  standard deviation. 
Time 
(hours) 
%188Re-PEI-MP 
% 188Re-Reduced/ 
Hydrolyzed 
%188Re-Perrhenate 
1 85.002.46 13.103.15 2.470.40 
2 87.971.81 8.501.42 2.430.93 
3 86.802.65 7.301.21 2.400.35 
4 90.500.92 4.801.06 2.470.45 
5 81.733.15 17.001.39 3.700.60 
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Table 19.Radiochemical purity of 99mTc-PEI-MP, at 22 ºC, 37 ºC and ºC 45 ºC, and for 
the same temperatures and the exposure to DMEM. The results express the average 
of 4 independent experiments  standard deviation. 
Conditions Time %99mTc-PEI-MP 
% 99mTc-
Reduced/ 
Hydrolyzed 
%99mTc-
Pertechnetate 
22ºC 
30 min 87.40  0.37 12.59  0.37 0.00  0.00 
1h 85.80  1.01 14.13  0.95 0.05  0.01 
3h 85.05  0.34 14.81  0.32 0.10  0.01 
5h 81.38  1.51 17.86  1.94 1.89  0.31 
22ºC + DMEM 
30 min 83.34  1.89 16.47  1.93 0.17  0.05 
1h 88.52  0.55 10.40  0.71 1.84  0.50 
3h 87.91  1.18 11.65  1.06 0.43  0.03 
5h 88.92  2.33 11.02  2.32 0.06  0.02 
37ºC 
30 min 85.70  3.48 14.30  3.48 0.01  0.00 
1h 85.09  3.70 14.86  3.70 0.05  0.01 
3h 79.10  1.80 20.73  1.78 0.04  0.01 
5h 82.02  3.24 16.05  3.52 2.30  0.48 
37ºC + DMEM 
30 min 84.29  3.27 15.55  3.26 0.17  0.01 
1h 90.13  0.71 8.77  0.78 1.14  0.05 
3h 86.70  1.06 12.74  1.30 0.42  0.06 
5h 88.05  2.09 11.85  2.07 0.10  0.04 
45ºC 
30 min 85.81  2.06 14.19  2.05 0.00  0.00 
1h 86.88  2.38 13.05  2.39 0.07  0.02 
3h 79.09  4.76 19.87  4.87 0.15  0.08 
5h 80.95 3.15 17.08  3.90 3.68  2.89 
45ºC + DMEM 
30 min 83.94  4.95 20.58  3.50 0.25  0.04 
1h 88.66  1.61 8.85  0.46 1.65  0.41 
3h 85.77  1.72 13.68  1.78 0.55  0.10 
5h 88.68 1.95 11.22  1.97 0.11  0.03 
Legend: Percentage of 
99m
Tc species over time (30 min, 1h, 3h and 5h after radiolabelling), 
when exposed to  temperatures of 22 ºC, 37 ºC and 45 ºC, and for the same temperatures when 
exposed to DMEM. 
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5.3.2. Determination of the partition coefficient of 99mTc-PEI-MP 
In order to determine the hydrophilicity or lipophilicity of 99mTc-PEI-MP, it was 
determined the partition coefficient over time. After obtained the counts of each 
phase (1-octanol/water), and calculated the partition coefficient of the 99mTc-
PEI-MP with the formula presented before, it was verified that the 1-
octanol/water partition coefficient was always negative during time (4 hours) 
and the values were relatively constant, ranging from -3.280.08 at 1 hour and -
3.820.01 at 4 hours (table 20). These results demonstrate that 99mTc-PEI-MP 
is a hydrophilic complex. 
 
5.3.3. Evaluation of the cytotoxicity of PEI-MP 
5.3.3.1. Metabolic activity 
It was intended to verify if the PEI-MP was cytotoxic to cells, and whether it 
could function as a carrier and not as a drug. To this, the effects of PEI-MP in 
the metabolic activity of the HT-1376 and MNNG/HOS cells were examined for 
different concentrations of PEI-MP and periods of incubation, using MTT assay. 
With the values obtained, it wasn’t possible to estimate the IC50 for each cell line 
and time of incubation, therefore it was compared the various concentration 
used for each cell line and time of incubation. The fig. 12 represents the 
percentage of metabolic activity of HT-1376 and MNNG/HOS cells 24, 48, 72 
and 96 hours after incubation. We can see in the fig. 12, that for each 
concentration of PEI-MP, the percentage of cellular metabolic activity for each 
cell line and incubation time was always equal or superior to 100%, 
demonstrating that PEI-MP doesn’t have a significantly inhibitory influence on 
Table 20.Partition coefficient of 99mTc-PEI-MP over time. The results express the 
average of 4 independent experiments  standard deviation. 
Time (hours) PO/W 
99mTc-PEI-MP 
1 -3.280.08 
2 -3.640.05 
3 -3.620.06 
4 -3.820.01 
Legend: Partition coefficient (PO/W) of 
99m
Tc-PEI-MP over time (1h, 2h, 3h and 4h after 
radiolabelling). The partition coefficient was always negative revealing the hydrophilicity of the 
complex. 
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cell metabolic activity. There are no significant statistical differences between 
the two cell lines, or within each cell line, for every concentration of PEI-MP and 
incubation time. 
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Figure 12.Percentage of metabolic cell activity 24, 48, 72 and 96 hours after exposure 
to concentrations of PEI-MP in HT-1376 and MNNG/HOS cell lines. The results 
express the average of 5 independent experiments  standard deviation. 
 
5.3.3.2. Flow cytometry 
In order to support the results obtained by the MTT assay, the effects of PEI-
MP, with the maximum concentration of 1000 µM, in HT-1376 and MNNG/HOS 
cells, was evaluated by flow cytometry, studying the cell viability, the ROS 
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production, the expression of GSH and changes in mitochondrial membrane 
potential. 
The assessment of cell viability was performed by flow cytometry using the 
AV/PI incorporation assay. This technique allows distinguishing different cell 
populations: viable cells, cells in early apoptosis, cells in late apoptosis/necrosis 
and necrosis. Cytometry studies demonstrated that after 24 hours of incubation 
with PEI-MP, there are no statistical significant differences in cell viability 
between the control and the exposed cells, remaining above 82% in both cell 
lines, as shown in fig. 13.  espite cell viability didn’t decrease, apoptosis 
increased in both cell lines after the incubation with PEI-MP, with a reduction of 
necrosis. Besides the small values, statistically significant differences were 
found for apoptosis in HT-1376 cells (p = 0.006) and MNNG/HOS cells (p = 
0.029). Also necrosis has reduced significantly for MNNG/HOS (p = 0.004).  
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Figure 13.Cell viability by flow cytometry using dual staining with AV and PI. Figure 
represents the percentage of viable cells, in early apoptosis, in late apoptosis/necrosis, 
and necrosis after 24 hours of incubation with 1000 µM of PEI-MP in HT-1376 and 
MNNG/HOS cells. The results express the average of 4 independent experiments  
standard deviation. 
 
The production of ROS was also evaluated by the quantification of the 
expression of peroxides and superoxide radicals. To evaluate the production of 
peroxide and superoxide radicals, it was used DCFH2-DA and DHE, 
respectively, for the analysis of the fluorescence intensities by flow cytometry. 
As can be seen in the fig. 14, there is an increase in the intracellular production 
of peroxides in both cell lines, particularly for HT-1376 cells, after 24 hours of 
incubation with 1000 µM of PEI-MP. However, it wasn’t found any statistically 
significant differences in the production of peroxides in relation to the control 
and between cells lines. Also is possible to see that the production of 
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superoxide seems not to alter with the exposure to PEI-MP, and comparing the 
values it wasn’t found any statically significant differences. 
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Figure 14.Production of peroxides and superoxide by flow cytometry using DCFH2-DA 
and DHE, respectively. HT-1376 and MNNG/HOS cells were incubated during 24 hours 
with 1000 µM of PEI-MP and subsequently the production of peroxides and superoxide 
was detected. The results are expressed as mean intensity normalized in relation to the 
control, comparing the results with the value of 1. The results express the average of 4 
independent experiments  standard deviation. 
 
To evaluate the expression of intracellular GSH, it was used the orange 
mercury probe and the fluorescence intensities was analysed by flow cytometry. 
Through the analysis of fig. 15, there is a decrease in the expression of GSH in 
both cell lines, particularly for HT-1376 cells, after 24 hours of incubation with 
1000 µM of PEI-MP. However, it wasn’t found statistically significant 
differences, between the control and the cell lines. 
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Figure 15.Expression of GSH by flow cytometry using orange mercury. HT-1376 and 
MNNG/HOS cells were incubated during 24 hours with 1000 µM of PEI-MP and 
subsequently the expression of intracellular GSH was detected. The results are 
expressed as mean intensity normalized in relation to the control, comparing the results 
with the value of 1. The results express the average of 4 independent experiments  
standard deviation. 
 
To evaluate the mitochondrial membrane potential, it was used the JC-1 probe, 
a molecule able to selectively enter the cell and which exists in two forms, 
monomers (M) and aggregates (A), depending on the state of 
polarization/depolarization of the mitochondrial membrane. As can be seen in 
fig. 16, there is a slightly decrease in mitochondrial membrane potential in both 
cell lines after 24 hours of incubation with PEI-MP, in the concentration of 1000 
µM. It wasn’t found statistically significant differences between the two cell lines 
or in relation to the control. 
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Figure 16.Analysis of mitochondrial membrane potential by flow cytometry using the 
fluorescent probe JC-1. HT-1376 and MNNG/HOS cells were incubated during 24 
hours with 1000 µM of PEI-MP and subsequently mitochondrial membrane potential 
was detected. The results are expressed as mean intensity normalized in relation to the 
control, comparing the results with the value of 1. The results express the average of 4 
independent experiments  standard deviation. 
 
5.3.4. Evaluation of the radiocytoxicity of 99mTc 
5.3.4.1. Clonogenic activity 
It was intended to verify if doses of 99mTc-Pertechnetate activities in the range of 
diagnostics had influence in cell survival based on the ability of a single cell to 
grow and form a colony, either being irradiated externally (evaluation of gamma 
rays effects) or internally (evaluation of gamma rays and auger electrons 
effects). To this, it was examined the clonogenic activity of HT-1376 and 
MNNG/HOS cells after external and internal irradiation with 2, 5, 10 and 20 
mGy of 99mTc. 
The fig. 17 and fig. 18 represents the medium survival factor of HT-1376 and 
MNNG/HOS cells after external and internal irradiation, respectively, with 2, 5, 
10 and 20 mGy of 99mTc.It can be seen in fig. 17 and fig. 18 that for each dose 
of 99mTc, independently of the irradiation be internal or external, the cell survival 
didn’t decrease, demonstrating that for diagnostic effective doses, the gamma 
rays and auger electrons, has no apparent effect on cell survival. In the 
comparison of all the conditions, it wasn’t found statistically significant 
differences. 
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Figure 17.Cell survival after external irradiation with doses of 99mTc in HT-1376 and 
MNNG/HOS cell lines. The results express the average of 5 independent experiments 
 standard deviation. 
 
Figure 18.Cell survival after internal irradiation with doses of 99mTc in HT-1376 and 
MNNG/HOS cell lines. The results express the average of 4 independent experiments 
 standard deviation. 
 
5.3.4.2. Flow cytometry 
In order to support the results obtained with clonogenic test, the effects of 20 
mGy of 99mTc, after external and internal irradiation of HT-1376 and 
MNNG/HOS cells, was evaluated by flow cytometry, studying the cell viability, 
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the ROS production, the expression of GSH, changes in mitochondrial 
membrane potential and distribution of cells in cell cycle. 
The assessment of cell viability was performed by flow cytometry using the 
AV/PI incorporation assay. This technique allows distinguishing different cell 
populations: viable cells, cells in early apoptosis, cells in late apoptosis/necrosis 
and necrosis. Cytometry studies show that after external irradiation with 20 mGy 
of 99mTc, cell viability didn’t decrease, remaining above 82% in both cell lines, as 
shown in fig. 19. To these values of cell viability it wasn’t found any statistical 
significant differences between the control and the irradiated cells, in both cell 
lines. Early apoptosis, late apoptosis/necrosis seems to increase for both cell 
lines after the external irradiation, especially for HT-1376 cells. However, 
statistical significant differences were not found. Necrosis seems to increase for 
HT-1376 and decrease for MNNG/HOS cells, however these differences were 
not statistically significant. 
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Figure 19.Cell viability by flow cytometry using dual staining with AV and PI. Figure 
represents the percentage of viable cells, in early apoptosis, in late apoptosis/necrosis, 
and necrosis after external irradiation with 20 mGy of 99mTc in HT-1376 and 
MNNG/HOS cells. The results express the average of 4 independent experiments  
standard deviation. 
 
For internal irradiation, cytometry studies show that after irradiation with 20 mGy 
of 99mTc, cell viability didn’t decrease, remaining above 84% in both cell lines, as 
shown in fig. 20. To these values of cell viability it wasn’t found any statistical 
significant differences between the control and the irradiated cells, in both cell 
lines. Late apoptosis/necrosis seems to increase for both cell lines after the 
internal irradiation, especially for HT-1376 cells. However, statistical significant 
differences were not found. Necrosis seems to decrease for HT-1376 and 
increase for MNNG/HOS cells, however these differences were not statistically 
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significant. Also, it was not found statistically significant differences for 
apoptosis in both cell lines. 
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Figure 20.Cell viability by flow cytometry using dual staining with AV and PI. Figure 
represents the percentage of viable cells, in early apoptosis, in late apoptosis/necrosis, 
and necrosis after internal irradiation with 20 mGy of 99mTc in HT-1376 and 
MNNG/HOS cells. The results express the average of 4 independent experiments  
standard deviation. 
 
The production of ROS was also evaluated by the quantification of the 
expression of peroxides and superoxide radicals. To evaluate the production of 
peroxide and superoxide radicals, it was used DCFH2-DA and DHE, 
respectively, for the analysis of the fluorescence intensities by flow cytometry. 
As can be seen in the fig. 21, there is slight increase in the intracellular 
production of peroxides for MNNG/HOS and superoxide in both cell lines, after 
external irradiation with 20 mGy of 99mTc. However, it wasn’t found any 
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statistically significant differences in the production of peroxides and superoxide 
in relation to the control and between cells lines. Also is possible to see that the 
production of peroxides in HT-1376 cells seems not to alter after the external 
irradiation with 20 mGy of 99mTc, and comparing the values it wasn’t found any 
statically significant differences. 
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Figure 21.Production of peroxides and superoxide by flow cytometry using DCFH2-DA 
and DHE, respectively. HT-1376 and MNNG/HOS cells were irradiated externally with 
20 mGy of 99mTc and subsequently the production of peroxides and superoxide was 
detected. The results are expressed as mean intensity normalized in relation to the 
control, comparing the results with the value of 1. The results express the average of 4 
independent experiments  standard deviation. 
 
For internal irradiation, as can be seen in the fig. 22, the production of peroxides 
in both cell lines and the production of superoxide for HT-1376 cells seem not to 
change after the internal irradiation with 20mGy of 99mTc, and comparing the 
values it wasn’t found any statically significant differences. Also, it was possible 
to visualize a slight increase in the intracellular production of superoxide in 
MNNG/HOS cells, after internal irradiation with 20 mGy of 99mTc. However, it 
wasn’t found any statistically significant differences in the production of 
superoxide in relation to the control and between cells lines. 
 
 
145 
 
A b s o rb e d  d o s e  (2 0  m G y )
M
e
a
n
 f
lu
o
r
e
s
c
e
n
c
e
 i
n
te
n
s
it
y
(n
o
r
m
a
li
z
e
d
 i
n
 r
e
la
ti
o
n
 t
o
 t
h
e
 c
o
n
tr
o
l)
P
e
ro
x
id
e
s
S
u
p
e
ro
x
id
e
s
0 .0
0 .5
1 .0
1 .5
2 .0
H T -1 3 7 6  c e ll lin e
M N N G -H O S  ce ll line
 
Figure 22.Production of peroxides and superoxide by flow cytometry using DCFH2-DA 
and DHE, respectively. HT-1376 and MNNG/HOS cells were irradiated internally with 
20 mGy of 99mTc and subsequently the production of peroxides and superoxide was 
detected. The results are expressed as mean intensity normalized in relation to the 
control, comparing the results with the value of 1. The results express the average of 4 
independent experiments  standard deviation. 
 
To evaluate the expression of intracellular GSH, it was used the orange 
mercury probe and the analysis of the fluorescence intensities by flow 
cytometry. As can be seen in fig. 23, the expression of intracellular GSH seems 
to decrease slightly for HT-1376 cells and not having alterations for MNNG/HOS 
cells. However, it wasn’t found any statistically significant differences in the 
expression of intracellular GSH in relation to the control and between cells lines. 
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Figure 23.Expression of GSH by flow cytometry using orange mercury. HT-1376 and 
MNNG/HOS cells irradiated externally with 20 mGy of 99mTc and subsequently the 
expression of intracellular GSH was detected. The results are expressed as mean 
intensity normalized in relation to the control, comparing the results with the value of 1. 
The results express the average of 4 independent experiments  standard deviation. 
 
For internal irradiation, as can be seen in fig. 24, the expression of intracellular 
GSH seems to increase slightly for both cell lines. However, it wasn’t found any 
statistically significant differences in the expression of intracellular GSH in 
relation to the control and between cells lines. 
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Figure 24.Expression of GSH by flow cytometry using orange mercury. HT-1376 and 
MNNG/HOS cells irradiated internally with 20 mGy of 99mTc and subsequently the 
expression of intracellular GSH was detected. The results are expressed as mean 
intensity normalized in relation to the control, comparing the results with the value of 1. 
The results express the average of 4 independent experiments  standard deviation. 
 
To evaluate the mitochondrial membrane potential, it was used the JC-1, a 
molecule able to selectively enter the cell and which exists in two forms, 
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monomers (M) and aggregates (A), depending on the state of 
polarization/depolarization of the mitochondrial membrane. For external 
irradiation, as can be seen in the fig. 25, the mitochondrial membrane potential 
seems not to alter in both cell lines after the external irradiation with 20mGy of 
99mTc, and comparing the values it wasn’t found any statically significant 
differences.  
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Figure 25.Analysis of mitochondrial membrane potential by flow cytometry using the 
fluorescent probe JC-1. HT-1376 and MNNG/HOS cells irradiated externally with 20 
mGy of 99mTc and subsequently mitochondrial membrane potential was detected. The 
results are expressed as mean intensity normalized in relation to the control, 
comparing the results with the value of 1. The results express the average of 4 
independent experiments  standard deviation. 
 
For internal irradiation, as can be seen in the fig. 26, the mitochondrial 
membrane potential seems not to alter in both cell lines after the internal 
irradiation with 20mGy of 99mTc, and comparing the values it wasn’t found any 
statically significant differences.  
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Figure 26.Analysis of mitochondrial membrane potential by flow cytometry using the 
fluorescent probe JC-1. HT-1376 and MNNG/HOS cells irradiated internally with 20 
mGy of 99mTc and subsequently mitochondrial membrane potential was detected. The 
results are expressed as mean intensity normalized in relation to the control, 
comparing the results with the value of 1. The results express the average of 4 
independent experiments  standard deviation. 
 
The assessment of cell cycle was performed by flow cytometry using the 
PI/RNase incorporation assay. This technique allows distinguishing the 
distribution of cells in cell cycle: pre G1, G0/G1, S and G2/M phases. Cytometry 
studies show that after external irradiation with 20 mGy of 99mTc, the distribution 
of cells in cell cycle didn’t alter for both type of cells, as shown in fig. 27, and 
comparing the values it wasn’t found any statically significant differences. 
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Figure 27.Cell cycle distribution by flow cytometry using PI/RNase. Figure represents 
the percentage of cells in pre G1, G0/G1, S and G2/M phases, after external irradiation 
with 20 mGy of 99mTc in HT-1376 and MNNG/HOS cells. The results express the 
average of 4 independent experiments  standard deviation. 
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For internal irradiation, cytometry studies show that after irradiation with 20 mGy 
of 99mTc, the distribution of cells in cell cycle didn’t alter for both type of cells, as 
shown in fig. 28, and comparing the values it wasn’t found any statically 
significant differences. 
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Figure 28.Cell cycle distribution by flow cytometry using PI/RNase. Figure represents 
the percentage of cells in pre G1, G0/G1, S and G2/M phases, after internal irradiation 
with 20 mGy of 99mTc in HT-1376 and MNNG/HOS cells. The results express the 
average of 4 independent experiments  standard deviation. 
 
5.3.5. Cellular uptake and retention studies 
To evaluate the in vitro cellular kinetics of 99mTc-PEI-MP and 188Re-PEI-MP it 
was proceeded to the evaluation of the cellular uptake and retention over time.  
From the results showed in fig. 29, fig. 30 and table 21, the maximum uptake for 
99mTc-PEI-MP in both cell lines was higher than for 99mTc-Pertechnetate. In cell 
line HT-1376 the maximum uptake of 99mTc-PEI-MP obtained was in the order 
of 1.16 instead of the lower value 0.27 of maximum uptake for 99mTc-
Pertechnetate, being the differences statistically significant (p = 0.001). Also it 
was verified that the maximum uptake was higher for 99mTc-PEI-MP, the time 
spend to reach half of the maximum uptake was higher for 99mTc-PEI-MP (55.46 
minutes) than for 99mTc-Pertechnetate (3.88 minutes), however it wasn’t found 
statistically significant differences. In cell line MNNG/HOS the maximum uptake 
of 99mTc-PEI-MP obtained was in the order of 1.00, a higher value than the 0.19 
of maximum uptake for 99mTc-Pertechnetate, being found statistically 
significance differences (p < 0.001). Similarly as for the HT-1376 cell line, the 
time spend to reach half of the maximum uptake was higher for 99mTc-PEI-MP 
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(10.12 minutes) than for 99mTc-Pertechnetate (0.89 minutes), however it wasn’t 
found statistically significant differences. 
 
 
Figure 29.Uptake of 99mTc-PEI-MP and 99mTc-Pertechnetate by HT-1376 cells over 
time. The cells were incubated with 0.925MBq/ml (25 µCi/ml), and after the percentage 
of uptake of the radiotracer formulation by influx studies was determined. The results 
express the mean of 4 independent experiments  standard deviation. 
 
Figure 30.Uptake of 99mTc-PEI-MP and 99mTc-Pertechnetate by MNNG/HOS cells over 
time. The cells were incubated with 0.925MBq/ml (25 µCi/ml), and after the percentage 
of uptake of the radiotracer formulation by influx studies was determined. The results 
express the mean of 4 independent experiments  standard deviation. 
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From the results demonstrated in fig. 31, fig. 32 and table 22, the minimum 
retention for 99mTc-PEI-MP in both cell lines was higher than for 99mTc-
Pertechnetate. In cell line HT-1376 the minimum retention of 99mTc-PEI-MP 
obtained was in the order of 3.89 instead of the lower value 1.03 for 99mTc-
Pertechnetate, being the differences statistically significant (p < 0.001). In cell 
line MNNG/HOS the minimum retention of 99mTc-PEI-MP obtained was in the 
order of 3.78, a higher value than the 0.54 for 99mTc-Pertechnetate, being found 
statistically significance differences (p < 0.001). There were no statistically 
significant differences between the Tm (min) of 99mTc-Pertechnetate and 99mTc-
PEI-MP in both cell lines.  
 
 
Table 21.Mean values of A (%) and T50% (min) for the uptake of 99mTc-Pertechnetate 
and 99mTc-PEI-MP in the cell lines HT-1376 and MNNG/HOS. The results analysed 
were obtained from 4 independent experiments. 
Cell Line Radiopharmaceutical A (%) T50% (min) 
HT-1376 
99mTc-Pertechnetate 0.270.02 3.880.90 
99mTc-PEI-MP 1.160.16 55.4621.60 
MNNG/HOS 
99mTc-Pertechnetate 0.190.01 0.893.02 
99mTc-PEI-MP 1.000.11 10.127.7 
Legend: Mean values of A   standard deviation and T50%  standard deviation, for the uptake of 
99m
Tc-Pertechnetate and 
99m
Tc-PEI-MP in the cell lines HT-1376 and MNNG/HOS. The A is the 
maximum uptake and T50% is the time needed to reach half of the maximum uptake. 
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Figure 31.Retention of 99mTc-PEI-MP and 99mTc-Pertechnetate by HT-1376 cells over 
time. The cells were incubated with 0.925MBq/ml (25 µCi/ml) during 150 minutes and 
then culture medium was substituted, and the percentage of retention of the radiotracer 
formulation by efflux studies was determined. The results express the mean of 4 
independent experiments  standard deviation. 
 
 
Figure 32.Retention of 99mTc-PEI-MP and 99mTc-Pertechnetate by MNNG/HOS cells 
over time. The cells were incubated with 0.925MBq/ml (25 µCi/ml) during 150 minutes 
and then culture medium was substituted, and the percentage of retention of the 
radiotracer formulation by efflux studies was determined. The results express the mean 
of 4 independent experiments  standard deviation. 
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From the results showed in fig. 33, fig. 34 and table 23, the maximum uptake for 
188Re-PEI-MP in both cell lines was higher than for 188Re-Perrhenate. In cell line 
HT-1376 the maximum uptake of 188Re-PEI-MP obtained was in the order of 
9.88 instead of the lower value 0.16 of maximum uptake for 188Re-Perrhenate, 
being the differences statistically significant (p = 0.001). Also it was verified that 
the maximum uptake was higher for 188Re-PEI-MP, the time spend to reach half 
of the maximum uptake was lower for 188Re-PEI-MP (0.06 minutes) than for 
188Re-Perrhenate (26.07 minutes), however it wasn’t found statistically 
significant differences. In cell line MNNG/HOS the maximum uptake of 188Re-
PEI-MP obtained was in the order of 13.09, a higher value than the 0.20 of 
maximum uptake for 188Re-Perrhenate, being found statistically significance 
differences (p < 0.001). The time spend to reach half of the maximum uptake 
was higher for 188Re-PEI-MP (0.09 minutes) than for 188Re-Perrhenate (0.06 
minutes), however it wasn’t found statistically significant differences. 
 
 
 
 
 
 
 
 
 
Legend: Mean values of A  standard deviation and Tm  standard deviation, for the retention of 
99m
Tc-Pertechnetate and 
99m
Tc-PEI-MP in both the cell lines HT-1376 and MNNG/HOS. The A is 
the minimum retention and Tm is the time delay to reach 50% of the retention plus A/2, or the 
midpoint between 100% and the minimal retention. 
Table 22.Mean values of A (%) and Tm (min) for the retention of 99mTc-Pertechnetate 
and 99mTc-PEI-MP, in the cell lines HT-1376 and MNNG/HOS. The results analysed 
were obtained from 4 independent experiments. 
Cell Line Radiopharmaceutical A (%) Tm (min) 
HT-1376 
99mTc-Pertechnetate 1.030.16 0.190.04 
99mTc-PEI-MP 3.890.06 0.150.02 
MNNG/HOS 
99mTc-Pertechnetate 0.540.13 0.200.09 
99mTc-PEI-MP 3.780.24 0.160.04 
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Figure 33.Uptake of 188Re-PEI-MP and 188Re-Perrhenate by HT-1376 cells over time. 
The cells were incubated with 0.925MBq/ml (25 µCi/ml), and after the percentage of 
uptake of the radiotracer formulation by influx studies was determined. The results 
express the mean of 4 independent experiments  standard deviation. 
 
Figure 34.Uptake of 188Re-PEI-MP and 188Re-Perrhenate by MNNG/HOS cells over 
time. The cells were incubated with 0.925MBq/ml (25 µCi/ml), and after the percentage 
of uptake of the radiotracer formulation by influx studies was determined. The results 
express the mean of 4 independent experiments  standard deviation. 
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From the results demonstrated in fig. 35, fig.36 and table 24, the minimum 
retention for 188Re-PEI-MP in both cell lines was higher than for 188Re-
Perrhenate. In cell line HT-1376 the minimum retention of 188Re-PEI-MP 
obtained was in the order of 45.67 instead of the lower value 0.24 for 188Re-
Perehenate, being the differences statistically significant (p < 0.001). In cell line 
MNNG/HOS the minimum retention of 188Re-PEI-MP obtained was in the order 
of 68.94, a higher value than the 0.21 for 188Re-Perrhenate, being found 
statistically significance differences (p < 0.001). There are no statistically 
significant differences between the Tm (min) of 188Re-Perrhenate and 188Re-
PEI-MP in both cell lines. 
 
 
 
Table 23.Mean values of A (%) and T50% (min), for the uptake of 188Re-Perrhenate 
and 188Re-PEI-MP in both the cell lines HT-1376 and MNNG/HOS. The results 
analysed were obtained from 4 independent experiments. 
Cell Line Radiopharmaceutical A (%) T50% (min) 
HT-1376 
188Re-Perrhenate 0.160.00 26.070.00 
188Re-PEI-MP 9.880.44 0.060.00 
MNNG/HOS 
188Re-Perrhenate 0.200.01 0.060.01 
188Re-PEI-MP 13.090.48 0.090.00 
Legend: Mean values of A  standard deviation and T50%  standard deviation, for the uptake of 
188
Re-Perrhenate and 
188
Re-PEI-MP in the cell lines HT-1376 and MNNG/HOS. The A is the 
maximum uptake and T50% is the time needed to reach half of the maximum uptake.  
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Figure 35.Retention of 188Re-PEI-MP and 188Re-Perrhenate by HT-1376 cells over 
time. The cells were incubated with 0.925MBq/ml (25 µCi/ml) during 150 minutes and 
then culture medium was substituted, and the percentage of retention of the radiotracer 
formulation by efflux studies was determined. The results express the mean of 4 
independent experiments  standard deviation. 
 
Figure 36.Retention of 188Re-PEI-MP and 188Re-Perrhenate by MNNG/HOS cells over 
time. The cells were incubated with 0.925MBq/ml (25 µCi/ml) during 150 minutes and 
then culture medium was substituted, and the percentage of retention of the radiotracer 
formulation by efflux studies was determined. The results express the mean of 4 
independent experiments  standard deviation. 
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5.4. Section discussion 
With the intention of analysing in vitro the potential of PEI-MP radiolabelled with 
99mTc for diagnosis and with 188Re for therapy of bladder cancer, in this chapter 
it was evaluated the chemical properties of PEI-MP, the radiotoxicity of 99mTc 
and the cellular uptake and retention of 99mTc-PEI-MP and 188Re-PEI-MP, using 
for this cell lines of human bladder transitional cell carcinoma and 
osteosarcoma (considering the first propose of using PEI-MP) [111, 317].  
Following the success in the synthesis of the polymer PEI-MP and the 
preparation of the labelling kits, it was proceeded with the radiolabelling with 
99mTc-Pertechnetate and 188Re-Perrhenate. Thus, once the aim was to use 
99mTc-PEI-MP for imaging and 188Re-PEI-MP for therapy, it was necessary to 
determine the radiochemical purity by ascendant microchromatography. The 
results demonstrated that the radiochemical purity for 99mTc-PEI-MP and 188Re-
PEI-MP, during 5 hours after radiolabelling, was always high and superior to 
89% and 85%, respectively for 99mTc-PEI-MP and 188Re-PEI-MP, just in the first 
hour. These results reveal the stability of the kit formulation, and thus ensure its 
use for a long period of time. After several experiments with different 
chromatographic systems, it was perceived that the two systems chosen were 
appropriated. 99mTc/188Re-PEI-MP are polar and water-soluble molecules, 
therefore by using a stationary phase that is strongly polar, like ITLC-SG, 
99mTc/188Re-PEI-MP will have a strong interaction with the stationary phase, and 
will not move with the solvent, in this case the acetone. On the other hand, 
Table 24.Mean values of A (%) and Tm (min), for the retention of 188Re-Perrhenate 
and 188Re-PEI-MP in both the cell lines HT-1376 and MNNG/HOS. The results 
analysed were obtained from 4 independent experiments. 
Cell Line Radiopharmaceutical A (%) Tm (min) 
HT-1376 
188Re-Perrhenate 0.240.00 3.820.00 
188Re-PEI-MP 45.670.47 2.211.39 
MNNG/HOS 
188Re-Perrhenate 0.210.00 2.670.00 
188Re-PEI-MP 68.940.44 0.080.00 
Legend: Mean values of A  standard deviation and Tm  standard deviation, for the retention of 
188
Re-Perrhenate and 
188
Re-PEI-MP in both the cell lines HT-1376 and MNNG/HOS. The A is the 
minimum retention and Tm is the time delay to reach 50% of the retention plus A/2, or the midpoint 
between 100% and the minimal retention.  
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99mTc-Pertechnetate and 188Re-Perrhenate that are non-polar molecules will 
have no affinity for the stationary phase and will be dragged by the polar 
solvent. The 99mTc/188Re-Reduced-Hydrolyzed being non-soluble molecules will 
remain in the origin, presenting an Rf equal to zero. This way it is possible to 
calculate the percentage of 99mTc-Pertechnetate and 188Re-Perrhenate that 
present an Rf equal to one. Upon use the stationary phase W3MM and the 
citrate as mobile phase the aim was to separate the 99mTc/188Re-Reduced-
Hydrolyzed from 99mTc/188Re-PEI-MP, 99mTc-Pertechnetate/188Re-Perrhenate. 
To this W3MM demonstrated to be an adequate stationary phase. Because 
W3MM is non-polar, using a polar solvent like citrate, 99mTc/188Re-PEI-MP will 
be drag by the solvent, as well as 99mTc-Pertechnetate or 188Re-Perrhenate, and 
99mTc/188Re-Reduced-Hydrolyzed being non-soluble molecules will remain in the 
origin [87, 271]. Therefore, knowing the percentage of 99mTc-Pertechnetate or 
188Re-Perrhenate and the percentage of 99mTc/188Re-Reduced-Hydrolyzed it 
was possible to calculate the percentage of 99mTc-PEI-MP or 188Re-PEI-MP.  
Also it was investigated the effect of temperature and presence of cell culture 
medium (DMEM) in radiochemical purity of 99mTc-PEI-MP over time, once to 
perform the in vitro studies, the complex is exposed to cellular culture medium 
and environmental temperatures that may vary from 22 to 45 ºC. The results 
demonstrated that the radiochemical purity was not affected significantly, being 
equal or superior to 85% in the first hour for all conditions, at least during 5 
hours after radiolabelling, when in contact with culture medium and exposed to 
different temperatures. Therefore the in vitro studies could be performed with 
99mTc-PEI-MP, ensuring that the results were not altered by the loss of 
radiochemical purity. Considering the similarities of 188Re-PEI-MP with 99mTc-
PEI-MP, the results discussed before were also expected for 188Re-PEI-MP. 
The hydrophilicity or lipophilicity of a labelled compound is crucial for the 
biodistribution in vivo, therefore the determination of the partition coefficient (log 
Po/w) of 
99mTc-PEI-MP was crucial. The results demonstrated that 99mTc-PEI-MP 
is a hydrophilic complex, with an increased hydrophilicity over time (at least 4 
hours after radiolabelling), but with no statistical significant differences. Also, it 
wasn’t possible to calculate the hydrophilicity of the 188Re-PEI-MP, however due 
to the similarity of the complexes, it is expected similar values of hydrophilicity. 
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This water solubility could be an advantage in terms of unnecessary liver and 
fat tissue uptake, and also a faster kidney-uptake, if administered in vivo [273]. 
These results may represent a theoretical advantage either for imaging and 
therapy however, in vivo studies must be performed for a final conclusion on 
this topic. 
To understand if PEI-MP would act as a carrier without any secondary effects to 
cells, it was verified the effects on cell metabolic activity after the incubation with 
several concentrations of PEI-MP, in different periods of time. To this it was 
used the human cell lines of bladder carcinoma and osteosarcoma. The results 
obtained by MTT assay demonstrated that, for any of the cell lines used for the 
experiment, and any of the concentrations in each period of time, PEI-MP didn’t 
had significantly inhibitory influence on metabolic activity, remaining equal or 
superior to 100%. To confirm and reinforce these last results, it was study other 
possible responses of cells when incubated with 1000 µM of PEI-MP during 24 
hours. To this it was resorted to flow cytometry, and it was studied the types of 
cell death and viability, the production of free radicals, the expression of 
reduced GSH, and changes in the mitochondrial membrane potential. The 
results demonstrated that cell viability didn’t decrease significantly, remaining 
superior to 82% in both cell lines, despite the increase of apoptosis and a slight 
decrease of the mitochondrial membrane potential, especially in the HT-1376 
cells. The intrinsic pathway of apoptosis involves the mitochondria, and 
mediates the release of cytochrome c that is associated with the opening of the 
mitochondrial permeability transition pore and loss of the mitochondrial 
membrane potential. Therefore it is expected that with the increase of apoptosis 
the mitochondrial membrane potential may also be decreased [299], as it was 
expressed in the previous results. However there are reasons to believe that 
this increase in apoptosis is not relevant, and does not preclude its use, 
considering the results obtained in the MTT tests and the other results of flow 
cytometry, where cell viability didn’t decrease and that weren’t found significant 
changes in the production of free radicals and in the expression of GSH. 
Therefore, the idea that PEI-MP can act as a carrier without significant side 
effects and that can be labelled with 99mTc for functional imaging or labelled with 
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188Re for therapy still remains, considering the consistent results obtained by 
the MTT assay and flow cytometry. 
Because it was intended to use 99mTc-PEI-MP for diagnosis, it’s important that 
the doses of radiation used don’t represent a risk. As described before 99mTc not 
also emits gamma rays of low energy (140 keV), but also highly energetic auger 
electrons, that could represent a risk [59]. Therefore it was proceeded with the 
analysis of the radiotoxicity of 99mTc with several doses in the range of 
diagnostics, for both bladder cancer and osteosarcoma cells. The effective 
doses for most nuclear medicine diagnostic procedures varies between 0.3 and 
20 mSv (equivalent to 0.3 and 20 mGy) [303], therefore it was performed 
clonogenic tests to evaluate cell survival based on the ability of a single cell to 
grow and form a colony after external and internal irradiation of cells with 
several doses, namely 2, 5, 10 and 20 mGy. After external irradiation it’s 
possible to evaluate the effects of gamma rays and not of auger electrons. Only 
with internal irradiation it’s possible to evaluate the effects of gamma rays plus 
auger electrons, considering the low range of these electrons, therefore it needs 
to be in close contact with cells to produce effects [302]. The results 
demonstrated, as expected, that for doses of 99mTc in the range of diagnosis, 
and independently of the irradiation being external or internal, there are no 
significant influence in cell survival for both bladder carcinoma and 
osteosarcoma cells. The cell survival didn’t decrease, at least in terms of 
capacity to grow and form a colony, demonstrating that for diagnostic effective 
doses, the gamma rays and auger electrons, has no apparent effect on cell 
survival. To support the results obtained with clonogenic assay, it was study 
other possible responses of cells when irradiated with 20 mGy of 99mTc. For this 
purpose, flow cytometry was used to study the types of cell death and viability, 
the production of free radicals and the expression of reduced GSH, the changes 
in the mitochondrial membrane potential and the cell cycle. The results 
demonstrated that cell viability didn’t decrease significantly, remaining superior 
to 82% for external irradiation and above 84% for internal irradiation in both cell 
lines, with no significant differences for apoptosis or necrosis. The absence of 
significant alterations in the production of peroxides and superoxide, expression 
of GSH, changes in the mitochondrial membrane and changes in the 
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distribution throughout the cell cycle, after external an internal irradiation 
support the results of flow cytometry for cell death and viability and the results 
obtained in clonogenic studies, demonstrating that doses of 99mTc in diagnostic 
range is considered harmless and 99mTc-PEI-MP may be used for nuclear 
medicine imaging. Unfortunately, given the impossibility of getting a new 
generator of 188W/188Re, it was not possible to evaluate the radiotoxicity 188Re. 
However taking into consideration that this radionuclide emits high-energy β- 
particles, we can predict a decrease of cell survival and all the consequences of 
the effects of ionizing radiation on human tissues [290, 291, 293, 295, 297, 306, 
309, 310]. And because 188Re is harmful for cancer cells, it is also for healthy 
cells, therefore there is a great need of specificity that may be given by PEI-MP 
for bladder cancer. 
To be used for imaging, 99mTc-PEI-MP should have a significant cellular uptake 
and retention over time. Thus it was evaluated the cell uptake and retention of 
99mTc-PEI-MP in both bladder carcinoma and osteosarcoma cells. From the 
results, it was possible to verify that in both cell lines the maximum percentage 
of uptake of 99mTc-PEI-MP (1.16% in HT-1376 cells; 1.00% in MNNG/HOS 
cells), was significantly higher than the maximum uptake of 99mTc-Pertechnetate 
(0.27% in HT-1376 cells; 0.19% in MNNG/HOS cells). Also the percentage of 
uptake of both 99mTc-PEI-MP and 99mTc-Pertechnetate in HT-1376 cells was 
higher than in MNNG/HOS cells, is not statistically significant. Relatively to the 
percentage of retention, it was possible to verify that in both cell lines the 
minimum percentage of retention of 99mTc-PEI-MP was relatively high (3.89% in 
HT-1376 cells; 3.78% in MNNG/HOS cells), and superior to 99mTc-
Pertechnetate (1.03% in HT-1376 cells; 0.54% in MNNG/HOS cells). Also it’s 
important to refer that the retention over time seems to be more stable for both 
cell lines, particularly for HT-1376 cells.  
These values of uptake and retention, demonstrate that PEI-MP is possible an 
excellent carrier for 99mTc to cancer cells, namely to bladder carcinoma and 
osteosarcoma cells. Therefore 99mTc-PEI-MP could be an excellent agent for 
imaging in vivo.  
To be used for therapy, 188Re-PEI-MP should also have a significant cellular 
uptake and retention over time. Thus it was evaluated the cell uptake and 
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retention of 188Re-PEI-MP in both cell lines, HT-1376 and MNNG/HOS, using 
the same procedures as for 99mTc-PEI-MP. From the results, it was possible to 
verify that in both cell lines the percentage of uptake of 188Re-PEI-MP (9.88% in 
HT-1376 cells; 13.09% in MNNG/HOS cells), over time, was significantly higher 
than the uptake of 188Re-Perrhenate (0.16% in HT-1376 cells; 0.20% in 
MNNG/HOS cells). Relatively to the percentage of retention, it was possible to 
verify that in both cell lines the minimum percentage of retention of 188Re-PEI-
MP was relatively high (45.67% in HT-1376 cells; 68.94% in MNNG/HOS cells), 
and superior to 188Re-Perrhenate (0.24% in HT-1376 cells; 0.21% in 
MNNG/HOS cells). Also it’s important to refer that the retention over time seems 
to be more stable for both cell lines, particularly for HT-1376 cells. Therefore, 
these results could be an indication that 188Re-PEI-MP could be used for 
therapy in vivo of both bladder and bone cancer. The results of uptake and 
retention obtained for 188Re-PEI-MP in proportion are a bit different to those 
obtained with 99mTc-PEI-MP, demonstrating that changing the radionuclide used 
for radiolabelling PEI-MP, the uptake and retention besides being always high is 
also superior when radiolabelled with 188Re. Given that 188Re has an atomic 
mass number superior to 99mTc [61], the complex 188Re-PEI-MP is possibly a 
larger molecule than 99mTc-PEI-MP and, as it is known, the cellular tumour 
uptake of large molecules is dominated by the EPR effect, and possibly for this 
reason the uptake and retention of 188Re-PEI-MP is higher. However, 
comparing the results of uptake and retention of 99mTc-PEI-MP or 188Re-PEI-MP 
with the ones of control (99mTc-Pertechnetate or 188Re-Perrhenate), the uptake 
and retention of the radiolabelled PEI-MP were always significantly higher, 
independently of the radionuclide used for labelling, being an indication of the 
possible specificity of PEI-MP to bladder carcinoma and osteosarcoma cells.  
Since in vitro studies are conducted in a controlled environment, the results may 
not correspond to those obtained in a living organism. Therefore it was 
important to conduct in vivo studies. 
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Section III. Experimental Studies 
Chapter 6.In vivo and Ex vivo 
 
6.1. Introduction 
Considering the in vitro results, and knowing that these studies are not enough 
to answer to all questions, including if the dynamic behaviour of the 99mTc-PEI-
MP or the 188Re-PEI-MP in tumour mass in terms of uptake and retention is 
maintained, what are the target organs, what are the routes of excretion, or if 
will they be good agents for imaging or therapy in vivo? Trying to answer these 
questions, in vivo and ex vivo studies were performed.  
Thus, the aim of this chapter was to explore through in vivo and ex vivo 
evaluations, the potential of PEI-MP radiolabelled with 99mTc or 188Re for the 
early diagnosis and/or therapy of bladder cancer, based on the results obtained 
in vitro. These in vivo and ex vivo studies include the biodistribution and 
biokinetics of 99mTc-PEI-MP and 188Re-PEI-MP, in controls and in animal 
models of bladder cancer and osteosarcoma, using imaging to control the 
administration of the complexes, and to see the biodistribution, which was 
complemented with the uptake quantification for each organ after animal 
sacrifice. 
Taking into consideration the results of the partition coefficients it was expected 
that the complexes would be mainly excreted by renal system what was 
confirmed by the image visualization and by ex vivo studies. These showed a 
high count rate in kidneys, bladder and urine after the intravenous 
administration of the 99mTc-PEI-MP or 188Re-PEI-MP.  
For this work it was necessary the development of animal models of bladder 
cancer and osteosarcoma, which could be used not only for nuclear medicine 
imaging but also for ex vivo, evaluations, to achieve the biodistribution studies 
after administration of 99mTc-PEI-MP and 188Re-PEI-MP complexes. All 
procedures described in this chapter were performed after approval by the 
Ethics Committee for Health of the Faculty of Medicine of the University of 
Coimbra.  
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6.2. Material and methods 
6.2.1. Animal tumour models 
Experimental models of cancer have played an important role in cancer drug 
discovery for more than 60 years. In vivo cancer models can be considered to 
fall within two broad classes, transplantable models, and in situ models, each 
with some subtypes. Additionally, with recent advances in preclinical imaging 
technologies, these models proved to be useful in the development and testing 
of new imaging techniques and contrast agents. There are several types of 
tumour models such as the transplantable syngeneic models, spontaneous and 
autochthonous models, orthotopic models, human tumour xenografts, models of 
metastasis and transgenic tumour models [318].  
Transplantable syngeneic leukaemia and solid tumour models were developed 
from spontaneous or induced tumours, subsequently adapted to a serial in vivo 
passage in the same animal strain. Disadvantages of these models are related 
with the different genetic background of murine cancer, not always identical to 
human counterparts, decreasing the expectation of a clinical correlation [319]. 
Spontaneous and autochthonous models may be relevant to understand the 
development of human disease because the tumours reside in the tissue 
appropriate for the histotype. However, these kind of studies are difficult 
because of low tumour incidence, characteristic variations, and delayed onset of 
tumour growth, as well as the deep location of the tumour tissues [318]. An 
orthotopic model involves the implantation of a tumour into the organ from 
which it arose [320-322]. Orthotopic models have additional advantages over 
subcutaneous besides the cellular microenvironment context. These 
advantages may include retention of differentiated structures within the tumour, 
vascular growth differences, more realistic tissue pharmacokinetics at the 
tumour site, and metastatic spread. However, tumour implantation for orthotopic 
models requires potentially complex surgery procedures. Observation of tumour 
growth in internal organs typically requires serial sacrifice of cohorts of animals, 
the acceptance and the growth tumour rates can be highly variable, and may be 
difficult and costly the pharmacodynamic and pathological analyses of the 
tumours. These factors increase costs and decrease the yield [318]. 
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The application of xenotransplantation (transplantation of tissues or organs from 
one species into different species) techniques to the growth of human tumours 
in experimental animals was a major breakthrough in cancer biology and drug 
discovery research [318]. One of the first of these models was to take 
advantage of the immunologically privileged status of the subrenal capsule 
(SRC) [323, 324], where human tumour fragments were implanted under this 
capsule. Unfortunately, the SRC xenograft assay is labour intensive and both 
tumour growth and response to therapy are often highly variable [318]. A major 
breakthrough in the in vivo evaluation of novel agents against human tumours 
was the development and the characterization of immunodeficient mice and 
rats. These animals have genetic immune deficiencies that minimize or prevent 
the rejection of the grafted tissues from other species. The difficulty in using 
immune compromised animals is that they are highly susceptible to viral, 
bacterial, and fungal infections. These infections can change the outcome and 
the reproducibility of experiments. Therefore, immunodeficient animals are 
maintained in specific pathogen-free environments, dramatically increasing 
research costs [318]. Nude, scid, xid and beige mice are the four primary types 
of immunodeficient mice. Each type of immunodeficient mouse has one or more 
mutations that diminish the animal´s capacity to reject transplantable allografts 
and xenografts. None of the mutations completely eliminates the immune 
system function [325-327]. Nude and scid mice are predominantly used for 
cancer drug evaluation. Xenografted tumours often exhibit a more neoplastic 
phenotype in scid mice than in nudes, presumably because of the more severe 
immunodeficiency of scid mice. The availability of these animals, has introduced 
new paradigms on the drug discovery. There are different approaches for 
xenograft studies in immunocompromised mice such as the subcutaneous 
xenografts and the hollow fibber assay. Subcutaneous xenografts are human 
tumour xenografts (cells, brei, or fragments) that are injected underneath the 
skin of immunodeficient animals and not into the underlying tissue or cavities. 
These models are cost effective, and provide a direct assessment of tumour 
size through simple, non-invasive calliper measurement of tumour axes. The 
accessibility of the tumour is also an advantage for harvesting of tumour tissue 
[328-330]. Although the use of human tumour xenografts has many advantages, 
there are also a number of disadvantages. Human cells are placed in a murine 
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environment generating interactions that may not faithfully reflect the human 
disease process (e.g., differences in the local cellular environment, cytokines, 
chemokines, growth factors or immunologic state, among others) [318]. The 
hollow fibber assay [331] uses polyvinylidene fluoride hollow fibbers inoculated 
with human tumour cell lines [332]. The fibbers are then sealed and implanted 
into the intraperitoneal cavity or subcutaneously of immunodeficient mice for 3-
10 days. After a treatment, the fibbers are removed and live cells are counted. 
Advantages of this method are that multiple cell lines can be tested 
simultaneously in one animal, contributing to low cost and high throughput. 
Disadvantages are that the technique requires surgery, the tumour cells are 
unable to interact with the normal animal stroma, and the cells have no 
opportunity to develop a blood supply. Hence, this assay does not reflect 
treatment-induced changes in stroma-tumour interactions nor vascular effects 
[318]. The general stability of the tumour tissue in the models discussed above 
are an advantage, however often they lack some key features of human cancer, 
such as dissemination to secondary organ. Several models of metastatic 
dissemination employ direct or systemic injection techniques. The choice of the 
site or route of administration is generally based on vascular proximity to the 
injection place. Spontaneous models of metastatic dissemination, including 
subcutaneous, transgenic, orthotopic, and autochthonous models provide a 
better representation of the entire process than direct injection models, and are 
especially suited for testing therapeutics for prevention of metastasis [318]. The 
massive shift of drug discovery efforts toward inhibition of specific oncogene or 
suppressor gene related targets has led to increased interest in the use of 
transgenic models for target validation and the evaluation of drug candidates 
[333-335]. Transgenic tumour models are created by the introduction of 
heritable (germ line) or somatic mutations that are implicated in neoplastic 
transformation. Target genes can be replaced by new alleles, conditionally 
expressed, conditionally turned off, or mutated. A key advantage of transgenic 
models is that the aetiology of the tumour development closely mimics that in 
humans. The animals can be treated with therapeutic agents at any stage of 
tumour development to further elucidate therapeutic efficacy and the 
mechanism of action [335]. Transgenic models driven by germ line mutations 
can be problematic. Mutations of interest are often embryonically lethal. 
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Additionally, adverse physiological or toxic effects during the development may 
occur that render the model unusable. Organ specificity can also be difficult to 
control and the study of multiple gene defects can require complex breeding 
efforts. Lastly, these animal models are often characterized by long tumour 
latency periods [318]. 
For the development of in vivo and ex vivo studies, and considering the animal 
models discussed before and the resources available, it was chosen as animal 
tumour model the balb/c nu/nu mice, 6 to 8 weeks old with a body weight 
ranging 20 to 31 g, for the development of subcutaneous xenografts of bladder 
carcinoma and osteosarcoma. In vivo studies allowed obtain information on the 
routes of metabolism and excretion, as well as the target organs of the 99mTc-
PEI-MP and 188Re-PEI-MP. This strain was chosen because of the advantages 
referred before and because these animals have gallbladder, allowing to obtain 
important information about biodistribution of 99mTc-PEI-MP and 188Re-PEI-MP. 
To obtain the xenografts of the tumours under study it was injected 
subcutaneously in the right axilla dug of blab/c nu/nu mice a suspension of 5 
million HT-1376 or MNNG/HOS cells, respectively for bladder carcinoma and 
osteosarcoma, in 0.1 ml of saline. This injection zone was chosen because it 
has several advantages with respect to the development of xenograft, 
emphasizing the fact that is contra lateral to the heart, is away from the liver, 
bladder and kidneys, avoiding the overlapping of structures in images. On the 
other hand, is a good area for expansion, and has good vascularisation, which 
allows the quick development of xenograft.  
The volume of tumours was controlled every week by simple calliper 
measurement. The determination of the tumour’s volume was calculated 
following the equation 7.  
    
     
 
 
  
Equation 7.Tumour volume determination. LT corresponds to the largest tumour 
diameter and S the smallest diameter (Dagrosa M.A. et al., 2003) 
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Studies with xenograft of bladder carcinoma and xenograft of osteosarcoma 
started when the tumour volumes reached 500-1000 mm3. 
 
6.2.2. Nuclear medicine imaging 
Molecular imaging is a growing research tool in preclinical area that allows 
testing novel drugs, reagents, and methods, giving fundamental information 
through image that mapping a specific step of a molecular pathways in vivo, 
some of them key-targets in disease processes [39, 55]. The current 
assessment of disease is based on anatomic or physiologic changes that are a 
late manifestation of molecular alterations which truly underlie disease. 
Functional information of these molecular changes will affect the patient care 
because they allow earlier detection of disease. In addition, with these 
functional images is possible to observe the effects of therapy shortly after its 
beginning, allowing to quickly determining the effectiveness of treatment. 
Oppositely, in the morphological imaging methods, many months are often 
required to determine whether pharmacologic or biological intervention has 
been beneficial [39, 55]. Widely used, molecular imaging agents are 
radiopharmaceuticals, paramagnetic materials, fluorescent/luminescent 
materials, and microbubbles, among others [55].  
Nuclear medicine imaging involves the image formation through the detection of 
gamma rays with energies preferably ranging 100-200 keV, or annihilation 
photons with energy of 511 keV, emitted during the decay of a radioisotope, 
which may be attached or not to a molecule. The gamma-camera, also known 
as Anger camera, emerged as the standard device for single photon nuclear 
imaging. The key element for image formation is a scintillation crystal with a 
high atomic number. In this crystal, radiation interactions occur, and gamma 
photons are converted into a multiple visible light photons. Sodium iodide doped 
with thallium (Na(Tl)) crystals meets the requirement for single photon nuclear 
imaging. A mechanical collimator is placed in front of the crystal, and is useful to 
define the direction of the gamma photons emitted by the radioactive source. 
The collimator will enable the selection of gamma-rays nearly perpendicularly to 
the crystal surface, while obliquely incident gamma-rays are absorbed in the 
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collimator septa. Each light photon generated in the scintillation crystal will 
undergo to low-noise amplification in a photomultiplier dynode system and 
further amplification and shaping in the preamplifier. The electrical output 
signals from these photomultipliers are used for localization (position (x,y) 
absorbed within the crystal) and for pulse height analysis following summation. 
The integrator smoothes the signal, while the pulse height analyser, performs a 
rough pre-selection of signal amplitude. The signal then undergoes analogue-
to-digital conversion and is passed on to a multichannel analyser, in which 
individual signals are binned according to their pulse amplitudes. Given that this 
pulse height is proportional to the energy of the absorbed gamma-ray photon, 
the accumulated spectrum of pulse heights will represent the energy spectrum 
of the gamma-radiation incident on the detector [336]. 
Therefore, for the in vivo evaluation of the biodistribution and biokinetics of 
99mTc-PEI-MP and 188Re-PEI-MP, nuclear medicine imaging after the 
administration of 99mTc-PEI-MP or 188Re-PEI-MP in mice, were performed. To 
obtain these images a gamma-camera (GE 400 AC) coupled with a low energy, 
parallel hole and high resolution collimator, as represented in fig. 37, was used.  
 
 
Figure 37.Gamma-camera (GE 400 AC) coupled with a low energy, parallel hole and 
high resolution collimator. 
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Before starting with the image acquisition, mice were anesthetized with a 
solution of ketamine 77% (Ketalar®, Parke-Davis) and chlorpromazine 23% 
(Largactil®, Vitoria Laboratories) injected subcutaneously in the back of the 
mice, with an adequate dosage considering weight. 
Taking into account that, one of the adverse effects of anaesthesia is the 
decrease on body temperature, it is necessary to maintain the body 
temperature of the mice during all the image acquisition. For this purpose the 
mice were kept in a box airy, spacious and heated with an electric blanket, as 
represented in fig. 38. The temperature was adjusted continuously in order to 
maintain the animal comfort condition.  
 
 
 
During image acquisition a warm light was projected over mice, to maintain 
body temperature, taking care to cover the eyes once they are photosensitive. 
For image acquisition, mice were placed in prone on top of the gamma-camera 
collimator, previously shield with a plastic to avoid direct contamination of the 
collimator, as can be seen in fig.39.  
Figure 38.Balb/c nu/nu mice with xenografts, anesthetized for holding images after 
administration of the radiopharmaceutical. 
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Images started with the intravenous administration in the animal tail vein, of the 
radiopharmaceuticals 99mTc-Pertechnetate, 99mTc-PEI-MP, 188Re-Perrhenate or 
188Re-PEI-MP. As control animal model balb/c mice 6 to 8 weeks old with a 
body weight ranging 20 to 31 g were used. As tumour animal models it was 
used the ones referred before.  
 
6.2.2.1. Imaging with 99mTc-Pertechnetate and 99mTc-PEI-MP  
Images were acquired in control mice, and in mice with xenograft of bladder 
carcinoma and osteosarcoma. For each type of mice it was administered 99mTc-
Pertechnetate or 99mTc-PEI-MP. For each group, taking in consideration the 
type of mice and the radiopharmaceutical administered, images were acquired 
up to 120 minutes and up to 240 minutes. The organization of these groups is 
summarized in the table 25.  
 
 
Figure 39.Positioning of balb/c nu/nu mouse in the detector of the gamma-camera 
(GE 400 AC). 
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Table 25.Number and organization of mice by type, administered radiopharmaceutical 
(99mTc-Pertechnetate or 99mTc-PEI-MP) and time of the final images.  
Mice Images  Radiopharmaceuticals 
99mTc-Pertechnetate 99mTc-PEI-MP 
Normal Up to 120 min 4 mice 4 mice 
Up to 240 min 4 mice 4 mice 
Xenograft of bladder 
carcinoma 
Up to 120 min 4 mice 4 mice 
Up to 240 min 4 mice 4 mice 
Xenograft of 
osteosarcoma 
Up to 120 min 4 mice 4 mice 
Up to 240 min 4 mice 4 mice 
Legend: Number of mice used for imaging studies, according to the radiopharmaceutical 
administered (
99m
Tc-Pertechnetate or 
99m
Tc-PEI-MP) and the type of animal model, that is, 
normal mice, mice with xenograft of bladder carcinoma and mice with xenograft of 
osteosarcoma. Each of these groups were divided in two, where depending if the images were 
performed until 120 minutes or 240 minutes hours after the intravenous administration of 
99m
Tc-
Pertechnetate or 
99m
Tc-PEI-MP. 
 
The images obtained with the 99mTc-Pertechnetate are controls for the 
biodistribution of the radiopharmaceutical under evaluation, since it can be a 
radiochemical impurity produced during the normal process of labelling of PEI-
MP kit with 99mTc-Pertechnetate. The normal 99mTc-Pertechnetate biodistribution 
show a high uptake in thyroid, stomach, and choroid plexus. In turn, if there was 
the presence of reduced/hydrolysed technetium species, as radiochemical 
impurities, is expected to see a high uptake in the liver and spleen. In fact, the 
biodistribution verified in the images will be a mirror of the radiochemical purity 
of the complex 99mTc-PEI-MP, which makes very important the quality control of 
the radiochemical purity after radiolabelling. 
After the administration of 18-37 MBq (0.5-1.0 mCi) of 99mTc-Pertechnetate or 
99mTc-PEI-MP in a small volume (0.1 ml) into the tail vein of the mice, a dynamic 
acquisition was carried out through the gamma-camera controlled by the Genie 
Acq computer to a workstation Xeleris for further visualization and data 
processing. The dynamic imaging sequence besides the distribution of the 
radiopharmaceuticals in the bloodstream of mice, gave us also information 
about the quality of the injection. The dynamic images acquisition was followed 
by the acquisition of static images until the predefined times in order to achieve 
information about the biodistribution of the radiopharmaceuticals. For that, the 
static images were performed every 30 minutes until 120 or 240 minutes, after 
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the administration of the radiopharmaceuticals. The image parameters used for 
the acquisition of dynamic and static images are summarised in table 26. 
 
Table 26.Gamma-camera image parameters for dynamic and static acquisition after 
the administration of 99mTc-Pertechnetate or 99mTc-PEI-MP. 
Image parameters Dynamic acquisition Static acquisition 
Number of images 60 images 8 images 
Time per image 10 seconds 2 minutes 
Total time for imaging 10 min 
Images at 30, 60, 90, 120, 
150, 180, 210 and 240 
minutes after administration 
Matrix 128x128 pixels 256x256 pixels 
Zoom 2 2 
Photopeak 140 keV 140 keV 
Energy window, centred 
at photopeak 
20% 20% 
Legend: Gamma-camera image parameters for the acquisition of dynamic and static images 
after the administration of 
99m
Tc-Pertechnetate or 
99m
Tc-PEI-MP, namely the number and time 
per image, the matrix, the zoom given to the image (considering the small size of mice), the 
photopeak that corresponds to the energy of the gamma rays emitted by 
99m
Tc, and the energy 
acceptance window that must be centred in the photopeak, accepting only gamma rays with 
energies ranging from 130 to 150 keV. 
 
After the end of the last image, the mice were euthanized to the achievement of 
ex-vivo studies.  
After mice with xenograft of bladder carcinoma or osteosarcoma, in which was 
administered 99mTc-PEI-MP were sacrificed, the tumour and a muscle of the 
thigh of the hind paw were collected and imaged. The tumour and muscle were 
positioned in an absorbent pad over the gamma-camera detector and in the 
centre of the collimator. The tumour was positioned in the right lower quadrant, 
and the muscle was positioned in the left higher quadrant. The image of the 
tumour and the muscle was acquired during 5 minutes, for a matrix of 256x256 
pixels, zoom of 2, a photopeak of 140 keV and an energy window of 20%, 
centred in the photopeak.  
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6.2.2.2. Imaging with 188Re-Perrhenate and 188Re-PEI-MP 
Images were also performed after the administration of 188Re-Perrhenate or 
188Re-PEI-MP. As described in the topic 6.2.2.1., these images were also 
acquired in control mice, and in mice with xenograft of bladder carcinoma and 
osteosarcoma. Equally, for each group, and taking into account the type of mice 
and the radiopharmaceutical administered, images were acquired up to 120 
minutes and up to 240 minutes. The organization of these groups is 
summarized in the table 27.  
The images obtained with the 188Re-Perrhenate are controls for the 
biodistribution of the radiopharmaceutical under evaluation, since it can be a 
radiochemical impurity produced during the normal process of labelling of PEI-
MP kit with 188Re-Perrhenate. As with the 99mTc-Pertechnetate, the normal 
188Re-Perrhenate biodistribution show a high uptake in thyroid, stomach, and 
choroid plexus. In turn, if there was the presence of reduced/hydrolysed 
rhenium species, as radiochemical impurities is expected to see a high uptake 
in the liver and spleen. In fact, the biodistribution verified in the images will be a 
mirror of the radiochemical purity of the complex 188Re-PEI-MP. 
 
Table 27.Number and organization of mice by type, administered radiopharmaceutical 
(188Re-Perrhenate or 188Re-PEI-MP) and time of the final images.  
Mice Images  Radiopharmaceuticals 
188Re-Perrhenate 188Re-PEI-MP 
Normal Up to 120 min 4 mice 4 mice 
Up to 240 min 4 mice 4 mice 
Xenograft of bladder 
carcinoma 
Up to 120 min 4 mice 4 mice 
Up to 240 min 4 mice 4 mice 
Xenograft of 
osteosarcoma 
Up to 120 min 4 mice 4 mice 
Up to 240 min 4 mice 4 mice 
Legend: Number of mice used for imaging studies, according to the radiopharmaceutical 
administered (
188
Re-Perrhenate or 
188
Re-PEI-MP) and the type of animal model, that is, normal mice, 
mice with xenograft of bladder carcinoma and mice with xenograft of osteosarcoma. Each of these 
groups were divided in two, where depending if the images were performed until 120 minutes or 240 
minutes after the intravenous administration of 
188
Re-Perrhenate or 
188
Re-PEI-MP. 
 
After the administration of 18-37 MBq (0.5-1 mCi) of 188Re-Perrhenate or 188Re-
PEI-MP in a small volume (0.1 ml) into the tail vein of the mice, a dynamic and 
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static acquisition was carried out through the gamma-camera controlled by the 
Genie Acq computer to a workstation Xeleris for further visualization and data 
processing. The dynamic and static imaging had the same proposes as 
described in the topic 6.2.2.1. Image parameters were similar to those chosen 
for the acquisition of images after the administration of 99mTc-Pertechnetate or 
99mTc-PEI-MP, with only changes in the parameters dependent of the physical 
characteristics of radionuclide used. The image parameters chosen for the 
acquisition of dynamic and static images after the administration of 188Re-
Perrhenate or 188Re-PEI-MP are summarised in table 28. 
 
Table 28.Gamma-camera image parameters for dynamic and static acquisition after 
the administration of 188Re-Perrhenate or 188Re-PEI-MP. 
Image parameters Dynamic acquisition Static acquisition 
Number of images 20 images 8 images 
Time per image 30 seconds 2 minutes 
Total time for imaging 10 min 
Images at 30, 60, 90, 120, 
150, 180, 210 and 240 
minutes after administration 
Matrix 128x128 pixels 256x256 pixels 
Zoom 2 2 
Photopeak 159 keV (I-123 photopeak) 159 keV (I-123 photopeak) 
Energy window, centred 
at photopeak 
20% 20% 
Legend: Gamma-camera image parameters for the acquisition of dynamic and static images 
after the administration of 
188
Re-Perrhenate or 
188
Re-PEI-MP, namely the number and time per 
image, the matrix, the zoom given to the image (considering the small size of mice), the 
photopeak that should correspond to the energy of the gamma rays emitted by 
188
Re, that is 155 
keV. Considering the options for photopeak selection in the computer acquisition, and that the 
energy of gamma rays emitted by 
188
Re during its decay is 155 keV, the choice of iodine-123 
photopeak (159 keV) seems to be the most suitable. Also the energy window selected will allow 
accepting gamma-rays with energies ranging between 149-169 keV, being contained in this 
interval the gamma-rays emitted by 
188
Re. 
 
Tumour and muscle images were also acquired for mice with xenograft of 
bladder carcinoma or osteosarcoma, in which was administered 188Re-PEI-MP, 
in the same way as described in topic 6.2.2.1. These images were only 
performed after the sacrifice of mice, and after the excision of the tumour and 
muscle of the thigh of the hind paw. The tumour and the muscle were 
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positioned in an absorbent pad over the gamma-camera detector and in the 
centre of the collimator. The tumour was positioned in the right lower quadrant, 
and the muscle was positioned in the left higher quadrant of the absorbent pad. 
The image of the tumour and the muscle was acquired during 5 minutes, for a 
matrix of 256x256 pixels, zoom of 2, a photopeak of 159 keV and an energy 
window of 20%, centred in the photopeak. 
 
6.2.3. Ex-vivo biodistribution studies  
For the evaluation of the biodistribution and biokinetics of 99mTc-PEI-MP and 
188Re-PEI-MP, in vivo imaging may not be enough to respond to all questions. 
These limitations result from the image characteristics once they are projections 
and the organs can be superimposed each other which makes the ROI’s 
drawing difficult. Also, the images resolution may not be adequate to obtain 
quantitative data, having into account the animal size Thereby, it was necessary 
to sacrifice the animals to collect the organs, tissues and tumours to quantify 
the percentage of 99mTc-PEI-MP or 188Re-PEI-MP administered activity per 
gram of organ/tissue/fluid. The ex-vivo studies performed in mice after the 
administration of 99mTc-Pertechnetate or 188Re-Perrhenate are controls of 99mTc-
PEI-MP and 188Re-PEI-MP, respectively. 
 
6.2.3.1. Ex-vivo biodistribution studies with 99mTc-Pertechnetate and 99mTc-
PEI-MP  
As referred before, each group of mice (controls, xenograft of bladder 
carcinoma and xenograft of osteosarcoma) who were administered 99mTc-
Pertechnetate or 99mTc-PEI-MP, was split in two, one in which the images were 
acquired up to 120 minutes and another in which images were acquired up to 
240 minutes. After last image acquisition, the mice were euthanized by cervical 
dislocation in accordance with the legislation. Subsequently several organs 
were collected (heart, lung, thyroid, gallbladder, liver, spleen, stomach, small 
intestine, large intestine, genital, urinary bladder, brain and cerebellum) as well 
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as some tissues (cartilage, muscle, bone, blood) and fluids (urine and bile). The 
preparation of mice for organ and tissue collection is presented in fig. 40. 
 
Figure 40.Euthanized mouse ready for collection of organs and tissues. 
 
Each organ, tissue or fluid was weighted (in grams) and placed in a 
radioimmunoassay (RIA) tube. Each tube was counted in a well-type gamma 
counter (Gamma-C 12 DPC, Berthold, Germany) to obtain counts per minute 
(CPM). For xenograft of bladder carcinoma or osteosarcoma, also the tumour 
was collected, weighted and counted in a well counter to obtain CPM. With the 
values of CPM obtained, and converted into activity, we calculated the 
percentage of activity (99mTc-Pertechnetate or 99mTc-PEI-MP) administered per 
gram of organ/tissue/fluid (% injected activity/gram), according to equation 8.  
 
 
 
 
178 
 
                       
                        
                           
 
Equation 8.Percentage of injected activity per gram of organ/tissue/fluid. It’s 
determined by dividing the ratio of counts per minute and mass of each organ/tissue 
/fluid with the total administered activity.    
 
Beyond the calculation of the percentage of activity injected per gram of 
organ/tissue/fluid, it was also determined the values of the ratios 
tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone, for 
all groups. The bladder cancer has its origin in the bladder wall and can invade 
surrounding organs even in an early stage [184]. In case of metastization the 
major target organs are the liver, the lungs and the bone. This dissemination 
justifies the choice of the organs to calculate the specific uptake and to 
determine the tumour ratios. These calculations allow to determine whether the 
tumour uptake of a administered radiopharmaceutical is higher or lower than 
those organs, which is important for nuclear medicine be able to distinguish the 
lesions, and consequently to make a clear diagnosis. If the uptake of the 
radiopharmaceutical by the tumour or its metastases is equal to the uptake of 
the other organs, it’s not possible to identify them, and therefore the diagnosis 
could be inconclusive or negative to metastases or tumour. 
 
6.2.3.2. Ex-vivo biodistribution studies with 188Re-Perrhenate and 188Re-PEI-
MP 
As referred before, for each group of mice (controls, xenograft of bladder 
carcinoma and xenograft of osteosarcoma) who were administered 188Re-
Perrhenate or 188Re-PEI-MP, was split in two, one in which the images were 
acquired up to 120 minutes and another in which images were acquired up to 
240 minutes. After last image acquisition, the mice were euthanized by cervical 
dislocation in accordance with the legislation. Subsequently several organs, 
some tissues, and fluids were collected following the procedures referred in the 
topic 6.2.3.1. Each organ, tissue or fluid was weighted (in grams) and placed in 
a radioimmunoassay (RIA) tube. Each tube was counted in a well-type gamma 
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counter (Gamma-C 12 DPC, Berthold, Germany) to obtain CPM. For xenograft 
of bladder carcinoma or osteosarcoma, also the tumour was collected, weighted 
and counted in a well counter to obtain CPM. With the values of CPM obtained, 
and converted into activity, it was calculated the percentage of 
radiopharmaceutical 188Re-Perrhenate or 188Re-PEI-MP administered per gram 
of organ/tissue/fluid (% injected activity/gram), according to equation 8 referred 
before.  
Beyond the calculation of the percentage of activity injected per gram of 
organ/tissue/fluid, it was also determined the values of the ratios 
tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone for 
all groups. Considering the evolution of a bladder carcinoma, explained in 
before, to determine whether the tumour uptake of an administered 
radiopharmaceutical is higher than these organs, is crucial to determine these 
tumour ratios, so that when performing radionuclide therapy the main target is 
the tumour and its metastasis, and the non-target organs are spared of the 
effects of high doses of ionizing radiation. If the uptake of the 
radiopharmaceutical by the tumour or its metastases is equal or lower to the 
uptake of the other organs, it’s not possible to perform the therapy, since it 
would be the non-target organs the most affected by ionizing radiation and the 
therapy would not be effective, and possibly it would result in serious side 
effects. 
 
6.2.4. Statistical analysis  
Results were analysed using the software IBM SPSS (IBM Corporation, 
Armonk, New York, EUA), version 20, at a significance level of 5% (p < 0.05). 
The comparison of the ratios tumour/muscle, tumour/bladder, tumour/liver, 
tumour/lung and tumour/bone, for mice with xenograft of bladder carcinoma and 
xenograft of osteosarcoma, both injected with 99mTc-PEI-MP or 188Re-PEI-MP, 
were made according to the t Student test for a mean, comparing the sample 
values to 1, that represents the equality of uptake for both tissues, and with the 
Bonferroni correction for multiple comparisons. 
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6.3. Results 
6.3.1. Animal tumour models and nuclear medicine imaging 
As animal tumour model it was chosen balb/c nu/nu mice with xenograft of 
bladder carcinoma and xenograft of osteosarcoma. To obtain the xenograft of 
bladder cancer and osteosarcoma it was injected subcutaneously in the right 
axilla dug of blab/c nu/nu mice a suspension of 5 million cells. The volume of 
tumours was controlled by calliper measurement and determined following the 
equation 7. For the development of xenografts of bladder carcinoma and 
osteosarcoma it was needed 4 and 3 weeks, respectively. Studies in vivo and 
ex-vivo using these animal models started when the tumour volumes reached 
500-1000 mm3.  
Images were performed after the development of the xenograft. For image 
acquisition, mice were anesthetized and placed in prone on top and in the 
middle of the gamma-camera detector. Images started immediately after the 
administration, in the tail vein of the mice, of 99mTc-Pertechnetate, 99mTc-PEI-
MP, 188Re-Perrhenate or 188Re-PEI-MP, with activities ranging 18-37 MBq (0.5-
1 mCi). Immediately after the administration and during 10 minutes dynamic 
images were acquired and posterior static images were performed every 30 
minutes after the administration of the radiopharmaceutical until 120 or 240 
minutes. The mice were always sacrificed after the last image. 
As a control of these animal models, mice with no tumour, namely balb/c mice, 
were used. To these mice it was also performed images after the administration 
of 99mTc-Pertechnetate, 99mTc-PEI-MP, 188Re-Perrhenate or 188Re-PEI-MP, 
following the same procedures explained before. 
 
6.3.1.1. Imaging with 99mTc-Pertechnetate and 99mTc-PEI-MP 
By analysing the image, presented in fig.41, obtained after the intravenous 
administration of 99mTc-Pertechnetate in the tail vein of balb/c without any 
tumour (normal mice), it is possible to visualize a high uptake by the thyroid 
gland, stomach and bladder. This biodistribution is considered normal as 
explained before. The activity present in bladder is explained by the fact that 
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99mTc-Pertechnetate is excreted by the renal system and therefore eliminated 
through urine. 
 
 
 
By analysing the images obtained after the intravenous administration of 99mTc-
Pertechnetate in the tail of balb/c nu/nu mice with xenograft of bladder 
carcinoma (fig. 42) and xenograft of osteosarcoma (fig.43), it was also possible 
to visualize a high uptake by the thyroid gland, stomach and bladder, 
corresponding to the same biodistribution verified in normal balb/c mice. The 
uptake of tumour, in both bladder carcinoma and osteosarcoma xenograft, is 
faintly visible and possible dependent on the blood flow.  
Figure 41.Images obtained after the administration of 99mTc-Pertechnetate in the 
dorsal vein of the tail of balb/c mouse. The first images are dynamic and obtained 
immediately after the administration of the radiopharmaceutical. After static images 
were acquired every 30 minutes after the administration until 240 minutes. 
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Figure 42.Images obtained after the administration of 99mTc-Pertechnetate in the 
dorsal vein of the tail of balb/c nu/nu mouse with a xenograft of bladder carcinoma. 
The first images are dynamic and obtained immediately after the administration of the 
radiopharmaceutical. After static images were acquired every 30 minutes after the 
administration until 240 minutes. 
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After obtaining the images of 99mTc-Pertechnetate in normal balb/c mice, and in 
mice with xenografts of bladder carcinoma and osteosarcoma, the same animal 
models were evaluated after administration of 99mTc-PEI-MP. By analysing the 
images obtained after the intravenous administration of 99mTc-PEI-MP in the tail 
of controls balb/c mice, presented in fig. 44, it is possible to visualize a high 
uptake in kidneys and bladder. This biodistribution may indicate that the 99mTc-
PEI-MP is mainly excreted through the renal system and therefore eliminated 
through urine. Also it’s visible a faint uptake by the lungs, demonstrating some 
retention on this organ. 
Figure 43.Images obtained after the administration of 99mTc-Pertechnetate in the 
dorsal vein of the tail of balb/c nu/nu mouse with a xenograft of osteosarcoma. The 
first images are dynamic and obtained immediately after the administration of the 
radiopharmaceutical. After static images were acquired every 30 minutes after the 
administration until 240 minutes. 
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By analysing the images obtained after the intravenous administration of 99mTc-
PEI-MP in the tail vein of balb/c nu/nu mice with a xenograft of bladder 
carcinoma (fig. 45) and xenograft of osteosarcoma (fig. 46), it is also possible to 
visualize a high uptake in kidneys and bladder. It is also possible to visualize a 
faint uptake by the lungs in both xenografts (bladder carcinoma and 
osteosarcoma), which seems to diminish over time. Moreover the tumour is 
small in both xenografts, and despite low resolution of the gamma camera, is 
possible to visualize a faint uptake of the 99mTc-PEI-MP by both type of tumours.   
The quantification of 99mTc-PEI-MP uptake by the tumour will be only possible 
with ex vivo studies. 
Figure 44.Images obtained after the administration of 99mTc-PEI-MP in the dorsal vein 
of the tail of balb/c mouse. The first images are dynamic and obtained immediately 
after the administration of the radiopharmaceutical. After static images were acquired 
every 30 minutes after the administration until 240 minutes. 
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Figure 45.Images obtained after the administration of 99mTc-PEI-MP in the dorsal vein 
of the tail of balb/c nu/nu mouse with a xenograft of bladder carcinoma. The first 
images are dynamic and obtained immediately after the administration of the 
radiopharmaceutical. After static images were acquired every 30 minutes after the 
administration until 240 minutes. 
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6.3.1.2. Imaging with 188Re-Perrhenate and 188Re-PEI-MP 
By analysing the images obtained after the intravenous administration of 188Re-
Perrhenate in the tail of balb/c mice, presented in fig. 47, it is possible to 
visualize a high uptake by the thyroid gland and stomach. This biodistribution is 
considered normal as explained before.  
Figure 46.Images obtained after the administration of 99mTc-PEI-MP in the dorsal vein 
of the tail of balb/c nu/nu mouse with a xenograft of osteosarcoma. The first images 
are dynamic and obtained immediately after the administration of the 
radiopharmaceutical. After static images were acquired every 30 minutes after the 
administration until 240 minutes. 
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By analysing the images obtained after the intravenous administration of 188Re-
Perrhenate in the tail vein of balb/c nu/nu mice with xenograft of bladder 
carcinoma (fig.48) and xenograft of osteosarcoma (fig 49), presented in fig.48 
and fig 49, it was is also possible to visualize a high uptake by the thyroid gland 
and stomach, corresponding to the same biodistribution verified in normal balb/c 
mice. The uptake of tumour is not visible in the mouse of the fig.48, and faintly 
visible on the mouse of the fig. 49, and possibly dependent on the blood flow. 
The fact that the photonic flow of gamma rays of 155 keV from 188Re is low, and 
in association with a low resolution of the gamma camera detector, considering 
the size of the animal and its organs, its normal that the resolution of the images 
with 188Re-Perrhenate or 188Re-PEI-MP will be lower comparing with the ones 
Figure 47.Images obtained after the administration of 188Re-Perrhenate in the dorsal 
vein of the tail of balb/c mouse. The first images are dynamic and obtained 
immediately after the administration of the radiopharmaceutical. After static images 
were acquired every 30 minutes after the administration until 240 minutes. 
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obtained with 99mTc-Pertechnetate or 99mTc-PEI-MP, considering the higher 
photonic flow of the 140 keV from 99mTc. 
 
 
 
 
 
 
 
 
 
 
Figure 48.Images obtained after the administration of 188Re-Perrhenate in the dorsal 
vein of the tail of balb/c nu/nu mouse with a xenograft of bladder carcinoma. The first 
images are dynamic and obtained immediately after the administration of the 
radiopharmaceutical. After static images were acquired every 30 minutes after the
administration until 240 minutes. 
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After obtaining the images of 188Re-Perrhenate in normal balb/c mice, and in 
mice with xenografts of bladder carcinoma and osteosarcoma, the same animal 
models were evaluated after administration of 188Re-PEI-MP. By analysing the 
images obtained after the intravenous administration of 188Re-PEI-MP in the tail 
of controls balb/c mice, presented in fig. 50, it is possible to visualize a high 
uptake by the bladder. This biodistribution may also indicate that the 188Re-PEI-
MP is mainly excreted through the renal system and therefore eliminated 
through urine. Also it’s possible to visualize a faint uptake by lungs that seem to 
diminish over time, but also the uptake seems more intense than the one 
verified in images of mice where 99mTc-PEI-MP was administered. For a more 
reasonable and quantitative conclusions it should be consider the results 
obtained in ex-vivo studies. 
Figure 49.Images obtained after the administration of 188Re-Perrhenate in the dorsal 
vein of the tail of balb/c nu/nu mouse with a xenograft of osteosarcoma. The first 
images are dynamic and obtained immediately after the administration of the 
radiopharmaceutical. After static images were acquired every 30 minutes after the 
administration until 240 minutes. 
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By analysing the images obtained after the intravenous administration of 188Re-
PEI-MP in the tail of balb/c nu/nu mice with a xenograft of bladder carcinoma 
(fig. 51 ) and xenograft of osteosarcoma (fig. 52), it is also possible to visualize 
a high uptake by the bladder, as in the case of control balb/c mice were 188Re-
PEI-MP was administered. For both xenografts it’s possible to visualize the 
uptake of 188Re-PEI-MP by lungs, which seem to diminish over time. Moreover 
the tumour is small in both xenografts, and because the low resolution of the 
gamma camera, the tumours are almost not visible in the images.  
The quantification of 188Re-PEI-MP uptake by the tumour will be only possible 
with ex vivo studies.   
Figure 50.Images obtained after the administration of 188Re-PEI-MP in the dorsal vein 
of the tail of balb/c mouse. The first images are dynamic and obtained immediately 
after the administration of the radiopharmaceutical. After static images were acquired 
every 30 minutes after the administration until 240 minutes. 
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Figure 51.Images obtained after the administration of 188Re-PEI-MP in the dorsal vein 
of the tail of balb/c nu/nu mouse with a xenograft of bladder carcinoma. The first 
images are dynamic and obtained immediately after the administration of the 
radiopharmaceutical. After static images were acquired every 30 minutes after the 
administration until 240 minutes. 
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6.3.2. Biodistribution studies ex vivo 
As explained before the images were performed until 120 or 240 after the 
administration of 99mTc-Pertechnetate, 99mTc-PEI-MP, 188Re-Perrhenate or 
188Re-PEI-MP, and then normal mice, mice with xenograft of bladder cancer 
and xenograft of osteosarcoma were euthanized by cervical dislocation.  
Several organs (heart, lung, thyroid, gallbladder, liver, spleen, stomach, small 
intestine, large intestine, genital, urinary bladder, brain and cerebellum), tissues 
(cartilage, muscle, bone, blood), fluids (urine and bile) and tumour (if applicable) 
were collected and placed in RIA tubes for gamma counting and weighing to 
obtain the percentage of radiopharmaceutical administered per gram of 
Figure 52.Images obtained after the administration of 188Re-PEI-MP in the dorsal vein 
of the tail of balb/c nu/nu mouse with xenograft of osteosarcoma. The first images are 
dynamic and obtained immediately after the administration of the 
radiopharmaceutical. After static images were acquired every 30 minutes after the 
administration until 240 minutes. 
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organ/tissue/fluid. Also the ratios tumour/muscle, tumour/bladder, tumour/liver, 
tumour/lung and tumour/bone were determined for all groups of mice with 
xenografts. 
 
6.3.2.1. Ex-vivo biodistribution studies with 99mTc-Pertechnetate and 99mTc-
PEI-MP 
By analysing the fig. 53 that correspond to the normal mice sacrificed 120 and 
240 minutes after the administration of 99mTc-Pertechnetate, it’s possible to 
visualize a high uptake in the thyroid gland and stomach. This biodistribution is 
considered normal as explained before and supports the results observed in the 
images of the biodistribution in vivo of 99mTc-Pertechnetate in normal mice. 
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Figure 53.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 99mTc-Pertechnetate 
and determined ex-vivo in normal mice.  
 
The results that correspond to mice with xenograft of bladder cancer (fig. 54) 
and xenograft of osteosarcoma (fig. 55), sacrificed 120 and 240 minutes after 
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the administration of 99mTc-Pertechnetate, showed a high uptake in the thyroid 
gland and stomach, supporting the results obtained in the images of the 
biodistribution in vivo of 99mTc-Pertechnetate in mice with xenografts of bladder 
cancer and osteosarcoma. Also it’s possible to visualize a small uptake by the 
tumours, which is possibly related with the blood flow to the xenograft. This 
uptake by the tumours was also verified in the in vivo biodistribution images, 
however faintly visible, but now confirmed by the ex vivo studies.  
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Figure 54.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 99mTc-Pertechnetate 
and determined ex-vivo in mice with xenografts of bladder cancer. 
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Figure 55.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 99mTc-Pertechnetate 
and determined ex-vivo in mice with xenografts of osteosarcoma. 
 
 
Additionally, tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and 
tumour/bone ratios were determined for both types of animal models, with 
xenograft of bladder cancer and with xenograft of osteosarcoma. Analysing the 
fig. 56, that represents the tumour ratios of mice with xenograft of bladder 
carcinoma injected with 99mTc-Pertechnetate, it is possible to visualize that 
tumour/muscle ratio is high comparing with the other tumour ratios, especially 
240 minutes after the administration of 99mTc-Pertcehnetate. For 120 and 240 
minutes after the administration, the tumour/muscle ratio was 1.670.72 and 
2.540.56, respectively, demonstrating that the uptake by the tumour is higher 
than of the muscle. However, comparing these values with 1, that represents 
the equality of the numerator and the denominator, the tumour/muscle ratio was 
statistically significantly higher than the unit (p=0.048) only at 240 minutes. 
Tumour/bladder (0.480.20 at 120 min; 0.690.45 at 240 min), tumour/liver 
(0.220.09 at 120 min; 0.250.26 at 240 min), tumour/lung (0.410.11 at 120 
min; 0.580.22 at 240 min) and tumour/bone (0.660.15 at 120 min; 1.020.30 
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at 240 min) ratios were always inferior or equal to one, demonstrating that the 
uptake by the tumour was inferior or equal comparing to these organs. However 
these tumour ratios were only statistically significant lower than one for 
tumour/liver at 120 minutes (p<0.001) and 240 minutes (p=0.040), and for 
tumour/lung at 120 minutes (p=0.008). Considering these results, metastasis 
from a bladder carcinoma in liver, lung and bones would appear as cold lesions 
in nuclear medicine images, after the administration of 99mTc-Pertechenetate. 
However, the probability of detecting metastases in the liver at 120 and 240 
minutes and in the lungs at 120 minutes after the administration of 99mTc-
Pertechnetate will be greater, considering that the values of these tumour ratios 
were significantly lower than one. 
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Figure 56.Tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone 
ratios obtained for balb/c nu/nu mice with xenografts of bladder carcinoma after 
administration of 99mTc-Pertechnetate.  
 
Analysing the fig. 57, that represents the tumour ratios of mice with xenograft of 
osteosarcoma and injected with 99mTc-Pertechnetate, it’s possible to visualize 
that tumour/muscle ratio is high comparing with the other tumour ratios, 
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especially 240 minutes after the administration of 99mTc-Pertcehnetate. For 120 
and 240 minutes after the administration, the tumour/muscle ratio was 
2.931.12 and 3.510.55, respectively, demonstrating that the uptake by the 
tumour is higher than of the muscle. However comparing these values with 1, 
the tumour/muscle ratio was not statistically significantly higher than the unit. 
Tumour/bladder (0.720.38 at 120 min; 0.660.46 at 240 min) and tumour/lung 
(0.650.10 at 120 min; 0.660.47 at 240 min) ratios were always inferior to one, 
demonstrating that the uptake by the tumour was inferior comparing to these 
organs. However these tumour ratios were only statistically significant lower 
than one for tumour/lungs at 120 minutes (p=0.028). Tumour/liver ratio was 
higher than one at 120 minutes (1.230.65) and lower than one at 240 minutes 
(0.350.31), demonstrating that at 120 minutes the uptake by the tumour is 
higher than the liver and at 240 minutes occurs the inverse situation. However 
these differences are not statistically significant. Tumour/bone ratios at 120 
minutes (2.020.69) and 240 minutes (1.190.96) were always superior to one, 
even at 240 minutes were the tumour/bone ratio decreases. However these 
differences are not statistically significant. Considering these results, metastasis 
from an osteosarcoma in lung would appear as cold lesions, in liver would 
appear at 120 minutes as hot lesions and at 240 minutes as cold lesions, and in 
bone it would appear as hot lesions in nuclear medicine images, after the 
administration of 99mTc-Pertechenetate. However, the probability of detecting 
metastases in the lungs at 120 after the administration of 99mTc-Pertechnetate 
will be greater, considering that the value of this tumour ratio was significantly 
lower than one. 
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Figure 57.Tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone 
ratios obtained for balb/c nu/nu mice with xenografts of osteosarcoma after 
administration of 99mTc-Pertechnetate.  
 
By analysing the fig. 58 that correspond to the normal mice sacrificed 120 and 
240 minutes after the administration of 99mTc-PEI-MP, it’s possible to visualize a 
high uptake by the bladder wall and kidneys. These results support those 
obtained in the images of the biodistribution in vivo of 99mTc-PEI-MP in normal 
mice. As explained before this may indicate that 99mTc-PEI-MP is mainly 
excreted through the renal system. However, considering that the bladder is 
carefully washed to remove any traces of urine, this uptake by the bladder wall 
demonstrates once again that 99mTc-PEI-MP as affinity for bladder cells, being 
this the primary reason to suspect that PEI-MP had some affinity to bladder 
carcinoma cells. The activity in the kidneys and bladder diminished at 240 
minutes. The high uptake by the gallbladder indicates that 99mTc-PEI-MP is also 
excreted through the hepatobiliary route. Being PEI-MP a polymer and a large 
molecule it is possible that 99mTc-PEI-MP is trapped by the Kupffer cells in the 
liver, that make part of the reticuloendothelial system. The activity in the liver 
and gallbladder diminished at 240 minutes. Also it is possible to verify some 
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uptake by the lungs, supporting the results obtained in the in vivo images of 
normal mice, however is diminished at 240 minutes. Considering the first 
propose of PEI-MP, that was for palliative therapy of bone metastases and also 
the results obtained in previous biodistribution studies [111], it’s not surprising 
the uptake at bones. Also it’s possible to visualize some retention of 99mTc-PEI-
MP in the spleen, demonstrating that some percentage of this complex is 
trapped by the reticuloendothelial system. The percentage of 99mTc-PEI-MP in 
blood is also high and seems to diminish over time. 
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Figure 58.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 99mTc-PEI-MP and 
determined ex-vivo in normal mice.  
 
By analysing the fig. 59 and fig. 60, which correspond to the mice with xenograft 
of bladder carcinoma and osteosarcoma, respectively, sacrificed 120 and 240 
minutes after the administration of 99mTc-PEI-MP, it is possible to visualize a 
high uptake by the bladder wall and kidneys. These results support those 
obtained in the in vivo images of mice with xenograft of bladder carcinoma and 
xenograft of osteosarcoma after the administration of 99mTc-PEI-MP, and are 
supported by the results of the biodistribution ex vivo for normal mice after the 
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administration of 99mTc-PEI-MP. As explained before this may indicate that 
99mTc-PEI-MP is mainly excreted through the renal system and that has an 
affinity for bladder cells. The high uptake by the gallbladder indicates once 
again that 99mTc-PEI-MP is also excreted through the hepatobiliary route. The 
activity in the liver and gallbladder diminished at 240 minutes. Also it is possible 
to verify some uptake by the lungs, supporting the results obtained in the in vivo 
images. In the same way as for ex vivo biodistribution studies in normal mice 
after the administration of 99mTc-PEI-MP, in fig.59 and fig.60 it is possible to 
visualize some uptake by spleen and bone, possibly explained by the reasons 
presented before. The percentage of 99mTc-PEI-MP in blood is also high and 
seems to diminish over time. 
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Figure 59.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 99mTc-PEI-MP and 
determined ex-vivo in mice with xenografts of bladder cancer. 
 
 
 
201 
 
%
9
9
m
T
c
-P
E
I-
M
P
 a
c
ti
v
it
y
 p
e
r 
g
ra
m
 o
f 
o
rg
a
n
/t
is
s
u
e
/f
lu
id
B
lo
o
d
L
iv
e
r
S
p
le
e
n
L
u
n
g
H
e
a
rt
S
m
a
ll
 i
n
te
s
ti
n
e
L
a
rg
e
 i
n
te
s
ti
n
e
T
h
y
ro
id
B
ra
in
C
e
re
b
e
lu
m
B
la
d
d
e
r
G
e
n
it
a
ls
B
o
n
e
C
a
rt
il
a
g
e
S
to
m
a
c
h
M
u
s
c
le
K
id
n
e
y
G
a
lb
la
d
d
e
r
B
il
is
T
u
m
o
u
r
0
5
1 0
1 0
2 0
3 0
4 0
4 0
5 0
6 0
1 2 0  m in u te s
2 4 0  m in u te s
 
Figure 60.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 99mTc-PEI-MP and 
determined ex-vivo in mice with xenografts of osteosarcoma. 
 
Analysing the fig. 61, that represents the tumour ratios of mice with xenograft of 
bladder carcinoma and injected with 99mTc-PEI-MP, it’s possible to visualize that 
tumour/muscle ratio is high comparing with the other tumour ratios. For 120 and 
240 minutes after the administration, the tumour/muscle ratio was 1.810.34 
and 1.880.38, respectively, demonstrating that the uptake by the tumour is 
higher than of the muscle. However comparing these values with 1, the 
tumour/muscle ratio was not statistically significantly higher than 1 at 120 or 240 
minutes. Tumour/bladder (0.230.27 at 120 min; 0.120.09 at 240 min), 
tumour/liver (0.500.38 at 120 min; 0.920.62 at 240 min), tumour/lung 
(0.290.16 at 120 min; 0.640.17 at 240 min) and tumour/bone (0.220.16 at 
120 min; 0.130.07 at 240 min) ratios were always inferior to 1, demonstrating 
that the uptake by the tumour was inferior comparing to these organs. However 
these tumour ratios were only statistically significant lower than 1 for 
tumour/bladder at 120 minutes (p=0.044) and 240 minutes (p<0.001), for 
tumour/lung at 120 minutes (p=0.012) and for tumour/bone at 120 minutes 
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(p=0.008) and 240 minutes (p<0.001). Considering these results, metastasis 
from a bladder carcinoma in liver, lung and bones would appear as cold lesions 
in nuclear medicine images, after the administration of 99mTc-PEI-MP. However, 
the probability of detecting metastases in the lungs at 120 and 240 minutes and 
in the bones at 120 and 240 minutes after the administration of 99mTc-PEI-MP 
will be greater, considering that the values of these tumour ratios were 
significantly lower than one. 
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Figure 61.Tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone 
ratios obtained for balb/c nu/nu mice with xenografts of bladder carcinoma after 
administration of 99mTc-PEI-MP. 
 
Analysing the fig. 62, that represents the tumour ratios of mice with xenograft of 
osteosarcoma and injected with 99mTc-PEI-MP, it’s possible to visualize that 
tumour/muscle ratio is high comparing with the other tumour ratios. For 120 and 
240 minutes after the administration, the tumour/muscle ratio was 1.900.53 
and 3.721.60, respectively, demonstrating that the uptake by the tumour is 
higher than of the muscle. However comparing these values with 1, the 
tumour/muscle ratio was not statistically significantly higher than 1 at 120 or 240 
minutes. Tumour/bladder (0.700.47 at 120 min; 0.330.26 at 240 min), 
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tumour/liver (0.420.25 at 120 min; 0.210.11 at 240 min), tumour/lung 
(0.210.06 at 120 min; 0.240.10 at 240 min) and tumour/bone (0.250.16 at 
120 min; 0.170.08 at 240 min) ratios were always less than 1, demonstrating 
that the uptake by the tumour was inferior comparing to these organs. However 
these tumour ratios were only statistically significant lower than one for 
tumour/liver at 240 minutes (p=0.004), for tumour/lung at 120 minutes (p<0.001) 
and at 240 minutes (p=0.04), and for tumour/bone at 120 minutes (p=0.008) 
and 240 minutes (p<0.001). Considering these results, metastasis from an 
osteosarcoma in liver, lung and bones would appear as cold lesions in nuclear 
medicine images, after the administration of 99mTc-PEI-MP. However, the 
probability of detecting metastases in the liver at 240 minutes, in the lungs at 
120 and 240 minutes and in bones at 120 and 240 minutes after the 
administration of 99mTc-PEI-MP will be greater, considering that the values of 
these tumour ratios were significantly lower than 1. 
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Figure 62.Tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone 
ratios obtained for balb/c nu/nu mice with xenografts of osteosarcoma after 
administration of 99mTc-PEI-MP. 
 
 
 
204 
 
6.3.2.2. Ex-vivo biodistribution studies with 188Re-Perrhenate and 188Re-PEI-
MP 
By analysing the fig. 63 that correspond to the normal mice sacrificed 120 and 
240 minutes after the administration of 188Re-Perrhenate, it is possible to 
visualize a high uptake by the thyroid gland and stomach. This biodistribution is 
considered normal as explained before and supports the results observed in the 
images of the biodistribution in vivo of 188Re-Perrhenate in normal mice. 
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Figure 63.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 188Re-Perrhenate 
and determined ex-vivo in normal mice.  
 
By analysing the fig. 64 and fig. 65, that correspond to mice with xenografts of 
bladder cancer and osteosarcoma, respectively, sacrificed 120 and 240 minutes 
after the administration of 188Re-Perrhenate, it’s also possible to visualize a high 
uptake by the thyroid gland and stomach, supporting the results obtained in the 
images of the biodistribution in vivo of 188Re-Perrhenate in mice with xenografts 
of bladder cancer and osteosarcoma, respectively. Also it is possible to 
visualize a small uptake by the tumours that can be related with the blood flow 
to the xenograft. This uptake by the tumours was verified in the in vivo 
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biodistribution images, however faintly visible, but now confirmed by the ex vivo 
studies.  
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Figure 64.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 188Re-Perrhenate 
and determined ex-vivo in mice with xenografts of bladder cancer. 
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Figure 65.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 188Re-Perrhenate 
and determined ex-vivo in mice with xenografts of osteosarcoma. 
 
In addition, tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and 
tumour/bone ratios were determined for all groups, with xenografts. Analysing 
the fig. 66, that shows the tumour ratios of mice with xenograft of bladder 
carcinoma and injected with 188Re-Perrhenate, it’s possible to visualize that 
tumour/muscle ratio is high comparing with the other tumour ratios. For 120 and 
240 minutes after the administration, the tumour/muscle ratio was 2.920.55 
and 2.800.51, respectively, demonstrating that the uptake by the tumour is 
higher than the muscle. Comparing these values with 1, that represents the 
equality between the tumour and muscle uptakes, the tumour/muscle ratio was 
statistically significantly higher at 120 minutes (p=0.024) and at 240 minutes 
(p=0.024). Tumour/bladder (0.450.27 at 120 min; 0.380.20 at 240 min) and 
tumour/lung (0.750.08 at 120 min; 0.730.18 at 240 min) ratios were always 
inferior to 1, demonstrating that the uptake by the tumour was inferior 
comparing to these organs. However these tumour ratios were only statistically 
significant lower for tumour/bladder at 240 minutes (p=0.032) and for 
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tumour/lung at 120 minutes (p=0.036). Tumour/liver (1.090.26 at 120 min; 
1.110.19 at 240 min) and tumour/bone (1.900.53 at 120 min; 1.250.44 at 
240 min) ratios were always superior to 1, demonstrating that the uptake by the 
tumour was superior comparing to these organs, however these ratios were not 
statistically significant. Considering these results, metastasis from a bladder 
carcinoma in lungs would appear as cold lesions, and metastasis in liver and 
bones would appear as hot lesions in nuclear medicine images. Therefore, if the 
goal was the therapy of bladder cancer metastases with 188Re-Perrhenate, it 
wouldn’t be possible taking into account the low selectivity of this 
radiopharmaceutical for metastatic tissue derived from a bladder carcinoma. 
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Figure 66.Tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone 
ratios obtained for balb/c nu/nu mice with xenografts of bladder carcinoma after 
administration of 188Re-Perrhenate. 
 
Analysing the fig. 67, that represents the tumour ratios of mice with xenograft of 
osteosarcoma and injected with 188Re-Perrhenate, it’s possible to visualize that 
tumour/muscle ratio is high comparing with the other tumour ratios, however the 
difference between tumour/muscle ratio and tumour/bone ratio is smaller than 
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the others. For 120 and 240 minutes after the administration, the tumour/muscle 
ratio was 2.711.19 and 0.940.46, respectively, demonstrating that the uptake 
by the tumour is higher than of the muscle at 120 minutes and inferior or equal 
at 240 minutes. However comparing these values with 1, these tumour ratios 
were not statistically significant. Tumour/bladder ratio (0.620.38 at 120 min; 
0.080.04 at 240 min) was always inferior to 1, demonstrating that the uptake 
by the tumour was inferior comparing with the bladder. However, 
tumour/bladder ratio was only statistically significant lower than unit at 240 
minutes (p<0.001). Tumour/liver (1.610.47 at 120 min; 0.370.10 at 240 min), 
tumour/lung (1.350.33 at 120 min; 0.330.08 at 240 min) and tumour/bone 
(2.290.93 at 120 min; 0.640.22 at 240 min) ratios, were always superior to 1 
at 120 minutes and inferior to one at 240 minutes. However these tumour ratios 
were only statistically significant lower for tumour/liver ratio at 240 minutes 
(p=0.004) and for tumour/lung ratio at 240 minutes (p<0.001). Considering 
these results, metastasis from an osteosarcoma in the liver, lung or bone at 120 
minutes would appear as hot lesions and at 240 minutes would appear as cold 
lesions, in nuclear medicine images, after the administration of 188Re-
Perrhenate. Therefore, if the goal was the therapy of osteosarcoma metastases 
with 188Re-Perrhenate, it wouldn’t be possible taking into consideration the low 
selectivity of this radiopharmaceutical for metastatic tissue derived from a 
osteosarcoma. 
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Figure 67.Tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone 
ratios obtained for balb/c nu/nu mice with xenografts of osteosarcoma after 
administration of 188Re-Perrhenate. 
 
By analysing the fig. 68 that corresponds to the normal mice sacrificed 120 and 
240 minutes after the administration of 188Re-PEI-MP, it is possible to visualize 
a high uptake by the bladder wall and some uptake by the kidneys. These 
results support those obtained in the images of the biodistribution in vivo of 
188Re-PEI-MP in normal mice. As explained before this may indicate that 188Re-
PEI-MP is mainly excreted through the renal system. As explained before, the 
hydrophilicity of 188Re-PEI-MP was not tested, however considering that 99mTc-
PEI-MP is similar to 188Re-PEI-MP it is expected that this complex is also 
hydrophilic and water soluble and the excretion should occur through the renal 
system. Considering that the bladder is carefully washed to remove any traces 
of urine, this uptake by the bladder wall demonstrates that 188Re-PEI-MP as 
affinity for bladder cells, being this the primary reason to suspect that PEI-MP 
had some affinity to bladder carcinoma cells. Also it is possible to verify a high 
uptake by the lungs, supporting the results obtained in the in vivo images of 
normal mice. This could be explained by the fact that PEI-MP is a large 
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molecule, being trapped in the lung capillaries. Also the activity present at the 
liver and gallbladder, even being small, demonstrates that this polymer is also 
excreted through the hepatobiliary system. Being PEI-MP a polymer and a large 
molecule it is possible that 188Re-PEI-MP is trapped by the Kupffer cells in the 
liver, that make part of the reticuloendothelial system. Considering the first 
propose of PEI-MP, that was for palliative therapy of bone metastases and also 
de results obtained in previous biodistribution studies [111], it’s not surprising 
the uptake at bones. Moreover it is possible to visualize some retention of 
188Re-PEI-MP in the spleen, demonstrating that part of this complex is trapped 
by the reticuloendothelial system. The percentage of 188Re-PEI-MP in blood is 
also high and seems to diminish over time. 
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Figure 68.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 188Re-PEI-MP and 
determined ex-vivo in normal mice. 
 
By analysing the fig. 69 and fig. 70, which correspond to the mice with xenograft 
of bladder carcinoma and xenograft of osteosarcoma, respectively, sacrificed 
120 and 240 minutes after the administration of 188Re-PEI-MP, it is possible to 
visualize a high uptake by the bladder wall and kidneys. These results support 
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those obtained in the in vivo images of mice with xenografts of bladder 
carcinoma or osteosarcoma after the administration of 188Re-PEI-MP, and are 
similar to the results of the biodistribution ex vivo in normal mice after the 
administration of 188Re-PEI-MP. As explained before this may indicate that 
188Re-PEI-MP is mainly excreted through the renal system and that has an 
affinity for bladder cells. The uptake by the liver and gallbladder indicates, once 
again, that 188Re-PEI-MP is also excreted through the hepatobiliary system, 
being possibly explained by the reasons discussed before. The activity in the 
liver diminished at 240 minutes. Also it is possible to verify some uptake by the 
lungs, supporting the results obtained in the in vivo images, and similar to the 
results of the ex vivo biodistribution in controls, being possibly explained by the 
reasons discussed before. In the same way as for ex vivo biodistribution studies 
in control mice after the administration of 188Re-PEI-MP, it is possible to 
visualize some uptake by spleen and bone, possibly explained by the reasons 
discussed before. The percentage of 188Re-PEI-MP in blood is also high and 
seems to decrease over time. 
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Figure 69.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 188Re-PEI-MP and 
determined ex-vivo in mice with xenografts of bladder cancer. 
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Figure 70.Biodistribution represented in percentage of activity per gram of 
organ/tissue/fluid, 120 and 240 minutes after the administration of 188Re-PEI-MP and 
determined ex-vivo in mice with xenografts of osteosarcoma. 
 
Analysing the fig. 71, that represents the tumour ratios of mice with xenograft of 
bladder carcinoma and injected with 188Re-PEI-MP, it is possible to visualize 
that tumour/muscle ratio is high comparing with the other tumour ratios. For 120 
and 240 minutes after the administration, the tumour/muscle ratio was 
1.790.71 and 1.850.36, respectively, demonstrating that the uptake by the 
tumour is higher than the muscle. However comparing these values with 1, the 
tumour/muscle ratio was not statistically significantly higher at 120 or 240 
minutes. Tumour/bladder (0.290.18 at 120 min; 0.170.06 at 240 min), 
tumour/liver (0.250.06 at 120 min; 0.240.03 at 240 min), tumour/lung 
(0.060.04 at 120 min; 0.090.15 at 240 min) and tumour/bone (0.700.21 at 
120 min; 0.750.10 at 240 min) ratios were always inferior to 1, demonstrating 
that the uptake by the tumour was inferior comparing to these organs. However 
these tumour ratios were only statistically significant lower for tumour/bladder at 
240 minutes (p<0.001), for tumour/liver at 120 minutes (p<0.001) and at 240 
minutes (p<0.001), for tumour/lung at 120 minutes (p=0.004) and at 240 
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minutes (p=0.004). Considering these results, metastasis from a bladder 
carcinoma in liver, lung and bones would appear as cold lesions in nuclear 
medicine images, after the administration of 188Re-PEI-MP. Therefore, the 
therapy of bladder cancer metastases with 188Re-PEI-MP it wouldn’t be 
recommended, since the irradiation of non-target tissues such as the liver, the 
lungs and bones would be higher than desirable, and can mean significant side 
effects, if this radiopharmaceutical was used. Also the uptake by these 
metastases would be too low so that the therapy with this radiopharmaceutical 
could be effective. 
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Figure 71.Tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone 
ratios obtained for balb/c nu/nu mice with xenografts of bladder carcinoma after 
administration of 188Re-PEI-MP. 
 
Analysing the fig. 72, that represents the tumour ratios of mice with xenograft of 
osteosarcoma and injected with 188Re-PEI-MP, it is possible to visualize that 
tumour/muscle ratio is high comparing with the other tumour ratios. For 120 and 
240 minutes after the administration, the tumour/muscle ratio was 1.580.45 
and 1.640.35, respectively, demonstrating that the uptake by the tumour is 
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higher than the muscle. However comparing these values with 1, the 
tumour/muscle ratio was not statistically significantly higher at 120 or 240 
minutes. Tumour/bladder (0.140.08 at 120 min; 0.110.02 at 240 min), 
tumour/liver (0.320.15 at 120 min; 0.560.13 at 240 min), tumour/lung 
(0.250.09 at 120 min; 0.420.15 at 240 min) ratios were always inferior to 1, 
demonstrating that the uptake by the tumour was inferior comparing to these 
organs. However these tumour ratios were only statistically significant lower 
than one for tumour/bladder at 240 minutes (p<0.001), for tumour/liver at 240 
minutes (p=0.028) and for tumour/lung at 240 minutes (p=0.016). Tumour/bone 
ratio (1.020.30 at 120 min; 0.600.17 at 240 min), was almost equal to one 
at 120 minutes and inferior at 240 minutes. However comparing these 
values with 1, these tumour ratios were not statistically significant. Considering 
these results, metastasis from an osteosarcoma in liver and lungs would appear 
as cold lesions, and in bones wouldn’t be visible at 120 minutes and would 
appear as cold lesions at 240 minutes in nuclear medicine images, after the 
administration of 188Re-PEI-MP. Therefore, if the goal was the therapy of 
osteosarcoma metastases with 188Re-PEI-MP, it wouldn’t be recommended 
because the irradiation of non-target organs like the liver, the lungs and bones 
would be higher than desirable, with significant side effects from the use of this 
radiopharmaceutical. Furthermore, the uptake by these metastases would be 
too low, and the treatment with this radiopharmaceutical wouldn’t be effective. 
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Figure 72.Tumour/muscle, tumour/bladder, tumour/liver, tumour/lung and tumour/bone 
ratios obtained for balb/c nu/nu mice with xenografts of osteosarcoma after 
administration of 188Re-PEI-MP. 
 
 
6.4. Section discussion 
As mentioned before, since in vitro studies are conducted in a controlled 
environment, and knowing that a tumour is not only a set of tumour cells but a 
complex aggregate of tumour cells, supporting cells, nerves and vascular and 
lymphatic vessels, the in vitro results may not correspond to those obtained in a 
living organism. Therefore, it was imperative to conduct in vivo studies to 
analyse the potential of PEI-MP radiolabelled with 99mTc for early diagnosis and 
with 188Re for therapy of bladder cancer, and to sustain the results obtained in 
vitro. The main purposes were to verify if the tumour cell uptake and retention of 
the referred complexes was maintained, to understand the biodistribution and 
biokinetics of these complexes in vivo, and identify the target organs, the routes 
of metabolism and excretion of 99mTc-PEI-MP and 188Re-PEI-MP, by nuclear 
medicine imaging in a first approach and, after using animals for determination 
of the biodistribution for each organ. It was also an objective to compare the 
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potential of the referred complexes in osteosarcoma animal models. For the 
fulfil of all procedures involving animals, first it was obtained the approval by the 
Ethics Committee for Health of the Faculty of Medicine of the University of 
Coimbra and all the studies were performed according to their legislation.  
The first step for carrying the in vivo and ex vivo studies was to choice a 
suitable animal tumour model. The animal tumour models chosen were the 
immunodeficient mice balb/c nu/nu with subcutaneous xenografts of bladder 
carcinoma or osteosarcoma. The balb/c nu/nu mice have genetic immune 
deficiencies, this is, has one or more mutations that minimize or prevent the 
rejection of the grafted tissues from other species [318]. These models have 
several advantages, namely, they are cost effective, provide a direct 
assessment of efficacy against a human cancer through calliper measurement 
of tumour size, and the tumour is accessible allowing the harvesting of tumour 
tissue [328-330]. The xenografts of osteosarcoma and bladder carcinoma 
developed well in 3 and 4 weeks, respectively, after the subcutaneous injection 
of a suspension of 5 million cells in the right axilla dug of the mice. The place 
chosen for the development of the xenografts demonstrated to be the best 
choice, given the fact that is contra lateral to the heart, is away from the liver, 
bladder and kidneys, avoiding the overlapping in the nuclear medicine images, 
once those organs can also be target of the administered radiopharmaceuticals. 
Also is a good area of expansion, and has a good vascularisation, which can 
explain the fast development of the xenografts, and is an area that allows a 
quick and easy excision of the tumour. Therefore for the planed experiments the 
animal tumour models chosen served its purpose. However it is important not to 
forget that human cells are placed in a murine environment, creating 
interactions that may not faithfully reflect the human disease process (e.g., 
differences in the local cell environment, cytokine, chemokine, and growth factor 
incompatibility, differences in immunologic state, etc.) [318]. Also, since for the 
development of these tumour models, immunocompromised animals are 
needed, and knowing that these animals are highly susceptible to viral, 
bacterial, and fungal infections, and that there are agents that can change the 
outcome and the reproducibility of the experiments, the animals must be 
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maintained in specific pathogen-free (SPF) environments, which increases the 
research costs [318].  
Studies in vivo and ex-vivo using balb/c nu/nu mice with xenograft of bladder 
carcinoma and xenograft of osteosarcoma started when the tumour volumes 
reached 500-1000 mm3, considered as sufficient for nuclear medicine imaging, 
taking into account the size of the mice. Also it is the maximum volume which 
will allow the least discomfort possible for the mice. 
For nuclear medicine images it is important to maintain the mice immobilized, 
because if they move during the acquisition images, makes impossible the 
image analysis. The best way to immobilize a mouse is to anesthetize him. The 
anaesthesia was performed after the subcutaneous administration in the back 
of the mouse of a solution of ketamine 77% and chlorpromazine 23%. Ketamine 
is a rapid-acting general anaesthetic producing an anaesthetic stated 
characterized by profound analgesia, normal pharyngeal-laryngeal reflexes, 
normal or slightly enhanced skeletal muscular tone, cardiovascular and 
respiratory stimulation, and occasionally a transient and minimal respiratory 
depression. Has a wide margin of safety and short period of action, allowing 
several administrations to maintain the anaesthetic state. The chlorpromazine is 
a dopamine antagonist, possessing anti-cholinergic properties that cause 
sedation [337]. This solution demonstrated to be effective in producing an 
anaesthetic state without significant side effects to the mice. One of the side 
effects of the anaesthesia is the decrease of body temperature, therefore during 
the anaesthetic state, it was controlled [337]. For image acquisition, mice were 
placed in prone on top of the gamma-camera collimator, with the superior and 
inferior members kept away from the trunk. This position is appropriate so that 
the organs are closer to the detector without interference of the spine, and 
allows the tumour stay well-defined in the images. 
Images started after the intravenous administration in the tail vein of the 
radiopharmaceuticals 99mTc-Pertechnetate, 99mTc-PEI-MP, 188Re-Perrhenate or 
188Re-PEI-MP in mice without and with xenograft of bladder carcinoma and 
osteosarcoma. The dynamic images proved to be useful to confirm the injection 
and the distribution of the radiopharmaceuticals in the bloodstream of mice. The 
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static images obtained each 30 minutes following the administration of the 
radiopharmaceuticals proved to be adequate to obtain images with a better 
resolution and to follow the biodistribution along the time. 
The images obtained with the 99mTc-Pertechnetate and 188Re-Perrhenate are 
controls and show the normal biodistribution of these radiopharmaceuticals, but 
they can also be radiochemical impurities produced during the labelling process 
of PEI-MP kit with 99mTc-Pertechnetate or with 188Re-Perrhenate. In these 
images is normal to obtain a high uptake in the thyroid, stomach, and choroid 
plexus. On another hand, if the radiochemical impurities exist the 
reduced/hydrolyzed technetium/rhenium species, it was expected to obtain a 
high uptake in the liver and the spleen. The biodistribution verified in the images 
will be a mirror of the radiochemical purity of the 99mTc-PEI-MP and 188Re-PEI-
MP, therefore is very important to control the radiochemical purity after 
radiolabelling. Images obtained after the administration of 99mTc-Pertechnetate 
and 188Re-Perrhenate in normal mice, in mice with xenograft of bladder 
carcinoma and in mice with xenograft of osteosarcoma, demonstrated the 
expected biodistribution mentioned above. In the mice with xenografts of 
bladder carcinoma and osteosarcoma, it was verified a small uptake by the 
tumour. Since the images had low resolution, the uptake quantification was 
difficult, whereby it was important to obtain more quantitative data with the ex 
vivo studies. 
After obtaining the images of the control mice without tumour and with 
xenografts of bladder carcinoma and osteosarcoma with 99mTc-Pertechnetate or 
188Re-Perrhenate, 99mTc-PEI-MP or 188Re-PEI-MP were intravenously injected in 
the same animal models. By analysing the images obtained in these animal 
models mice, it was possible to visualize a high uptake in kidneys and bladder, 
indicating that these radiopharmaceuticals are excreted mainly through the 
renal system. In fact, taking in consideration the results of the partition 
coefficient demonstrated in Chapter V, clearly demonstrating that 99mTc-PEI-MP 
is a hydrophilic molecule, and therefore water soluble, it’s not surprising that the 
main way of excretion is through the renal system and consequently eliminated 
through urine. This is an advantage because there are no retention in liver and 
fat tissue, and the faster kidney excretion allows for a higher target/background 
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ratio [273]. The hydrophilicity of the 188Re-PEI-MP was not tested, however 
considering that 99mTc-PEI-MP is similar to 188Re-PEI-MP it is expected that this 
complex is also hydrophilic and water soluble, what seems to be proved by the 
obtained images. 
Also it was found a faint uptake by the lungs in the in vivo images that seem to 
decrease over time, especially after the intravenous administration of 188Re-PEI-
MP. This could be explained because the PEI-MP is a large molecule, being 
trapped in the lung capillaries, and as the 188Re has a number of atomic mass 
bigger than the 99mTc, the complex 188Re-PEI-MP may be larger than 99mTc-PEI-
MP [61]. 
In mice with xenografts of bladder carcinoma and osteosarcoma was verified a 
small uptake of 99mTc-PEI-MP or 188Re-PEI-MP by the tumour. Also the images 
had low resolution to be possible to quantify the uptake, therefore it was 
important to obtain more quantitative data with the ex vivo studies. 
The evaluation of the biodistribution and biokinetics of 99mTc-PEI-MP and 188Re-
PEI-MP by in vivo imaging may not be enough to respond to all questions, given 
the low resolution of the conventional gamma-camera. Therefore, it was 
necessary to obtain the percentage of uptake of the radiopharmaceutical 
administered for each organ and tissue, as well as the uptake ratios of between 
the tumour and some organs, especially those where it is expected that have 
metastases from the tumours. This information was only gathered after the 
sacrifice of mice and the collection of every organs, tissue, fluid and tumour. 
The ex vivo studies performed after the administration of 99mTc-Pertechnetate 
and 188Re-Perrhenate in mice without tumour and with xenografts of bladder 
carcinoma and osteosarcoma supports the results obtained in the in vivo 
images, being the target organs the thyroid, the stomach, and the choroid 
plexus. Also it was verified a small uptake by the tumours, supporting the 
results obtained in the in vivo images after the administration of 99mTc-
Pertcehnetate and 188Re-Perrhenate. The uptake by bladder carcinoma and 
osteosarcoma xenografts may be related with the blood supply to these 
xenografts, which is in accordance with the rich vascularisation of the axillary 
dug where the xenografts grew. 
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The ex vivo studies performed after the administration of 99mTc-PEI-MP and 
188Re-PEI-MP in mice without tumour and with xenografts of bladder carcinoma 
and osteosarcoma supports the results obtained in the in vivo images, where it 
is verified a high count rate in the kidneys and the bladder, demonstrating that 
these complexes are mainly excreted through the renal system. However, 
considering that the bladder was carefully washed to remove any traces of 
urine, this activity of the bladder wall demonstrates, once again, that 99mTc-PEI-
MP or 188Re-PEI-MP as affinity for bladder cells, being this the primary reason 
to suspect that PEI-MP could have some affinity to bladder cancer cells.  
Supporting the results of the in vivo images it was possible to verify in the ex 
vivo studies, some uptake in lungs, possibly explained by reason referred 
before. 
What was not possible to visualize in the in vivo images, but was verified in the 
ex vivo studies, for mice injected with 99mTc-PEI-MP or 188Re-PEI-MP, was 
some uptake by the liver and the gallbladder demonstrating that, in part, these 
radiopharmaceuticals are also excreted through the hepatobiliary system. Being 
PEI-MP a polymer and being a large molecule, it is possible that these 
radiopharmaceuticals may be trapped by the Kupffer cells in the liver that make 
part of the reticuloendothelial system, are degraded and subsequently released 
in the gallbladder. Also it was possible to visualize some retention of 99mTc-PEI-
MP and 188Re-PEI-MP in the spleen, demonstrating that some percentage of 
this complex is trapped by the reticuloendothelial system. 
Considering the first propose of PEI-MP, that was for palliative therapy of bone 
metastases and also de results obtained in previous biodistribution studies 
[111], it’s not surprising the uptake of 99mTc-PEI-MP and 188Re-PEI-MP by the 
bone.  
Also, it was verified some uptake by the tumours, what supports results 
obtained in the images after the administration of 99mTc-PEI-MP and 188Re-PEI-
MP. The uptake by bladder carcinoma and osteosarcoma xenografts may be 
related not only with the good blood supply to these xenografts,, but also with 
the EPR effect associated to this polymer.  
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As discussed by Maeda et al. [169] and Seymour [170] the EPR effect, is the 
process in which water soluble macromolecules accumulate passively within 
tumour tissue, either primary or metastatic in nature, due to leaky blood vessels 
and poor lymphatic clearance. Therefore, theoretically, being PEI-MP a water 
soluble macromolecule it would follow this principle. Several studies were 
already conducted that assigns to PEI-MP this characteristic. For example, 
Dormehl IC et al. developed PEI-MP considering the EPR effect [111], and 
studied the biodistribution of several molecular sized PEI-MP radiolabelled with 
99mTc. The results demonstrated that the smaller fraction of PEI-MP (10-30 kDa) 
had the best tumour uptake. In the same way Jansen D et al., demonstrated 
that 117mSn-PEI-MP, in the same fraction, also presented a higher affinity for 
tumour tissue [176]. Therefore it was expected that 99mTc-PEI-MP and 188Re-
PEI-MP, in the chosen fraction 10-30 kDa, would have a good uptake by the 
tumour tissue, which was confirmed by the in vivo and ex vivo studies. The 
retention of these complexes in the tumour, at least for 240 minutes, may be 
related with the EPR effect. As mentioned before tumour tissues have poor 
lymphatic drainage and slow venous return, allowing that macromolecules like 
PEI-MP are retained in the tumour, whereas extravasation into the tumour 
interstitium continues [171, 173]. The high period of retention of 99mTc-PEI-MP 
may be an advantage to perform diagnostic nuclear medicine images, to 
localize and delineate the tumour. Also for 188Re-PEI-MP the tumour retention 
for a long period of time could be an advantage since gives time to deliver the 
high energetic β- particles to the tumour cells, inducing tumour cell death [59]. 
Because the accumulation of macromolecules by the EPR effect is a 
progressive phenomenon, it is essential that the molecules are stable in the 
plasma for long periods [173]. In the ex vivo biodistribution studies was clear a 
high percentage of 99mTc-PEI-MP or 188Re-PEI-MP in the blood, despite its 
reduction at 240 minutes after the administration. Owing to the prolonged 
retention of the polymeric complexes like 99mTc-PEI-MP or 188Re-PEI-MP by the 
EPR effect and the enhanced plasmatic half-life, less frequent administrations 
would be needed, which is of great benefit to patients [173, 175]. 
However, the affinity of PEI-MP to bladder carcinoma or osteosarcoma is 
related not only with the vascularisation and the EPR effect, but also with the 
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fact that PEI-MP is a phosphonate derivative. Taniguchi M. et al. reported a 
case of a calcified transitional cell carcinoma of the bladder visualized in a bone 
scintigraphy performed with 99mTc-HMDP (a diphosphonate) and suggested 
possible uptake mechanisms. Calcification in uroepithelial tumours of the 
bladder is a rare radiographic finding and clearly characterized by a high 
concentration of calcium. As it is known, phosphonates has a particular affinity 
for calcium (Ca2+) [102], hence its uptake. In the transitional cell carcinoma of 
the bladder, the most common location of calcifications is on the surface of the 
tumour epithelium creating incrustations. It is believed that the incrustation 
reflects a local interaction of pH related with urinary calcium and the tumour 
epithelium, since calcium precipitation is favoured by an alkaline urinary pH 
[338]. On the other hand, Moreno AJ et al. reported a case of transitional cell 
carcinoma of the kidney identified by imaging with 99mTc-MDP, that after 
histopathological examination it wasn’t found any calcification in the tumour, 
suggesting several uptake mechanisms other than chemisorption, such as a 
possible selective binding of 99mTc-MDP with the tissue receptors or a 
hypervascularization [339]. Therefore, being PEI-MP a diphosphonate, the 
uptake of 99mTc-PEI-MP or 188Re-PEI-MP by bladder carcinoma could be related 
with some of the factors mentioned by the referred authors. For osteosarcoma, 
the uptake is related with the presence of high concentrations of Ca2+ and with 
the strong affinity of phosphonates to the hydroxyapatite crystals, as already 
mentioned [102, 108]. 
In addition of calculating the percentage of activity per gram of 
organ/tissue/fluid, it was also determined the values of the tumour/muscle, 
tumour/bladder, tumour/liver, tumour/lung and tumour/bone ratios for all groups. 
Considering that, in case of metastases of a bladder carcinoma, the major 
target organs are the liver, lungs and the bone, and knowing that the bladder 
carcinoma has its origin in the bladder wall and in an initial stage the tumour will 
invade the muscle adjacent to this organ [184], is crucial to determine these 
tumour ratios, which can be done by nuclear medicine images. If the 
radiopharmaceutical uptake by the primary tumour or its metastases is equal to 
the uptake of the other organs, it’s not possible to identify them, and therefore, 
the diagnosis could be inconclusive or negative to the tumour or to the 
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metastases. Also, the determination of those tumour/organ ratios is important, 
mainly when radionuclide therapy with 188Re-PEI-MP in an option. In these 
circumstances, the main target should be the tumour and its metastases, and 
the non-target organs should be spared of high doses of ionizing radiation. If the 
radiopharmaceutical uptake by the tumour or its metastases is equal or lower to 
the uptake of the other organs, it is not possible to perform the therapy, since it 
would be the non-target organs the most affected by ionizing radiation and the 
therapy would not be effective, and possibly it would result in serious adverse 
effects. 
For mice with xenografts of bladder carcinoma or osteosarcoma, after the 
administration of 99mTc-PEI-MP or 188Re-PEI-MP, the tumour/muscle ratios were 
always superior to 1, demonstrating that the uptake by the tumour (bladder 
carcinoma or osteosarcoma) was bigger than muscle. The fact of the 99mTc-PEI-
MP uptake by the tumour is higher than by the muscle, is an advantage and 
could allow to determine the degree of muscle invasion and could assist the 
surgery to determine how much muscle should be excised with the tumour and 
the bladder [188]. Also the high tumour/muscle ratio obtained with 188Re-PEI-
MP is an advantage for the therapy, allowing sparing the muscle from the action 
of high doses of ionizing radiation. 
For the mice with xenografts of bladder carcinoma and osteosarcoma where 
99mTc-PEI-MP were administered, tumour/bladder, tumour/liver, tumour/lung 
and tumour/bone was always inferior to 1 demonstrating that the uptake by the 
tumour was inferior to the quoted organs. Considering these results, the tumour 
of the bladder wall, and the metastases from a bladder carcinoma or 
osteosarcoma in liver, lung and bones would appear as cold lesions in nuclear 
medicine images, after the administration of 99mTc-PEI-MP. Therefore, it would 
be possible to identify the tumour and its metastases, in a non-invasive and in 
an effective way, after intravenous injection of 99mTc-PEI-MP, and the images 
must be acquired until 240 minutes after the radiopharmaceutical 
administration. Equally, for mice with xenografts of bladder carcinoma and 
osteosarcoma where 188Re-PEI-MP were administered, tumour/bladder, 
tumour/liver, tumour/lung and tumour/bone was always inferior to 1 
demonstrating that the uptake of the tumour was inferior comparing with these 
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organs. Considering these results, the primary tumour and its metastases from 
a bladder carcinoma or osteosarcoma in liver, lung and bones would appear as 
cold lesions in nuclear medicine images, after the administration of 188Re-PEI-
MP. Therefore, if the goal was the therapy of bladder carcinoma or 
osteosarcoma, and their metastases after the intravenous administration of 
188Re-PEI-MP, it wouldn’t be possible taking into consideration that the 
irradiation of non-target tissue like the bladder wall, the liver, the lungs and the 
bones would be higher than desirable, and could present significant adverse 
effects from the use of this radiopharmaceutical. Also the uptake by these 
metastases would be too low, so that the therapy with this radiopharmaceutical 
could be non-effective. 
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Section IV. Discussion, Conclusions and Future Perspectives 
Chapter 7.Final Discussion 
 
Cancer is a serious disease and the bladder cancer (primary or secondary) is a 
catastrophic event for the patient and has a negative impact on quality of life 
and on social environment [67, 340].  As referred in Chapter 2, cancer is easier 
to treat and cure, if it is diagnosed early [35, 36]. Current diagnostic methods for 
bladder cancer are mainly morphologic imaging techniques like pyelography, 
ultrasonography, CT scanning, magnetic resonance imaging and cytoscopy, 
having each of these methods advantages and disadvantages [183, 194, 219-
221]. The potential of functional imaging techniques is not being fully availed for 
this type of cancer. The advantage of being able to visualize physiopathological 
processes is based on the fact that they arise prior to morphological changes, 
which allows the diagnosis in a very early stage of the disease [183, 194, 219-
221]. If we had a molecule with specificity affinity to a particular target of the 
bladder cancer, it could be used, if properly radiolabelled, to give information 
about the physiopathological processes through an image, helping to identify 
neoplastic masses of reduced size, and evaluate the eventual spread of bladder 
cancer, that could be impossible or very difficult to identify early with the 
diagnostic methods currently used. Until now, has not yet been developed a 
molecule with specific affinity for the bladder tissue. 
Therefore, it seems urgent to identify new molecules that could be radiolabelled 
for diagnostic nuclear medicine imaging or for metabolic radiotherapy. 
Non-invasive and early diagnosis of cancer is of crucial importance for effective 
treatment, and also would allow a more conservative management and therapy 
[35, 36]. Systemic treatment options for bladder cancer include surgery, 
chemotherapy, radiation, and immunotherapy. The choice on the therapeutic 
modality will depend on the tumour staging. In early stage of bladder cancer 
transurethral resection is a common surgical option while partial or radical 
cystectomy is performed for muscle-invasive and locally advanced bladder 
cancer [177]. Conservative management with organ preservation is now the 
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standard of care in numerous malignancies, and for bladder cancer patients it is 
imperative, because less surgery means no need for an urinary diversion, and 
the possibility of a normal sexual life [252]. Non-surgical treatment of invasive 
bladder cancer has been traditionally reserved for patients who are unfit for, or 
refuse radical cystectomy, but there are growing evidences that the evolution of 
radiotherapy (XRT) techniques and the availability of new chemotherapeutic 
protocols, have made bladder-saving treatment a competitive alternative to 
radical cystectomy in selected patients [198]. Historically, it is shown that local 
disease is controlled in only about 20% of patient treated with transurethral 
resection alone [253, 254] and 40% treated with XRT alone [255, 256]. Some 
studies have shown that combined transurethral resection with chemotherapy 
[230, 257] or XRT with chemotherapy [258, 259] can improve the treatment of 
the disease, but the best results are obtained using a trimodality strategy in 
which radiochemotherapy follows transurethral resection. As mentioned in 
Chapter 4 there is no reference to the use of radiopharmaceuticals for 
radiotherapy in bladder cancer. If we think in diagnose, the alliance of a 
radionuclide with a molecule with specific affinity to a particular cell or organ, 
gives specific functional information about that cell or organ. In terms of bladder 
cancer therapy, if we have a radiolabelled molecule with specific affinity to 
bladder tumour cells, it could improve the therapy of the primary tumour and its 
metastasis, enabling the delivery of high radiation doses to the target tissue with 
minimal side effects.  
As described in Chapter 3, polyethyleneiminomethyl phosphonic acid (PEI-MP) 
was developed by Dormehl IC et al. for use in palliative therapy of bone 
metastases after suitable radiolabelling [67, 111]. Besides to be a bone-seeking 
agent, PEI-MP would accumulate in solid tumours due to the EPR effect [169, 
170]. The studies that followed have established the biodistribution and 
pharmacokinetic properties of different complexes PEI-MP/metal radionuclides 
(99mTc, 117mSn and 186Re) [129, 174, 267]. For any of the three complexes 
obtained and studied the dosimetric calculations have shown that the critical 
organ was consistently the bladder [111, 267]. The high count rate in the 
bladder wall with the different PEI-MP/metal radionuclides seems something 
that deserves to be further and better studied. As referred in Chapter 4, the 
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possibility of a high uptake of PEI-MP complexes by bladder tumour cells, and 
the EPR effect associated with this polymer [169, 170], assigns a high potential 
to the PEI-MP, if conveniently radiolabelled, for diagnosis and therapy of 
bladder cancer, more specifically, through the 99mTc-PEI-MP for diagnosis and 
188Re-PEI-MP for therapy of bladder cancer. As described in Chapter II, the 
technetium-99m (99mTc) is the most widely used radioisotope in diagnostic 
nuclear medicine due to its availability, its favourable physical properties and its 
versatile chemistry that allows the labelling of a great variety of ligands [55, 71], 
including the PEI-MP, making possible to apply this molecule for the diagnostic 
imaging. Also in Chapter 2, rhenium-188 (188Re) is described as an excellent 
candidate for β- particle therapy, particularly for large tumour masses given to 
the energy and tissue penetration of their β- particles [66, 76-78, 81]. Other 
physical characteristics of 188Re that constitute an advantage is its gamma ray 
emission that can be used for dosimetry purposes and to monitor biological 
distribution during therapy [61, 66, 76, 82, 83], and the relatively short physical 
half-life of 16.9 hours that allows the use of high activities and reduces the 
problem of radioactive waste handling and storage [82, 84]. The rhenium is a 
chemical congener of 99mTc, which means that 99mTc agents can be used as the 
“matched pair” for the corresponding 188Re agent. This particularity associated 
with its physical characteristics of the rhenium makes feasible to obtain 
excellent diagnostic imaging, allowing pre- and post-assessment of patients 
treated with 188Re radiopharmaceuticals [41]. According to these physic-
chemical characteristics, the PEI-MP may also be radiolabelled with 188Re, 
whereby it is possible to evaluate the potential of 188Re-PEI-MP for therapy. 
Therefore, the aim of this work was to verify the potential of PEI-MP 
radiolabelled with 99mTc for the early diagnosis, and radiolabelled with 188Re for 
therapy of bladder cancer. Also, taking into account the initial purpose of PEI-
MP the same studies were conducted in parallel for bone cancer [102, 111]. 
After a successful synthesis of the polymer and preparation of the kits, it was 
proceeded to labelling of the PEI-MP kits with 99mTc-pertechenetate and 188Re-
perrhenate, and radiochemical purity of the complexes was evaluated. The 
results of radiochemical purity showed to be better for 99mTc-PEI-MP (superior 
to 89%) than for the 188Re-PEI-MP (superior to 85%). This high radiochemical 
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purity was maintained during at least 5 hours, revealing the stability of the kit 
formulation, and ensuring its use for a long period of time which is an 
advantage, since allows performing several experimental studies in the same 
day, which would also be an advantage for clinical use. To determine the 
radiochemical purity of these labelling kits the chromatographic systems chosen 
demonstrated to be adequate and efficient in separating the contaminant 
radiochemical species of 99mTc and 188Re (free and reduced/hydrolyzed forms) 
[61, 71, 87].  
Considering that during the experimental studies the complexes 99mTc-PEI-MP 
and 188Re-PEI-MP would be exposed to cellular culture medium (DMEM) and to 
variations of room temperature (22 ºC to 45 ºC), radiochemical purity of 99mTc-
PEI-MP complex was evaluated in those conditions. Given the impossibility of 
performing this experiment with 188Re-PEI-MP, the results of radiochemical 
purity of this complex in cellular culture medium and at several temperatures, 
can only be extrapolated according to its similarities with 99mTc-PEI-MP 
complex. The results demonstrated that the exposure to temperatures of 22, 37 
and 45 ºC didn’t change significantly the radiochemical purity of 99mTc-PEI-MP 
during 5 hours. Similarly, the addition of cellular culture medium didn’t change 
significantly the radiochemical purity, independently of the temperature, 
remaining superior to 85%. These results demonstrated that experimental 
studies could be performed without the worrying of loose the high radiochemical 
purity of 99mTc-PEI-MP, and certainly of 188Re-PEI-MP. 
The hydrophilicity and lipophilicity of a radiolabelled molecule has 
consequences on the biodistribution and biokinetics of the complex. Therefore 
the hydrophilicity of 99mTc-PEI-MP was evaluated over 4 hours after the 
radiolabelling. The results demonstrated that this complex was hydrophilic, and 
hence water soluble. Although it was not possible to perform these evaluations 
with 188Re-PEI-MP, but considering their similarities, it would be expected the 
same hydrophilicity, which in turn was confirmed by the results obtained in the 
in vivo and ex vivo studies. These characteristic, perhaps means that the 
complexes would not be uptaked significantly by the liver or fat tissue, and 
would be eliminated very quickly through the renal system [273]. However, 
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these expected results didn’t correspond totally with those obtained in the in 
vivo and ex vivo studies as it will be discussed after. 
For diagnostic and therapeutic purposes PEI-MP should act only as a carrier 
and having no therapeutic or harmful effect. Therefore the cytotoxicity of PEI-
MP was analysed through the evaluation of the inhibition of the cellular 
metabolic activity by MTT assay and the cell viability, the types of cell death, the 
production of peroxides and superoxide anion, and the expression of reduced 
GSH by flow cytometry. The results demonstrated that PEI-MP didn’t inhibit the 
metabolic activity of bladder carcinoma or osteosarcoma cells, and the cell 
viability didn’t decrease, there were no significant changes in the production of 
peroxides or superoxide anion that are harmful to cells [291, 293], and there 
were no significant changes in the expression of GSH, a major antioxidant that 
maintains a tight control of the redox status [295, 297]. Although the results 
have shown that the percentage of apoptosis has increased, and consequently 
decrease the mitochondrial membrane potential, these results should be 
carefully seen, since cellular viability did not change, as well as no changes 
were observed in the production of reactive oxygen species (ROS) or in the 
expression of GSH. In fact, the production of ROS and the depletion of GSH are 
associated with the induction of apoptosis [291, 295], and taking into account 
that none of these parameters was changed significantly, the result of the 
increased apoptosis seems not to be relevant. Therefore, PEI-MP would act as 
a carrier, not producing significant adverse effects to cells, thus it may be 
radiolabelled with 99mTc or 188Re to study its potential for diagnosis (99mTc-PEI-
MP) and for therapy (188Re-PEI-MP) of bladder carcinoma and osteosarcoma. 
As described before 99mTc not also emits gamma rays of low energy (140 keV), 
but also highly energetic auger electrons, that could represent a risk [59]. 
Additionally, as the objective is to use 99mTc-PEI-MP to perform safely 
diagnostic nuclear medicine images after its intravenous administration, is 
important to understand, if activities in the range of diagnostics represent or not 
a risk. Therefore it was evaluated the effects of equivalent doses until 20 mGy, 
(considering that the equivalent doses of most nuclear medicine diagnostic 
procedures varies between 0.3 and 20 mGy [303], after internal and external 
irradiation of bladder carcinoma and osteosarcoma cells. For this purpose, it 
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was analysed the ability of a cell to form a colony though the clonogenic assay, 
and it was also evaluated the cell viability, the types of cell death, the production 
of peroxides and superoxide anion, the expression of GSH, the changes in 
mitochondrial membrane potential and the cell cycle by flow cytometry. The 
results show that, for diagnostic equivalent doses, 99mTc didn’t had any 
significant effects in the inhibition of cell growth, cell viability, cell death, and 
there were no changes in the production of ROS, in expression of GSH, and in 
mitochondrial membrane potential or cell cycle arrest. Therefore it is safe the 
use of 99mTc-PEI-MP for nuclear medicine imaging taking into account that the 
equivalent dose should not overcome the 20 mGy. The cytotoxicity of 188Re 
doses was not determined, once again given the lack of a 188W/188Re generator, 
however considering the emission of high energetic β- particles by the 188Re, is 
possible to extrapolate the response of cells to its exposure, especially if 
internally irradiated where the cells were exposed to these particles and also to 
gamma photons of 155 keV. High energetic β- particles may interact with 
cellular DNA and cause double or single-strand breaks and if these are not 
repaired correctly may lead to cellular death. This ionizing radiation may interact 
directly with the cellular DNA or indirectly with water molecules inside the cell, 
which may lead to an avalanche process in which are produced reactive oxygen 
species that, indirectly, will react with the cellular DNA and other cellular 
components producing damage [304, 306]. As consequence of the production 
of reactive oxygen species, the expression of GSH may be increased in order to 
control the redox status [295, 297]. Additionally, if the intrinsic pathway of 
apoptosis is activated, the mitochondria membrane potential goes eventually 
decrease [290, 304]. Therefore, the selection of 188Re for therapy would be a 
good choice, but only if the selectivity for the target tissue is guaranteed. 
For a radiolabelled molecule with diagnostic or therapeutic purposes it is 
important that the uptake and retention by the target tissue or organ is high and 
that at the non-target organs are as low as possible. Therefore, cellular uptake 
and retention studies were performed after adding 99mTc-PEI-MP or 188Re-PEI-
MP to bladder carcinoma or osteosarcoma cells in culture. The results showed 
that the uptake by cells of 99mTc-PEI-MP or 188Re-PEI-MP was, during the 240 
minutes of study, significantly higher than the uptake of 99mTc-Pertechnetate or 
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188Re-Perrhenate, respectively. These results demonstrated clearly that PEI-MP 
has a particular affinity to cells of bladder carcinoma and osteosarcoma, and 
therefore can be an excellent carrier for 99mTc or 188Re to perform diagnostic 
nuclear medicine images or therapy, respectively, in cases of bladder 
carcinoma or osteosarcoma. However, there are significant differences between 
the uptake of 99mTc-PEI-MP and 188Re-PEI-MP, being the in vitro uptake of the 
last higher.  A possible explanation is that 188Re has a high atomic mass that 
makes 188Re-PEI-MP a larger molecule than 99mTc-PEI-MP, and as mentioned 
before the tumour uptake of large molecules is dominated by the EPR effect. 
Related with this phenomenon, it is known that smaller molecules are cleared 
more rapidly and easier than larger molecules, and as a result the uptake and 
retention of larger molecules may be higher [169, 170, 341]. Schmidt M et al. 
[341] stated that smaller molecules require tighter binding to maintain significant 
tumour uptake than larger molecules, considering that larger molecules with 
some affinity to tumour cells (that is possibly the case of PEI-MP for bladder 
carcinoma and osteosarcoma cells) even losing the bound to the tumour cells, 
because they are cleared slowly, they have time to rebind to tumour cells. 
Therefore, the uptake and retention of larger molecules, like 188Re-PEI-MP, 
would be higher than 99mTc-PEI-MP that is comparatively smaller. These results 
will be discussed again, when those obtained in vivo and ex vivo are analysed. 
Manual techniques for determining the cellular uptake and retention of 99mTc-
PEI-MP and 188Re-PEI-MP have some limitations like any other techniques. 
During the procedures is very difficult to maintain the cells at 37 ºC, being this 
the normal temperature in which the cells would be in real physiological 
conditions, once to obtain cell samples over time they must be removed from 
the incubator. Also the procedures are per se relatively aggressive to cells that 
may lead to changes in their behaviour. Therefore, as a future prospect, it would 
be interesting the study of cellular uptake and retention using a device such as 
the LigandTracer Yellow. This instrument is equipped with a scintillator-based 
detector suitable for all nuclides used in PET/SPECT imaging, allowing for real-
time detection of tracer cell-interactions [342]. With this equipment it would be 
less human interaction and the cells could be maintained at 37 ºC during all 
procedure. 
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After finished the in vitro studies it was proceeded to the in vivo studies. To 
animal tumour models it was chosen the balb/c nu/nu mice (immunodeficient 
mice) with xenografts of bladder carcinoma or osteosarcoma. As referred in the 
discussion of the Chapter 6, this type of animal tumour model has several 
advantages and disadvantages. The advantages of using this animal tumour 
model is the accessibility, the low costs, and as a first approach gives 
information about the behaviour of the administered radiopharmaceutical in an 
animal with a tumour implanted. However, as discussed before, this type of 
tumour model may not faithfully reflect the human disease process, because 
lacks some of the features of human cancer, such as, metastasis development 
to secondary sites, enabling only to understand the biodistribution of 99mTc-PEI-
MP or 188Re-PEI-MP. Spontaneous models of metastasis, like orthotopic 
models have several advantages over subcutaneous xerograph models. These 
advantages may include the development of differentiated structures within the 
tumour, such as vascular and lymphatic vessels, and possibility of metastatic 
spread, which turns the model more realistic [318]. Therefore, this type of 
animal models is very important for imagiologic nuclear medicine evaluation 
after the administration of 99mTc-PEI-MP and for therapy evaluation after 
administration of 188Re-PEI-MP in cases of invasive and metastatic bladder 
carcinoma. However, tumour implantation for orthotopic models sometimes 
requires complex surgical procedures. Observation of tumour growth in internal 
organs typically needs the sacrifice of cohorts of animals because tumour 
acceptance and growth rates can be highly variable, as well as may be difficult 
and costly, to harvest tumour tissue for pathological analysis. These factors 
increase cost and decrease yield of the animal model [318]. 
Images obtained after the administration of 99mTc-PEI-MP or 188Re-PEI-MP in 
control mice without tumour and with xenografts of bladder carcinoma and 
osteosarcoma, showed a high count rate in the kidneys and the bladder, results 
that were supported by the ex vivo studies. These results demonstrated that 
one of the main ways of excretion of these complexes is through the renal 
system, and therefore, eliminated with urine. Taking into account the results of 
the partition coefficient revealed in Chapter 5 and discussed before, 
demonstrating that 99mTc-PEI-MP is a hydrophilic molecule, and therefore water 
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soluble, it’s not surprising that the main way of excretion is through the renal 
system. The same can be extrapolated to the 188Re-PEI-MP due to their 
similarities. This characteristic, theoretically would mean a small liver and fat 
tissue uptake and a higher target/background ratio [273], however through the 
in vivo images and ex vivo studies it was possible to identify other target 
organs, such as the lungs, the liver and gallbladder, the spleen and the bone. 
Nevertheless, these results are not related to its hydrophilicity, but due to the 
fact that PEI-MP is a polymer, a large molecule and a phosphonate derivative, 
as discussed in the discussion section of the Chapter 6.  
The uptake of 99mTc-PEI-MP or 188Re-PEI-MP by bladder carcinoma or 
osteosarcoma xenografts is only faintly visible in gamma-camera images, 
especially in the 188Re-PEI-MP images. This can be explained due to the 
different photonic flow of the two complexes. In fact, the photonic flow of 155 
keV gamma rays from the 188Re is low when compared with those from 140 keV 
coming from the 99mTc. This small photonic flow associated with the low 
resolution of the gamma camera detector, considering the animal size, justifies 
the reduced referred tumour visualization. This reduced visualization, turns very 
difficult or even impossible the quantification of the tumour uptake in relation to 
other organs. If there was the possibility to make precise measurements by in 
vivo imaging, and even perform measurements over time to better characterize 
the biokinetics of these radiopharmaceuticals, the number of sacrificed animals 
could be reduced greatly. A possible solution was to perform this nuclear 
medicine images in small animal dedicated gamma-cameras, equipment that 
would allow an higher spatial resolution and sensitivity [343]. 
The ex vivo studies also showed reduced uptake by the tumours of animals 
injected with 99mTc-PEI-MP or 188Re-PEI-MP. As discussed previously the 
uptake by bladder carcinoma and osteosarcoma xenografts may be related not 
just with the xenografts blood perfusion, but also with the EPR effect associated 
to this polymer, besides being a phosphonate derivative. The EPR effect related 
with this polymer, would allow the accumulation within the tumour for a long 
period of time due to leaky blood vessels and poor lymphatic clearance of the 
tumour [169, 170]. In fact the results of the ex vivo studies demonstrated that 
the uptake of 99mTc-PEI-MP and 188Re-PEI-MP (fraction 10-30 kDa ) by the 
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xenografts of bladder carcinoma and osteosarcoma was relatively high and 
stable during 240 minutes. Because accumulation of macromolecules by the 
EPR effect takes time, it is essential that the molecules are stable in the plasma 
for long periods [173], what was found with the ex vivo biodistribution studies 
that clearly revealed a high percentage of 99mTc-PEI-MP or 188Re-PEI-MP in the 
blood. The long period of retention of 99mTc-PEI-MP may be an advantage to 
perform diagnostic nuclear medicine images, to localize and delineate the 
tumour. Also for 188Re-PEI-MP this high retention for a long period of time in the 
tumour could be an advantage to deliver the high energetic β- particles to the 
tumour cells, causing tumour cell death [59]. Also the fact that PEI-MP be a 
phosphonate may explain its particular affinity to bladder carcinoma and 
osteosarcoma cells. Taniguchi et al. [338], had reported the diphosphonate 
99mTc-HMDP uptake by a calcified transitional cell carcinoma of the bladder, 
relating this uptake with the particular affinity of phosphonates to calcium (Ca2+) 
[102], that would be in abundance in a calcified tumour. On the other hand 
Moreno et al. [339], reported the diphosphonate 99mTc-MDP uptake by a non-
calcified carcinoma of the kidney, and therefore it suggested that this uptake 
was possible due to the presence of selective tissue receptors or due to 
hypervascularity. Therefore being PEI-MP a diphosphonate, the uptake of 
99mTc-PEI-MP or 188Re-PEI-MP by bladder carcinoma could be related with 
some of the factors mentioned by the authors Taniguchi et al. and Moreno et al. 
For osteosarcoma this affinity is related with the presence of high 
concentrations of Ca2+ and with the strong affinity of phosphonates to the 
hydroxyapatite crystals, as mentioned many times before [102, 108]. 
Considering these possibilities, the high uptake and retention obtained in the in 
vitro studies, could be related with the uptake mechanism suggested by those 
authors, and demonstrates that PEI-MP has a particular affinity for bladder 
carcinoma and osteosarcoma cells. The same possible uptake mechanism, in 
addition to the EPR effect, may explain the fact that 188Re-PEI-MP uptake and 
retention was significantly higher than 99mTc-PEI-MP. This difference is not 
visible in the in vivo and ex vivo studies, and is possibly related with the 
biodistribution upon intravenous administration, when much of 188Re-PEI-MP is 
uptaken by other organs. 
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A manner of better characterize the biokinetics of 99mTc-PEI-MP and 188Re-PEI-
MP after intravenous administration it would be useful to choose more 
appropriate endpoints guided by functional imaging information. However, 
besides the eventual increase of animal number, what collides with the 3Rs 
principle, the obtained information would be much more rich and perhaps more 
clinically relevant. 
The fact that the biodistribution of 99mTc-PEI-MP and 188Re-PEI-MP remain with 
minor changes until 120 and 240 minutes after the intravenous administration, 
demonstrates the radiochemical stability of these complexes in vivo. This 
behaviour gives the guarantee that the nuclear medicine images show the 
biodistribution of the labelled PEI-MP and not the contaminant species after 
labelling break. Also for therapy it is important that 188Re-PEI-MP has a high 
stability in vivo, to ensure the delivery of β- particles of 188Re to tumour tissue 
coupled to PEI-MP vehicle, and according to the principle of the EPR, the 
complex gradually would accumulate into the tumour. To support the results 
regarding the radiochemical stability of 99mTc-PEI-MP and 188Re-PEI-MP in vivo 
blood sample collected over the time, and the radiochemical purity can be 
obtained, using the same quality control procedures. In order to avoid the 
sacrifice of more animals, these stability tests could be performed in vitro using 
human serum samples maintained at 37°C. 
Considering that presence of metastasis of a bladder carcinoma, the major 
target organs are the liver, the lungs and the bone, and knowing that the 
bladder carcinoma has its origin in the bladder wall and in an initial stage the 
tumour can invade the muscle adjacent to this organ [184], to determine 
whether the tumour uptake of an administered radiopharmaceutical is higher or 
lower than the surrounding organs, is crucial to determine tumour/muscle, 
tumour/bladder, tumour/liver, tumour/lung and tumour/bone ratios. These 
results would be useful to clarify if it’s possible to perform the diagnosis with 
99mTc-PEI-MP and therapy with 188Re-PEI-MP. For mice with xenografts of 
bladder carcinoma or osteosarcoma, after the administration of 99mTc-PEI-MP or 
188Re-PEI-MP, the tumour/muscle ratios were always superior to 1, 
demonstrating that the uptake by the tumour was superior to the muscle. The 
fact that the uptake of 99mTc-PEI-MP by the tumour is higher than the muscle, is 
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an advantage to determine the degree of muscle invasiveness, and could assist 
the surgeon in determine how much muscle should be excised along with the 
tumour and the bladder [188]. Also the high tumour/muscle ratio obtained for 
188Re-PEI-MP is an advantage for the therapy, allowing sparing the muscle from 
the action of high doses of ionizing radiation. 
For mice with xenografts of bladder carcinoma and osteosarcoma where 99mTc-
PEI-MP or 188Re-PEI-MP were administered, tumour/bladder, tumour/liver, 
tumour/lung and tumour/bone ratios were always inferior to 1 demonstrating 
that the uptake of the tumour was inferior comparing with these organs. 
Considering these results, the tumour in the bladder wall, and the metastasis 
from a bladder carcinoma or osteosarcoma in liver, lung and bones would 
appear as cold lesions in nuclear medicine images, after the administration of 
99mTc-PEI-MP. Therefore it would be possible to identify the tumour and its 
metastases, in an effective way, by intravenous administration of 99mTc-PEI-MP, 
in the late images. The results are not so good if the objective is the therapy 
with 188Re-PEI-MP, because after the intravenous administration the irradiation 
of non-target tissues such as the bladder wall, the liver, the lungs and the bones 
would be higher than desirable, and can mean significant adverse effects. Also 
the uptake by its metastases would be too low for the therapy with this 
radiopharmaceutical could be effective. Thus, the use of 188Re-PEI-MP for 
systemic therapy of bladder carcinoma and its metastasis by intravenous 
administration wouldn’t be suitable. However, for the therapy of bladder 
carcinoma alone, direct instillation of 188Re-PEI-MP to the bladder could be a 
viable option, considering the high uptake of this complex by the tumour cells. 
Nevertheless, with this option the bladder wall would also be exposed to 
radiation, whereby more studies should be conducted to review the feasibility of 
this hypothesis. 
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Section IV. Discussion, Conclusions and Future Perspectives 
Chapter 8.Conclusions and Future Perspectives 
The presented work, unique and innovative, allowed pre-clinical evaluation of 
the potential of 99mTc-PEI-MP to perform images in the scope of diagnostic 
nuclear medicine, and thus allowing to take a step for future clinical studies. 
Studies with 188Re-PEI-MP were not fully completed, given the lack of an 
188W/188Re generator, however the uptake and retention studies performed in 
vitro plus the biodistribution studies performed in vivo and ex vivo, allowed to 
draw preliminary conclusions regarding its potential. 
In this work it was possible to develop a pharmaceutical formulation of the and 
constitute a reproducible cold kits that allows to obtain high radiochemical purity 
after labelling with 99mTc (>90%) or 188Re (>85%). Also the in vitro stability was 
demonstrated to be high, ensuring the possible use of the labelling kit for a long 
period of time, being this an advantage for clinical application. Also the 
radiochemical stability of 99mTc-PEI-MP was not changed by the exposure to 
cellular culture medium or to room temperatures that could vary from 22 to 45 
ºC when carrying out the in vitro studies. The same results would be expected 
for 188Re-PEI-MP given the complexes’ similarity. The chromatographic systems 
used to determinate the radiochemical purity demonstrated to be efficient, 
allowing calculating the different radiochemical species present in the labelling 
kits after adding 99mTc or 188Re. 
The polymer PEI-MP was confirmed to be a hydrophilic molecule, given the fact 
that partition coefficient was always inferior to -3. Also, PEI-MP demonstrated to 
be harmless to cells of bladder carcinoma and osteosarcoma, at least in terms 
of metabolic activity and cell viability. Therefore PEI-MP could be used as a 
carrier of 99mTc or 188Re to target cells, tissues or organs.  
Equivalent doses of 99mTc in the diagnostic range (0.3 to 20 mGy) to bladder 
carcinoma and osteosarcoma cells demonstrated that significant adverse 
effects were not produced, at least in terms of clonogenic activity and cell 
viability, whereby 99mTc-PEI-MP could be used for nuclear medicine imaging, 
 
 
238 
 
considering that the activity administered doesn’t mean equivalent doses 
superior to 20 mGy. 
In vitro studies demonstrated that the maximum uptake of 99mTc-PEI-MP was 
about 4 times the maximum uptake of the 99mTc-Pertechnetate in HT-1376 cell 
line, and approximately 5 times higher in the MNNG/HOS cell line. The 
minimum retention of 99mTc-PEI-MP was about 4 times the minimum retention of 
the 99mTc-Pertechnetate in HT-1376 cell line, and approximately 7 times higher 
in the MNNG/HOS cell line. The same studies demonstrated that the maximum 
uptake of 188Re-PEI-MP was about 62 times the maximum uptake of the 188Re-
Perrhenate in HT-1376 cell line, and approximately 65 times higher in the 
MNNG/HOS cell line. The minimum retention of 188Re-PEI-MP was about 194 
times the minimum retention of the 188Re-Perrhenate in HT-1376 cell line, and 
approximately 328 times higher in the MNNG/HOS cell line. These studies 
demonstrated that in vitro the uptake and retention of 99mTc-PEI-MP or 188Re-
PEI-MP was significantly higher than their controls, evidencing the specificity of 
PEI-MP. 
In vivo and ex vivo studies demonstrated that 99mTc-PEI-MP and 188Re-PEI-MP 
were mainly excreted through the renal system, possible explained by the fact 
that PEI-MP is a hydrophilic molecule. Also a small amount of 99mTc-PEI-MP 
and 188Re-PEI-MP in the liver and gallbladder was confirmed by the ex vivo 
studies, demonstrating that a small part is excreted through the hepatobiliary 
system.  
The in vivo and ex vivo studies confirmed the uptake of 99mTc-PEI-MP and 
188Re-PEI-MP by lungs, possible explained by the fact that these complexes are 
large molecules that could be trapped in the lung capillaries. 
Some uptake was observed in xenografts of bladder carcinoma and 
osteosarcoma. This tumour uptake can be related not only with the blood 
perfusion to the tumour or the EPR effect associated with PEI-MP, but also  with 
the presence of specific membrane receptors in the case of bladder carcinoma 
and high concentrations of Ca2+ in both tumour types. 
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The tumour/muscle ratio for 99mTc-PEI-MP and 188Re-PEI-MP for both 
xenografts of bladder carcinoma and osteosarcoma was superior to 1. For 
nuclear medicine imaging, the high tumour to muscle ratio would ensure the 
tumour visualization and allows understanding of the degree of invasiveness of 
muscle and assisting the surgeon, especially for bladder carcinoma. 
Tumour/bladder, tumour/liver, tumour/lung and tumour/bone ratios for 99mTc-
PEI-MP and 188Re-PEI-MP and for both xenografts of bladder carcinoma and 
osteosarcoma were always inferior to 1. These results demonstrated that for 
diagnostic nuclear medicine the tumour and its metastases would present as 
cold lesions allowing to identify them in the images. One the other hand the 
therapy of bladder carcinoma or osteosarcoma and its metastasis seem not to 
be feasible if administered intravenously, considering the high dosimetry to 
other organs. 
 
In order to improve or complement the obtained results it would be interesting to 
complete the studies with 188Re, namely determining the partition coefficient of 
188Re-PEI-MP, analysing the cytotoxicity of 188Re and increasing the sample 
size of the studies already conducted. 
Considering the limitations associated with the manual techniques for 
determining the cellular uptake and retention, and to overcome these 
limitations, it would be interesting to complete the cellular uptake and retention 
studies using the device LigandTracer Yellow. 
The xenograft model may not faithfully reflect the human disease process, 
because it lacks some of the features of human cancer development. The 
orthotopic models overcomes these limitations, therefore it would be interesting 
to conduct in vivo studies after the administration of 99mTc-PEI-MP or 188Re-PEI-
MP in orthotopic models of bladder carcinoma or osteosarcoma, to analyse 
more realistically the biodistribution and the pharmacokinetics of those 
complexes. 
Using a gamma-camera that was built for human imaging to perform images of 
a small animal, turns it very difficult due to the resolution of this equipment that 
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is not highly enough for the small structures of a mouse. As a consequence it 
was not possible to quantify the tumour uptake in relation to other organs only in 
images, and therefore the need of sacrifying the animals. A possible solution 
was to perform this nuclear medicine images in small animal dedicated gamma-
cameras, equipment that would allow a higher spatial resolution and sensitivity. 
The uptake of 99mTc-PEI-MP and 188Re-PEI-MP by the bladder cancer cells may 
be related not only with the blood perfusion or EPR effect, but also with the high 
concentration of Ca2+ if tumour microcalcifications are present as well as the 
expression of specific membrane receptors. Therefore it would be exciting the 
identification of these receptors and eventually associate them as one of the 
possible reasons for the high uptake of the radiolabelled PEI-MP by bladder 
tissue and bladder tumour tissue. 
Considering the high uptake of 188Re-PEI-MP by the bladder carcinoma 
xenograft, this complex could still be considered for therapy of bladder 
carcinoma, if administered directly by instillation to the bladder. However 
dosimetry to the bladder wall should be always considered. Nevertheless it 
would be attractive to conduct studies to confirm or not the feasibility of this 
hypothesis. 
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